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PART I 
DIAGNOSIS AND TREATMENT OF PITUITARY TUMOURS 

CHAPTER I 
INTRODUCTION 
RECOGNITION AND THERAPEUTIC APPROACH 
OF THE PITUITARY TUMOUR; 
Developments between 1500- 1980 
A. CLINICAL SYNDROMES 
One of the earliest depictions of the symptoms of a pituitary tumour 
dates back to 1365 BC, in which the portrait head of the Pharaoh 
Akhenaten displays features suggestive for acromegaly (Belchetz 
1984a). In 1524 the Italian anatomist Berengario da Carpi described 
for the first time the human pituitary gland (Gauger 1979) and in 1670 
Richard Lower concluded from his own observations that substances 
passed from the brain via the infundibulum and pituitary stalk and 
thence were distilled in the blood. A few years later, in 1679, 
Theophile Bonet reported the occurrence of a pathological enlargement 
of the pituitary gland. Subsequently pituitary tumours causing visual 
loss were described by Vieussens in 1705 and hydrocephalus by Petit in 
1718 (Belchetz 1984a). In 1759 de Haen referred to the presence of a 
pituitary tumour in an amenorrhoeic woman. 
The term ~£E2~~g~±X was first used by Marie in 1886 to describe two 
patients with hypertrophy of the extremities, marked enlargement of 
the hands and feet, prognathism, macroglossia, thickened skin 
associated with headache, arthralgia and lethargy (Marie 1886). In a 
number of earlier case reports Marie recognized acromegaly 
retrospectively, beginning with Saucerottes's patient described in 
1772. In 1882 already Minkowski reported the constant finding of pitu-
itary enlargement in acromegaly and he suspected for the first time 
that these two findings were connected. It was in 1909 that Harvey 
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Cushing used the term "hyperpituitarism" in relation to acromegaly. 
Since in the last 20 years assays for serum growth hormone became 
available, a clear relationship was proven between hypersecretion of 
growth hormone and acromegaly (Daughaday 1968, Lamberts et al 1979b, 
Klijn et al 1980b, Lamberts 1986b). 
Functional disturbances as ~-~~g~EEE2~-~-~g~-~~~£t£I~F-~~~ are 
classically described in three clinical syndromes (Boyd et al 1977, 
Archer 1977, Blackwell 1985); (1) the Chiari-Frommel syndrome (Chiari 
1855, Frommel 1882) with persistence of postpartum amenorrhoea and 
galactorrhoea for more than one year after delivery and without 
evidenc.e of a pituitary tumour; (2) the Argonz-Del Castillo syndrome 
(1953), the spontaneous onset of amenorrhoea and galactorrhoea without 
a pathological sella turcica and not related with pregnancy; (3) the 
Forbes-Albright syndrome, since Forbes et al in their original 
description (1954) speculated that inappropiate breast secretion was 
caused by abnormal and presumably excess secretion of prolactin from a 
pituitary tumour radiologically diagnosed by a pathological sella 
turcica. Prolactin was discovered in 1928 as a lactogenic substance 
present in extracts of the pituitary gland of the cow but only since 
1970 definitely identified in the blood by a sensitive bioassay 
(Frantz and Kleinberg 1970, Frantz 1978). In 1971 Friesen et al 
developed a radioimmunoassay (Hwang et al 1971) and showed increased 
plasma prolactin concentrations and increased tumoural prolactin 
synthesis in a patient with a Forbes-Albright syndrome (Friesen et al 
1972). Since that time a rapidly expanding literature has accumulated 
on the human physiology of pituitary prolactin secretion in normal and 
various pathologic conditions. 
With the development of more sophisticated radiological techniques 
for visualization of the pituitary fossa it appeared that these three 
clinical syndromes are all part of the same condition and in the 1970s 
the terms "hyperprolactinaemic-anovulatory syndrome" (Bohnet et al 
1976) or "galactorrhoea-amenorrhoea syndrome" (Boyd 1977) were used as 
more practical ones. The pituitary tumours were indicated as 
microprolactinomas (diameter less than 1 em) and macroprolactinomas. 
In 1932 Cushing described pituitary basophilism occurring in the 
pituitary-dependent form of hypercortisolism with bilateral adrenal 
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hyperplasia, which is eponymously named after him as ~~~higg~~-~i~~~~~ 
(Cushing 1932, Lamberts et al 1980a and 1982c). 
All other types of pituitary tumours without clinical signs of 
hypersecretion often are indicated as :ig~!:.!:: __ o_F __ :g~g:f~g.£~i~g!.I!&.::. 
.£~!:~~~E~~E~-~~~g~~~2· In general, these tumours are very large at 
diagnosis and cause local problems as bone destruction and 
neurological disturbances with visual loss. Recently, however, it 
appeared that the majority of these tumours secrete other hormonal 
substances like inactive parts of hormones like for instance the 
~1Eh~=~~2~gi!~_2l-~ll£~~~t~!.~_hg~gE~S (Ridgway et al 1981, Borges 
et al 1984, Horvath and Kovacs 1984, Whitaker et al 1985). 
B. DIAGNOSIS OF PITUITARY GLAND TUMOURS 
In general, the diagnostic procedures in patients with (suspected) 
pituitary tumours consist of neuroradiological ophthalmological and 
endocrine investigations. 
1. Radiological Evaluation 
In the evaluation of the sella turcica 21~!E-~~ll __ til~~ are the 
common mainstays of radiologic diagnosis (Laws and Houser 1979). The 
earliest published radiograph of a confirmed pituitary adenoma 
appeared in Harvey Cushing's 1909 article reporting a patient with 
acromegaly, who was operated upon successfully via a transsphenoidal 
approach. On plain skull films the most obvious pathologic change is 
gross enlargement. Furthermore "doubling" of the floor, erosion, clear 
bone destruction, blistering, slanting, or straightening of the dorsum 
sellae can be observed. Intrasellar calcification may occur normally 
or in association with craniopharyngiomas, pituitary adenomas or 
carotid aneurysms. However, detection of minimal changes in the form 
of the sella caused by microadenomas need more sophisticated 
techniques. The development of ~~!~!.~!.E~.£~!.~~~!-E~!l~~~~~E~E~l consti-
tuted an important step forwards in the diagnosis of microadenomas 
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(Vezina and Sutton 1974, Laws and Houser 1979, Wolpert 1980 and 1986, 
Hall 1984b). Tomograms offer detailed evaluation of the bony sella and 
focal changes can more readily be recognized. However, there is also 
evidence against the diagnostic value of sellar tomography (Muhr et al 
1980 and 1981, Hall et al 1984a), showing that it is not as accurate 
(compared to variations of the configuration of the normal sella) as 
many original workers made out. 
The earlier introduction of v-~~~~~~~~~~~~-~~~-Eg~~~~g£~E~~!~­
gE~E~l--i~~~) by Walter Dandy provided valuable tools for the 
assessment of suprasellar extension of -pituitary tumours, while 
~gg!~gE~E~l is more important for detecting carotid artery aneurysms 
(Laws and Houser 1979). However, since the advent of ~o~~u~~~ 
!~~~gE~E~l scanning (CT-scan) in the second half of the 1970's these 
invasive investigations lost their important role in radiographic 
diagnosis (Wolpert 1980, Kendall 1983). The CT-scan appeared not only 
useful in the detection of intrasellar and suprasellar tumour masses, 
but is also superior to carotid angiography and cavernous sinus 
venography with respect to detection of lateral tumour spread 
(Hoffman 1979). High-resolution CT-scan even demonstrate microadenomas 
within the sellar fossa (Bamberger Bozo 1980, Bernasconi 1982, Houser 
1984, Buchfelder et al 1984, Nakagawa et al 1985, Schneider 1985). The 
PEG has the advantage to delineate an empty sella from a necrotic 
intrasellar tumour and to identify small suprasellar tumours not seen 
on CT (Wolpert 1980). However the indications for PEG have been 
reduced yet further by the introduction of CT metrizamide cisterno-
graphy which may give additional information about the nature and 
extent of intrasellar and extrasellar tumour mass (Wolpert 1980 and 
1986, Hall 1984c). 
Recently investigations with g~£!~~E-~~gg~!!£_E~~~g~g£~ (NMR) have 
been reported to identify again more details of pituitary tumours 
(Wolpert 1986). Also, NMR has a greater potential value for tissue 
characterization (Kendall 1983). Metabolic studies can be performed 
with E~~!!E~g-~~!~~!Q~-!~~QgE~EQl (Muhr et al 1984). 
2. Ophthalmological Evaluation 
The relationship between pituitary tumours and visual impairment 
20 
was first noted in the late 1800s (Stefanis et al 1979). Since then 
therapeutic efforts have focused on operative removal of tumour to 
restore and preserve vision. Before the 1970s the reported incidence 
of visual disturbances in some large series were relatively high i.e. 
42-80%, but today the incidence dropped to about 20% due to better 
radiological and biochemical techniques allowing earlier detection of 
pituitary disease ( Gittinger 1980, Buchanan 1984). The characteristic 
visual field defect caused by a pituitary tumour is bitemporal hemi-
anopsia (Stefanis 1979, Gittinger 1980, Buchanan 1984). In a typical 
case of progressive chiasma! compression from suprasellar tumour 
growth, the superior temporal quadrants are affected initially 
followed by the inferior temporal, the inferior nasal and ultimately 
the superior nasal quadrant (in that order) resulting in blindness. 
Besides optic nerve atrophy papilloedema can occur when obstruction of 
the third ventricle by a large tumour mass causes increased intra-
cranial pressure. The combination of optic atrophy on one side and 
papilloedema on the other has been described by Foster Kennedy. 
Furthermore lateral extension of pituitary tumours can cause 
partial or complete palsies of the oculomotor, the abducens or the 
trochlear nerves resulting in paralysis of the extraocular muscles 
with diplopia or panophthalmoplegia. A pituitary apoplexy can cause 
acute visual disturbances accompanied by headache, nausea and 
sometimes meningismus or altered mental status (Stefanis et al 1979, 
Gittinger 1980). 
The most common ophthalmological evaluation (Stefanis 1979, 
Gittinger 1980, Buchanan 1984) consists of a) f~£~~~££E~£-~~~~!~~!!£~ 
b) Snellen's .Y.!2E2.!_2.£,.:t.!.E..L.!~..?.!J...!l.S, and c) E.~~!.~~l;.;)" with the Goldman 
perimeter. Visual field defects caused by glaucoma have to be 
excluded. Tangent screen testing for small deficits !~-E~~:££~£E 
Y!~!£~ may detect early abnormalities. A more recent technique for 
early detection of chiasma! compression consists of electroretino-
graphy with ~!~~~!-~~2~~2-E2!~g!!~!~ (VEPs). Abnormalities of the VEP 
occur in various lesions of the visual pathway and in fact may be the 
only sign of these lesions (Gittinger 1980). This method is particu-
larly useful in patients in whom perimetric data are unreliable. 
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3. Endocrine Evaluation 
The endocrinology of the pituitary gland and its target organs 
started really in the 1920s (Belchetz 1984a). Pituitary extirpation 
experiments and the use of pituitary extracts established gradually 
the spectrum of pituitary hormones, namely: the early experiments of 
Evans and Long on the growth in rats (1921), the restoration of 
thyroid function by pituitary extract in 1926 by Foster and Smith, and 
the separation of the gonadotrophins into Prolan A and B by Ascheim 
and Zondek in 1928 (Belchetz 1984a). 
The major achievements have been made since 1930, in which year the 
endocrinologist Philip Smith published his results of experiments in 
hypophysectomized rats (Sawyer 1982). These experiments showed clearly 
that the pituitary gland produces hormones stimulating the thyroid, 
adrenal cortex, gonads, and growth. In the early 1930s the steroid 
hormones of the gonads (oestradiol and testosterone) were identified 
and synthesized. Is his excellent review on neuroendocrinology Sawyer 
(1982) stated that the anterior pituitary was soon recognized as the 
"leader of the endocrine orchestra". In 1932 Meyer et al and Moore and 
Price showed that gonadal hormones had a reciprocal action on the 
anterior pituitary activity, later called negative feedback. In the 
same year Hohlweg and Junkman noted that "castration cells" failed to 
develop in the pituitary when separated from the brain by 
transplantation, and they proposed that a "hypothalamic sex-center" 
was involved in the feedback circuit. In 1933 the pituitary portal 
vascular system was discovered by Popa and Fielding and the idea 
concerning humoral mediators from the hypothalamus controlling 
pituitary functions was first proposed by Hinsey and Markee. The 
downward direction of blood flow was first observed by Houssay et al 
.(1935) and Wislocki and King (1936). In the 1940s Geoffrey Harris and 
Green established the neurovascular regulation of the anterior 
pituitary by humoral factors synthesized in the hypothalamus and 
secreted into the hypophyseal portal system (Harris 1955). Also since 
1940, the history of the isolation of pure pituitary hormones has been 
dominated by Chok Hao Li (see review Sawyer 1982). 
Meanwhile progress was being made in research on the hypothalamus 
22 
(Sawyer 1982). In 1951 Bargmann and Scharrer published their classic 
concept of neurosecretion. In the next years Du Vigneaud elucidated 
the structure of the posterior pituitary octapeptides vasopressin and 
oxytocin. In the early 1960s McCann and Harvis · independently 
demonstrated the existence of a specific gonadotrophin releasing 
factor (LHRH). However, the simpler tripeptide thyrotrophin releasing 
hormone (TRH) was the first hypophysiotrophic factor that was 
chemically identified simultaneously in 1969 by Guillemin and Schally. 
The structure of LHRH as a decapeptide was published two years later 
by Matsuo and Schally (1971). Again two years later Guillemin's 
laboratory reported the structure of somatostatin being a tetradeca-
peptide (Brazeau 1973). 
After the discovery of prolactin as a lactogenic substance present 
in extracts of the pituitary gland of the cow, it was not until 1970 
that Frantz and · Kleinberg identified prolactin definitely as a 
distinct hormone in man separate from growth hormone by means of a 
sensitive bioassay (Frantz and Kleinberg 1970, Frantz 1978). In the 
following year Friesen et al developed a radioimmunoassay for the 
measurement of human prolactin in plasma (Hwang et al 1971). Since 
then an enormous number of papers about the regulation of prolactin 
secretion and its clinical significance have been published (Thorner 
1977' Lamberts et al 1978, Macleod et al 1984, Macleod and Lamberts 
1986). With the general availability of the prolactin radio-
immunoassay, the more widespread use of electron microscopy and the 
immunohistochemical investigations, it has become clear that prolactin 
hypersecretion occurs in approximately 50-80% of all patients with 
pituitary tumours. Many of these had previously been considered to be 
nonfunctional. 
With the introduction in the 1970s of radioimmunoassays for most 
pituitary hormones, bioassays became obsolete. Simultaneously, 
radioimmunoassays for the hormones produced in the target organs of 
pituitary hormones became available. In the same decade a great number 
of stimulatory and inhibitory pituitary function tests were 
introduced, for instance the TRH- LHRH- and metyrapone test, insulin 
tolerance test (I.T.T.) and glucose tolerance test (GTT) (Christy 
1979, Jackson 1980b and 1982). In the investigations described in this 
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thesis most of these tests have been used extensively. The reader is 
referred to section 2.b. of chapter II. All these revolutionary 
developments in endocrinologic evaluation together with the advances 
in neuroradiological techniques and the expanding use of trans-
sphenoidal microsurgery appeared to be of great value in improving 
diagnosis, treatment and follow-up of patients with pituitary tumours. 
After the extensive research in the last 30-40 years on the 
influence of electrical stimuli and neurotransmitters on pituitary 
function, we have seen in the past few years an explosive expansion of 
the research on brain pep tides. The structures of CRF and GRF have 
recently been unraveled. However, not only releasing and inhibitory 
hormones are found but also a wide spectrum of peptides determined 
both in and outside the central nervous system, for instance in the 
gut and various endocrine glands. It can be expected with confidence 
that other hypothalamic hormones will be identifi-ed and synthesized 
and that many as yet unknown peptides will be discovered. In addition, 
the production of potent analogues of some neuropeptides as LHRH and 
somatostatin has contributed to the development of new treatment 
modalities in cancer therapy also in our hands (Klijn and de Jong 
1982, Klijn et al 1984b-e, Klijn et al 1985a and b, Klijn 1986a and b, 
Klijn et al 1987a-f, Blankenstein et al 1985, Debruyne et al 1985, 
Foekens et al 1986 and 1987, Schroder et al 1987a and b, de Jong et 
al 1987, Setyono-Han et al 1987). 
C. TREATMENT OF PITUITARY ADENOMAS 
In this century many approaches of therapy for patients with 
pituitary tumours have been developed and tried out (Table 1). 
However, there are only three main types of therapy: surgery, 
radiotherapy and medical treatment. In the past 15 years major 
advances in treatment were the development of transsphenoidal 
(micro)surgery and the discovery of bromocriptine. This dopamine 
agonist inhibits particularly the hormonal activity · of prolactin 
secreting pituitary adenomas and decreases the size of the adenomas 
considerably in many of them. Furthermore, the recent development of 
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Table 1. Potential types of therapy for patients with pituitary tumours. 
1 Surgical Treatment 
A) Directed at the pituitary 
1: transfrontal or intracranial extirpation of tumour. 
2: transsphenoidal or extracranial operation with: 
- microsurgery 
- cryosurgery 
- thermal ablation 
- implantation of radioactive implants (see below) 
3: stereotactic 
a) cryosurgery 
b) radiofrequency 
c) ultrasound 
B) Directed at end organ (adrenalectomy in Cushing's disease) 
2 Radiation Treatment 
l) Conventional external radiotherapy (supravoltage or 60 Co) 
2) Heavy-particle radiation 
3) Implants 
a) yttrium - 90 
b) gold - 198 
c) radium 
3 Medical Treatment 
see Table 2 
4 Combined Treatment 
5 None 
a) proton beam with Bragg peak 
b) alpha particles (helium ions) 
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potent somatostatin analogues will probably become important for the 
treatment of acromegaly. Also the techniques used in radiation therapy 
have been improved 
1. Surgery 
l.a. Intracranial Surgery 
In the first two decades after Marie's suggestion about a 
relationship between acromegaly and pituitary tumours most surgeons 
had the opinion that pituitary tumours were inoperable. However, in 
1889 the first pituitary adenoma was removed by Victor Horsley 
(Fahlbusch and Marguth 1978, Post 1980a). This earliest surgical 
approach was by the intracranial route to decompress the optic chiasm 
from a pituitary tumour. By 1893, Caton and Paul reported an attempt 
at removal of a growth hormone producing tumor via craniotomy and 
middle fossa approach. In 1905 Krause c .s. suggested an approach 
through the anterior cranial fossa. The first small series of patients 
was reported by Horsley, who approached the tumours via the middle 
fossa using intrasellarly moved rhinoscopic mirrors (Horsley 1906). 
Two out of ten operated patients died. After the introduction of an 
extracranial approach (Schloffer 1907, Cushing 1909) Frazier performed 
both operations, transsphenoidal and transcranial, before 1913, with 
the. view of using the transsphenoidal approach for small enclosed 
tumours and tumours growing downward, and the transcranial approach 
for tumours growing upward (Post 1980a). The mortality rates differed 
significantly: 3. 4 .% for the former and 30% for the latter. Af.ter a 
period of popularity a gradual reversion to the intracranial procedure 
occurred in the 1920's. After more than 200 transsphenoidal operations 
Cushing abandoned this approach in the late 1920's and became the 
champion of the transcranial approach which until recently was 
favoured by most neurosurgeons (see Laws et al 1979a). He developed 
the midline subfrontal approach which still remains a standard 
procedure. Cushing returned to the transcranial operation because of 
higher incidence of infection, cerebrospinal fluid rhinorrhoea (which 
would be overcome later) and higher rate of tumour recurrence after 
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transsphenoidal operation alone (67,2 %within five years versus 42,5 
% after transfrontal surgery alone). Also the frequent occurrence of 
chiasmatic compression as an indication for surgery made the 
transcranial approach the more popular for the next several decades 
(Henderson 1939). The optic chiasm syndrome has always remained the 
most important indication for the subfrontal approach. In the absence 
of an optic chiasm syndrome or neurologic disorders, in general, most 
doctors were inclined to apply radiotherapy or to remain expectative 
because of the high mortality rates and the bad results of surgery in 
recurrent tumours. The findings of Jefferson (1940 and 1969) regarding 
the relationship between tumour size and operative risks have been 
confirmed by many subsequent workers (Bakay 1950, Horrax et al 1955, 
Svien et Colby et al 1969, Elkington and McKissock 1967, Wirth et al 
1974). In patients with large tumours and massive suprasellar 
extension the mortality rate was higher (16.7-36 %) than in those with 
small tumours (2.5-6,4 %) with an overall mortality rate per series of 
5.4 to 14.1 % (Post 1980c). For re-operations the mortality rate was 
very high: between 33 % (Wirth et al 1974) and 55 % (Elkington and 
~ 
McKissock 1967). Ray and Patterson (1971), reaching a very low overall 
primary mortality rate of 1,2 % found a mortality of 25 % with 
re-operations. The most frequent causes of death were intracranial or 
intratumoural bleeding, cerebral oedema or infarction, and brain-stem 
damage. The mortality rate decreased impressively (to 2-5 %) after the 
introduction of perioperative protection with high doses of cortico-
steroids preventing cerebral oedema and adrenal insufficiency (Ray and 
Patterson 1971; van der Zwan 1971; Taekman 1979; Post 1986). 
Nevertheless, the transsphenoidal operation is more and more favoured 
now even in the case of suprasellarly extending tumours (Laws et al 
1977) because of good results and lower morbidity and mortality. 
1.b. Extracranial Surgery 
In 1907 Schloffer performed the first successful extracranial 
extirpation of a pituitary tumour via the transsphenoidal route in a 
man with symptoms of panhypopituitarism, severe headache and an optic 
chiasm syndrome. He gained access to the sella turcica by way of the 
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ethmoid cells and the sphenoid sinus by a modification of the 
operation of Giordano ( 1897), who used a route through the frontal 
sinus. In 1909 Cushing attempted to control acromegaly surgically by 
his first operation using the transsphenoidal approach. The symptoms 
and signs of acromegaly rapidly improved, and there ensued a large 
series of 247 pituitary adenoma patients operated transsphenoidally. 
Until then the operation involved considerable dissection of the 
frontal sinus, nose, ethmoids and sphenoids and was very disfiguring. 
In 1910 Halstead started with a transoronasal route with an incision 
through · the mucosa above the upper teeth, utilizing the submucosal 
techniques of Kocher. Also in 1910, Oscar Hirsch performed the first 
of his 413 transsphenoidal operations (Hirsch 1910). The 
transsphenoidal route to the sella turcica was the operative method of 
choice until the 1920's (Halstead 1910, Hirsch 1910, Cushing 1912 and 
1914, Frazier 1913). 
After the return of Cushing to the subfrontal approach in spite of 
an overall mortality rate of only 5 % in a series of 231 
transsphenoidally operated patients, C~shing's pupil Norman Dott 
(1925) and Hirsch remained faithful to the open transsphenoidal route. 
In 1959 the first report of lasting remissions of 20 to 30 years 
followed' (Hirsch et al 1959a and b). Probably the longest reported 
survival is that of Mr. Owens, first operated transsphenoidally by 
Cushing and four years later reoperated by Hirsch utilizing the same 
approach for radium implantation to restore failing vision. He was in 
a good condition and introduced to the Cushing Society by Hirsch 48 
years after the first operation (Hirsch 1959b, Hardy and Wigser 1965). 
After 1940 Hamlin used transsphenoidal surgery successfully in a 
series of 104 patients (1962) with a mortality rate of 2 %, but the 
subfrontal approach was favoured by most surgeons especially because 
of the lower recurrence rate. However., the open transsphenoidal 
approach revived after the introduction of image-intensified 
fluoroscopy by Guiot (a student of Dott) in 1959 (Guiot and Thibaut 
1959) and the further modernization of this procedure by the 
introduction of the operating microscope by Hardy (1962, 1965), who 
was trained by Guiot. The radiological control, the magnification and 
improved focal illumination has made the operation safer and 
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identification of tumour tissue easier. These technical advances made 
microsurgery possible. More than the technical improvements, however, 
Hardy's introduction of the concept of selective microsurgical removal 
of functioning pituitary adenomas has been responsible for the current 
intense neurosurgical interest. This has also been stimulated by the 
better detection of small hormonally active tumours due to the 
advances in endocrinology and radiology (radioimmunoassays for 
prolactin and growth hormone, polycyclic tomography of the sella). 
Later several surgeons have made their own modifications of this 
surgical technique (Wilson 1978 and 1984, Tindall et al 1978, Post 
1980b). Some excellent reviews has been published by Post (1980a,b,c). 
In Europe the transsphenoidal operation became also very popular in 
the 1970's outside France (Giovanelli et al 1976, 1980 and 1984, 
Fahlbusch et al 1978, 1980, 1984 and 1985, Landolt 1984a and 1985b, 
Liidecke et al 1983 and 1984). Some surgeons use the transsphenoidal 
route for cryosurgery, thermal ablation or implantation of radioactive 
isotopes (Post 1980b). 
In 1969 de Lange started as the first surgeon in the Netherlands 
with the transsphenoidal technique using the operating microscope and 
radiological control in patients with pituitary adenomas. The results 
of the transsphenoidal operations performed in his department are 
reported in chapter II. In the beginning transsphenoidal microsurgery 
has been restricted to patients with prolactin and growth hormone 
secreting pituitary tumours, but later on it was applied also in 
patients with Cushing's disease and with hormonally inactive tumours. 
Together with the advances in endocrinology transsphenoidal 
microsurgery, aimed at a selective removal of microadenomas, improved 
insight into the pathogenesis of pituitary tumours. So, it is clear 
now· that there exist at least three types of pituitary dependent 
Cushing's disease: ACTH-producing microadenomas in the anterior 
pituitary, in the pars intermedia, and diffuse hyperplasia of 
corticotrophic cells in the anterior pituitary (Lamberts et al 
1980a,c,d,e, 1981, 1982c, 1984a). However, other authors did not tind 
evidence of intermediate lobe origin of corticotroph adenomas (McNicol 
et al 1986). 
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2. Radiation Treatment 
Radiation therapy was first applied in the management of 
acromegaly. In 1907 successful treatment was carried out by Gramegma 
in a 45-year-old acromegalic female and by Biklere in a 16-year-old 
girl with gigantism. Gramegma utilized an intraoral glass applicator 
and an early Crooks tube with voltage in the range of 80 KV, while 
Beclere used 100 KV delivered via a five-field-treatment technique, a 
technique that is still being used in modified form by many 
radiotherapists (Emami 1980). Then in the 1910's local application of 
radium into the sphenoid sinus was tried by surgeons via the 
transnasal route (Quick 1920, Hirsch 1921), but soon abandoned because 
of high morbidity and mortality. A series of patients treated by 
external radiotherapy was first reported by Heinismann and Czerny 
(1926). 
In the 1930's considerable controversy existed between 
neurosurgeons and radiotherapists as to which treatment modality was 
superior. Cushing did not favour radiotherapy above surgery. However, 
in a follow-up study of his series of 338 surgically treated patients, 
Henderson ( 1939) reported that the frequency of tumour recurrences 
within 5 years postoperatively decreased considerably by radiotherapy 
after surgery (from 58 to 26 %) • The five year recurrence-free ·rate 
was 32.8 % with transsphenoidal operation alone and 57,5 %with 
subfrontal surgery alone, but increased to 65,3 % and 87,1 % 
respectively if the operation was followed by irradiation. This was a 
surprising result because radiation therapy consisted of only 500 rad 
given in two treatments. After the earlier recommendation of 
postoperative radiotherapy by Pfahler and Spachman (1935), Henderson's 
study can be considered the basis for combined surgical ·and 
radiotherapeutic approach to pituitary tumours. Subsequently, primary 
radiotherapy became also customary, especially in patients with 
tumours which did not compress the optic chiasm and/or the third 
ventricle. 
In the 1940's, radiotherapy of pituitary tumours consisted of 
multiple small courses of low-dose exposure, separated by periods 
ranging from several weeks to years· (Emami 1980). In 1949 Kerr as well 
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as Ellis advised a single intensive course, which in the next decades 
appeared superior over the prolonged low-dose technique. Currently 
conventional irradiation is given as a single course consisting of 
fractions of 180-200 rads, four or five per week, with a total dose of 
about 4.000 to 4.6QO rads, calculated at the 95% isodose line. The 
total dose may be increased to 5.500 rads in the case of very large 
invasive tumours (Sheline 1979, 1982 and 1984). Detailed descriptions 
of the external radiation therapy techniques are given in the 
excellent articles of Emami (1981) and Sheline (1979, 1982 and 1984). 
External radiotherapy has meanwhile improved with the development 
of high-energy sources of rontgen irradiation and with the use of the 
cyclotron to produce high-energy particles proton beam: (Tobias et al 
1952, McCombs 1957, Linfoot et al 1970, Linfoot 1979 and 1984, 
Lawrence 1957 and et al 1970, Kjellberg et al 1968 and 1980). After 
the development of stereotactic approaches to the pituitary in the 
1950 1 s, the use of intrasellarly placed radioactive isotopes also 
appeared successful in a considerable number of patients with 
pituitary tumours (Greenwood et al 1965, Hartog et al 1962 and 1965, 
Northfield 1949, Wright et al 1970, Joplin et al 1979 and 1984). 
In conclusion, after 70 years of experience, there is no longer 
doubt that radiotherapy plays a major role in the management of 
pituitary adenomas. Almost all pituitary tumours treated by surgical 
excision (with the exception of the smaller ones) recurred within 
seven years, unless radiotherapy was added (Henderson 1939; Bakey 
1950; Guiot et al 1967, Erlichman et al 1979). After the introduction 
of the GH and PRL assays, it appeared that after primary radiotherapy 
GH and PRL hypersecretion decreased gradually in nearly all patients 
with acromegaly or prolactinoma. However, in 50-75 % of the patients 
normal levels were not reached. Also in Cushing 1 s disease external 
pituitary irradiation as the primary modality of therapy does not 
induce definite cure in the majority of the patients. On the other 
hand, there is in general no difference between radiotherapy alone and 
surgery in combination with radiotherapy with respect to the efficacy 
of tumour growth control (Emami 1980, Erlichman et al 1979). The 
average disease-free rate in 11 studies was 85 % five to ten years 
after treatment compared to 41% for surgery alone in patients with 
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pituitary tumours (Emami 1980). Erlichman et al (1979) found a median 
time to recurrence of 3.5 years. One patient showed a recurrence 17 
years after initial therapy. 
The frequency of failures after proton beam radiosurgical treatment 
is reported to be low (10 %) • Kjellberg, who was an assistant of 
Hirsch and who became a supporter of focal radiosurgery with Leksell 
(in Stockholm), found an overall improvement in 90 % of patients with 
acromegaly and in 85 % of patients with Cushing's disease 24 months 
after radi.osurgery with a remission rate of 60-65 % (Kjellberg and 
Kliman 1980). 
Treatment of pituitary tumours by interstitial irradiation has also 
been proven to be an attractive type of radiotherapy (Joplin et al 
1979 and 1984, Linfoot 1979 and 1984), especially in acromegaly and 
Cushing's disease. It causes a quick fall in GH and ACTH levels, i.e. 
of about 60 % within one year. 
3. Medical Treatment 
Before the extensive use of bromocriptine in medical practice for 
pituitary adenomas, various pharmacologic agents have been tried to 
control the secretion and/or the effects of pituitary hormones 
produced by hormonally active pituitary tumours (Table 2, Goldfine and 
Vigneri 1979, Soman 1979, Molitch 1980). The results of these types of 
treatments have generally been disappointing. 
Q~2!~~Jl~~~ do not appear to decrease circulating GH levels. The 
moderate beneficial clinical effects in acromegaly are due to 
suppression of GH-mediated somatomedin generation in the liver 
(Wiedemann and Schwartz 1972, Wiedemann et al 1976). The amelioration 
of clinical symptoms is also apparent from reduction of urinary 
calcium and hydroxyproline excretion as well as a decrease of the 
serum phosphorus level (Schwartz et al 1969). There is no wide-spread 
use of this therapy because of the relatively short lived effect, the 
increased cardiovascular risks and the possible predisposition to 
apoplexy in pituitary tumours (Molitch 1980). It might be applied in 
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Table 2. Medical Treatment of pituitary tumours 
Acromegaly Prolactinoma 
1) somatostatin analogues 
2) dopaminergic 
agents i.e .• 
bromocriptine 
lysuride 
lergotrile mesylate 
3) antioestrogens 
4) oestrogens 
1) dopaminergic 
agents 
2) antioestrogens 
3) serotonine 
antagonists ' 
(probably via dopa-
minergic action) 
5) medroxyprogesterone 4) pyridoxine 
acetate 
6) Alpha-adrenergic antagonists 
-phentolamine 
-fenfluramine 
7) Serotonine antagonist 
-cyproheptadine 
-metergoline-methysergide 
(probably via dopaminergic action) 
8) chlorpromazine 
Cushing's disease 
A) Directed at pituitary 
tumour. 
1)dopaminergic agents 
2)serotonine antagonists 
B)Directed at adrenals 
3)o'p' - DDD 
4)aminoglutethimide 
5)metyrapone 
6)ketoconazole 
C) Antiglucocorticoids 
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acromegalic patients, who have not responded to other therapy. In 
patients with prolactinomas or mixed tumours oestrogens are 
contraindicated because of the stimulatory effects on prolactin 
secretion and on tumour growth; this is also applicable to patients 
with Cushing's disease because of retention of salt and water with 
cardiovascular risks. 
~~~!2~XE!2S~2!~!2~~--~~~t~t~ may decrease basal GH levels and the· 
response of normal and tumourous GH-secretion to various stimuli as 
hypoglycemia ·and arginine (Simon et al 1967, Lawrence and Kirsteins 
1970). Long-term follow-up showed improvement of soft-tissue swelling 
and headache in acromegalic patients (Lawrence and Hagen 1973). 
However, the success_rate appeared to be low (10-20 %) with sometimes 
even a rise in circulating GH levels during this type of treatment 
(Soman 1979, Molitch 1980). 
MEh!!::~!!E~~~!:S!£_1l.!l..!=ll.ru>.!1J..§..!=.§ as phentolamine and fenfluramine ( Soman 
1979), have been shown to lower plasma GH levels acutely in 
acromegalic patients (Nakagawa and Mashino 1973), probably by 
depletion of catecholamine concentration in the hypothalamus. There is 
search for new suitable drugs, but until now an agent effective in the 
majority of acromegalic patients is not available (Lamberts 198Sa). 
£!!!2!:1!!2~!!:~!!!:~ was initially reported by Kolodny et al (1971) to be 
effective in reducing GH levels and improving clinical features in a 
young man with acromegaly. However, the effectiveness has not been 
confirmed in later reports (Dimond et al 1973, Alford et al 1974). 
Chlorpromazine stimulates normal prolactin secretion. This stimulating 
effect is absent or decreased in patients with prolactinomas, but 
inhibition has been not observed. This drug is of no use in patients 
with prolactin secreting pituitary tumours. 
§.~!:2!:.2~!~ _ _a_I!_t_a_g_o_n_i_s_t_s have been reported to inhibit both basal and 
stimulated plasma · GH levels in normal people (Bivens et al 1973, 
Smythe and Lazarus 1974, Nakai et al 1974), and in acromegalies 
(Deli tala et al 1976, Feldman et al 1976). However, Chiodini et al 
(1976) found no acute effect of cyproheptadine in four acromegalies. 
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Metergoline indeed inhibited GH release, but appeared to have 
dopaminergic effects because it can be blocked by the dopamine-
receptor blocker pimozide. 
Because serotonin is known to be stimulatory to PRL secretion 
several serotonin blocking agents have been used for treatment of 
patients with (micro)prolactinomas. Cyproheptadine and methysergide 
are relatively ineffective in lowering PRL levels, especially in 
long-term therapy and in patients with very high PRL levels (D'Agata 
et al 1977, Crosignani et al 1978, Ferrari et al 1976 and 1978, 
Wortsman et al 1979). However, metergoline, an antiserotoninergic drug 
but with dopaminergic properties (Chiodini et al 1976), appeared to be 
effective in restoring menses and PRL levels to normal in about 
one-third of the women treated (review Molitch 1980). 
In Cushing's disease and Nelson's syndrome cyproheptadine has been 
reported to decrease· ACTH secretion (Krieger et al 1975 and 1976, 
Cassar et al 1976). In ectopic ACTH secretion cyproheptadine may also 
be effective. Krieger reported successful responses in about 60 % of 
80 patients with Cushing's disease (1979). Relapses occur in all 
patients .when treatment is discontinued. 
The drug ~2£~:~~~ (by selective destruction of the zona fasciculata 
and zona reticularis of the adrenal cortex (Lubitz et al 1973)) and 
~~!~~g!~!£!~!~!~~ or ~£!l!~£~~£ (by blocking the production of cor-
tisol) are effective in Cushing's disease (Child et al 1976, Molitch 
1980). Recently, also treatment with high dose ~~t~£~~~~ol~ appeared 
effective (Loli et al 1986). However, they will not induce definitive 
cure in the patients. 
~l!!~~~!~£ (vit B6), a cofactor in the biosynthesis of dopamine, was 
in 1976 reported to be effective in women with the galactorrhoea-
amenorrhoea syndrome (Mcintosch). However, Tolis et al (1977) found no 
effect of pyridoxine on normal PRL as well as GH secretion and an 
absence of therapeutic effects in the galactorrhoea-amenorrhoea 
syndrome. 
Up to now EE~~~iE~E~I~-~~Ei2!2 have turned out to be the ~ost effec-
tive drugs in patients with pituitary tumours, especially in patients 
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with prolactinomas. In 1954 Shelesnyak noted that certain ergot 
alkaloids suppress prolactin secretion in rats (Thorner 1980b). Later 
on Zeilmaker and Carlsen (1962) showed that one of these drugs, 
ergocornine, acts directly at the pituitary. In the early 1960's a 
systematic pharmacolog~cal study of ergot alkaloids and ergot 
derivatives started with the goal to find an orally effective drug 
which could specifically inhibit prolactin secretion. These studies 
were carried out with the aid of bioassays of prolactin and measure-
ment of clinical effects as galactorrhoea. The development of 2 - Br -
Alpha - ergocryptine mesylate (CB-154, bromocriptine, Parlodel R) by 
Fllickiger and Wagner in 1965 appeared in the 1970's to be a fundamen-
tal improvement of the medical treatment of pituitary tumours. In 1967 
the drug was selected for further development as a therapeutic agent 
(Fllickiger and Wagener 1968). At that time the mode of action was not 
known while interest in the role of dopamine in the regulation of 
prolactin secretion was growing rapidly (van Maanen and Smelik 1968; 
Fuxe et al 1970, Kordon 1971, Macleod and Lehmeyer 1973 and 1974, 
MacLeod et al .1984, Macleod and Lamberts 1986). After the 
identification (Frantz and Kleinberg 1970), isolation and purification 
(Guyda et al 1971) of prolactin and the development of a 
radioimmunoassay for this hormone (Hwang et al 1971), it appeared that 
the catecholamine dopamine is the most important physiological factor 
in the inhibition and regulation of prolactin release. There is 
abundant evidence that dopamine is identical or at least one of the 
previously proposed hypothalamic Prolactin Inhibiting Factors (PIF) 
.(van Maanen and Smelik 1968; Schally et al 1976). Dopamine acts 
directly on the pituitary as proved in vitro (MacLeod and Lehmeyer 
1973). In addition to this observation dopamine receptors have been 
found on lactotroph cells in the pituitary (Calabro and Macleod 1978, 
Caron et al 1978, Cronin et al 1978, 1979 and 1980). 
Bromocriptine was shown to act by stimulating dopamine receptors 
(Corrodi et al 1973, Fux et al 1974). Dopamine receptors have been 
demonstrated in PRL, GH and ACTH secreting pituitary tumours (Cronin 
et al 1980). Following animal pharmacologic experiments (Fllickiger and 
Wagner 1968; Billeter and Fllickiger 1971) Lutterbeck et al (1971) 
showed that bromocriptine therapy can be used in the treatment of 
36 
galactorrhoea. The drug decreased plasma PRL concentrations in normal 
persons (Del Pozo et al 1972) and proved to be successful in restoring 
menstruation and fertility in hyperprolactinemic patients with an 
amenorrhoea-galactorrhoea syndrome (Besser et al 1972, Del Pozo et al 
1974, Rolland et al 1974), which syndrome often appeared to be caused 
by a prolactin secreting (micro)adenoma (Vezina and Sutton 1974). 
Ovulation returned during bromocriptine therapy in about 85% of the 
patients within 10 months (Thorner et al 1980b), unless the reserve of 
the gonadotrophin secretion is disturbed (Lamberts et al 1978a and b). 
On the basis of 805 pregnancies documented by Sandoz (Thorner et al 
1980~) and 1410 pregnancies reported by Turkalj et al (1982) there is 
no evidence that bromocriptine used until establishment of pregnancy 
is associated with an increased incidence of multiple births, fetal 
abnormalities, or increased abortion rates (Thorner et al 1980b, 
Griffith et al 1978, Rolland 1980, de Wit et al 1985, Weil 1986). 
Confirming earlier animal work (Quadri et al 1972) Corenblum et al 
(1975) and other authors reported reduction in the size of 
prolactinomas (Corenblum 1978, McGregor et al 1979, Wass et al 1979, 
Thorner et al 1980a and b). This has been demonstrated by radiological 
and ophthalmological methods. This effect may become manifest within 
days to weeks after the start of bromocriptine treatment. Reviewing a 
great number of series Molitch (1980) reported that bromocriptine was 
successful in normalizing serum PRL levels in 80-90% of the patients 
with cessation of galactorrhoea in over 90% and restoration of normal 
menstrual pattern in 80.,..90%. In addition, I would like to refer to 
Chapter II, section 3.c.3. 
In 1972 Liuzzi et al demonstrated that L-dopa which stimulates GH 
secretion in normal individuals has an paradoxical inhibitory effect 
on GH secretion in acromegaly. In 1974 he also reported an acute 
inhibitory effect of bromocriptine on GH levels in some acromegalies 
(1974a and b). This effect was more prolonged than that after L-dopa. 
Since then many investigators have reported fairly good results of 
long-term treatment of acromegaly with bromocriptine. Reviews of these 
studies (Goldfine and Vigneri 1979, Soman 1979, Molitch 1980, Vance et 
al 1984) show that bromocriptine causes a significant fall in GH 
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levels in about 70-75% of the acromegalic patients. However, a 
decrease to normal GH levels, less than 5 ng/ml, is achieved in only 
20% of the patients (Wass et al 1977, Vance et al 1984). Liuzzi et al 
(1974a) as well as our group (Lamberts et al 1979a, 1982a, 1983, 
Chapter VII) showed that bromocriptine was more effective in 
acromegalic patients with increased PRL levels and high responses of 
GH to TRH. In contrast to the report of Wass et al (1979) concerning 
reduction of tumour and sellar size by long-term treatment with 
bromocriptine in acromegalies, Lindholm et al (1981) reported no 
effect even on GH levels of bromocriptine in a double-blind study. 
After the reports of the lowering of PRL and GH level in patients 
with prolactinomas and acromegaly by bromocriptine, Lamberts and 
Birkenhager (1976; Lamberts et al 1980a, c and e) and Benker et al 
(1976) showed that bromocriptine also reduces ACTH and cortisol levels 
in some patients with Cushing's disease or Nelson's syndrome by a 
direct effect on the ACTH-secreting pituitary adenoma (Lamberts et al 
1980a,c and e). Later, it became clear that bromocriptine reduced ACTH 
and cortisol level_s, especially in patients with ACTH-secreting 
tumours originating from the intermediate pituitary lobe (Lamberts et 
al 1982c, Lamberts 1984a). However, especially in the practical 
management of Cushing's disease medical treatment should be regarded 
as a temporary adjunct to more definite treatment. 
~!1:=~~~~!:~g~!!~ as tamoxifen appear to enhance the sensitivity of 
prolactin secreting pituitary tumour cells to dopamine and 
bromocriptine (Lamberts et al 1980b). The use of the combined 
treatment with bromocriptine and tamoxifen may prove to be more 
effective than treatment with bromocriptine alone in some patients 
with PRL-secreting pituitary tumours (Lamberts et al 1982b, Volker et 
al 1982). 
~~~~~~~~~~!!! is a hypothalamic hormone acting at the level of the 
pituitary. It is capable of inhibiting the release of basal and 
stimulated GH secretion in healthy people and in patients with 
acromegaly (Brazeau et al 1973, Hall et al 1973, Besser et al 1974a 
and b, Yen et al 1974). This type of treatment with the natural 
hormone is not useful because of the short biological half-life, the 
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need of continuous parenteral administration, and the effect on the 
secretion of other hormones as insulin, glucagon, gastrin, renin, GIP 
and VIP and the postinfusion rebound hypersecretion (Guillemin and 
Gerich 1976; Reichlin 1983). After synthesis of the somatostatin 
analogues with a longer half-life (Sarantakis et al 1976, Grant et al 
1976), it was not before 1983 that the first clinical trials have 
started. 
Recently a long-acting somatostatin analogue (SMS 201-995, 
Sandoz)was shown to exert a profound inhibitory effect on GH release 
in most acromegalic patients without a rebound hypersecretion 
(Lamberts et al 1985b and c, Ch'ng et al 1985). Preliminary studies 
show that chronic treatment of acromegalic patients with SMS 201-995 
results in (near) normalization of plasma GH and somatomedin-C levels, 
disappearance of the clinical symptoms and shrinkage of the pituitary 
tumours in many acromegalies (Lamberts et al 1985b and c and 1986a). 
For additional data see Chapter II, 3.b.3.b •• 
D. REFERENCES 
The references of this chapter are cited together with those of 
chapter II. 
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CHAPTER II 
OWN RESULTS AND RECENT LITERATURE DATA 
A. AIMS OF THE STUDY 
In order to make a well-founded choice between the therapeutic 
modalities presently available it is important to have a clear picture 
of the differences in the natural history of the various types of 
pituitary tumours. One of the most important questions regards 
possible differences in the tendency of the various tumours to grow 
extrasellarly. A related question concerns the relationship between 
the secretion rate of growth hormone, prolactin etc. and the size of 
the respective tumour. In other words: do high serum levels of these 
hormones in general indicate the presence of a large tumour and do 
moderately increased levels point to a smaller tumour? 
A parallel and for the management sometimes crucial question is a 
possible relationship between tumour growth rate and the age of the 
patient. Furthermore, one can ask what - in a therapeutic sense - may 
be the significance of a combined secretion of growth hormone and 
prolactin by a pituitary tumour. 
The therapeutic part of our study concerns the efficacy and the 
rapidity, with which the desired therapeutic endpoint may be reached 
by means of (transsphenoidal) surgery, irradiation or the combination 
of these treatments in the various types of pituitary tumours. 
Furthermore, we have considered the value of medical treatment as an 
additional or - possibly - as primary therapy. 
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B. PATIENTS, METHODS AND MATERIALS. 
1. Patients 
During the time period of this study (1980 - 1985) the records of 
357 patients, investigated and treated since 1950 in the University 
Hospital "Dijkzigt" and in the Dr. Daniel den Hoed Cancer Center/ 
Rotterdam Radio-Therapeutic Institute for intrasellar and suprasellar 
tumours were reviewed. The diagnostic and therapeutic results of 
specific studi~s in subgroups of patient• have been reported in 
different publications. For the description of the patients the reader 
is referred to chapters III-VIII. 
2. Methods and Materials 
For radiological and ophthalmological examinations, and endocrine 
investigations we refer to chapter III. With a few exceptions, in all 
patients operated upon for an intrasellar tumour neurological and 
ophthalmological examination, plain sellar radiography, sellar 
tomography (sagittally and in part also frontally), pneumencephalo-
graphy (PEG) and/or computertomography (CT), and/or bilateral carotid 
angiography have been performed preoperatively. When preoperatively a 
patient was examined in our own department a standard endocrine 
investigation was carried out, whenever possible, comprising 
estimation of basal plasma hormone levels (PRL,GH,TSH,LH,FSH,ACTH in 
Cushing disease, thyroid hormones, cortisol, testosterone or 
oestradiol-17betha) as well as stimulation tests (TRH-test, LHRH-test, 
metyrapone test). In acromegalic patients also a glucose tolerance 
test (G.T.T.) was performed. In some patients the response of GH and 
PRL to bromocriptin has been evaluated. In a few patients an insulin 
tolerance test and/or lysine-vasopressine test (later on replaced by 
the CRF-test) was carried out also. About 2-3 weeks postoperatively 
and with variable intervals after the subsequent external pituitary 
irradiation these endocrine investigations were repeated. 
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3. Measures and Procedures 
3.a. Prae- and Postoperative Measures 
A preoperative check-up was carried out by the ENT-specialist, who 
would perform the first part of the operation. This included nasal 
swab cultures. All patients received prophylactic ampicilline 
treatment. Peroperatively a corticosteroid cover was used in all 
patients. Patients operated upon subfrontally received over the day of 
operation 4 x 4 mgr. dexamethasone and patients operated upon 
transsphenoidally 4 x 100 mgr. hydrocortisone. In 7-10 days these 
corticosteroid dosages were diminished to a substitution level in the 
department of neurosurgery and terminated after transfer of the 
patients to the endocrine department. At least 4 days after 
terminating corticosteroid administration the stimulation tests were 
carried out on subsequent days in the following order: LHRH-, TRH-, 
metyrapone and glucose tolerance test. 
3.b. Operative Procedure (transsphenoidal adenomectomy) 
After an incision under the upper lip the nasal septum is uncovered 
and - after preparing off the mucosal membranes - largely removed and 
kept. A tunnel is made up to anterior wall of the sphenoid sinus. Here 
the neurosurgeon takes over, opens the sinus, removes the mucosal 
membrane and opens the sella with radiological monitoring by means of 
an image-intensifyer and using the operation microscope (magnification 
lOx). After coagulation the intrasellar dura is opened and the 
pathological content of the sella is removed. The sellar diaphragm is 
seen to descend. To prevent liquorrhoea, that may ensue when the 
diaphragma has been cut, the sella is filled with muscle tissue taken 
from the right thigh at the onset of the operation. Subsequently the 
sella is closed with muscle tissue that has been dipped in biological 
acryl-glue, that hardens after having been put in place. The 
ENT-specialist puts back the nasal septum and places tampons. 
Morbidity is usually small and the patient is mobilized within 24 
hours. 
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3.c. Radiotherapeutic Procedure 
The radiotherapeutic procedure is described in chapter VIII. 
During the period of irradiation cortisone substitution therapy was 
reinstituted until the results of the metyrapone test were known 
(after the end of the irradiation). 
C. RESULTS AND DISCUSSION 
1. Epidemiological and Clinical Features 
1.a. Prolactinomas 
The prolactinoma is probably the most collllllon kind of pituitary 
tumour (Kovacs et al 1984, von Werder 1984, Landolt 1985a). The 
reported percentage of prolactinomas in groups of patierits with 
pituitary tumours varies and is probably dependent on the referral 
patterns in the different centres. Epidemiologic studies have shown an 
increased incidence (more than twice) of pituitary adenomas in the 
last 10-15 years compared to prior decades, which increase may be 
partly due to a better detection of the adenomas and maybe partly due 
by the use of oral contraceptives (Peillon et al 1984, Molitch 1986). 
A population study performed by the Mayo Clinic . found a mean annual 
incidence of diagnosis of pituitary tumours of 8.2 per 100.000 women 
aged 15 or greater (Molitch 1986). This figure is only about 0.1% of 
the actual frequency of tumours known from autopsy studies. 
Subclinical microadenomas have been discovered in 1.5-26.7 % of 12 
autopsy series, 40-50 % of them being prolactinomas (Burrow et al 
1981, Peillon et al 1984, Molitch 1986). 
Two types of prolactinomas with different symptomatology can be 
distinguished clinically: microprolactinomas and macroprolactinomas 
(von Werder 1984). They have different sex distributions, presenting 
symptoms and natural histories. Microprolactinomas are mainly detected 
in premenopausal woman and rarely in men (Fig. 1, Chapters III and IV, 
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Klijn et al 1980a and b, 1980, Nabarro 1982). Macroprolactinomas occur 
at all ages with a small preponderance in men namely about 60% (Klijn 
et al 1980, Nabarro 1982). In patients with microprolactinomas most 
symptoms are caused by hyperprolactinaemia per se (menstrual 
disorders, infertility, galactorrhoea, hypoestrogenism and sexual 
disfunction), while in patients with large tumours symptoms caused by 
local tumour extension (neurological and visual disturbances, 
hypopituitarism) are more predominant. With respect to the natural 
history microadenomas have on the average a slower growth rate while 
macroprolactinomas develop faster and are often invasive (von Werder 
1984, Landolt 1984a). The frequency of capillaries in· macroadenomas 
has been found to be decreased, but macroadenomas appear to be more 
sensitive than microadenomas to dopamine and bromocriptine both in 
vivo and in vitro (see review of Molitch 1986). 
For detailed description of symptomatology I refer to articles of 
Biller et al (1980), Nabarro (1982) and Molitch (1986). Vetter et al 
(1974) found galactorrhoea in only 0,9% of nearly 5600 women examined, 
while in a study of Jones and Gentile (1975) concerning 800 women 
galactorrhoea occurred in 3,6% and 1% of women •ithout and with 
ovulations, respectively. In other studies, however, galactorrhoea was 
observed in up to 46% of the examined women (Molitch 1986). Such 
variability might be caused by differences in breast examination 
technique, definition of galactorrhoea and selection of the examined 
population. The likelihood of detecting a pituitary adenoma in 
patients with galactorrhoea lies between 15-48% and rises to 34-59% 
when galactorrhoea is accompanied by amenorrhoea (Biller et al 1980). 
When amenorrhoea occurs alone, in the average 15% of the patients 
(range 2-26%) may have hyperprolactinaemia which occurs in even 30% of 
patients with menstrual dysfunction (Biller et al 1980, Molitch 1986). 
In patients with amenorrhoea for longer than 6 months detectable 
pituitary adenomas are found in 9-34% of the cases. When galactorrhoea 
occurs alone, hyperprolactinaemia has been found in 28% (range 0-60 %) 
of the patients (Molitch 1986). In combined series totaling 471 
patients with both amenorrhoea and galactorrhoea, even 75 % were found 
to have hyperprolactinaemia (Molitch 1986). In most of these series, 
radiological evidence of tumour was apparent in about 50 % of the 
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patients. Absence of galactorrhoea does not exclude a prolactinoma. In 
patients with a pathological sella and hyperprolactinaemia 
galactorrhoea occurs in 28-56% of the patients with a higher incidence 
in young women with microprolactinomas (Chapter III, Klijn et al 
1980a, Nabarro 1982) than in men or older women. In 70-90% of female 
patients with suspected prolactinomas menstrual disorders occur. The 
likelihood of the presence of a pituitary tumour increases with the 
duration of amenorrhoea and/or galactorroea (Biller et al 1980). In 
contrast to what is found in acromegaly (Chapter IV, Klijn et al 
1980b) the age at diagnosis of a prolactinoma has no relationship to 
the duration of symptoms (Nabarro 1982). In our study (Chapter III) 
the mean duration of the galactorrhoe for the female patients was 4.25 
years (for the male patients 6.5 years) and of the menstrual disorders 
8 years. Headache is reported in (more than) half of patients with 
(micro)prolactinomas. In 469 women with secondary amenorrhoea and/or 
galactorrhoea Strebel et al (1986) found that headaches were four 
times more frequent in the presence of an adenoma than in its absence, 
suggesting that the space-occupying mass effect of a prolactinoma is 
responsible for headache. Weight increase (up to 40% of the patients) 
and hirsutism are observed in a minority of the patients. 
In men with prolactinomas decreased libido and impotence are the 
most frequent symptoms besides local signs of tumour growth; 
galactorrhoea is found in 5-30 % (Chapter III, Klijn et al 1980a, Muhr 
et al 1985, Hulting et al 1985a, Weber et al 1985) in contrast to 
about 75% in female patients. Hyperprolactinaemia seems to be a minor 
cause of reproductive dysfunctions in men. The incidence of 
hyperprolactinaemia among 598 infertile men in our clinic was 2% 
(Weber et al 1985). 
l.b. Acromegaly 
Acromegaly is in nearly all cases caused by a GH secreting 
pituitary tumour. Only a few cases are reported with ectopic GRF 
secretion (Thorner et al 1982, Asa et al 1984, Spero and White 1985). 
The annual incidence is three cases per million in the Newcastle 
region in England and the prevalence of diagnosed cases up to 40 per 
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million (Alexander et al 1980). These numbers are comparable with the 
estimated incidence in our own region of the South-West part of the 
Netherlands. Davidoff (1926) found a family history in 4 of 100 cases 
(1 sister, 1 father, 1 uncle, 1 aunt). In our series of 117 patients 
acromegaly affecting a near relative occurred in 2 families (father 
and son; brother and sister). 
The symptoms of acromegaly may be divided in those which result 
from local effects of the pituitary tumour itself (destruction and 
displacement of surrounding tissues) and those that results of 
excessive GH secretion. The clinical effects of excessive GH are 
numerous and are dominating the clinical picture. In fact, all systems 
and organs are more or less involved in the disease causing a broad 
spectrum of symptomatology as indicated in Table 1 of Chapter IV. 
The clinical features and mode of presentations in our patients are 
generally in agreement with those in the literature. More detailed 
data of the clinical symptoms and pathology have been described in 
some reviews and more specific reports (Davidoff 1926, Cushing and 
Davidoff 1927, Atkinson 1932, Davis 1941, Kellgren et al 1952, 
Mastaglia et al 1970, Hirsch et al 1969, van der Zwan 1971, Daughaday 
1974, Wass et al 1982, Quabbe 1984, Dinn and Dinn 1985); for 
epidemiology and mortality studies see the reports of Alexander et al 
(1980) and Wright et al (1970). 
Our findings (Chapter IV) showed a few conspicuous differences with 
the early description by Davidoff (1926). In his series of 100 
patients 62% of the patients had visual disturbances in contrast to 
14% in our experience. Also headache was more frequent (87 vs 52%). 
This might be caused by an earlier detection at the present time· or 
selection by differences in referral pattern to a surgical clinic on 
the one hand and to an endocrine clinic on the other hand. The mean 
delay between start of symptoms and time of diagnosis was 13 years in 
Davidoff's series and 6.5 years in our series. On the other hand the 
mean age at diagnosis appeared the same in both series (40 years). In 
addition, van der Zwan (1971) reported a mean delay of 8.4 years in a 
group of 89 acromegalic patients with roughly the same age 
distribution as in our series. The average age at diagnosis in 
Davidoff's series was lower in men (33 years) than in women (45 years) 
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in contrast to our findings. While in our material there is no 
selection in the direction of visual disturbance as a presenting 
symptom, the fact that the delay in diagnosis in men is twice as long 
as in women may be reconciled with Davidoff's data: in our material 
the men probably developed symptoms of acromegaly at an earlier age 
than the women. 
Furthermore we observed arthropathy and back pain in 30 and 20% of 
the patients respectively while Davidoff and Cushing did not mention 
joint disease in their review (1926). A few years later Atkinson 
(1932) in his review of 1.319 cases reported the occurrence of joint 
pain in half of the patients. In our series a remarkable high 
frequency of inguinal hernia has been observed in the male patients 
(30%). This may be caused by chronic pulmonary disease and/or an 
inferior quality of soft tissue and/or a wide inguinal canal. 
Most striking in our series is the negative relationship between 
tumour size and age on the one hand and a relatively short period 
intervening between onset of symptoms and the time of diagnosis on the 
other hand in the younger patients (Chapter IV). We concluded that in 
general the growth rate in the tumours which develop earlier in life 
is greater than in the others. Therefore these patients need to be 
treated rather agressively. Another reason for aiming at reaching 
normal GH levels is the relatively high contribution of 
cardiovascular, pulmonary, and malignant disease to the overall 
mortality, which is twice as high as expected in a normal population 
(Wright et al 1970; Chapter VIII). 
2. Diagnosis of Pituitary Gland Tumours 
2.a. Radiological and Ophthalmological Evaluation 
The sella turcica can be pathological by abnormalities in form, 
size and bone density. Abnormal calcifications in and around the sella 
may indicate pathology, too. A diagnostic problem is the observation 
of a rather great variation in the configuration and size of the 
normal sella turcica (Di Chiro 1960). On the one hand small 
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differences or alterations in relation to the "average" sella will 
sometimes not be recognized as pathological or wrongly labeled as 
pathological. On the other hand a microadenoma of less than 5 mm can 
be present in the pituitary gland without visible abnormalities of the 
sella turcica (Vezina and Sutton 1974). Although high-resolution 
computer tomography can detect such small tumours in some patients, 
the endocrine evaluation is of great importance in this situation. 
Microadenomas of s·-10 mm generally cause local alterations or 
asymmetry (of the front wall, the floor or dorsum) without enlargement 
of the sella. These local alterations frequently exist of thinning of 
the lamina dura and local bulging in the sphenoid sinus or deepening 
into the clivus. Adenomas larger than 1 em (macroadenomas) always 
cause sellar enlargement. The form _of the sella is dependent on the 
development of pre-and postsphenoid, planum sphenoidale, clivus and 
some ligaments. 
During the growth the sella turcica increases gradually in size 
until the age of 18-20 years (Silverman 1957, Underwood et al 1976). 
Some authors have reported an increase in sellar size during the whole 
life period (Finby and Kraft 1972). This could be caused by a higher 
incidence of hyperplasia and "physiological" formation of adenomas at 
higher age. Costello (1936) and Mosca (1975) observed one or more 
microadenomas in respectively 22.5 and 20% of routine autopsies, 
especially above the age of 50 years. These observations are in 
contrast to other series with a lower incidence (see review Molitch 
1986). On the average over 9.637 autopsies in 12 studies the incidence 
of microadenomas was 10.8 %. 
In a study of our own (shortly referred to in chapter III ) 100 
consecutive neurological patients have been reviewed with respect to 
form and size of the sella turcica. We did not find a relationship 
between age and sellar size (Fig. 2). However, in older age groups the 
variation in size appeared to be greater than in the younger ones. In 
this control group of 100 patients without evidence of pituitary 
pathology length, height and width of the sella varied between 10-15 
mm, 7-12 mm and 11-20 mm respectively. Camp (1923) found maximal 
values of 16 and 12 mm for length and height respectively. The 95% 
range of the normal lateral sellar area in our study was between 70 
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and 140 mm2• Hare et al (1949) observed a maximal normal sellar area 
of 130 2 mm • The volume of the sella turcica can be calculated 
according to the formula (~ x length x height x width) of Di Chiro and 
Nelson (1962). In 17 out of our 100 "control" patients the sellar 
floor was not visible on plain frontal radiographs. In the other 83 
individuals there was a good correlation (r= +0.69, p < 0.0005) 
between the results of our area measurement and those of the volume 
calculation (Fig. 3). We found a normal range of sellar volume of 
454-1305 mm3 • The pituitary occupies about 70-80% of the sellar 
content. As Fischer and Di Chiro (1964) demonstrated in normal people 
a small lateral sellar area does not always indicate a small pituitary 
or sellar volume, but can be accompanied by a large width (and vice 
versa). This is in agreement with the absence of a correlation between 
sellar area and width (n= 83, r= -0.179) in our control group (Fig. 
4). Seki ( 1965) even observed a tendency to a negative correlation 
between these 2 parameters in 500 normal adults. However, in 36 
patients with an enlarged sella and hyperprolactinaemia (Fig. 5, 
r= +0.63, p < 0.-0005: chapter III) and in 36 acromegalicpatients 
(r= +0.62, p < 0.0005) we found a significant positive correlation 
between (log) area and (log) sellar width • Furthermore, we found a 
stronger correlation between (log) area and (log) volume in the 
patients with a pituitary tumour (Fig. 6, both groups with r= +0.96, p 
< 0.0005) than in the control group (Fig. 3). Therefore, the lateral 
area of the sella turcica, when necessary complemented with that of 
extrasellar tumour tissue (Table 3), is a good practical parameter of 
pituitary tumour size. A sella with a length larger than 15 mm and/or 
a height larger than 12 mm and/or a width larger than 20 mm, an area 
larger than 140 mm2 or a volume larger than 1300 mm3 has to be 
considered as pathological. In fact a sellar enlargement is a late 
symptom because· in case of a hypersecreting pituitary tumour the 
clinical picture has already developed. Other causes of sellar 
enlargement than pituitary tumours could be extrasellar tumours 
(craniopharyngeomas·, meningiomas, gliomas, neurinomas, chordomas, 
ependymomas, fibrous dysplasia, chondromas, metastases), granulomas, 
aneurysms, primary hypothyroidism, sphenoid mucocele, increased 
intracranial pressure, etc. 
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Fig. 4 
Fig. 5 
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Table 3. Incidence of normal and pathological configuration of 
the sella turcica in relation to mean tumour size in 62 
patients with hyperprolactinaemia and a pituitary 
tumour. 
Radiological examination 
percentage x tur:nor size 
- Normal sella 6% 1.1 em 2 
-Asymmetrical sella 19% 1.2 em 2 
- Enla~ged without extra- 31% 2.3 em 2 
sellar extension 
- Extrasellar extension 44% 7.3 em 2 
100% 
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A sella turcica with a normal size may have an abnormal 
configuration. An asymmetrical sella frequent~y, but not always, 
indicates pathology. In that way Swanson and du Boulay (1975) found a 
thinning of the lamina dura in 16.5% and an asymmetrical sella in 
31.7% of 85 normal indivuals. In our own study we observed an 
"asymmetrical" sella on the lateral X-ray in 19% of 100 controls, but 
after detailed investigation this appeared to be explained by 
overprojection of somewhat oblique X-ray or overprojection of lateral 
structures. Therefore plain frontal radiographs are necessary for 
judgment of possible asymmetry of the sellar floor. However, in 17% of 
our control group the floor was not visible. 
2.b. Endocrine Diagnosis 
After the introduction of radioimmunoassays for estimation of an 
increasing number of hormones the possibilities for endocrine 
evaluation of pituitary function are clearly ameloriated by means of 
measurement of basal plasma concentrations of different· hormones and 
by the development of stimulation and inhibition tests. These 
endocrine function tests are focussed on hormonal hypersecretion and 
pituitary insufficiency. 
2.b.l. Basal hormone concentrations and dynamic tests for 
hypersecretion. 
In untreated patients with hyperprolactinaemia and a pituitary 
tumour we found a positive correlation between basal plasma PRL 
concentrations and both sellar or tumour area (Chapter III) and volume 
(Fig. 7A). In patients with acromegaly we also observed a positive 
correlation between basal plasma GH levels and both tumour area 
(Chapter IV) and volume (Fig. 7B). These results are confirmed by 
different other studies (Hardy 1983, Bertrand et al 1983, Fahlbusch et 
al 1984, Landolt 1984a). However there are only a few reports about 
the relationship between age, tumour size and basal plasma hormone 
concentrations (Landolt 1984a). We were the first to show a negative 
correlation between tumour size and age in patients with acromegaly 
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(chapter IV). In patients with prolactinomas we did not observe such a 
relationship (Chapter IV). In patients with prolactinomas Landolt 
(1984a) found a comparable scatter diagram for age in relation to 
tumour size as in our study. 
Dynamic tests for PRL and GH hypersecretion are described in 
various reviewing articles (Archer 1977, Christy 1979, Jackson 1980b, 
Guillemin 1983, Assies 1984, ·Davis and Hipkin 1984, Ho et al 1985, 
Faglia et al 1985, Holl et al 1985). 
2.b.1.a. Hyperprolactinaemia and prolactinomas 
~IE~!E!~!~~.~!~~~~.!~~ can occur in different physiological and 
pathological conditions (Thorner 1977, Lamberts et al 1978, Ho et al 
1985); for instance associated with prolactinomas, suprasellar 
tumours, hypothalamo:-pi tui tary non-tumoural disease, various 
medications, thyroidal dysfunction, pregnancy and lactation, chronic 
renal failure etc. For differential diagnostic purposes the TRH-test 
is most commonly used wether or not in combination with other 
stimulation tests such as chlorpromazine and metoclopramide. In our 
patients with a prolactinoma, in whom a TRH-test was carried out, we 
found no relationship between basal PRL level and ~PRL expressed in 
nanograms per milliliter, but there appeared a negative correlation 
between the basal PRL level and I:J. PRL as a percentage (chapter V, 
Klijn et al 1981)). No correlation was found between ~PRL and tumour 
size, ~ TSH, T4, T3 or age. 
The clinical value of the TRH-test with respect to the possibility 
to distinguish prolactinomas from other causes of hyperprolactinaemia 
is still controversial (Chapter V, Klijn et al 1979 and 1981, Barbieri 
et al 1985). In a survey of the literature concerning 548 patients 
with a prolactinoma (reported in 35 studies) we found a blunted PRL 
response to TRH (increase < 100%) in 89% of the patients. Later on 
Barbieri et al found a somewhat higher incidence of an abnormal 
response to TRH (96%) in 167 patients with the clinical diagnosis 
prolactinoma, but no significant difference in the incidence in the 
patients with surgically documented prolactinomas (95% versus 91% in 
our report). The peak value and the range of the PRL response to TRH 
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in the control group in Barbieri's study was nearly the same as in our 
control group. The only difference found concerned the time of the 
peak value after the TRH injection: in Barbieri's study 49% of the 
individuals had a maximal PRL response at 10 minutes in contrast to 
only 7 (24%) of 29 control subjects in our study. The somewhat higher 
incidence of a blunted PRL response to TRH in prolactinoma patients in 
Barbieri's study may be explained by a) a difference in referral 
pattern (selectively to the neurosurgical department in Barbieri's 
centre in contrast to more varied disciplines in our study), b) lack 
of uniform guidelines for the diagnosis of prolactinoma, c) 
differences in sampling times. As we found no difference in effect 
between 200 and 400 1ug TRH (chapter V) the influence of the use of a 
different dose seems less important. 
In agreement with our study Barbieri et al (1985) reported about 
50% occurrence of a blunted PRL response to TRH in patients with 
hypothalamic or other pituitary disease. Furthermore, they observed 
blunted responses in half of the patients using dopamine antagonistic 
drugs and in a substantial proportion of patients with 
hyperthyroidism, while patients with hypothyroidism showed a normal or 
exaggerated response. On the basis of the two large studies of 
Barbieri et al. and of our group and of a number of other studies we 
conclude that the TRH-test may discriminate well between normal 
subjects and patients with prolactinoma, but in the differential 
diagnosis of hyperprolactinaemia it is of less value. Furthermore in 
patients with basal PRL levels of more than 500 1ug/l a TRH test is 
not strictly necessary because such high values are only observed in 
patients with prolactinomas and in a few patients with acromegaly. 
!'!E1-2.£-E1-EE~22 show a wide spectrum of insufficient responses to 
inhibition with dopamine. On the average twice as much dopamine 
appears to be necessary to decrease PRL secretion in 
hyperprolactinaemic states in comparison to control subjects (Bansal 
et al 1981, Assies 1984). The observed hyposensitivity may be the 
result of decreased dopamine binding to prolactinoma tissue and/or 
defective biological events after binding of dopamine to the cell 
membrane (Macleod et al 1984, Faglia et al 1985). Such biochemical 
defects in the pituitary may be a cause of prolactinoma development. 
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Fig. 8 
Fig. 9 
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0 1 2 3 4 5 6 7 8 9 10 11 12 24 hours 
The effect of the administration of one dose of 2.5 mg 
bromocriptine on percentual decrease of plasma prolactin 
concentrations in 14 patients with a prolactinoma (values in 
mean:!:_ SEM). 
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The relationship between (log) tumour size (cm2) and (log) 
basal plasma concentrations of TSH in 42 patients with 
hyperprolactinaemia and a pituitary tumour (r = 0.32, p < 
0.025; • =I?. 0 = c!).· 
In most of the applied dynamic tests drugs are used which interfere 
with dopamine synthesis, release, metabolism, reuptake or receptor 
binding (Assies 1984). For suppression tests various direct and 
indirect dopamine agonists are used. In our experience one dose of 
bromocriptine caused a mean maximal decrease 'to 15% of the 
pretreatment value 7 hours after administration to patients with a 
prolactinoma (Fig. 8), but a great variability in sensitivity of the 
lactotroph cell to bromocriptine and to endogenous dopamine has been 
described (Thorner et al 1980c, Ho et al 1985, Macleod and Lamberts 
1986). More recently, the use of nomifensine, an agent which inhibits 
the re-uptake of dopamine in the central nervous system, appeared also 
not to be fully discriminative between physiological and pathological 
hyperprolactinaemic states (Ho et al 1985). Therefore the basal plasma 
PRL level appeared to be the best predictor of the presence of a 
prolactinoma, while in patients with only slight or moderate 
hyperprolactinaemia ( <300 1ug/l) a subnormal or absent response to 
either stimulatory or inhibitory agents is indicative for a 
pathological condition with the possibility of the presence of a, 
microprolactinoma. 
2.b.1.b. Acromegaly. 
For the assessment of GH secretion a number of test are described 
(Ho et al 1985). Besides measurement of basal plasma GH levels some 
physiological (sleep, exercise) and pharmacological stimulation tests 
(L-dopa, arginine, insulin-induced hypoglycaemia, propranolol, 
clonidine) are applied, to which recently the GRF-test has been added. 
Furthermore, plasma GRF measurements may be helpful in diagnosing 
ectopic GRF producing tumours as a rare cause of acromegaly (Thorner 
et. al 1984). Measurement of somatomedin C (SM-C) may be useful in 
patients with acromegaly, because of a possibly better correlation of 
the elevated SM-C levels with the clinical activity of acromegaly than 
the GH levels generally show (see reviews of Vance et al 1984 and 
Nortier and Croughs 1985c). However, increased SM-C concentrations are 
found in some physiological conditions (puberty, pregnancy) and in 
patients with acromegaloidism. 
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Since the observation in 1963 of Roth et al that glucose 
administration caused no or a subnormal suppression of plasma GH in 
acromegaly the oral glucose tolerance tests (OGTT) is commonly used as 
an inhibition test in patients with increased basal plasma GH levels. 
Even a paradoxical rise of plasma GH occurs in 20% of acromegalic 
patients (Ho et al 1985). However, an abnormal GH response to glucose 
cannot be taken as diagnostic because abnormal GH responses may occur 
in adolescents (Pieters et al 1980)and in some pathological conditions 
(anorexia nervosa, chronic renal failure, liver cirrhosis, Wilson's 
disease, acute intermittent porphyria, thyrotoxicosis). In acromegalic 
patients treated with dopamine agonists the interval between the last 
dose of the drug and the performance of an OGTT may be critical 
(Nortier and Croughs 1985c). 
The most common cause of acromegaly is a GH secreting pituitary 
tumour. There is still considerable controversy as to whether these 
tumours arise by hypothalamic dysfunction or primary pituitary 
abnormalities (Ho et al 1985). The finding of an abnormal GH response 
to TRH and sometimes LHRH also suggests a pathological function of the 
tumour somatotrophic cells. However, there is recent in vivo and in 
vitro evidence that GRF may permit or facilitate GH responsiveness to 
TRH (Thorner et al 1983, Borges et al 1983). The TRH-test is commonly 
used in the diagnosis of acromegaly. However, like the GH response to 
oral glucose loading an abnormal GH response to TRH is not specific 
for acromegaly in the differential diagnosis of increased plasma GH 
levels. TRH-induced GH responsiveness may occur in patients with 
anorexia nervosa, diabetes mellitus, chronic renal failure and in 
children with tall stature. Therefore, the diagnosis of acromegaly is 
mainly made on clinical grounds although an abnormal GH response to 
glucose and TRH as well as elevated SM-C levels are helpfull to 
establish this diagnosis. On the other hand, in the differential 
diagnosis of acromegaly, syndromes with acromegaloid features in the 
presence of normal basal GH levels and function tests have been 
described (Mims 1978). In some studies increased levels of SM-C 
(Hoffenberg et al 1977) or other growth-promoting factors in the serum 
of the patients· (Aschraft et al 1983) have been observed. We also 
described increased biological SM-C activity in four members of a 
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Plate 1 Ductus craniopharyngeus (arrow on cysternoplanigraphy) in a 
patient with acromegalic features and congenital 
abnormalities especially in the midline. 
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family with acromegaloid features, congenital abnormalities and a 
persistant ductus craniopharyngeus (Plate 1, Klijn et al 198lb). 
Although dynamic tests can not specifically distinguish between the 
causes of elevated GH concentrations, it is our experience (Chapter 
VII Lamberts et al 1979a, 1982a and 1983) as well as of other groups 
(Liuzzi et al 1974a, Roelfsema et al 1979) that the GH response to TRH 
and/or to a single dose of bromocriptine are of prognostic value with 
respect to the effect of chronic bromocriptine therapy (see section on 
medical treatment 3.b.3.a.). Also the plasma PRL level and the 
simultaneous presence of PRL and GH in a GH-secreting pituitary tumour 
help to predict which patients with acromegaly are likely to respond 
to bromocriptine with an inhibition of GH secretion (Chapter VII, 
Lamberts 1979a, 1982a and 1983). Furthermore, the degree of GH 
suppression during somatostatin infusion may also have predictive 
value with respect to the results of chronic bromocriptine treatment, 
but this procedure appears to offer no additional information as 
compared to that obtained by the acute bromocriptine test (Nortier and 
Croughs 198Sc). 
2.b.2. Hormonal insufficiency 
Both pituitary tumours with and without suprasellar extension as 
well as suprasellar tumours can cause insufficiency of the 
hypothalamo-pituitary-target organ axis. Endocrine test protocols vary 
among institutions, but· they should be comprehensive enough to assess 
anterior and posterior pituitary lobe function. Measurement of the 
basal levels of pituitary hormones (LH, FSH, TSH, ACTH, PRL, GH) and 
of hormones derived from the target. organs (testosterone, oestradiol, 
T4, T3, cortisol) offers often an insufficient reflection of the 
pituitary function. Therefore basal hormonal measurements are commonly 
combined with stimulation tests especially those directed at 
measurement of pituitary hormone reserve. The endocrine investigations 
and assays, used in our department, are described in chapter III. The 
most common tests for measurement of the dynamics of TSH, LH/FSH and 
ACTH are the TRH-, LHRH- and metyrapone-tests, respectively. 
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2.b.2.a. The pituitary-thyroidal axis. 
In patients with hyperprolactinaemia and a pituitary tumour (Klijn 
et al 1980a) we found a negative correlation between pituitary tumour 
size and basal TSH (Fig. 9), the response of TSH to TRH (~ TSH) and 
circulating T4 and T3 levels (Chapter III and VI, Table 4). These 
correlations were not present in the acromegalic patients (Klijn et al 
1980c). The high incidence of an impaired TSH response (without 
hypothyroidism and independent of tumour size) is probably caused by 
suppression of TSH secretion rather than by destruction of 
thyrotrophic cells. This suppression of TSH secretion may be caused by 
an autonomous thyroid function in the presence of a more or less 
.enlarged thyroid or by increased hypothalamic somatostatin secretion 
or both. 
Patients with hypothyroidism due to hypothalamo-pituitary disease 
sometimes have slightly elevated TSH levels (Lamberton and Jackson 
1983). In some patients with suprasellar tumour mass the TSH is 
immuno-reactive but not fully bioactive (Faglia et al 1979), while in 
others there may be an altered "set-point" of TSH secretion possibly 
resulting from deficient hypothalamic somatostatin secretion (Jackson 
1980a). Increased plasma TSH concentration in the presence of 
hyperthyroidism can occur in patients with TSH (and TSH + GH) 
secreting pituitary tumours, which are very rare (Jackson 1980a, 
Meinders et al 1981). 
Some authors (Faglia et al 1973) concluded that the TRH test could 
indeed be used in the differential diagnosis of secondary (subnormal 
TSH response) and tertiary hypothyroidism (exaggerated, delayed TSH 
rise). Other authors, however, observed a considerable overlap in the 
TSH response to TRH in patients with pituitary or hypothalamic 
hypothyroidism (Patel and Burger 1973, Snyder et al 1974, Jackson 
1982, Lamberton and Jackson 1983). Furthermore, it has to be noted 
that TSH-secretion can be more or less influenced by spontaneous 
variation, sex, age, pregnancy or menstrual cycle, drugs, other 
endocrine diseases, systemic illnesses, anorexia nervosa, renal 
failure etc. These influences on TSH secretion are not always of 
clinical importance. In practice, the therapeutic decisions are made 
on the results of direct thyroid hormone measurements. 
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Table 4. Summary of radiological and endocrine data in 44 
_patients with acromegaly and 62 patients with a 
prolactinoma. 
patients 
mean age 
mean tumor size 
rod. extrasellar extension 
rod. suprasellar extension 
visual field defect 
rod. extrasel. extension (tumorsize < 3 cm2) 
" . ( " > 3 cm2) 
" ( > 4 cm2) 
tumor size: basal GH or PRL level 
tumor size: age 
ATSH vs. control group (or< 5 mU/1) 
hypothyroid ism 
log tumor size: log ATSH 1 T41 T3 
log tumor size: log AFSH 1 log ALH 
.6.FSH: aLH 
increased basal LH in men 
" FSH " " 
mean testosterone level in men 
impaired metyrapone test 
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Acromegaly 
21 S?l 23 d' 
S? = 39 yr 1 d' = 40 yr 
S? = 3 . 50 1 d' = 3 .7 6 cm2 
32 o/o 
23 o/o 
14 o/o 
Oo/o 
64 o/o 
92 o/o 
p < 0.0005 
p < 0.005 (neg.) 
56 o/o ( 48 %) 
2% 
n.s. 
n .s . 
n.s. 
14 o/o (n = 14) 
64 o/o (n = 14) 
0.32 JJg o/o 
11 o/o 
Prolactinoma 
38 S? 1 24 d' 
S? = 32 yr 1 d' = 35 yr 
S? = 2.88 1 o"'= 6.08 cm2 
44% 
35 o/o 
35 o/o 
3% 
92 o/o 
95 o/o 
p < 0.0005 
n .s. 
44 o/o (22 o/o) 
25 o/o 
P < 0.011 P < 0.0051 
p < 0.005 
p < 0.005 (both) 
p < 0.0005 
7 o/o (n = 14) 
7 o/o (n = 14) 
0.34 JJg o/o 
17 o/o 
2.b.2.b. The pituitary-gonadal axis 
In patients with hyperprolactinaemia and a pituitary tumour we 
found a negative correlation between pituitary tumour size and 
gonadotrophin secretion under basal conditions (Fig. lOA and lOB for 
LH and FSH respectively) and after LHRH (Fig. 11 for LH, see Chapter 
III for b. FSH). In female patients with microprolactinomas 
hyperresponses of FSH and LH to LHRH (in 50 and 60% of the patients, 
respectively) were frequently observed in contrast to the findings in 
patients with macroprolactinomas, in whom an insufficient response 
occurred in (more than) half of the patients (Klijn et al 1980a). Muhr 
et al (1985) found also elevated LH levels in 5 of 37 male patients 
with a prolactinoma and (sub)normal plasma testosterone concentration 
(4 men with microadenomas and one patient with a macroadenoma). Weber 
et al (1985) observed hyperresponses in a group of 13 men with 
microprolactinomas compared to normal controls. 
In our acromegalic patients (Chapter IV) a decreased gonadotrophin 
secretion was present in 12 out of 42 (29%) investigated patients in 
contrast to about 50% of the prolactinoma patients with the same range 
of tumour size (Chapter III). All these 12 patients had macroadenomas 
with tumour sizes of more than 2. 5 cm2 • On the other hand it was 
striking that a significant number of the acromegalies had increased 
basal FSH levels (Fig. 12B, Table 4 and 5) in the presence of normal 
LH and testosterone concentrations and normally sized (even sometimes 
large) testes. Lindholm et al (1977) have also observed a discrepancy 
between LH and FSH secretion. Elevated FSH with low or normal LH 
levels have also been described in patients with a gonadotrophin 
subunits producing tumour (Lamberton and Jackson 1983, Borges et al 
1984). After exclusion of postmenopausal acromegalic women we did not 
observe a significant correlation between tumour size and the 
gonadotrophin response to LHRH (Fig. 12A). 
Decreased plasma sex steroid concentrations in the presence of low 
gonadotrophin levels indicate hypothalamo-pituitary insufficiency. 
Failure to respond to a single dose of LHRH does not necessarily 
differentiate between hypothalamic and pituitary dysfunction since 
prolonged LHRH deficiency may impair pituitary responsiveness to 
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Fig. lOA The relationship between (log) tumour size (cm2) and (log) 
basal plasma concentrations of LH in 48 patients with 
hyperprolactinaemia and a pituitary tumour (r = 0.38, 
p < 0.005; • =~ ' 0 =d' ) • 
bas. FSH 
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Fig. lOB The-relation~hip between (log) tumour size (cm2) and (log) 
basal plasma concentrations of FSH in 48 patients with 
hyperprolactinaemia and a pituitary tumour ((r = 0.41, p < 
0.005; • = ~. 0 = d')· 
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Fig. 11 The relationship between (log) tumour size (cm2) and (log) 
the response of LH to LHRH ( /:; LH) in 40 patients with 
hyperprolactinaemia and a pituitary tumour (p < 0.0005; 
•=~,o=cf). 
Fig. 12A The 
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2 relationship between (log) tumour size (em ) and the LH 
FSH re.sponse to LHRH in 6 acromegalic premenopausal women 
and 9 acromegalic men (o) (r = 0.26 for /:; FSH and -0.35 
/:;LH, both n.s.). 
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bas. LH bas. FSH 
(U/1) (U/1) 
13 PRL ACR 13 PRL ACR 
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Fig. 12B Comparison of basal plasma LH and FSH levels in 14 male 
patients with prolactinomas (PRL) and 14-15 male patients 
with acromegaly (ACR). Increased basal FSH levels in 64% 
(9/14) of the acromegalic and in 7% (1/14) of the 
prolactinoma patients (p < 0.01). 
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Function 
basal TSH 
6TSH (mU/1) 
Table 5. Effects of surgery and radiotherapy on various endocrine 
parameters in patients with acromegaly and in patients 
with prolactinomas or a non functioning tumour. 
SUMMARY OF RESULTS 
ACROMEGALY PROLACTINO~~+NON-FUNCTIONING TUMOURS 
before --+ after surgery before ...-.after p.o. rad.ther. before ~after surgery before-...after p.o. rad<thec 
n 1 rean value 
I 
30 : 1.8 --.;. 1.8 1 n.s. 
I I 
30 17.7 ..... 4.3 lp<0.002 
14 
14 
I I 
39 18.7->9.1 I0.2>p>0.1 34 
n.s. 
n.s. 
I 
I I 21 1 1 n.s. 
I I 
21 1 10.4-6.1 p:0.02 
I I 
38 1 7.2--+7.2 1n.s. 
n I 
I 
I 
17 1 1 n.s. 
17 : 8.1 - 12.4 : p<0.02 
29 : 8.2 - 6.8 : p<0.01 
I I 
---------- --'------ _r_----I I 
I I I I 
--1-------1------:- -------1---- --..a.------1---
basal LH 
basal FSH 
6LH (U/1) 
6FSH (U/1) 
115 11 ()Jg%) after 
rretyrapone 
30 14.1 .-. 3.5 I n.s. 
29 ~0.6 ~ 9.8 I n.s. 
I 
29 ~0.6 - 7.6 I p<0.01 
I I 
28 I 9.1 --+ 6.8 I p<0.01 
I I 
I I 
---~-------~-----
31 I 17 ~ 18 I n.s. 
I 
I 
1 : 
I I 
I I 
I I 
I 6 • I 
: 4 ' I I I 
I I 
--~-------- i----
18 20.8 - 12.6 p<0.001 
23 
22 
23 
22 
1 
1n.s. l7 
I 
1n.s. 17 1 
6.0- 3.4 ~<0.01 17 : 3.1 -
4.6- 3.0 ~<0.01 17 : 2.7-+ 
I 
I 
I 
I 
3.1 : n.s. 
3.2 : n.s. 
I I I I 
--1------1---
--1-------+----
23 : 16.0--+16.1 :n.s. 
I I 
24 p .6 -12.7 : p=0.05 
I 
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exogenous LHRH. Also the clomiphene test cannot differentiate between 
these two possibilities (Lamberton and Jackson 1983). Furthermore, it 
has to be noted that some drugs (antiphlogistic agents as 
indomethacin) and some systemic disorders (malnutrition, Cushing's 
syndrome, hypothyroidism, diabetes mellitus, renal failure, etc) may 
influence gonadotrophin secretion. 
2.b.2.c. The pituitary-adrenal axis 
A low plasma cortisol concentration (< 180 nmol/1) between 8-9 a.m. 
and a low 24-hour urinary 17-hydroxycorticosteroid and 17-ketosteroid 
excretion suggest adrenocortical failure (Lamberton and Jackson 1983). 
On the other hand, a normal basal a.m. cortisol value does not exclude 
ACTH deficiency. Furthermore, women taking oral contraceptives 
containing oestrogen may have spurious high plasma cortisol levels due 
to elevation of cortisol binding globulin (transcortin). To prove 
pituitary corticotrophic insufficiency stimulation tests are 
necessary. A rapid ACTH stimulation test is of restricted value in the 
diagnosis of pituitary-adrenal insufficiency because only prolonged 
ACTH deficiency is associated with adrenal atrophy. A metyrapone test 
is more commonly used and of greater value. In addition, pituitary 
ACTH reserve can directly be measured by determination of plasma ACTH 
or cortisol levels after an injection of lysine-vasopressin. However, 
at present the synthetic 41-peptide corticotrophin-releasing hormone 
(CRF) will doubtless become more widely used in the wake of TRH and 
LHRH administration (Hermus et al 1985). An insulin hypoglycaemia 
(I.T.T.) may be particularly sensitive in demonstrating ACTH 
deficiency when this deficiency is recent in onset (Lamberton and 
Jackson 1983), but on the whole discrepancies with the outcome of oth-
er tests are not uncommon as also in our experience (Table 6). 
In nearly all our patients we have used the metyrapone test as the 
most practical and reliable one. As for pituitary thyrotrophic and 
gonadotrophic function we observed a negative correlation between 
pituitary tumour size and corticotrophic function (chapter III and IV, 
Fig. 13). Again the value of the index of tumour size (3 cm2) proved 
to be critical, while the incidence of hormonal insufficiency appeared 
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Table 6. Comparison of four pituitary-adrenal function tests in 17_ 
patients with a prolactinoma or a non-functioning tumour. 
C.D.R. = cortisol dayrhithm; L.V.P.= lysin-vasopressin test. 
+ = normal test; - = disturbed function or decreased cortisol 
response (<7 /ug%); n.d. = not done 
( ) insufficient hypoglycaemia 
Patient CDR Metyrapone-t I.T.T. L.V.P. 
1 + 
2 + n.d. 
3 + + (-) n.d. 
4 + + + 
5 n.d. + + n.d. 
6 n.d. + 
7 + n.d. 
8 + + + n.d. 
9 + + + 
10 + + + + 
11 + + n.d. n.d. 
12 + 
13 n.d. + + n.d. 
14 n.d. + + 
15 n.d. + + n.d. 
16 n.d. + (-) n.d. 
17 n.d. + n.d. + 
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Fig. 13 The relationship between (log) tumour size and plasma 
desoxycortisol (compound S) concentrations after metyrapone 
in 36 patients with hyperprolactinaemia and a pituitary 
tumour (p < 0.025; • = ~. o = ~). 
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to be much lower in acromegalic than in prolactinoma patients. A 
disturbed pituitary-adrenal axis occurred only in one patient with a 
prolactinoma and in one patient with acromegaly with a tumour size 
less than 3 cm2 (Klijn et al 1980a and 1980b). In patients with 
2 
macroadenomas (~ 1.5 em ) an impaired metyrapone test was found in 24% 
of the prolactinoma patients versus 11% of acromegalic patients, while 
the highest incidence (44%) occurred in patients with large 
2 
macroprolactinomas (~ 3 em). 
2.b.2.d. Growth hormone deficiency 
The tests commonly used to evaluate GH reserve are the insulin 
hypoglycaemia, L-dopa- and L-arginine test. Recently, a human 
pancreatic GH releasing factor (hpGHRF, a 40 aminoacid peptide 
isolated by Rivier et al 1982) appeared to be useful in the evaluation 
of pituitary GH reserve (Thorner et al 1983) in analogy with to TRH, 
LHRH and CRF. The I.T.T. is still considered the standard by which all 
others are judged, but may carry risk for patients who have low 
adrenal reserve, heart disease and epilepsy. Some investigators 
suggest pretreatment with oestrogen to enhance the response to the 
stimulus used, but this is no common practice. 
In our patients with pituitary tumours we have not systematically 
looked for GH deficiency because of the lack of clinical relevance in 
adult patients. GH deficiency may predispose the patients to 
hypoglycaemia by increased sensitivity to insulin. Furthermore, it may 
also contrib~te to a loss of anabolic action as manifested by skin and 
muscle changes and to the development of osteoporosis in patients with 
hypopituitarism (Belchetz 1984b). Impaired GH secretion regularly 
occurs as an early phenomenon (Landon et al 1966) and is described as 
the most frequently disturbed pituitary anterior lobe function in 
patients with non GH-secreting pituitary tumours (Lamberton and 
Jackson 1983, Luger 1985). 
2.b.2.e. Prolactin deficiency 
Basal PRL levels of the deficient patient with a "non-functioning" 
pituitary tumour overlap with the lower range of normal necessitating 
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the use of stimulation tests to determine PRL reserve. TRH or a 
dopamine blocking agent, e.g. chlorpromazine, are used for this 
purpose. Low baseline levels of PRL with failure to respond to one or 
more stimulatory agents is good evidence for deficiency of PRL 
secretion by the lactotrophs of the anterior pituitary gland. In 
humans, however, the clinical relevance of PRL deficiency has not been 
proven. We did not investigate this aspect of pituitary disease. 
2.b.2.f. Vasopressin deficiency 
Diabetes insipidus is more common in patients with suprasellar tumours 
than in patients with intrasellar pituitary tumours (and after 
hypophysectomy). It is sometimes masked by adrenal insufficiency and 
became then manifest after cortison substitution. 
In conclusion pituitary function testing is important to confirm 
clinically suspected insufficiency and to detect early dysfunction 
without clinical symptoms. In patients with microadenomas pituitary 
hormone deficiencies are uncommon (Chapter III and IV; Valenta et al 
1982), but pituitary function testing may be useful in such patients 
to provide baseline information for future care. In patients with 
macroadenomas GH and gonadotrophin secretion are most commonly 
affected, followed by TSH and ACTH secretion. Pituitary insufficiency 
occurs less frequently in acromegalic patients than in patients with 
prolactinomas or non-functioning tumours. 
Investigators have to keep in mind that hypersecretio~ of hormones 
as PRL and GH can influence target organ function without destruction 
of trophic cells. For instance hyperprolactinaemia can lead to 
hypogonadism by partial interference with gonadotrophin actions on 
their gonadal receptors and by disturbance of pulsatile LH release 
(Bouchard et al 1985) while on the other hand macroprolactinomas can 
cause diminished gonadotrophin reserve. Another example is the 
described suppression of TSH secretion by GH excess mimicking 
destruction of thyrotrophic cells (Chapter VI). 
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3. Treatment of Pituitary Tumours 
3.a. Introduction 
Pituitary tumours may manifest themselves by 1) symptoms caused by 
extension of tumour growth locally and pressure upon the adjacent 
structures (mostly the optic chiasm) 2) symptoms caused by 
hypersecretion of various hormones (PRL, GH, ACTH) 3) symptoms caused 
by loss of normal pituitary functions. 
Trying to combat these symptoms and complaints the treatment of 
pituitary tumours aims at l)reducing pituitary tumour size 2) 
decreasing or normalizing hormonal hypersecretion 3) preserving normal 
pituitary functions 4) preventing tumour recurrence and 5) improving 
survival in the absence of serious side effects. Three main types of 
therapy are available: surgical, radiotherapeutical and medical 
treatment (Chapter I and VIII). We have studied retrospectively these 
therapeutical effects in (subgroups of) 336 patients with a pituitary 
tumour treated since 1950 in the University Hospital "Dijkzigt" and 
the Rotterdam Radio-Therapeutic Institute. For patients, methods and 
materials I would like to refer to section B. 
3.b. Acromegaly 
3.b.l. Surgical Treatment of Acromegaly 
3.b.l.a. Transsphenoidal surgery 
During the past two decades the transsphenoidal approach to the 
sella turcica has supplanted intracranial exploration for pituitary 
adenomas with only few exceptions in the case of brain invasion by the 
tumour. Even in the presence of supra- or parasellar extension of the 
pituitary adenoma with visual impairment, the transfrontal surgical 
approach has been generally replaced by the transsphenoidal one in 
view of the excellent results of decompression of the surrounding 
structures and the low morbidity of this operation. 
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3.b.l.a.l. Effects on clinical symptoms, 
Together with the effects of irradiation these will be discussed in 
section 3.b.2.a. 
3.b.l.a.2. Effects on plasma basal and TRH stimulated growth 
hormone concentrations 
The effect of transsphenoidal surgery on basal GH levels in our 
series is described in chapter VIII. The mean immediate decrease in 
plasma GH was found to be about 50%. The results of transsphenoidal 
surgery appeared to be dependent on preoperative GH levels. Patients 
with preoperative GH levels of higher than 31 ng/ml never reached 
"cure" by operation only. Some series showed better results than in 
our study with up to 60-90% of patients showing normalization of basal 
GH level within the first few months after surgery (Laws et al 1979a, 
Pearson et al 1981, Llidecke et al 1984, Giovanelli et al 1984,Quabbe 
1984, Serri et al 1985). This may be caused by the fact that these 
series includes more patients with microadenomas, in which treatment 
group the best results are achieved (Laws et al 1979, Serri et al 
1985). However normal GH secretion is rare even after microsurgical 
normalization of plasma GH levels in acromegaly (Lamberts et al 1979e, 
Hulting et al 1982) and it does not guarantee complete removal of all 
tumour tissue. This can be shown by the persistence of a paradoxical 
increase of GH levels in response to TRH (Chapter VIII, Faglia et al 
1978, Schaison et al 1983, LUdecke et al 1984). In our experience none 
of the patients with a positive GH response to TRH before operation 
and a normal basal GH level after operation (< 5 ng/ml) showed absence 
of a response to TRH after operation. In general, the percentual GH 
response was similar before and immediately after operation (Fig. 14) 
Some authors report annihilation of the GIL response to TRH after 
operation in a few patients, but a positive response may reoccur 
(Serri et al 1985). This may be explained by the observation that 
invasion of the dura mater was present in some 50 percent of the cases 
(Wrightson 1978, Ludecke 1984). On the basis of these findings it can 
be concluded that postoperative external pituitary irradiation 
(Chapter VIII) is probably indicated in most or all cases in order to 
prevent regrowth of the tumour. 
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Fig. 14 The percentual growth hormone response to TRH before and 
immediately after operation. For a few patients only one 
measurement immediately after operation or later on was 
available (I). 
Fig. 15 The effect of transsphenoidal surgery on plasma prolactin 
concentrations in 37 acromegalic patients (---7; • = ~ , 
o =~). In 6 patients plasma prolactin was measured 0.5-1 year 
after postoperative irradiation (----)). The shaded zone 
separates the upper limits for normal women and men 
respectively. 77 
3.b.l.a.3. Effect on basal prolactin concentrations 
In 37 out of 45 patients with acromegaly basal plasma PRL level was 
measured before transsphenoidal operation. In 20 of them (54%) an 
increased value was found (in women> 15 ng/ml, in men> 12 ng/ml). In 
31 of these 37 patients plasma PRL levels were again measured in the 
postoperative phase, in 3 within 0.5 year after postoperative radio-
therapy and in 3 other patients within one year after radiotherapy. In 
most patients we observed a significant decrease of the plasma PRL 
concentration after transsphenoidal surgery (Fig. 15). In 8 of the 20 
patients (40%) with increased plasma PRL before surgery the PRL level 
became normal after operation. In 2 men, one with a slightly increased 
basal PRL of 22 ng/ml in the presence of a very large suprasellar 
tumor mass, no significant change in plasma PRL was found after 
transsphenoidal operation. In the 20 patients with increased 
preoperative PRL levels the mean percentual decrease by surgery was 53 
+ 6.0% (x 2:_ SEM). In 13 out of the 17 patients with normal 
preoperative plasma PRL levels also a "decrease" in basal PRL was 
found. However the mean decrease in the total group of 17 patients was 
only 20 ~ 83% (i.e. to 80% of the preoperative value). 
In general, there was no correlation between the percentual 
decrease of plasma PRL and of plasma GH by transsphenoidal surgery 
neither in the hyperprolactinaemic (Fig. 16A) nor in the 
normoprolactinaemic group (Fig. 16B) of acromegalic patients. However 
it was conspicuous that in 9 of the 10 patients with the highest basal 
PRL level (~ 40 ng/ml) the percentual decrease of plasma PRL by 
operation was higher than that of plasma GH 0to 38 and to 70% of the 
preoperative value respectively). In contrast to that finding the mean 
percentual decrease of basal GH in the whole group of 20 
hyperprolactinaemic patients was equal to that of the group of 17 
normoprolactinaemic patients, namely to 54.7 ~ 7.3% and to 51.3 + 6.7% 
of the preoperative values respectively. 
In 6 out of the 45 patients treated by transsphenoidal surgery 
plasma PRL was measured for the first time some years after 
postoperative irradiation. In only one patient plasma PRL (42.7 ng/ml) 
appeared t'o be elevated (4 years after irradiation). In the remaining 
two other patients plasma PRL has not been measured. 
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Fig. 16 The percentua1 decrease (100% = preoperative value) of plasma 
growth hormone and prolactin in 20 hyperprolactinaemic (A) 
and 17 normoprolactinaemic (B) acromegalic patients after 
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Fig. 17 Relationship between plasma growth hormone and phosphorus 
concentration in 45 acromegalic patients before 
transsphenoidal surgery (r = 0.64, p < 0.0005; • = ~ , o = cf). 
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3.b.l.a.4. Metabolic effects 
Preoperatively there was a rough posit±ve correlation between 
plasma GH and plasma phosphorus concentrations (Fig. 17). Immediately 
after operation there appeared to occur no significant decrease in 
plasma phosphorus levels. However, in the years after postoperative 
irradiation (Fig. 18A) or after irradiation only (Fig. 18B), plasma 
phosphorus clearly decreased in more than half of the patients. We 
have not systematically examined changes in the urinary excretion of 
calcium or hydroxyproline, which after successful therapy are known to 
decrease together with the GH levels (Roelfsema thesis 1972, Wass et 
al 1977, Wass 1984b). In addition, the carbohydrate tolerance can 
improve after therapy (Roelfsema et al 1979, Wass 1984b). 
3.b.l.a.5. Effects on pituitary function 
3.b.l.a.5.a. pituitary - thyroidal axis. There appeared to be 
no significant difference lE--~~~~1-~~~~~~ TSH before and after 
transsphenoidal surgery (n=30, n.s.). High normal levels before with 
low levels after operation and vice versa were found (Fig. 19). Mean 
plasma TSH level before and after operation were 1.80 mUll and 1.84 
mUll, respectively (Table 5). In 7 of the 9 patients with a 
postoperative increase of the basal TSH level T4 appeared also 
slightly increased. However, yj~~-~~a~y __ !~~-~~~~~~~ measured with TRH 
stimulation had significantly fallen after transsphenoidal surgery 
(Fig. 20): mean + SEM: 7.65 + 1.01 mUll and 4.32 ~ 0.63 mUll, 
respectively (p(0.002). Twenty-two of 30 patients showed 
postoperatively a lower response to TRH. There was no significant 
decrease of the mean Y-~~~11!.~_!_4 level (Fig. 21) after surgery, but 
rather a tendency to increase ( 8. 6 7 1ug% and 9. 06 1ug% respectively 
n=39, n. s.). Twenty-four of the 39 patients investigated showed a 
postoperative increase of T4. In 7 of the 10 patients with an increase 
above 10 ug% a TRH-test was carried out. Strikingly, in all of them a 
decrease of the TSH response to TRH was found. 
In 14 patients ~~~~l!!.~_:r~. was measured before as well as after 
operation. No significant difference between the averages was 
observed. In 8 patients there was an increase, in 6 a decrease of 
plasma T3. 
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Fig. 18 Decrease in plasma phosphorus concentration after combined 
surgical and radiotherapeutical treatment (A) and after 
radiotherapy only (B) in 31-and 12 acromegalic patients 
respectively. 
8 
7 
::l 
E 
1: 
6 
. 2 
..... 
5 ro 1.. 
<11 
a. 
0 4 
1.. 
<11 
..... 
.... 3 ro 
J: 
Ill 
2 1-
~ 
Ul 
ro 
.0 
0 
• 
0 
• 
2 
• 0 
-
3 
• 
• 
4 5 6 7 
basal TSH before operation (mU /1) 
8 
Fig. 19 Basal plasma TSH concentrations before and after 
transsghenoidal surgery in 30 acromegalic patients (n.s.). 
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surgery in 39 acromegalic patients (n.s.; • = ~ , o = ~). 
In 3 out of the 45 transsphenoidally operated acromegalic patients 
(6.7%) the thyroid function (measured by T4, FTI or PBI) was already 
subnormal before operation. This percentage increased to 11.1% (5 out 
of 45) postoperatively because 2 of the 42 euthyroid patients (4.8%) 
became hypothyroid after operation (see Chapter VIII). 
3.b.l.a.S.b. pituitary gonadal axis. No significant 
difference was present between prae-and postoperative ~~~~~-~~ (Fig. 
22, n=30) and _b,.!i...,?,.!i] __ ~~!!--~.YJ!_l2 (Fig.23, n=31). Postoperatively the 
mean basal level appeared only slighly decreased (Table 5) for LH 
(4.1 to 3.5 U/1) as well as for FSH (10.6 to 9.8 U/1). In contrast 
E!!!:!!!~!:.L}.!LJ!.I!..c!.._~§.~-E~2~E.Y~ ( DLH and f:l FSH after LHRH) decreased 
significantly by transsphenoidal surgery (Fig. 24 and 25; both p(0.01, 
Wilcoxon rank test). Twenty two out of 30 patien;s and 21 out of 29 
patients showed postoperatively a lower response to LHRH with regard 
to LH and FSH, respectively. Mean ~LH decreased from 10.6 to 7.6 and 
mean 6. FSH from 9.12 to 6. 79 U/1 (Table 5). ~!~~"!!!~-~~~J:..e.!~~t~!~I!.~ was 
measured in 13 men preoperatively as well as immediately 
postoperatively. There was no significant change after operation 
(average from 0.24 ug% to 0.21 ug%). In 7 women ~~~t.:.:l!.<!.~~!::.lJ~ was 
measured pre- as well as postoperatively. The mean plasma level fell 
from 33 to 15 pg/ml with a marked decrease in 2 patients. 
In 19 out of the 45 acromegalic patients transsphenoidally operated 
upon (42%) pituitary-gonadal function, measured by LHRH-test or 
urinary gonad stimulating hormone (GSH), was disturbed already before 
operation. The percentage of patients with a disturbed function 
increased to 24 out of 44 (54%) postoperatively as in 6 of the 26 
patients (23%) the initially normal pituitary gonadotrophin reserve 
had decreased after surgery (Tables IIA and ItB in chapter VIII). In 
the immediate postoperative period none of the patients showed 
normalization of a decreased function already present before 
operation. 
3. b .1: a. 5. c. pituitary - adrenal axis. The pituitary-adrenal 
function was measured by determination of 11-desoxycortisol in plasma 
or increase of 17-0HCS in urine after metyrapone (see Chapter III). 
83 
50 
20 
10 
1 
::> 
! 
c 
~ 
a. 0 0 
~ 
~ 1.0 
:X: 
.J 
~ 0.5 
JJ 
0.2 
0.2 
• 
0 
• 
0.5 1.0 
0 
0 
• 
• 
• 
10 
basal LH before operation (mU/ml) 
• 
•• 
• 
20 50 
Fig. 22 Basal plasma LH concentrations before and after 
transsphenoidal surgery in 30 acromegalic patients (n.s.; 
•=~,o=ct). 
0.2 
0.1 
0.1 0.2 0.5 1.0 10 20' so 
basal FSH before operation (mU/ml) 
Fig. 23 Basal plasma FSH concentrations before and after· 
transsphenoidal surgery in 30 acromegalic patients (n.s.; 
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Before operation the metyrapone-test appeared to be disturbed in 9 out 
of 45 patients (20%). Immediately after operation 3 patients received 
substitution with cortisone on clinical indication without available 
biochemical proof of pituitary-adrenal insufficiency. In 4 out of 33 
patients with a normal test preoperatively (12%) pituitary-adrenal 
function became disturbed by transsphenoidal surgery, while in 5 
patients a preoperatively subnormal function remained so. On the other 
hand in 4 out of 9 (44%) patients a preoperative insufficient function 
had become normal immediately after operation (Chapter VIII). So, in 
total a disturbed metyrapone-test was found in 9 out of 42 patients 
examined shortly after surgery (21%). 
In 31 patients the metyrapone-test was carried out before as well 
as after operation with the determination of the 11-desoxycortiso1 
concentration in plasma. In this group there was no significant 
decrease by operation (Chapter VIII). Mean 11-desoxycortisol level 
after metyrapone amounted to 18 ~ 1.56 ug% postoperatively as compared 
to 17 ~ 1.35 ug% before operation (Table 5). 
3.b.1.b. Subfrontal surgery 
Subfronta1 surgery occurred rarely and this approach has been 
gradually replaced in the 1970s by transsphenoidal surgery even in the 
presence of clear suprasellar.extension of tumour. By this approach it 
namely appeared possible to perform decompression and descent of the 
hypothalamus with minimal manipulation of the cerebrum causing no or 
less serious complications as sometimes observed after the subfronta1 
approach. Only 6 patients (3 women and 3 men) were treated by 
subfrontal surgery because of suprasellar extension. Amoung them was 
the young woman with the highest GH level. The patient with the 
largest tumour had undergone a subfrontal operation elsewhere without 
postoperative irradiation before his referral to our department. The 
effect of all forms of treatment on GH levels in these patients are 
summarized in Table 7. 'Two patients (A and E) appeared to be cured by 
subfrontal operation and postoperative radiotherapy. Three patients 
(B, C and G) were reoperated via the transsphenoidal route because of 
tumour growth or insufficient effect of the previous therapy on GH 
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Table 7 Effects of subfrontal surgery plus postoperative irradiation and subsequent forms of therapy on plasma growth hormone 
levels in 6 acromegalic patients (A-F). In another patient (G) operated elsewhere no postoperative irradiation was 
given. 
GH value (ng/ml) years of follow-up 
Patient Sex Age preop. postop. ~ , 1 1' 2 2": 3 3' 4 4' 5 5' 6 6' 7 r 8 9 10 11 
A (j 14 )80 38 • 17 11 1 1 1 1 
B (j 22 )80 33 t 25 60 ~ 18 10 7 4 2 
CB CB ...,.. _________ -..c 
190' 260 
~----
c C.( 25 720 840 t 320 130 81 250 x=160(45-283) 410 185 195 225 236 
CB CB + TAM 
1----------~------
D C.( 56 l83 61 67 25 31 25 31 17 22 23 16 15 
CB CB 
t 
I-- - --t 1-- --t 
E C.( 20 49 24 129 9 14 13 11 9 8 5 
F C.( 32 7 9 4 11 s h2 6 8 
CB 
285 ' 201 l 410 
1----------
G (j 25 37 10 18 40 160 203 180 
I 
330 
! = radiotherapy 
J = transsphenoidal surgery 
~-~ = period of medical treatment (CB = bromocriptine; TAM = tamoxifen) 
levels. One patient (F) had preoperatively a relatively low GH level 
(7 ng/ml) for the size of the tumor (3.6 cm2). There was no 
significant decrease in GH level during a follow-up of 2~ years. In 
another patient (D) normal GH levels have not been obtained after 8 
years in spite of treatment with irradiation, subfrontal surgery, 
transsphenoidal surgery and bromocriptine plus tamoxifen. The 
estimated mean decrease in GH level by subfrontal operation in all 
patients is about 30% (i.e. to 70% of the preoperative GH level). 
3.b.2. Radiation Treatment of Acromegaly 
Sixtyfour of the 67 acromegalic patients received radiotherapy in 
the course of their disease: 20 as the first form of therapy, 40 as 
additional treatment after surgery and 4 as the third or fourth form 
of therapy. One patient refused radiotherapy and two patients with 
only slightly increased GH levels were treated with bromocriptine 
only. Four patients were treated without success with bromocriptine 
only before irradiation. So 24 patients were irradiated before or 
without surgery: 22 with conventional radiotherapy, one with yttrium 
and one with ·proton beam irradiation. Another patient was treated 
after transsphenoidal surgery and conventional radiotherapy with 
proton beam irradiation. 
3.b.2.a. Effect of surgery and irradiation on clinical symptoms 
Twentyfour of the 45 patients operated upon transsphenoidally had 
complaints about ~~~E~EE~ of varying intensity before operation. In 9 
of these 24 (37%) patients headache disappeared or. became less after 
operation. In one patient headache developed and in another pa.tient 
the complaint worsened after operation because of sinusitis. In 4 
patients headache increased after postoperative radiotherapy. Seven 
out of 23 patients, who had been irradiated primarily, started to 
complain or showed an increase of headache after radiotherapy (one of 
them after proton beam therapy). 
In 22 of 45 patients l.!l£.~E.l.!l.c!E.~si~ disappeared or lessened markedly 
after surgery and radiotherapy: in 12 of them immediately after 
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operation and before postoperative irradiation. Seven of the patients 
primarily irradiated showed a decrease of hyperhydrosis later on. 
-~~~~~~~~~~~~~~~s had disappeared or had become less prominent in 
16 patients after operation and radiotherapy; in 8 this was already 
apparent after operation only. In 17 E!!E_!ents soft tissue swelling 
decreased during the years of follow-up after transsphenoidal surgery-
and irradiation as observed by the patient and/or his medical doctor. 
-~~J[~~~~~~ it can be stated that we observed progressive loss of 
complaints concerning hyperhydrosis, acroparaesthesias and soft tissue 
swelling over the years after surgery and irradiation or after primary 
radiotherapy. 
With respect t~-£~!:~!.£~~~£~!.~!:-E..!-~~2~~ it has to be pointed out 
that a study of Baldwin et al (1985) suggests that a slow reduction in 
serum GH levels does not delay the development of cardiovascular 
complications. 
3.b.2.b. Effects on growth hormone secretion 
3.b.2.b.l. Effects on basal plasma growth hormone concentration 
In 18 out of 22 patients, treated primarily with conventional 
radiotherapy, evaluation of the effect on GH levels was possible. One 
other patient received radiotherapy because of a recurrence of tumour 
growth two years after transsphenoidal surgery (without postoperative 
irradiation because of serious postoperative complications). The 
individual results of conventional radiotherapy in these 19 patients 
are shown in Chapter VIII. In one patient no plasma GH value before 
irradiation was known. In -general a satisfying decrease of GH levels 
was obtained during the years of follow-up after irradiation. 
Seven out of the 19 patients reached a GH level of (less then) 5 
ng/ml and an other two less than 10 ng/ml. Subsequently 5 patients 
have undergone transsphenoidal surgery and 4 were treated with 
bromocriptine because of an insufficient decrease of plasma GH. Some 
patients had very high levels before irradiation. Before treatment the 
mean GH level in this group of primarily irradiated acromegalic 
patients was much higher than that in the group of patients that 
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underwent transsphenoidal surgery (Fig 26). This can be explained by 
the fact that irradiation was the first choice of therapy for patients 
without suprasellar extension of pituitary tumour in the time period 
before transsphenoidal surgery was introduced in our academic hospital 
and by the fact that some patients had already been irradiated 
elsewhere before referral to our department. The mean GH level fell in 
7 years from 112 ng/ml to 19 ng/ml and subsequently remained at about 
that level (Fig. 26). In contrast, the mean GH level in patients 
treated with transsphenoidal surgery followed by irradiation fell. in 4 
years to below 5 ng/ml (Fig. 26). Comparing the results as a 
percentage of the GH level before treatment, radiotherapy as single 
treatment caused a decrease in plasma GH of 40% in the first year 
(Chapter VIII). After 1~- 2 years the same effect as immediately by 
transsphenoidal surgery was reached, i.e. a decrease of about 50% of 
the preoperative value. After 3 years of treatment there was no 
significant difference between the percental decrease in GH level 
after irradiation only or after transsphenoidal surgery followed by 
irradiation. However, when we divide the group of surgically treated 
patients in subg;roups with a relatively successful or unsuccessfull 
surgical intervention, the "successfull" group showed over seven years 
a significantly larger percental decrease of GH level than the group 
of patients treated with radiotherapy only (Chapter VIII). The group 
of patients in whom immediately after surgery no or only a decrease of 
the GH level of less than 30% was found, showed the same curve of the 
mean GH level after postoperative irradiation as the group of patients 
treated with primary radiotherapy only (Chapter VIII). Comparing the 
results of combined surgical and radiotherapeutical treatment with 
those of radiotherapy only it has to be pointed out that his study was 
non-randomized and retrospective. 
3.b.2.b.2. Effect on growth hormone response to TRH 
In only 4 patients a TRH-test with estimation of GH could be 
carried out before treatment with irradiation because in most patients 
radiotherapy had already been applied before the TRH-test came into 
use or because of referral after radiotherapy. The percentual increase 
of GH in response to TRH in these 4 patients was 914, 685, 31 and 2%, 
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Fig. 26 Absolute plasma growth hormone levels (mean + SEM) before and 
after combined surgical and radiotherapeutical treatment (n 
43) and before and after single treatment with radiotherapy 
(n = 18) in 61 acromegalic patients. 
91 
respectively. In the first patient the GH response to TRH decreased 
from 914 to 437% 6 months and to 32% one year after radiotherapy. In 
another 11 patients a TRH-test was performed after an average of 8 
years (after radiotherapy only). In 5 patients the GH response to TRH 
appeared more than 100%, in 3 patients 50-100% and in 3 less than 50%. 
3.b.2.c. Effect on basal prolactin level 
In 4 patients basal plasma PRL levels were measured before 
radiotherapy. In 2 of them the prolactin concentration was increased 
(96 and 22 ng/ml). In the patient with .the highest value plasma PRL 
decreased to about 30 ng/ml in one year after radiotherapy and 
remained at that level for the following 3 years of follow-up. In the 
patient with 22 ng/ml before radiotherapy plasma PRL level did not 
decrease significantly in the first 2 years after radiotherapy (18 
ng/ml), but a~peared to be 3 ng/ml 5 years after radiotherpy and after 
cessation of treatment with bromocriptine for 2 years. 
In 14 patients basal PRL level was measured for the first time 
after radiotherapy (after an average of five years). Plasma PRL was 
increased in 6 patients. In three of these six patients plasma PRL was 
followed for several years without other therapy. In the first patient 
plasma PRL decreased from 77 to 37 ng/ml during a follow-up of 5 
years, in the second PRL fell from 45 to 27 ng/ml during 2 years 
follow-up and in the third from 142 to 71 ng/ml during one year 
follow-up. In general, in the hyperprolactinaemic acromegalic 
pa:tients, in so far evaluable, a decrease of the total plasma PRL 
concentration with at . least 50% after single treatment with 
conventional irradiation was noted. 
3.b.2.d. Metabolic effects 
Plasma phosphorus decreased in 9 of the 12 evaluable patients 
treated by radiotherapy only (Fig. 18B). The reader is further 
referred to section 3.b.l.a.4. of this chapter. 
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3.b.2.e. Effect on pituitary function 
3.b.2.e.1. Pituitary-thyroidal axis 
In 5 patients treated by radioth~rapy only, the response of TSH to 
TRH ( ~ TSH) was measured before as well as in the years after 
radiotherapy. In 3 there was a decrease, in 2 an increase of ~ TSH. 
Also in 14 patients transsphenoidally operated upon, who were without 
substitution therapy, a TRH-test was carried out before giving 
postoperative radiotherapy and again after at least half a year 
following radiotherapy (mean: 2 year). In 9 there appeared an increase 
of~ TSH; in 5 patients a decrease was found. In the whole group of 14 
patients ~TSH was 6.2 2:_ 0.9 (S.E.M.) mU/1 before postoperative 
irradiation (Table 5) versus 7.4 :!::_ 1.4 after (not significant). 
In only one of 23 patients treated with radiotherapy only, 
hypothyroidism existed already before treatment. In the 22 patients 
who were euthyroid before treatment (one subsequently treated with 
proton beam irradiation) no hypothyroidism developed after 
radiotherapy (Chapter VIII). 
As mentioned before, in 5 out of 45 patients (11%) treated by 
transsphenoidal surgery hypothyroidism was found immediately after 
operation. In two of them this was caused by the operation itself (see 
section 3.b.1.a.5.a.). In 34 patients thyroid function was determined 
in the follow-up after postoperative irradiation. In the other 
patients the follow-up was too short or thyroid function has not been 
checked. In 5 of these 34 patients investigated in follow-up 
hypothyroidism was already present before irradiation. In 5 out of the 
29 euthyroid patients ( 17%) hypothyroidism developed in the years 
after radiotherapy (range 1-4 year; mean: 2 years). Overall, 
therefore, after the combination of transsphenoidal surgery and 
postoperative radiotherapy hypothyroidism was found in 10 out of 34 
patients (29%) (see Tables IIA and B in Chapter VIII). 
3.b.2.e.2. Pituitary-gonadal axis 
In the majority of the patients treated with radiotherapy only, no 
LHRH test was carried out. 
In only 9 of the 45 patients treated surgically by transsphenoidal 
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operation puitary LH and FSH reserve was measured without substitution 
before postoperative irradiation as well as in the years after 
irradiation (range 1-3 year, mean 1.5 years). In the other patients no 
evaluable data are available because of measurement of urinary GSH 
after operation instead of carrying out a LHRH test, the prescription 
of substitution therapy after surgery or no LHRH test being carried 
out in the (short) period of follow-up. In these 9 evaluable patients 
/::, LH decreased in 6 patients, and !J. FSH in 4 of 7 patients (Table 5). 
In 14 of the 22 patients, treated with radiotherapy only, pituitary 
gonadal function was measured before therapy by LHRH-test or 
measurement of urinary GSH. In 3 of them (21%) this function was 
disturbed. After radiotherapy pituitary-gonadal function was 
investigated in 18 patients, and appeared to be disturbed in five of 
them (28%). In 12 patients the same type of investigation before and 
after radiotherapy revealed the development of an impairment in one 
(8%) and recovery of pituitary-gonadal function in another patient 
(8%). 
After transsphenoidal surgery (see section 3.b.1.a.5.b.) a 
decreased pituitary-gonadal function was observed in 24 out of 44 
patients (54%). After postoperative radiotherapy a disturbed 
pituitary-gonadal function appeared in 20 of 33 (61%) patients 
examined (Table IIA and B in Chapter VIII). In one (8%) of the 12 
remaining patients with a normal function after operation this 
function became impaired after radiotherapy. In contrast, in 1 of 20 
patients (5%) with an impaired function after surgery recovery of the 
pituitary-gonadal function was observed after additional radiotherapy, 
while another patient (not examined after operation) after both 
surgery and radiotherapy showed normalization of a preoperatively 
decreased reserve. 
3.b.2.e.3. Pituitary - adrenal axis 
In the group of acromegalic patients, primarily treated with 
conventional radiotherapy, two out of 22 examined patients (9%) showed 
the development of a disturbed metyrapone test before treatment· In 
another patient this test was not repeated after radiotherapy. In 4 of 
the 19 patients (21%) with a normal pituitary-adrenal function before 
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primary irradiation an insufficient reserve was detected in the years 
after irradiation (range 2-13 years). 
As mentioned before (see section 3.b.l.a.5.c. of this chapter), a 
subnormal result of the metyrapone test was found in 21% of the 
patients after transsphenoidal surgery as compared to 20% 
preoperatively. This percentage turned out to be increased to 59% 
after radiotherapy, namely in 19 out the 32 who could be examined in 
that period (Chapter VIII). In 10 out of 23 patients (43%) with a 
normal pituitary-adrenal function after operation this function became 
subnormal in the years after postoperative irradiation (Tables IIA and 
B in Chapter VIII) with a median duration of 1 year (mean of 2 years; 
range \ - 6 years). No recovery of an impaired function was observed 
after additional radiotherapy. In 18 patients the metyrapone test was 
carried out with determination of plasma desoxycortisol both before as 
well as after postoperative irradiation (median: 1 year, mean 1. 7 
year, range 0. 5-6 years) There was a significant decrease of the 
response of 11-desoxycortisol after metyrapone in the years after 
radiotherapy (Fig. 9 of Chapter VIII) with a mean value of 20.8 ug/% 
before and 12.6 ug/% after postoperative irradiation (p < 0.001; Table 
5). 
3.b.3. Medical Treatment of Acromegaly 
3.b.3.a. Treatment with bromocriptine 
Thirty-one acromegalic patients have been treated with 
bromocriptine. For 10 of them this was the primary treatment, for 8 
the second therapy, for 12 the third and for 1 the fourth form of 
therapy. 
3.b.3.a.1. Effects on clinical symptoms 
Seven of 10 patients with mote or less severe complaints of 
headache had relief during treatment with bromocriptine. In 6 out of 
17 patients with hyperhydrosis and 3 of 13 patients with paraesthesias 
these complaints diminished during bromocriptine treatment. Of all 31 
patients 8 patients found the soft tissue swelling unchanged or had 
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doubt about it. We have not exactly measured the degree of soft tissue 
swelling. Side effects are reported in section 3.d.3. 
3.b.3.a.2. Effect on basal growth hormone during chronic 
treatment 
For the plasma GH concentration before and under bromocriptine 
treatment the mean of-two or more samples was taken. Nine of the 10 
patients, untreated before institution of bromocriptine therapy, could 
be evaluated with regard to change in plasma GH levels. The mean 
decrease in plasma GH concentration appeared to be 45%. Six patients 
had a decrease of more than 30% (Fig. 27A). 
In the group of 20 evaluable patients, previously treated with 
surgery and/or radiotherapy, the mean decrease in GH was 21%. Ten of 
them had a decrease of more than 30% (Fig. 27B). In some of them this 
decrease may be regarded as a (late) effect of radiotherapy, but part 
of the patients had stable plasma GH concentrations before 
bromocriptine treatment. In a few patients (3 or 4) a clearcut 
increase of plasma GH was seen under treatment with bromocriptine. 
Four patients showed an escape of plasma GH during chronic 
bromocriptine treatment after an initial good response as previously 
reported in detail with respect to one of these 4 patients (Lamberts 
et al 1979a). 
3.b.3.a.3. Relationship between plasma prolactin, the magnitude 
of the increment of growth hormone to TRH, and the 
acute and chronic effects of bromocriptine 
The relationship between plasma PRL, the magnitude of the increment 
of GH in response to TRH and the decrease of plasma GH after one 
~!gg1~ dose of 2.5 mg bromocriptine have been reported by our group 
before (Lamberts et al 1979a, 1982a, 1983, Chapter VII). The degree of 
suppression of plasma GH in response to 2.5 mg bromocriptine appeared 
positively correlated with the plasma PRL level and with the increase 
of GH after TRH. A homogeneity in the responsiveness of GH to TRH and 
to bromocriptine was confirmed in 74% of all 72 patients and in 92% of 
clearly hyperprolactinaemic acromegalic patients (Lamberts et al 
1982a). 
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Fig. 27 Absolute decrease of plasma growth hormone concentrations 
during chronic bromocriptine treatment in 9 otherwise 
untreated patients (A) and in 20 acromegalic patients 
pretreated by surgery and/or irradiation (B). 
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In a collaborative study we found hyperprolactinaemia in 33 (42%) 
of 79 untreated acromegalic patients (Lamberts et al 1982a). 
Inhibition of GH secretion by more than 50% after administration of 
~~~-c!o~~ (2.5. mg) bromocriptine occurred in 22% of normoprolactin-
aemic, in 53% of the mild hyperprolactinaemic and in 88% of the 
clearly hyperprolactinaemic patients. An increase of GH secretion by 
more than 100% of the basal value in response to TRH was observed in 
44% of the normoprolactinaemic, in 59% of the mildly hyperprolactin-
aemic and in 7 5% of the clearly hyperprolactinaemic patients. In a 
later study (Lamberts et al 1983, Chapter VII) we found that the 
immunohistochemical presence or absence of PRL in pituitary tumour 
tissue of 35 transsphenoidally operated acromegalic patients was 
correlated with the in vivo sensitivity of GH secretion to one test 
dose of bromocriptine and to TRH. Plasma GH levels from 2 till 10 hour 
after the. administration of one dose of 2.5 mg bromocriptine measured 
before operation were significantly more suppressed in patients with 
mixed GH/PRL containing adenomas than in those with pure GH-containing 
pituitary adenomas, being 38 ~ 4% and 65 + 4% (S.E.M.) of basal 
values, respective~y (p < 0.01). 
In this paragraph we describe the results of a study of the GH 
lowering effect of £h!2!!!£: bromocriptine treatment in relation to 
plasma PRL levels, the response of GH to TRH and response to 
bromocriptine in the ~£:.!!!.~ test measured before start of chronic 
bromocriptine treatment. 
- Significance of the basal plasma PRL level for the effect of 
treatment with bromocriptine. 
A positive relationship between the plasma PRL level and the 
percentual decrease in GH during ~~~~~~~-~~~~~~~nt with bromocriptine 
was !ound (Fig.28). Untreated and pretreated patients with high plasma 
PRL levels ()40 ng/ml) -showed a pronounced decrease of GH during 
chronic treatment: in 6 of 7 cases this amounted to more than 50%. The 
untreated and pretreated patients with normal or only slightly 
increased plasma PRL levels showed a highly variable response of GH to 
chronic bromocriptine treatment: in 4 of 21 the level was reduced by 
more than 50%, while in most cases there was no response and in a few 
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Fig. 28 Growth hormone levels during chronic bromocriptine treatment 
as percentage of pretreatment values in relation to plasma 
prolactin concentrations before bromocriptine treatment in 9 
otherwise untreated (A) and 19 acromegalic patients 
pretreated by surgery and/or irradiation (B). "Pretreatment 
level" means the level before bromocriptine treatment. 
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D Surgery + irradiation. 
~ = Radiotherapy only. 
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even an increase in GH. An increase of GH in a few patients during 
chronic treatment with bromocriptine has been also reported by 
Roelfsema et al (1979) and Belchetz (1984c). 
- Significance of the GH response to TRH for the effect of treatment 
with bromocriptine. 
Only 1 out of 10 untreated and pretreated patients with a response of 
GH to TRH of less than two times the basal value showed a decrease of 
GH by more than 50% during chronic treatment with bromocriptine (Fig. 
29). Furthermore, only three out of 18 untreated and pretreated 
patients with an increment of GH after TRH up to four times the basal 
value ex hi bi ted a good response of plasma GH i.e. a decrease of the 
mean level by more than 50% during treatment. However, in all 6 
patients with an increment of more than four times the basal value of 
GH after TRH chronic treatment with bromocriptine was successful ()50% 
decrease). 
- Significance of the acute bromocriptine test for the effect of 
chronic treatment. 
A highly significant positive correlation between the decrease of GH 
after one test dose of 2.5 mg and the decrease during chronic 
treatment was observed (Fig. 30; in previously untreated patients 
p(0.005, in ·treated patients p(0.01). Five of the patients, treated 
before with surgery and/or radiotherapy (Figure 30B) showed a stronger 
effect during chronic treatment than in the acute test in contrast to 
the patients not treated before (Figure 30A). Possibly there was an 
addi tiona! effect of the previous radiotherapy in these patients. 
On ~he other hand, 10 of the 15 previously treated patients showed a 
fall of more than 50% of the GH level after one dose of bromocriptine. 
Five out of these 10 patients with a good decrease of GH during the 
acute test did not show a decrease of more than 50% during chronic 
treatment. 
Overall, we observed a mean decrease of plasma GH concentration by 45% 
during chronic bromocriptine treatment. This is comparable with the 
results reported by Cozzi et al (1986) who found a reduction of 53% of 
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Fig. 29 Growth hormone levels during chronic bromocriptine treatment 
as percentage of pretreatment values in relation to the 
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Closed symbols = ~ , open symbols= ~. 
0 = Surgery + irradiation. 
~ = Radiotherapy only. 
the mean GH level (from 34 to 16 ng/ml) in 24 active acromegalic· 
patients, and with the results of Bell et al (1986), who reported a 
58% reduction during 2 treatment periods in 10 patients (decrease from 
49.6 to 20.5. and 20.8 ng/ml respectively). Roelfsema et al (1979) 
reported a mean decrease of 62% in 10 responding and no change in 5 
non-responding patients after one year of treatment. 
In general, approximately 50-80% of patients treated with 
bromocriptine (10-60 mg per day) have a significant ()50%) reduction 
in serum GH levels (Lamberts et al 1979e, Vance et al 1984, Nortier 
and Croughs 1985c), with a fall to the normal range (<5 ng/ml) in only 
15-20% of the patients. In a review of 10 studies Vance et al (1984) 
reported suppression of GH levels in 210 (73%) out of 288 patients and 
normalization of GH levels in 35 (20%) out of 172 patients. Clinical 
improvement with regard to sweating, ring size, urinary hydroxyproline 
excretion, and glucose tolerance occurred in the majority (70-92%) of 
the patients. Some authors (Clemmons et al 1979, Wass et al 1982) 
found that the clinical activity of the disease correlated better with 
plasma concentrations of somatomedin-C, through which the biological 
effects of GH are considered to be mediated. However in 3 other 
studies (Moses et al 1981, Stonesifer et al 1981, Nortier et al 
1985a), the contrary was found. Roelfsema et al (1987) observed that 
somatomedin-C levels were increased without exception in 24 patients 
with active acromegaly and normal in 45 inactive treated patients. 
Somatomedin-C levels were significantly correlated with GH levels. 
Bromocriptine treatment induced preferentially a reduction of little 
GH (Nortier et al 1985b); a very good correlation between the decrease 
of little GH and total GH was found, and both were significantly 
correlated with the clinical response. 
Five predictive tests for GH suppression 
bromocriptine treatment have been reported. We 
I 
during chronic 
showed that in 
general GH suppression during chronic treatment was more pronounced 1) 
in patients with hyperprolactinaemia, 2) in patients with a high GH 
response to TRH, and 3) especially in patients with a pronounced 
decrease of GH after one test dose of bromocriptine. Other authors did 
also observe a good correlation between the plasma GH response to a 
single dose of bromocriptine and that to chronic bromocriptine 
103 
treatment (Belforte et al 1977, Roelfsema et al 1979, Nortier et al 
1984a). The value of hyperprolactinaemia is controversial 
(Nieuwenhuijzen Kruseman et al 1983, Nortier and Croughs 1985c, Cozzi 
et al 1986). The degree of GH suppression during somatostatin infusion 
(fourth test) may also have predictive value but Nortier and Croughs 
(1985c) concluded that the somatostatin infusion did not offer 
additional information to that of the acute bromocriptine and TRH test 
in normoprolactinaemic acromegalies. Recently, Cozzi et al (1986) 
reported the predictive value of the GHRH-test (fifth test) with 
respect to response to chronic bromocriptine therapy. It appeared that 
GH release after GHRH was lower in patients responsive to bromo-
criptine than in bromocriptine nonresponders. In addition, the initial 
response of GH to· GHRH was unaffected by bromocriptine treatment in 
contrast to the response to TRH, which, statistically significant 
initially only in bromocriptine responders, was reduced by 
bromocriptine treatment. These authors suggested that cells sensitive 
to bromocriptine and TRH but not to GHRH (Iactotroph-like) and cells 
sensitive to GHRH but not to bromocriptine (pure somatotrophs) may 
coexist in GH-secreting adenomas. 
3.b.3.b. Treatment with somatostatin analogues 
For the effects of somatostatin analogue treatment I refer to our 
paper on: The sensitivity of growth hormone and prolactin secretion to 
the somatostatin analogue SMS 201-995 in patients with prolactinomas 
and acromegaly (Lamberts et al 1986a) and previous reports (Lamberts 
et al 1984c, 1985b and c). 
The somatostatin analogue SMS 201-995 (Sandostatin) has recently 
been shown to be effective in suppressing GH secretion in most 
acromegalic patients. In .the present study it was investigated whether 
PRL release in prolactinoma and acromegalic patients might also be 
sensitive to SMS 201-995 and whether co-secretion of PRL in acromegaly 
plays a role in determining the sensitivity of GH secretion to SMS 
201-995. The subcutaneous administration of 50 1ug SMS 201-995 did not 
affect high plasma PRL levels in four microprolactinoma patients. 
Therapy of one of these patients for 3 days with 50 1ug three times a 
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day also did not affect PRl levels. The single administration of 50 
1ug SMS 201-995 in 22 acromegalic patients lowered plasma GH levels 
for 2-6 hours to less than 5 1ug/l in 14 patients and to less than 50% 
of control values in 16 patients. In 18 of these 22 patients the 
immunohistochemical picture of the pituitary tumour was known. Eleven 
patients had pure GH-containing tumours and in seven patients there 
were mixed GH/PRL-containing tumours. In two of these latter patients 
there was evidence for GH and PRL being secreted by the same tumour 
cells. The sensitivity of GH secretion to SMS 201-995 did not differ 
between the patients with pure GH or mixed GH/PRL-containing adenomas. 
Plasma PRL levels were not affected by SMS 201-995 in the patients 
with pure GH-secreting tumours, but were significantly suppressed in 
four of the seven patients with mixed GH/PRL-containing tumours. 
Chronic treatment for 16 weeks of one patient with a mixed 
GH/PRL-containing tumour with SMS 201-995 (100 1ug three times a day) 
resulted in normalization of both the increased GH and PRL levels. It 
is concluded that SMS 201-995 does not affect tumorous PRL secretion 
in patients with pure prolactinomas. In acromegalic patients with 
mixed GH/PRL-containing tumours PRL secretion in some patients is 
sensitive to SMS 201-995, making these patients. good candidates for 
chronic treatment with the analogue. The simultaneous presence of PRL 
in the GH-secreting pituitary tumour or the presence of 
hyperprolactinaemia in acromegalies does not play a role in the 
sensitivity of GH secretion to the somatostatin analogue. 
3.c. Prolactinomas and "Non-Functioning" Tumours 
Patients with "non-functioning" pituitary tumours mainly have 
macroadenomas. Microadenomas are especially found in the group of 
premenopausal patients with prolactinomas because hyperprolactinaemia 
early caused symptoms like menstrual disorders and infertility. The 
world over there is no uniform approach as to the treatment of 
microadenomas. In the United States and some large neurosurgical 
centres in Europe there is a preference for microsurgical adenomectomy 
while in other centres medical treatment with dopamine agonists is 
commonly used. Some centres combine these two lines of treatment. In 
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Rotterdam we have usually treated patients with microprolactinomas 
with dopamine agonists and patients with large tumours with both 
surgical and medical treatment. Primary radiotherapy is not suitable 
for obtaining immediate effects with respect to recovery of fertility 
or de bulking of a large tumour mass, but secondary radiotherapy is 
effective in preventing tumour recurrences. 
3.c.l. Surgical Treatment (transsphenoidal and subfrontal) of 
Prolactinomas and Non-Functioning Tumours 
The results of surgical treatment are dependent on tumour size, 
preoperative basal PRL level, age and duration of amenorrhoea, which 
· parameters are more or less related to each other (Wilson 1984, Hardy 
1983, Fahlbusch 1980, Fahlbusch et al 1984, Fahlbusch and Buchfelder 
198S, Landolt 1984a, Landolt and Froesch 198Sb, Derome et al 1980 and 
1984, Ltidecke et al 1983, Teasdale 1983, Randall et al 198S, Post 
1980a,b,c, and 1986, Maira et al 198S). In several large series the 
best results of transsphenoidal surgery were shown in patients with 
microprolactinomas (< 10 mm) and patients with preoperative PRL-levels 
less than 200 ng/ml ( Fahlbusch 1980, Fahlbusch et al 1984, Fahlbusch 
and Buchfelder 1985, Hardy 1983, Derome et al 1980 and 1984, Bertrand 
et al 1983, Ltidecke et al 1983, Post 1986). Normalization of plasma 
PRL concentrations was obtained in about 60-8S% of patients with 
microprolactinomas. The best results were seen in patients with 
microprolactinomas less than S mm and plasma PRL levels less than 
100-200 ng/ml (80-93% normalization). 
Restoration of menses varied in the reported series with a range of 
about 40-70% with approximately a SO percent success rate in achieving 
pregnancy in those who chose to become pregnant (Post 1986). Normal 
menses and fertility may be restored even when postoperative prolactin 
values remain slightly or moderately elevated. 
Transsphenoidal microsurgical treatment appeared successful both in 
female and male patients with prolactinomas (Serri et al 1980, Hardy 
1983, Bertrand et al 1983, Muhr et al 198S), but the results in women 
are better because in the average men have larger tumours. 
Recurrence of hyperprolactinaemia is reported in 6 - SO% of the 
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patients with normalization of plasma PRL immediately after surgery 
(Bertrand et al 1983, Faglia et al 1983, Serri et al 1983, Fahlbusch 
et al 1984, Rodman et al 1984, Parl et al 1986, Buchfelder et al 1985, 
Schlechte et al 1986). In none of these series postsurgical 
irradiation was applied. In his review concerning 8 studies Parl noted 
recurrence of liyperprolactinaemia after surgical removal of 
microprolactinomas in 47 out of 238 (20%) patients during long-term 
follow-up of 0.5 - 10 years. Zervas calculated a recurrence rate at 5 
years of 5% in 222 patients with preoperative plasma prolactin levels 
less than 200 ng/ml and of 7% in 132 patients with preoperative plasma 
levels greater than 200 ng/ml (Post 1986). Serri et al (1983) reported 
recurrence of hyperprolactinaemia after selective transsphenoidal 
adenomectomy in 50% of 24 patients after a mean follow up of more than 
6 year (range 5-10 year). There was no radiological evidence of tumour 
recurrence in any patient. Clinical and biological features before 
surgery had no predictive value with regard to the long-term outcome. 
However, the immediate postoperative level of plasma PRL was 
significantly lower in patients in whom normoprolactinaemia was 
maintained than in those who relapsed. Post (1986) reported that a 
postoperative prolactin level of more than 10 ng/ml seems predictive 
of patients who might relapse. Maybe the best results with respect to 
both short and long-term effects are reached in the centres where 
aethanol irrigation of the removal cavity is applied after 
adenomectomy (Wilson and Dempsey 1978, Nicola et al 1980, Bertrand et 
al 1983). 
In patients with macroadenomas the incidence of surgical failure is 
very high (70-100%) increasing with tumour size from 72% failures in 
patients with small intrasellar macroadenomas to 95-100% failures in 
patients with a large suprasellar extension (Fahlbusch 1980, Fahlbusch 
et al 1984, Fahlbusch and Buchfelder 1985). Normalization of a pre-
operative PRL level of more ~han 500-600 ng/ml appeared to be 
difficult i.e. only in about 15% (Hardy 1983, Fahlbusch and Buchfelder 
1985). 
In 16 consecutive transsphenoidally operated patients with a 
macroprolactinoma and known pre- and postoperative PRL levels we 
observed an immediate decrement of the mean plasma PRL concentration 
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by surgery to 67 + 9% (mean ~ SEM) of the preoperative value (Fig. 31; 
chapter VIII) without normalization in any of the patients. Subfrontal 
extirpation of tumour is mainly meant for decompression of surrounding 
tissues and causes on the average less decrease in plasma PRL levels 
(Fig. 32). 
In 65 patients with a prolactinoma or "non-functioning" tumour 
transsphenoidal or subfrontal surgical treatment did not cause a 
significant decrease of basal TSH, LH and FSH or the reaction of 
desoxycortisol to metyrapone (Fig. 33, left). In contrast a 
significant decrease of the pituitary reserve of TSH (Fig. 34), LH 
(Fi_g.· 35) and FSH (Fig. 36) occurred (cf. Chapter VIII). While the 
mean TSH response to TRH decreased from 10.4 to 6.1 mU/1 (Table 5) the 
plasma thyroxine level remained unchanged at 7.2 1ug% (Fig. 37, Table 
5). Mean !:J. LH and l:J. FSH (LHRH-test) decreased from 6. 0 to 3. 4 and 
from 4.6 to 3.0 U/1, respectively. In general these results are in 
agreement with data in the literature, which show that the incidence 
of hormonal insufficiency after surgery is very low in patients with 
microadenomas but not uncommon in patients with macroadenomas. We did 
not observe · a significant improvement of preoperative impaired 
pituitary reserve after (partial) removal of a macroadenoma as 
reported by some authors (McLanahan et al 1979, Baha'Uddin et al 1982, 
Teasdale 1983, Ohta et al 1985). 
For the effects of surgery, recurrence-rate and survival I refer to 
Chapter VIII. In our study it appeared for the first time that the 
combined therapy of surgery and postoperative radiotherapy was 
superior to radiotherapy alone with respect to long-term survival. 
Both subfrontal and transsphenoidal decompression can result in 
recovery of visual acuity (Teasdale 1983). Indeed, sometimes a rapid 
improvement is noticed immediately after operation. Marked improvement 
is more likely when the history is short and when the loss of vision 
before surgery is not extensive. Fahlbusch (1980) and Post (1986) 
reported that visual improvement can be expected in more than 80% of 
the patients (see also 3.e.). 
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Fig. 33 Plasma desoxycortisol (compound S) concentrations after 
metyrapone measured before and after transsphenoidal or 
subfrontal surgery (n = 23, n.s.) and before and after 
postoperative irradiation (n = 24, p = 0.05) in patients with 
a prolactinoma or a non-functioning tumour. The 45° angle is 
indicated. 
Closed symbols = !i' , open symbols= d'. 
0= Prolactinoma- transsphenoidal operation. 
0= Non-functioning tumour- transsphenoidal operation. 
¢ = Prolactinoma - subfrontal operation. 
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Fig. 34 The TSH response to TRH (~ TSH) before and after 
transsphenoidal or subfrontal surgery in 21 patients with a 
prolactinoma or a non-functioning tumour (p = 0.02). The 45° 
is indicated. 
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Closed symbols = !i! , open symbols =d'. 
0= Prolactinoma - transsphenoidal operation. 
0= Non-functioning tumour - transsphenoidal operation. 
~= Prolactinoma - subfrontal operation. 
~= Non-functioning tumour - subfrontal operation. 
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Fig. 35 The LH response to LHRH (6 LH) before and after 
transsphenoidal or subfrontal surgery in 23 patients with a 
prolactinoma or a non-functioning tumour (p < 0.01). 
For symbols: see legends of figure 34. 
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Fig. 36 The FSH response to LHRH (6 FSH) before and after 
transsphenoidal or subfrontal surgery in 22 patients with a 
prolactinoma or a non-functioniag tumour (p < 0.01). 
For. symbols: see legends of figure 34. 
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subfrontal surgery in 38 patients with a polactinoma or a 
non-functioning tumour (n.s.). 
For symbols: see legends of figure 34. 
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3.c.2. Radiation Treatment of Prolactinomas and Non-Functional 
Tumours 
Radiotherapy is not commonly used as primary treatment of patients 
with prolactinomas because of the observation that irradiation appears 
rarely to be curative on a short-term basis. Only a few small series 
have been published (Gomez et al 1977, Samaan et al 1977, Antunes et 
al 1977, Sheline 1982, von Werder 1982, Nabarro 1982, Sheline and 
Tyrell 1984, Coulter 1984b). Radiation therapy has mostly been applied 
in patients who continued to have elevated PRL levels after surgery or 
who had large adenomas. Normalization of serum PRL is related to 
pretreatment PRL level and tumour size (Sheline 1982, Nabarro 1982). 
In patients with large tumours and very high PRL levels, irradiation 
has produced a progressive decrease in PRL levels but only 
occasionally to normal values (Sheline 1982). When the PRL levels are 
below 6-9 times the upper limit of the normal range reduction to 
normal values may occur within 2-3 year (Sheline 1982, Nabarro 1982). 
Nevertheless both in patients with micro- as wel as macroprolactinomas 
there is a wide variation in response. 
The decrease in mean PRL concentration by irradiation has been 
reported to vary from 62 to 93% (Antunes et al 1977, Gomez et al 1977, 
Kleinberg et al 1977, Sheline 1982, von Werder 1982) 2-6 years after 
external irradiation. Kleinberg et al (1977) showed in 15 patients 
treated with surgical resection and in 8 treated with radiotherapy 
that transsphenoidal surgery and radiotherapy were equally effective 
with a similar reduction in mean PRL level. Menses occasionally 
resumed. After the suggestion of Landolt et al (1979) that 
postoperative radiotherapy might have a synergistic effect together 
with bromocriptin treatment, Eversmann et al (1979) showed no 
difference in PRL levels in patients with macroprolactinomas treated 
with radiotherapy and bromocriptine or with bromocriptine alone. 
For our results I refer to chapter VIII and Table 5. Sixteen 
patients, who had been operated upon transsphenoidally for a 
macroprolactinoma showed up to 6 years (x = 3 years) after surgery and 
postoperative irradiation a maximal decrease of PRL levels of 90% 
(Fig. 31A). Only four patients were treated with radiotherapy alone 
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(Fig. 31B). Two patients reached normal PRL levels 7 and 4 years after 
the radiotherapy while menses returnedinthe first patient. 
In our patients with prolactinomas and non-functioning tumours 
gonadotropin secretion appeared to fall not significantly in the years 
after postoperative radiotherapy (Figs. 38 and 39). However, mean 
plasma T4 decreased significantly from 8.2 to 6.8 1ug% (n=29, p<O.Ol, 
Fig. 40, Table 5) in the presence of an increase of the TSH response 
to TRH from 8.1 to 12.4 mU/1 (n=l7, p<0.02, Fig. 41, Table 5) indi-
cating hypothalamic insufficiency as reported to occur also in 
patients irradiated for non-pituitary disease (Shalet 1983, Ahmed and 
Shalet 1984, Lam et al 1986). In our group of patients the mean 
desoxycortisol concentration after metyrapone administration decreased 
also: from 17.6 to 12.7 1ug% (n=24, p=0.05, Fig. 33 right, Table 5). 
Three patients developed severe adrenal insufficiency. 
External radiotherapy has been advocated as prophylactic treatment 
before induction of ovulation in patients with large prolactinomas who 
wish to become pregnant (Thorner et al 1979, Albrecht and Betz 1986). 
Although prophylactic radiotherapy might reduce this number of 
complications during pregnancy, complications cannot be totally 
prevented (von Werder 1982, Albrecht and Betz 1986) as described 
before in 3 of our patients (Lamberts et al 1977 and 1979c). 
The majority of large pituitary adenomas with hyperprolactinaemia 
or without known endocrine function can not be resected completely. 
Therefore postoperative irradiation is useful for growth control 
rather than for curation. Patients treated with radiotherapy alone and 
those treated by partial resection plus postoperative irradiation 
experienced approximately equal recurrence-free rates i.e. 90% after 5 
years of follow-up in contrast to 25% of patients treated by surgery 
alone (Erlichman et al 1979, Sheline 1982, Chapter VIII). Although 
radiotherapy alone is effective, particularly in patients with smaller 
tumours, it is generally preferred to surgically "de bulk" the tumour 
mass before the application of irradiation because of 1) the 
possibilities of confirmation of diagnosis, 2) rapid decompression of 
the optic system in case of suprasellar extension, and 3) improvement 
of long-term survival (Chapter VIII). 
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Fig. 38 The LH response to LHRH ( nLH) before and after postoperative 
irradiation in 17 patients with a prolactinoma or a 
non-functioning tumour (n.s.). 
For symbols: see legends of figure 34. 
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Fig. 40 Plasma T4 concentrations before and after postoperative 
irradiation in 29 patients with a prolactinoma or a 
non-functioning tumour (p < 0.01). 
For symbols: see legends of figure 34. 
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3.c.3. Medical Treatment of Prolactinomas and Non-Functioning 
Tumours 
3.c.3.a. Background 
The medical management of pituitary tumours has advanced rapidly 
over the past 15 years. Especially in the treatment of prolactinomas 
medical treatment plays an important role. An increasing number of PRL 
lowering drugs has been investigated and are available. Nearly all of 
them are dopamine receptor agonists. Dopamine inhibits the PRL 
secretion (van Maanen and Smelik 1968, Macleod and Lehmeyer 1974). 
Most experience has been obtained with bromocriptine (Parlodel R , 
Sandoz) which drug was developed by Fli.ickiger (Fli.ickiger and Wagner 
1968, Thorner et al 1980b, Fli.ickiger 1985). This ergot .derivative with 
long-acting dopamine agonistic properties (Corrodi et al 1973, Fuxe et 
al 1974, Calabro and Macleod 1978) suppresses PRL secretion by a 
direct effect at the level of the lactotrophs via the dopamine 
receptor (Pasteels et al 1971, Tashjian and Hoyt 1972, Mashiter et al 
1977). Prolactin secreting adenomas contain a high affinity dopamine 
receptor which interacts with both agonists and antagonists in a 
similar fashion as reported for the anterior pituitary gland of 
several species (Cronin et al 1978, 1979 and 1980). In the early 
seventies a favourable effect in patients with galactorrhoea and/or 
amenorrhoea and hyperprolactinaemia has been described with a fall in 
PRL levels and restoration of gonadal function (Varga et al 1972, 
Besser et al 1972, Del Pozo et al 1974, Thorner et al 1974, Rolland et 
al 1974). Later on bromocriptine appeared to cause tumour size 
reduction in animal models (Macleod and Lehmeyer 1973, Lloyd et al 
1975) and in patients with prolactinomas (Corenblum et al 1975, 1978 
and 1983, Vaidya et al 1978, Ezrin et al 1978, McGregor et al 1979, 
Landolt et al 1979, Wass et al 1979, von Werder 1982). 
3.c.3.b. Pharmacokinetics 
The pharmacokinetics of bromocriptine (Moult 1984b) were studied by 
Schran et al (1980) and Thorner et al (1980b and c). After oral 
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administration resulting in 28% absorption from the gastrointestinal 
tract blood peak levels are achieved 1-1.5 hour later. A linear 
relationship was found between dose and serum level. The half-life 
appeared to be 3 hours and no bromocriptine was detectable after 11-14 
hours. The fall of plasma PRL concentration starts within one hour 
with a nadir at 7 hours to about 15% of the pretreatment value (Fig. 
8; Thorner 1980b and c). Two major metabolites of bromocriptine have 
been identified. A daily dose of 5-7.5 mg bromocriptine is commonly 
used, but in patients with plasma PRL concentrations of more than 1000 
ng/ml these levels do not always return to normal even with a dose o·f 
40 mg per day (von Werder 1984). Bromocriptine is almost exclusively 
excreted in the feces (98%), and there is a 21 hour lag time 
representing intestinal passage of the drug. Total urinary excretion 
is 2% of the dose (Vance et al 1984). 
3.c.3.c. Effects on plasma prolactin levels 
The aims of medical treatment are 1) suppression of 
hyperprolactinaemia and galactorrhoea 2) restoration of gonadal 
function and 3.) reduction of tumour size. Bromocriptine appears 
effective in all forms of hyperprolactinaemia, physiological (Rolland 
and Schellekens 1973) or pathological (Moult 1984b). In patients with 
prolactinomas there is a broad spectrum of responsiveness. A 
significant decrease of plasma PRL levels occurs in 90-95% of the 
patients (del Pozo et al 1983, Landolt 1985a, and Landolt and Froesch 
1985b). Normalization of plasma PRL, however, has been reported in 
65-95% of women with prolactinomas (Fossati et al 1976, del Pozo et al 
1983, Hall et al 1984a, Winkelmann et al 1984, Vance et al 1984, 
Landolt 1985a, von Werder 1984, Kuhn et al 1985, Robbins 1986), and in 
54% of men with hyperprolactinaemia persisting after surgery (Grisoli 
et al 1980). Reviewing the literature, Vance et al (1984) reported 
normalization of PRL in 229 (82%) of 280 hyperprolactinaemic women and 
in 66 (72%) of 92 patients with macroprolactinomas. There is a trend 
towards higher PRL normalization rates in patients with lower than in 
patients with higher (> 160 ng/ml) plasma PRL concentrations (del Pozo 
et al 1983). 
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3.c.3.d. Effects on clinical symptoms 
As a consequence of (near- )normalization of plasma PRL concen-
tration galactorrhoea ceases in 95% of the patients (del Pozo et al 
1983) and gonadotrophin pulsatility returns (Bohnet et al 1976, Moult 
1984b) followed by restoration of LH positive feedback (Aono et al 
1979) and rise in circulating oestradiol levels. Vaginal lubrication 
and libido improve during treatment and the risk of premature 
osteoporosis will be diminished. Within 3 months after start of 
treatment menstruation recurs in 70% of the patients but delays up to 
10 months have been reported (Thorner et al 1978 and 1980, Moult 
1984b). Ultimately in about 90% of the patients regular menstruation 
is seen within one year (Thorner and Besser 1978, Thorner et al 1980b, 
Franks and Horrocks 1984). The delay in the recurrence of menstruation 
was greater in patients with macroprolactinomas but unrelated to the 
duration of amenorrhoea. In the series of 31 patients of Thorner and 
Besser 26 (84%) conceived on bromocriptine. In 54 infertile women 
Bergh and Nillius (1982) reported a pregnancy rate of 91% and an 
ovulation rate of 94% by bromocriptine treatment. Rolland (1980) 
observed pregnancies in 80% of 57 infertile women mostly with 
microprolactinomas within 10 months. In a review of the literature 
Weil (1986) reported an average pregnancy rate of 81% in 614 
hyperprolactinaemic infertile women in 26 studies. 
3.c.3.e. Effects in men with prolactinomas 
In men with prolactinomas (mostly macroadenomas) plasma testos-
terone may increase during treatment (Prescott et al 1982, Mancini et 
al 1984, Franks and Horrocks 1984, Vance et al 1984, Muhr et al 1985) 
but recovery of potency occurs mainly after normalization of plasma 
PRL levels. Thorner and Besser (1978) and del Pozo et al (1983) 
reported normalization of libido in about 80% of the subjects. In 
patients with persisting gonadotrophin deficiency bromocriptine 
treatment has been combined with testosterone replacement 
(Nagulesparen et al 1978, Moult 1984b). Sperma counts may increase 
during treatment (Mancini et al 1984, Murray et al 1984). 
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3.c.3.f. Effects on tumour size 
Reduction in tumour size occurs in 30 to 100% of patients with 
prolactinomas. In five reviews of series of patients the incidence of 
tumour regression has been reported to be 90% of 49 (Bergh and Nillius 
1982a, Nillius and Bergh 1984), 73% of 105 (Frantz 1982), 58% of 71 
(del Pozo et al 1983), 62% (Landolt 1985a), and 73% of 147 patients 
(Robbins 1986). Improvement or normalization of campimetric lesions 
during therapy was recorded in 26 (59%) of 44 subjects (del Pozo et al 
1983). Muhr et al (1985) reported reduction of tumour size measured by 
CT-scan in 8 of 10 males with prolactinomas and normalization or 
improvement in 13 of 15 men with visual field defects. 
The extent of reduction in tumour size varies between 30-99% (Boyd 
1982, Wolleson et al 1982, Liuzzi et al 1985, Landolt et al 1984b and 
1985c, Molitch et al 1985) with an average of about 50% (Landolt 
1985). In about 5% of the. patients an increase in tumour size has been 
observed during bromocriptine treatment, sometimes despite a 
significant fall in serum prolactin (Franks and Horrocks 1984). These 
patients may have had non-hormone-secreting tumours causing secondary 
hyperprolactinaemia by compression of the pituitary stalk. An escape 
after remission of prolactinomas and during continuing treatment with 
bromocriptine has been shown in a few patients (Breidall et al 1983, 
von Werder 1984, Wass 1984c). In case of morphological increase in 
tumour size during bromocryptine therapy an intratumoural haemorrhage 
has to be considered (Hallet al 1984a). Until now tumour response can 
not be predicted. 
Tumour shrinkage can occur rapidly within 3 days (Thorner et al 
1980a) or more delayed. Shrinkage of tumour occurs nearly almost in 
the first 6-12 months of treatment (Thorner et al 1981, Johnston et al 
1983, Warfield et al 1984, Landolt et al 1985c, Robbins 1986). 
Improvement of disturbed visual fields and endocrine functions may 
occur in up to 50% of patients with macroprolactinomas. Molitch et al 
(1985) even reported an improvement of visual fields in even 9 of 10 
patients in whom they were abnormal; Sieck et al (1986) observed 
improvement of visual abnormalities in 7 of 12 patients within one 
week. However, in some patients, first neuroradiological signs of 
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tumour shrinkage can be observed only after prolonged medical 
treatment up to 2 years (Liuzzi et. al 1985). If the tumour shrinks 
during the first year, further tumour reduction after the first year 
appeared to occur in only 2 of a series of 38 patients (Liuzzi et al 
1985). 
A reduction of plasma PRL levels can occur without reduction in 
tumour size and vice versa (von Werder 1984, von Werder et al 1985). 
On the long-term sella-volume reduction and/or recalcification of the 
bony structures of the sella has been observed (Liuzzi et al 1985). 
Tumour size reduction seems to occur more frequently in patients with 
microprolactinomas than in those with macroadenomas as reported for 
the former in 44 of 46 patients (96%) by Cecotto et al'(l985). 
Addition of tamoxif.en may improve responsiveness to bromocriptine (de 
Quijada et al 1980, Lamberts et al 1980b and 1982b, Volker et al 
1982). Recently Koizumi and Aono (1986) reported two patients who 
could not tolerate a large dose of bromocriptine but became pregnant 
after combined treatment with bromocriptine and tamoxifen. 
3.c.3.g. Histological effects 
Bromocriptine induces inhibition of prolactin gene transcription 
from DNA to messenger RNA (Maurer 1980 and 1981). The cells present 
the morphological pattern of reduced protein synthesis. Histological 
and cytological features of prolactinoma cells during treatment are· 
extensively described in some reports (Nissim et al 1982, Tindall et 
al 1982, Landolt 1984a, 1985a and c, Derome et al 1984). Shrinkage of 
the nucleolus, the rough endoplasmatic reticulum and the golgi system 
has been shown. The cells shrink by an average of 25% in comparison 
with cells in untreated samples (Landolt 1984a, 1985a and c). Cell 
death is rare. In a study of Gen et al (1984 and 1985) microscopic 
examination of biopsy specimens from only one bromocriptine treated 
prolactinoma showed signs of tumour cell necrosis. 
3.c.3.h. Praeoperative treatment with bromocriptine 
Landolt et al (1982 and 1985a) reported increased perivascular 
fibrosis when patients had been treated for periods of 3 months or 
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longer giving the adenoma a rubber-like consistency and rendering 
surgical removal more difficult. _After pretreatment with bromocriptine 
for one year or more normalization of PRL levels could not be achieved 
surgically. These findings are not completely confirmed by other 
studies (Faglia et al 1983). Derome et al (1984) found a slightly but 
significantly lower surgical cure rate of 65% in bromocriptine-treated 
patients as compared with 78% in non-pretreated cases; there was no 
such difference between pretreated and non-pretreated acromegalic 
patients. On the other hand Ludecke et al (1983) found that 
normalization of PRL levels by transsphenoidal surgery was slightly 
more common in patients who had been pretreated with bromocriptine 
(58%) than it was in untreated patients (46%) with macroprolactinomas. 
Also our surgeons did not meet specific problems in bromocriptin-
pretreated patients. 
3.c.3.i. Effects after withdrawal of bromocriptine 
A complete (morphological) remission of prolactinomas obtained by 
medical treatment is rare. Very few patients with large prolactinomas 
enjoy continuing benefit after stopping bromocriptine treatment 
(Thomas and Hall 1983, Liuzzi et al 1985). Reexpansion may occur 
within a few days after dopamin~ agonist withdrawal with shrinkage 
again after reinstitution of the treatment (Thorner et al 1981). This 
-can not be explained by a cytotoxic effect of dopamine agonists. 
However, persisting (partial) suppression of PRL secretion after 
terminating long-term treatment has been observed in some patients 
with macro-and microadenomas (Eversmann et al 1979, Hall et al 1984a, 
Moriondo et al 1983 and 1985, Robbins 1986). For 6 to 25 months after 
withdrawal of bromocriptine treatment Winkelman et al (1984) found 
persisting bromocriptine induced normoprolactinaemia in 7 of 38 
patients (18%) with micro-and macroprolactinomas. The remaining 
patients showed an increase of serum PRL after bromocriptine 
withdrawal, the extent of which was dependent on the duration of the 
preceding normoprolactinaemia. In the patients with persisting partial 
PRL suppression they found a significant correlation between the 
degree of persisting PRL suppression and the duration of bromocriptine 
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therapy, such in agreement with the findings of Eversmann et al 
(1979). However, in contrast to the findings of Eversmann the 
suppression of serum PRL did not correlate to the value of PRL levels 
before treatement. In patients with microprolactinomas Moriondo et al 
(1983 and 1985) observed persisting normoprolactinaemia in 5 out of 30 
patients (17%) after stopping bromocriptine treatment. On the other 
hand Bergh and Nillius (1982) reported a return of PRL concentrations 
to pretreatment values in 42 of 49 patients (86%) within 2 months of 
stopping bromocriptine and in 5 other patients PRL levels rose 
steadily over the next 1-2 years. However the return of hyper-
prolactinaemia does not necessarily signify reexpansion of the tumour 
(Franks and Horrocks 1984). 
3.c.3.j. Effects in patients with non-functioning pituitary tumours 
Although isolated case reports on the occurrence of tumour size 
reduction have been published, dopamine agonists seems to be of 
limited value in patients with "non-functioning" pituitary adenomas 
(Liuzzi et al 1985). Bromocriptine. was effective in reducing tumour 
size in only 1 out of 20 patients, but did not prevent tumour growth 
in 4 other patients as was suggested by the worsening of visual fields 
(Verde et al 1985). Grossman et al (1985b) found no significant tumour 
shrinkage in 15 patients with large "non-functioning" pituitary 
tumour. In a small comparative study Pullan et al (1985) observed that 
macroprolactinomas frequently shrink rapidly when treated with 
bromocriptine, whereas non-functioning tumours seldom show such a 
dramatic response. Bevan and Burke (1986) found that non-functioning 
tumours possess high affinity membrane-bound dopaminergic binding 
sites similar to those in normal pituitary and macroprolactinomas, but 
apparently fewer in number than in the latter resulting in absence of 
tumour regression. 
3.c.3.k. Bromocriptine induced pregnancy 
After. institution of bromocriptine treatment in infertile women 
with (micro)prolactinomas about 80-90% will become pregnant within one 
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year (Rolland 1980, Be.rgh and Nillius 1982). Weil (1986) found an 
average success rate of 81% (range 56-100%) in 26 studies concerning 
totally 614 patients. Bromocriptine crosses the placenta but no 
teratogenic effects of bromocriptine have been observed (Thorner et al 
1980b, Weil 1986). Data collected from 1410 pregnancies in which 
bromocriptine had been given during early pregnancy showed a normal 
incidence of congenital malformations (Turkalj et al 1982). No adverse 
effects upon placental function or increased abortion rate has been 
found. Plasma oestradiol and progesterone levels appeared not 
significantly different from those in patients with spontaneous 
pregnancies (Rolland 1980). Multiple pregnancy rate (1. 77%) was 
reported not to be increased. The body weight of the children was 
found to be normal (Rolland 1980). Bromocriptine treatment during 
pregnancy appeared not harmful to the fetus (de Wit et al 1985, Weil 
1986), but is not necessary because the risk of tumour complications 
in carefull supervised patients is low (Nillius and Bergh 1984). 
Visual field defects were observed in 4 and radiologic progression in 
17 out of 300 pregnancies. Later on Nillius et al (1985) reported an 
incidence of 2% of 3. 7% of these c.omplications respectively during 488 
pregnancies in 430 hyperprolactinaemic women •. Other authors reported a 
higher incidence (5-35%) especially in untreated patients with 
macroprolactinomas (see reviews of von Werder et al 1985, Nillius et 
al 1985, Albrecht and Betz 1986, Weil 1986). Radiotherapy before 
pregnancy induction is not always effective (Lamberts et al 1977 and 
1979c). If necessary, bromocriptine treatment may be reinstituted or a 
transsphenoidal operation may be performed (Nillius and Bergh 1984, 
Weil 1986). 
Although some authors have discouraged patients with prolactinomas 
to breast-feed their babies in order to prevent stimulation of the 
pituitary lactotrophs Nillius and Berg (1984) find no reason to 
withhold their patients from the adv~ntage of breast-feeding because 
they did not observe any untoward effects. After pregnancy plasma PRL 
levels are in some patients reported to be lower than before it, 
sometimes followed by spontaneous recovery of the menstrual cycle (see 
review Franks and Jacobs 1983a). In 31 patients with micro-
prolactinomas the mean PRL level decreased .significantly from 110 to 
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76 ng/ml after bromocriptine-induced pregnancy (Nillius and Bergh 
1984). Franks and Jacobs (1983a) and Franks and Horrocks (1984) 
observed "cure" in about half of 28 patients with microprolactinomas 
after bromocriptine induced pregnancies, but the PRL response to TRH 
remained abnormal. Rolland (1980) observed a spontaneous second 
pregnancy without reinstitution of bromocriptine induction treatment 
in 4 out of 19 patients. 
3.d. Side effects 
3. d. 1. Surgery 
Since the use of high dose corticosteroid treatment peroperatively 
(Kendall 1949) the mortality rate of subfrontal hypophysectomy has 
been decreased significantly (Post 1986). Vander Zwan (1971) reported 
a mortality rate of 5% in 80 patients operated in Leiden and Rotterdam 
between 1959 and 1970. After the introduction of microscopical 
transsphenoidal surgery the risk of cerebral bleeding, cerebral oedema 
and death decreased further in comparison with the results of the 
subfrontal approach of pituitary tumours. The operative mortality of 
transsphenoidal surgery in earlier large series ranged between 0 and 
2% and is at present about 0.25% (range 0-1%) (Wilson 1984, Post 1986, 
Laws and Kern 1979c, Llidecke et al 1984). 
The complications of transsphenoidal surgery in the first one 
hundred of our patients since 1969 are summarized in Table 8. Sixty 
patients had no complication at all, while 8 patients needed 
pitressine for less than one day. Sixteen patients developed diabetes 
insipidus for more than one day, but in only one patient permanent 
substitution with a synthetic analogon of antidiuretic hormone (ADH) 
was necessary. In 2 of the 11 patients with CSF rhinorrhoea a 
reoperation was necessary to stop the leakage of liquor. Six out of 
these 11 patients with CSF rhinorrhoea developed meningitis. Severe 
sinusitis occurred in 2 patients. Six patients had nasal compli-
cations. Three patients showed transient neurological deficits: one 
with diplopia, two with hemiparesis. A more serious complication has 
been observed in an acromegalic patient with carotid-cavernosus 
127 
Table 8. Incidence of various kinds of complications in 100 
transsphenoidally operated patients. 
In Acromegaly Prolactinomas 
tota,l and non-
functioning 
tumours 
Patients 100 48 47 
Mortality 0 0 0 
No complications 60 25 32 
Diabetes insipidus 8 6 1 
(< 1 day) 
Transient diabetes 15 6 9 
insipidus (> 1 day) 
Permanent diabetes 1 0 1 
insipidus 
CSF rhinorrhoea 5 5 0 
without meningitis 
CSF rhinorrhoea with 6 2 3 
meningitis 
Sinusitis 2 2 0 
Epistaxis 4 3 1 
Anosmia 1 1 0 
Nasal septum perforation 1 1 0 
(Transient) neurological 3 3 0 
disturbances (pareses) 
Carotid-cavernosus 1 1 0 
shunting 
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Suprasellar 
tumours 
5 
0 
3 
1 
0 
0 
0 
1 
0 
0 
0 
0 
0 
0 
shunting. In one patient the sella turcica was not reached by the 
surgeon. In conclusion, no significant complications occurred in about 
70% of the patients, while permanent complications have been 
encountered in only a few percent ((5%) of them. 
The incidence of complications was higher (7 out of 8) in the first 
years (1969-1972) after introduction of this surgical technique in 
comparison to later on. It has to be noted that in the first four 
patients the sella turcica was approached via the sinus frontalis and 
ethmoidalis, and not transnasally. The overall incidence of these 
complications in our series are more or less comparable with those 
reported in the literature. For a more detailed description of 
specific complications of transsphenoidal surgery I would like to 
refer to some reviewing articles (Laws and Kern 1979c, Post 1980b and 
1986). 
Nicola et al (1980) reported occurrence of diabetes insipidus in 
11% of 289 patients and Fahlbusch et al (1980) in 17% of 366 patients. 
However, in the latter study only 3% of the patients needed treatment 
for diabetes insipidus for more than 3 months. In other studies 
permanent diabetes insipidus has been found in 4-5% of the patients 
(Post 1980b and 1986, Llidecke et al 1984). Derome et al (1980) 
observed a secondary rhinorrhoea in 1.6% of 1200 transsphenoidal 
operation for pituitary adenomas; a part of these patients was cured 
by mere lumbar punctures (or a lumbar drainage); only 1% required a 
second transsphenoidal surgical procedure while multiple reoperations 
(2 and 3) were necessary for 2 patients. This author suggested a 
relationship with radiotherapy (shrinkage of a residual tumoural plug) 
in patients with occurrence of secondary rhinorhoea later on, i.e. a 
few weeks or months after surgery. Nicola et al (1980) described this 
complication in 2.9% of 289 patients and Llidecke et al (1984) in 4.5% 
of 224 patients. Furthermore Nicola reported occurrence of 
neurological disturbances in 3% and death in 1% of his patients. In 
total, transient complications were observed in 17.6% of his series 
(20% in patients with macroadenomas) while permanent complications 
occurred in 6% of his patients, especially in patients with firm 
tumours. 
Nicola et al (1980) reported 4 cases with postoperative visual 
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deterioration and 3 out of 294 cases with oculomotor palsy. The 
frequency of meningitis was low (less than 1%). In his review Post 
(1980b and 1986) reported an incidence of 1% for intracranial 
hematomas, 1-4% for visual complications, and 1-4% for meningitis. 
Dobozi and Landolt (1980) reported nasal septum perforation in 30% of 
their 199 patients, but only 2% of the patients had clinical symptoms. 
Five percent of their patients judged the nasal function worsened 
(dry, crust formation), but 17% better because of correction of a 
nasal septum deviation. Surgical treatment of pituitary tumours often 
results in a further reduction of the pituitary functions making 
substitution therapy with hormones necessary, but an amelioration can 
be obtained in some patients (Happ et al 1980). 
The value of cauterizing fluids in the tumour bed is uncertain. 
Nicola et al (1980) reported a higher frequency of diabetes insipidus 
after rinsing with cauterizing fluids such as alcohol, but the 
percentage of patients cured by surgery for microadenomas increased 
from 61 to 77% by the use of alcohol, but not with Zenker solution 
(64% cure). Bertrand et al (1983) found no correlation between the 
appearance of transient diabetes insipidus and the use of 94% ethanol 
irrigation of the removal cavity. Giovanelli et al (1980) stated that 
preventive swabbing of the residual cavity with chemical agents does 
not seem to be effective in reducing the failure rate; because of this 
point of view they have never used chemicals. Our surgeons have used 
Zenker solution in the first few patients, but abandoned this 
additional treatment because of a serious complication in one patient 
(paresis of the nervus abducens postoperatively) and because of their 
impression that the solution was not effective. 
3.d.2. External radiotherapy 
Conventional external radiotherapy is usually considered to involve 
a low risk for the patients. Early radiation effects of the cranium 
and soft tissues occurred in up to 40% of patients (Baglan and Marks 
1981). Indeed serious complications are rare, but occur as reported in 
2-3% of a series of 249 patients by Landolt (1980). Serious 
complications are death by cerebral radionecrosis (0.8%), blindness, 
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motor hemiparesis, extrapyramidal motor symptoms by damage of the 
temporal lobes, personality changes and development of sarcomas 
(Landolt 1980, Sheline and Tyrrell 1984). Histologically the vascular 
changes with partial to complete fibrinoid necrosis are the most 
striking. Small hemorrhages occur in the area of necrotic vessels 
accompanied by a inflammatory reaction. There is an increasing risk 
for complications in patients treated with total doses above .50 gray 
or after irradiation with fraction of more than 2 gray as occurred in 
one of our patients irradiated elsewhere. Symptoms appear generally 
1-2 years after the radiotherapy (Landolt 1980). 
More common but often not recognized is a stepwise increasing loss 
of recent memory, sometimes many years after the radiotherapy, as 
observed in 15 % of the patients in our own series (Chapter VIII). 
Other complications that are not uncommon consist of transient 
headache and of permanent hormonal insufficiency caused by radiation 
damage of the hypothalamus and/or the normal pituitary tissue (Chapter 
VIII, Eastman et al 1979, Snyder et al 1986). 
Proton beam irradiation is a specific form of external radiotherapy 
and only applied in a few centres in the world. Headache and also 
hormonal insufficiency are reported as side effects. 
3.d.3. Dopaminergic drugs 
In our experience the most common side effects of dopaminergic drug 
such as bromocriptine are nausea and postural hypotension, especially 
shortly after the initiation of therapy. Robbins (1986) reported the 
occurrence of nausea in at least 50% of all patients during the first 
few weeks and vomiting in 5-10%. Nasal congestion seems to be most 
prominent 2 to 3 hours after taking the drug and may last up to 6 
hours (Robbins 1986). Furthermore, in our experience cold-sensitive 
digital vasospasm is a not uncommon side effect especially in 
acromegalic patients during the winter time. Thorner (1980b) reported 
an incidence of 30% in acromegalic patients. A lot of other side 
effects have been reported, as indicated in Table 9. One or more side 
effects may occur in 27-63% of the patients (Landolt 1985b), but 
persisting side effects are found in not more than 13% (Johnston et al 
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Table 9. Reported side effects of bromocriptine 
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Nausea, vomiting 
Postural hypotension 
Nasal stuffiness 
Exertional headaches 
Cold-sensitive digital vasospasm 
Dyspepsia, constipation, gastrointestinal bleeding 
Alcohol intolerance 
Increased arousal state, insomnia 
In Parkinson patients : dyskinesia 
erythromelalgia 
• 
Neuropsychiatric disorders, depression, blurring of vision 
Photosensitive skin rashes 
In rats: Increased incidence of endometrial and myometrial 
tumours 
1983), while in only 3% of the patients bromocriptine treatment has to 
be stopped (Landolt 1985b) because of persisting side effects. The 
chance on (initial) side effects such as nausea and postural 
hypotension can be decreased by starting with a low dose (1.25 mg per 
day) taken before sleeping time. Subsequently the drug may be taken 
with meals, increasing the dose gradually in one week to 2 times 2.5 
mg. Also a new injectable form of bromocriptine may be helpful in 
patients with pronounced nausea (Landolt 1984b, Rolland et al 1984). 
Relatively late side effects of dopaminergic drugs are 
neuropsychiatric disorders. Turner et al (1984) describes psychotic 
reactions in 8 out of 600 patients. Oversuppression of PRL secretion 
may impair fertility (Moult 1984b). For a more detailed description of 
side effects I refer to other reports (Parkes 1979, Thorner et al 
1980b, Thomas and Hall 1983, Moult 1984b, Vance et al 19.84, Harris 
1984, Robbins 1986). 
Q~~~E-~~E~~!~~E~!£-~E~~~ (such as mesulergine, pergolide, lisuride, 
terguride) have more or less the same PRL lowering effects (Kendall-
Taylor et al 1983, Lamberts et al 1984b, Eskildsen et al 1984, 
Grossman et al 1985a, Thomas and Hall 1983, Dallabonzana et al 1985). 
No difference in side effects between lisuride or metergoline and 
bromocriptine have been reported (Stracke et al 1985, Thomas and Hall 
1983). Grossman et al (1985a) observed that mesulergine and pergolide 
caused generally similar side-effects compared to bromocriptine. 
Pergolide showed more side effects according to Boyd (1982), but it 
has the advantage of being dosed once daily (in the evening). 
Furthermore, some patients who are intolerant to bromocriptine may 
accept pergolide (Franks et al 1983b) or as in our experience 
mesulergine (Lamberts et al 1984b)·. More clinical experience is needed 
before the value of these new drugs is established. 
3.e. Recovery of vision 
Both subfrontal and transsphenoidal decompression can result in 
recovery of vision (Post 1980c, Teasdale 1983). The improvement in 
visual deficits after transcranial removal of pituitary adenomas is 
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comparable to that achieved by the transsphenoidal route; however, 
there is some risk that as many as 7 % of patients will have worse 
vision following manipulation of the optic nerves (Post 1980c). 
Indeed, sometimes a rapid improvement is noticed immediately after 
operation. Visual evoked potentials (VEPs) have been measured in 
patients undergoing removal of adenomas, with demonstration that there 
is immediate improvement in the VEPs during decompression (Feinsod et 
al 1976). Marked improvement is more likely when the history is short 
and when the loss of vision before surgery is not extensive. Visual 
improvement can be expected in up to 85% of the patients (Fahlbush 
1980, Post 1980c). In patients with prolactinomas also a rapid 
recovery of vision within a few days can occur during medical 
treatment (Thorner 1980a). Visual improvement has been reported to 
occur in 50-90% (see section 3.c.3.f). 
Results of transsphenoidal surgery with regard to vision in 
patients operated upon in our university hospital have been reported 
by Blaauw et al (1985 and 1986). Sixty out of 204 transsphenoidally 
operated patients with a pituitary tumour had a disturbed visual 
function before operation. Visual acuity and visual fields measured 
both before surgery and about one year after surgery were compared. By 
preoperative examination a significant correlation appeared between 
the disturbances of visual acuity and of visual fields. Seriously 
decreased visual acuity occurred mainly in patients with more than 50% 
loss of the visual fields. After·surgery the eyesight normalized in 16 
patients (27%). In 45 (63%) out of 72 eyes with diminished visual 
acuity an improvement and in 7% a deterioration of the visual function 
was observed. Visual field loss was present in 102 eyes and this 
improved in 71 eyes (70%). Improvement of either visual acuity and/or 
visual field was found in 84 eyes. (78%). In general, patients with 
less visual disturbances preoperatively had a better chance .of 
normalization, while patients with extensive visual disturbances 
showed more frequently no improvement or even deterioration. So it 
appeared that patients with a score of less than 30% preoperatively 
had complete recovery of the visual disturbances. On the other hand 
the results of surgical treatment seemed unpredictable in patients 
with serious visual disturbances (more than 30% loss of function) 
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before treatment, some of them showing rapid (complete) improvement 
other no improvement. The kind of response was not correlated with 
age, sex, duration of symptoms, extent of suprasellar expansion or 
bilateral occurrence of disturbances. 
3.f. Histological examination 
Pituitary tumours are mainly adenomas. Carcinomas of the pituitary 
gland and metastases occur rarely (Myles et al 1984, Scheithauer et al 
1985, Gasser et al 1985, Landgraf et al 1985). 
Prolactiriomas are mostly chromophobe adenomas, GH producing tumours 
acidophyl and ACTH producing tumours basophyl adenomas. However 
chromophobe adenomas or chromophobe tumour components (mixed adenomas) 
occur in about half of the patients with acromegaly (Chapter IV and 
VII) and in a significant part of patients with Cushing's disease. On 
the other hand 3 of 25 operated patients with a prolactinoma appeared 
to have by histological examination a mixed acidophyl-chromophobe 
adenoma, one patient a basophyl adenoma, another a mixed 
chromophobe-basophyl adenoma and one a neuroectodermal tumour, while 
19 patients showed a chromophobe adenoma (2 cystic). Non-functioning 
tumours are mostly also chromophobe adenomas or oncocytic adenomas. In 
the last 10 years immunohistochemical examination of pituitar'y 
adenomas appeared to be more important than classic morphologic 
examination (Chapter VII, Lamberts et al 1982c, 1983, 1985a, 1986a, 
Nieuwenhuijzen Kruseman 1983). 
Pituitary tumours are often circumscript (micro)adenomas, but 
tumours can be invasive (especially in men and in patients with large 
tumour~ or diffuse in 10-35% of the cases (Saeger 1983, Randall et al 
1986). In the latter situation transsphenoidal adenomectomy will be 
insufficient (Lamberts et al 1980f). 
3.d. Present management of pituitary tumours 
A number of factors play a role in the decision on the treatment of 
patients with pituitary tumours (Table 10). Important factors are 
treatment efficacy, side effects, tumour size, age, hormonal 
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Table 10. Factors, which has to be considered in the choice of therapy 
for patientswith pituitary tumours. 
l.a. Treatment efficacy. 
b. Side effects and risks of treatment. 
c. Previous treatment. 
2. Age and general health of the patient. 
3. Tumour size and location. 
Extrasellar extension with or without visual disturbances. 
Time period of visual loss. 
Presence of CSF leakage or pituitary apoplexia. 
4. Hypersecretory status of tumour (PRL, GH, ACTH, TSH, LH, 
~-subunits). 
5. Presence or absence of hormonal insufficiency. 
Infertility or fertility. 
6. Type of the tumour (cystic, solid). 
Need for histology in patients with uncertain diagnosis. 
7. Diagnosis by chance or because of symptoms. 
8. Therapeutic goals: a. reversal of hypersecretory syndrome 
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b. preservation of vision 
c. preservation of fertility and normal 
pituitary function 
d. control of tumour growth 
hypersecretion, and last but not least the therapeutic goals. 
Therapeutic goals may be preservation of vision, control of tumour 
growth, reversal of hypersecretory syndrome, preservation of normal 
pituitary function and fertility. All these factors being more or less 
related with each other have to be considered in choosing the optimal 
treatment for one particular patient. On the .other hand, each centre 
uses its own general treatment guidelines depending on the historical 
background of the institution, the number of modes of treatment 
available and its present fields of research interest. The decision to 
utilize a particular form of primary therapy varies from centre to 
centre. Today a practical problem is still the lack of randomized 
studies comparing the efficacy and side effects of two or more kinds 
of treatment. Therefore, the choice of treatment is mostly based on 
the results of non-randomized studies with one treatment modality in 
certain centres. For an overview of the general considerations in the 
treatment of pituitary tumours we would like to refer to some 
overviews (Kohler 1980, von Werder 1984, Quabbe 1984, overviews of 
Belchetz 1984, Sterman and Schlechte 1986). 
In a considerable proportion of patients with prolactinomas cure 
can be obtained by surgery. This is especially valid in patients with 
microprolactinomas. However, postoperatively about 40% of these 
patients have still elevated plasma PRL levels, while 30% of the 
patients with normal postoperative PRL levels show recurrence within 
5-10 years after surgery. One of the problems of surgical treatment 
can be the fact that after exploration of the sella turcica a 
circumscipt adenoma is sometimes not visible or that nests of tumour 
cells or hyperplasia may occur in the paraadenomatous tissue; in 
addition an adenoma can be also invasive. On_ the other hand medical 
treatment with bromocriptine causes prompt normalization of PRL levels 
and restoration of gonadal function and fertility in the majority of 
the patients with microadenomas. In patients with macroprolactinomas 
bromocriptine can cause significant reduction of tumour size within a 
few days without serious side effects or damage of normal pituitary 
function. However, the treatment is no~ sufficiently effective in all 
patients and has to be continued for long-term control of tumour 
growth. On the other hand, thus far no serious side effects of 
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treatment with bromocriptine for over 10 years have been reported and 
persisting suppression of prolactin secretion after withdrawal of 
long-term treatment with dopamine agonists has been observed in some 
patients. Short-term pretreatment with bromocriptine may facilitate 
surgery by tumour size reduction but according to some authors 
long-term pretreatment may jeopardize the results of subsequent 
surgery by changes in mechanical properties of the tumour. However, 
our surgeons did not observe specific problems in bromocriptine-
pretreated patients. Primary surgery remains the first choice of 
treatment in patients with cystic or very large tumours with 
neurologic disturbances. The choice of surgical approach depends on 
the size and location of the tumour. External radiotherapy is less 
effective- in patients with prolactinomas. Only in a few pat'ients 
normal plasma PRL levels were reached mostly years after irradiation. 
Therefore radiotherapy is certainly not -suitable for obtaining 
short-term effects as for induction of pregnancy. However, 
conventional external radiotherapy is an excellent adjunctive therapy 
for preventing recurrence of tumour or for long-term tumour growth 
control, especially in patients in whom surgical or medical treatment 
proved to be insufficient. In addition the area of irradiation can be 
smaller after (partial) shrinkage of the tumour induced by 
bromocriptine. Ultimately, no treatment can be proposed in patients 
with microprolactinomas without serious complaints or infertility, 
especially in patients above 40 years of age, because most 
microprolactinomas do not progressively increase in size or activity. 
Bone mineral content has than to be checked for development of 
osteoporosis. 
In Rotterdam we prefer to use bromocriptine as primary mode of 
treatment for patients with prolactinomas with the exception of 
patients with very large tumours and neurologic disturbances, while 
external radiotherapy is used as adjunctive treatment especially in 
patients with macroprolactinomas. 
In patients with acromegaly microadenomas without enlargement of 
the sella turcica are rare,. but the macroadenomas extend less 
frequently extrasellarly than other macroadenomas (prolactinomas and 
non-functioning tumours). Therefore and because it would appear that 
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the disease rarely spontaneously "burns out" as suggested in the older 
literature, cure by transsphenoidal selective adenomectomy still is 
the main goal of treatment. However, using strict criteria (normal 
TRH-test, and a value of GH less than 2 ng/ml after an oral glucose 
load) complete cure pccurred in only 8% of the patients. But. at 
present transsphenoidal surgery in combination with postoperative 
external radiotherapy is the most effective way of treatment certainly 
with respect to long-term results and survival. It should be pointed 
out that the results with heavy-particle or proton-beam therapy for 
intrasellar tumours are nearly comparable with the ·surgical results 
and that lowering of plasma GH levels occurs more rapidly than after 
conventional external radiotherapy. Although medical treatment with 
bromocriptine causes a significant decrease of plasma GH concentration 
in th~ majority of the patients, bromocriptine usually does not reduce 
GH levels to normal. An escape phenomenon (increase of plasma GH 
concentration after initial decrease) or even an initial increase of 
plasma GH during treatment may occur in a few patients. In general 
bromocriptine or other dopaminergic drugs are given as adjunctive 
therapy in patients who continue to have elevated GH levels after 
surgery and radiotherapy. External radiotherapy as single primary 
treatment is less effective in rapidly lowering the plasma GH levels 
than combined therapy and does not prevent or combat cardiovascular 
disease effectively. However, in older patients with surgical risks 
and relatively low GH levels external radiotherapy can be applied as a 
primary form of treament. It may be concluded that 20-40% of the 
patients still have GH levels of more than 5 ng/ml after 10 years of 
treatment and that complete cure of acromegaly is probably not the 
rule with present forms of treatment, even when applied in 
combination. Tr:eatment with somatostatin analogues may resolve this 
problem. 
In Rotterdam, acromegalic patients are generally . treated with 
transsphenoidal surgery followed by irradiation and with bromocriptine 
as adjunctive therapy. Recently it appeared in our hands that primary 
medical treatment with somatostatin analogues is an very effective 
treatment, but his form of treatment has at present the disadvantage 
that it has to be administered by· multiple subcutaneous injections 
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daily. After future introduction of slow release depotpreparations 
treatment with somatostatin analogues, possibly in combination with a 
dopamine agonist, may be expected to become the primary form of 
treatment. 
Patients with Q.u2J!:Ln_g~~- !!!~e~~~ mostly have microadenomas and 
selective transsphenoidal adenomectomy is the first choice of treat-
ment. However, in a substantial number of patients additional external 
pituitary irradiation and/or bilateral adrenalectomy appeared 
necessary because of postoperatively persisting elevated cortisol 
secretion rates or late recurrences. Medical treatment with 
bromocriptine, serotonin antagonists as cyproheptadine or adrenal 
blockers (metyrapone, aminoglutethimide, ketoconazol etc.) are only of 
temporary value in a few patients. 
Patients with ~~~~~~~~~~~~~~~~~-~~~~~~s mostly have macro-adenomas 
freq1.1ently with extrasellar extension. Surgical debulking of tumour 
mass followed by radiotherapy is the treatment usually chosen. 
Subtotal removal followed by radiation therapy is often safer and just 
as effective as an attempt to complete surgical removal. Incidental 
non-functioning tumours may become surgical candidates if there .i.s 
evidence of progressive growth. Radiotherapy is very important with 
respect to preventing recurrences and for long-term control of tumour 
growth. Medical treatment is of less value in the treatment of 
non-functioning tumours. Preoperative radiation does not preclude 
surgical intervention, but it can make selective removal of an adenoma 
more difficult because of scarring and increased difficulty in 
distinguishing adenoma tissue from the normal gland. 
In conclusion: Surgery, mostly in combination with postoperative 
irradiation, is the first choice of treatment in patients with 
acromegaly, Cushing's disease, and non-functioning .tumours, while 
primary medical therapy has become generally accepted in patients with 
prolactinomas. Unfortunately, no single form of therapy is uniformly 
successful in all patients. Therefore multidisciplinary treatment is 
very important. It has to be pointed out that, although more 
sophisticated hormonal and radiological diagnostic procedures have 
resulted in the detection of pituitary tumours at an earlier stage and 
despite impressive improvements in operative, radiation and drug 
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therapy over the last 15 years, complete permanent cures are still not 
achieved in some patients with prolactinomas and in a significant 
number of patients with Cushing's disease and acromegaly. Therefore, 
it is to be hoped that new modes of treatment, especially medical 
ones, will be developed. 
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CHAPTER ill 
THE IMPORTANCE OF PITUITARY TUMOUR SIZE 
IN PATIENTS WITH HYPERPROLACTINAEMIA IN 
RELATION TO HORMONAL VARIABLES AND 
EXTRASELLAR EXTENSION OF TUMOUR 
J.G.M. KLUN, S.W.J. LAMBERTS, F.H. DEJONG, R. DOCTER, 
K.J. VAN DONGEN AND J.C. BIRKENHAGER 
Departments of Medicine (III), Clinical Endocrinology and Department of 
Neuroradiology, University Hospital 'Dijkzigt', Erasmus University, Rotterdam, 
The Netherlands 
SUMMARY 
In sixty-two patients with hyperprolactinaemia and a pituitary tumour (without growth 
hormone excess) we studied the importance of the size of the sella turcica plus extrasellar 
tissue (if present) in relation to the prevalence of extrasellar extension and impaired hor-
monal reserve. A lateral tumour area of 3 cm2 turned out to be a critical value both in 
the development of extrasellar extension of the pituitary adenoma as well as in the deve-
lopment of insufficiency of the pituitary-gonadal, - thyroidal and -adrenal axis. Extrasel-
lar extension occurred in 44% of the patients. Below the value of 3 cm2 (n = 36) there 
was only one patient with radiologically detectable significant suprasellar extension. 
Above the value of 3 cm2 twenty-four out of twenty-six patients had significant extrasel-
lar extensions at radiological and perimetrical examination. Taking the size of the sella 
only, extrasellar extension occurred in one third of the cases with a sellar size between 
2 and 3 cm2 • There was a strongly positive correlation between (log) tumour size and 
(log) basal prolactin level (P < 0·0005). LH, FSH, TSH and ACTH secretion were eva-
luated by the consecutive administration of LHRH, TRH and metyrapone. Negative cor-
relations were observed between (log) pituitary tumour size and (log) basal LH, FSH 
and TSH (respectively P < 0·005, P < 0·005, P < 0·025) and between (log) tumour 
size and (log) A LH, A FSH, A TSH and the plasma CompoundS concentration after 
metyrapone (respectively P < 0·0005, P < 0·005, P < 0·01, P < 0·025). Again the 
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value of the index of tumour size (3 cm2) proved to be critical. Above 3 cm2 a highly 
significant increase in the incidence of insufficient responses to the stimuli mentioned 
was observed. Pituitary tumour size may be one of the most important indices used in 
the management of patients with hyperprolactinaernia and a pituitary tumour. 
The incidence of extrasellar extension and hormonal insufficiency is higher among pa-
tients with large rather than small adenomas. It is not known however, whether there 
is a critical tumour size above which these problems are more likely to occur. In the 
galactorrhoea-amenorrhoea syndrome associated with hyperprolactinaernia, one distin-
guishes patients with a normal sized sella (with or without localized abnormalities) and 
an enlarged sella (Child et al., 1975; Kleinberg et al., 1977; Boyd et al., 1977; Asfour 
et al., 1977). We know of no previous data, however, on the quantitative aspects of the 
relationship between tumour size and the incidence of extrasellar extension or endocrine 
deficiencies. 
We have studied sixty-two patients with hyperprolactinaernia and a pituitary tumour in-
vestigating the significance of tumour size in relation to extrasellar extension, plasma 
prolactin levels and anterior pituitary hormone secretory reserve. 
PATIENTS, MATERIALS AND :METHODS 
Patients 
Sixty-two consecutive patients with hyperprolactinaernia and evidence of a pituitary tu-
mour (without growth hormone excess) were inve~tigated. They were referred to our en-
docrine clinic directly or indirectly by specialists in internal medicine (29%), 
gynaecology (35%), neurology or neurosurgery (26%) and ophthalmology (10%). In 
fifty-eight patients the sella turcica was enlarged or asymmetrical on plain lateral and 
antero-posterior radiography and lateral polytomography, while in four female patients 
hyperprolactinaernia, galactorrhoea and secondary amenorrhoea were not accompanied 
by radiol0gicai evidence of a pituitary adenoma. Patients with primary hypothyroidism 
and/or circulating thyroid antibodies were excluded. All patients were untreated at the 
time of investigation. In thirty the presence of a pituitary tumour was later proven by 
surgery. 
Radiological and ophthalmological examination 
All patients were investigated by plain radiography, lateral polytomography (hypocycloi-
dal, sections of2 mm) and complete ophthalmological evaluation, including visual fields. 
Further radiological examination consisted of air-encephalotomography and in most ca-
ses angiography. Antero-posterior polytomography was only carried out in exceptional 
circumstances. 
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For practical, as well as theoretical reasons, we have chosen the largest lateral area of 
the sella in combination with that of extrasellar tissue (if present) as a measure of tumour 
size instead of a volume measurement. Direct surface measurement with a planimeter 
is easily carried out and remains reliable even in cases of large irregular tumour masses. 
A disadvantage of volume measurement is that on plain frontal radiograms, the sellar 
floor which is commonly used as a measure of sellar width, is not always clearly visible, 
either because of problems of projection or because of bone destruction. Furthermore, 
in patients with sellar asymmetry it turned out to be difficult to estimate consistently the 
width of the sellar floor because of marked variation in the configuration. In the case 
of large adenomas, the largest width of the tumour may not coincide with the width of 
the sellar floor or dorsum. On the other hand, the largest lateral area of the sella and 
extrasellar tumour tissue was always easily assessable by plain lateral radiography and 
air-encephalography. In the case of large adenomas the hirgest lateral area is good mea-
sure of the tumour size, because the size of the remaining normal pituitary tissue may 
be disregarded in relation to the size of the adenoma. Although a microadenoma often 
influences the outline of the sella by local bulging, it does not fill up the whole sella and 
the size of the sella therefore does not correspond with that of the microadenoma. For 
this category of patients we had to compromise and we used the largest lateral area of 
the sella. 
Description of measurements 
When there was no extrasellar extension present on the air-encephalogram (AEG) we 
measured the largest lateral area of the sella turcica on the plain lateral X -ray of the skull, 
after verification of the true sellar lining by means of lateral polytomography. The upper 
limit of the sellar content was taken as a straight line between the tuberculum sellae and 
the tip of the dorsum sellae. In the case of extrasellar extension, measurements were ma-
de on the plain lateral X-ray of the skull, obtained at air- encephalography. On this X-
ray, the circumference of the tumour was outlined after verification of the true lining 
of the sella, and the suprasellar and/or infrasellar tumour mass, by means of· the tomo-
grams of the AEG. We measured the area of the sella and extrasellar tumour tissue (EST) 
directly with a planimeter (manufactured by A. Ott, Western Germany, type 30-115), 
going clockwise with the planimeter from the tip of the dorsum or the tuberculum sellae 
along the circumference of the sella, and in the case of extrasellar extension, the extrasel-
lar tissue. The measurement of this area was carried out in all patients at least six times 
and the average coefficient of variation of this estimation was 3 ·4% . In 100 consecutive 
patients having neurological investigations for non-endocrine indications the 95% range 
of sellar area was between 0· 7 and 1·4 cm2 • The magnification factor on the plain X -ray 
varied from 1-05 -1·1 (distance from focus to film 1 m and from focus to object as large 
as possible). 
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Endocrine investigations and assays 
Plasma prolactin (PRL) concentrations were determined according to Kwa et al. (1973). 
Normal basal PRL levels are up to 12 ng/ml in men and up to 15 ng/ml in women. 
The dynamics of the secretion ofTSH, LH, FSH and ACTH were investigated by TRH-, 
LHRH- and metyrapone-tests. Only the result obtained in untreated patients are reported 
(in de majority of the remaining patients stimulation tests were not carried out because 
of the urgency of surgical intervention). 
The pituitary-thyroidal axis 
. This was investigated in forty-one untreated patients (age between 15 and 44 years with 
the exception of one 67-year-old female) by measuring the response of plasma TSH to 
the intravenous administration of TRH (400 p.g, Hoechst) and the measurement of basal 
thyroxine and free thyroxine index. Blood for determination of TSH was collected imme-
diately before and 20, 30, 60 and 120 min. after the intravenous administration of TRH. 
The absolute difference between the highest value for TSH during the test and the basal 
value (maximal increment) was taken as .::l TSH. Serum TSH was measured with a 
double-antibody radioimmunoassay technique using the materials supplied by Calbio-
chem AG Lucerne, Switzerland. TSH was iodinated with the lacto-peroxidase method 
described by Mukhtar et al. (1975), using 0·4 mol/1 instead of 4 mol/1 acetate buffer pH 
5·4. Preparation MRC 63/38 was used as a human TSH standard. Normal basal values 
of TSH are lower than 4·9 mU/1 (95% range of seventy-one controls). In our laboratory 
A TSH was between 8·1 and 38·7 mU/1 in ten females aged 2040 years, between 7·1 
and 16·0 mU/1 in eight females aged 40-60 years and between 4·9 and 14·0 mU/1 in se-
ven females aged 61-72 years. In eight normal men A TSH varied between 6·1 and 13·1 
mU/1. 
The pituitary-gonadal axis 
This was tested in forty untreated patients by intravenous administration of LHRH (1 00 
p.g, Hoechst). The maximal increment of LH and FSH during the test was taken as A 
LH and A FSH. LH and FSH were measured by double-antibody radioimmunoassay 
with materials purchased from KABI AB (Stockholm) using preparation MRC 69/104 
as a standard (Bangham et al., 1973). Ten units FSH and twenty-five units LH of prepa-
ration MRC 60/104 are equivalent ot 0·5 mg LER 907. In our laboratory basal LH levels 
were between 0·6-2·8 U/1 and basal FSH levels were between 1·2-4·2 U/1 in the early 
to mid-proliferative phase of the menstrual cycle of normal women, while A LH in 
response to 100 p.g LHRH varied between 3-12 U/1 and A FSH between 2-8 U/1. In 
nine normal men basal levels of LH and FSH varied from 0·6-2·5 U/1 and from 
0·7-3·3 U/1 respectively, while A LH varied between 3·7 and 8·8 U/1 and A FSH bet-
ween 1· 3 and 5 · 5 U /L Oestradiol-17 (3 was measured by radioimmunoassay without 
chromatography (de Jong et al., 1973). 
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The pituitary-adrenal axis 
This was evaluated in forty-six untreated patients by means of a metyrapone test (750 
mg every 4 h for 24 h orally). Four hours after the last dose of metyrapone, blood was 
taken for determination of plasma 11-desoxycortisol (Compound S) with the method of 
Meikle et al. (1969); who reported normal values of 11-desoxycortisol of 10-30 t-tgldl 
after 6 x 750 mg metyrapone. Our normal values after metyrapone exceeded 15 t-tg/dl, 
while the range of 10-15 t-tgldl may be regarded as borderline. In ten patients the integrity 
of the pituitary-adrenal axis was judged by the increase of urinary 17 -OHCS only (Liddle 
et al., 1959). A response to the administration of metyrapone of plasma 
11-desoxycortisol of less than 10·0 t-tg/dl and/or less than a doubling of the urinary. 
17-0HCS (with an absolute increase ofless than 10 mg/24 h) was considered abnormal. 
Statistical analysis 
Statistical analysis of the data was performed using regression analysis, two-tailed Stu-
dent's t-test or x2-test. Partial correlation coefficients were calculated according to Sne-
decor & Cochran (1967). 
RESULTS 
Epidemiological and clinical evaluation 
Of our group of sixty-two patients twenty-four were male (39%). The mean age of the 
male patients was 35 years (median = 35 years, range 15-19 years) and of the female 
patients 32 years (median = 29 years, range 17-67 years). There was a fairly even dis-
tribution of the male patients with regard to age in contrast to a preponderance of female 
patients between 25-35 years. 
The referral patterns and clinical features of these patients are summarized in 
Table I. 
Most frequent were complaints concerning menstrual disorders coupled with infertility 
and headache. Galactorrhoea was (or had been) present in twenty-nine of the thirty-eight 
females (76%) and in five of the twenty-four males (21 %). If the galactorrhoea had been 
noted by the patient, the mean duration of the galactorrhoea for the female patients was 
4·25 years, for the male patients, 6·5 years. The mean duration of the secondary ame-
norrhoea or oligomenorrhoea, present in twenty-seven patients, was 8 years. Three fe-
males had primary amenorrhoea, two menstruated regularly, four were postmenopausal 
and two had previously a hysterectomy. Because of documented insufficiency of thyroid, 
adrenal and/or gonadal function, substitution treatment was eventually instituted in 17, 
18 and 14 out of sixty-two patients, respectively. In all of them a· sellar plus EST size 
of 3 cm2 or more was observed with the exception of a 14-year-old boy with a :t:nainlY 
. . 
suprasellar -located chromophobe adenoma. 
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TABLE 1. Referred pattern and clinical features in sixty-two consecutive patients with hyper-
prolactinaernia and a pituitary tumour. 
Menstrual disorders and infertility 
Galactorrhoea 
Masopathia cytica 
Male infertility 
Impotence 
Headache 
Visual disturbances 
Complaints related to endocrine deficiencies 
Paresis (eye muscles excl.) 
Cerebrospinal fluid rhinorrhoea; 
Via examination of family with MEN I II 
Increase of weight§ 
Total 
* % of the female patients 
t twenty-two female patients (see text) 
:j: % of the male patients 
§ without hypothyroidism 
II MEN I = Type I multiple endocrine neoplasia syndrome 
Radiological evaluation 
Mode of 
presentation 
n % 
20 
3 
2 
2 
2 
9 
10 
7 
3 
I 
4 
62 
32 
5 
3 
3 
3 
15 
16 
11 
5 
2 
6 
IOO 
Overall 
prevalence 
n % 
30 79* 
241 39 
5 
2 8l 
9 38t 
35 56 
I2 I9 
I2 I9 
3 5 
2 
7 11 
A normal sella was present in 6% (mean sellar size: 1·1 cm2), sellar asymmetry 
without enlargement in 19% (mean sellar size: 1·2 cm2), and an enlarged sella without 
extrasellar extension in 31% of the patient~ (mean sellar size: 2·3 cm2). In 44% of the 
patients extrasellar extension was present as judged by radiological and perimetrical exa-
mination (mean sellar plus EST size: 7·3 cm2). The lateral area of the sella and EST 
varied between 1 and 25 cm2 • In our male patients the average sellar and EST size was 
considerably larger than in the female patients (6·08 ± 5·15 cm2 as opposed to 2·88 ± 
2·74 cm2 ; mean ± SD; P < 0·01). No correlation was observed between age and sellar 
and EST size. 
Only one of the thirty-six patients with a sellar plus EST size of less than 3 cm2 showed 
radiological evidence of suprasellar extension of the tumour (Fig. 1). This 14- year-old 
boy, to whom we referred above, turned out to have a chromophobe adenoma that was 
located mainly above the diaphragma sellae while on plain radiography only minor ab-
normalities .of the sella turcica was observed. Apart from this patient, who had bitempo-
ral hemianopsia, three others out of thirty-six patients with a sellar size of less than 3 
cm2, showed slight visual field defects without radiologically evident suprasellar extensi-
on. One of these three patients had a partially empty sella. 
193 
0 Extension mto sphenoid sinus 
C Visual field defect 
B Suprasellar extension 
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Fig. 1. Tumour size (=lateral area of the sella plus extrasellar tissue) in relation to the presence of extrasellar 
extension by radiological and perimetrical criteria (n = 62). It may be noted that there is some over-
lap of the groups of patients represented in the upper three panels (B, C, D). A patient may be repre-
sented in one, two or three of these panels, while all patients represented in the lowest panel by 
definition do not occur in one of the other three. Closed symbols represent female patients. 
Twenty-four out of the twenty-six patients (92%) with a lateral area of the sella plus EST 
above 3 cm2 showed extrasellar extension (suprasellar and/or into the sphenoid sinus) 
as shown by radiography and examination of the visual fields. Two out of these twenty-
four patients (sellar plus EST size: 4·9 and 10·1 cm2) showed only impairment of the 
visual fields without radiologically detectable suprasellar extension of the tumour. One 
patient with a sellar plus EST size of 9·1 cm2 showed infrasellar extension of the tumour 
only. Twenty-one patients had radiological evidence of suprasellar extension of the pitui-
tary tumour, in five cases without impairment of the visual fields. Eight of the twenty-
one patients also showed extension of the tumour into the sphenoid sinus. 
When we take into consideration the size of the sella only (i.e. without the area of EST 
if present) six patients with a tumour size of more than 3 cm2 turned out to combine ex-
trasellar extension with a sellar size ofless than 3 cm2 (five of them between 2-3 cm2). 
This means that of the forty-two patients with a sellar size of less than 3 cm2 , seven had 
evidence of extrasellar extension (17%), in contrast to eighteen out of twenty patients 
with a sellar size exceeding 3 cm2 (90%). 
In a control group of 100 patients without evidence of pituital!' pathology, the sellar floor 
was not visible on plain frontal radiographs in seventeen cases. In the other eighty-three 
individuals in this control group there was a good correlation (r = +0·69, P < 0·0005) 
between the results of our area measurement and those of the volume calculation accor-
ding to Di Chiro & Nelson (Vz x length x height x width) (1962). In thirty~six patients 
with a pituitary tumour and hyperprolactinaernia, in whom we have perfoniled volume 
measurements, there was a stronger correlation· between (log) area and (log) volume 
(r = +0·96, P < 0·0005) than in the control group. In these patients there was a signifi-
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cant positive correlation between (log) area and (log) sellar width (r = +0-63, P < 
0-0005), while in the control group (n = 83, r = -0-179, P < 0-05) this correlation 
was lacking. 
Endocrinological evaluation 
Prolactin levels 
Basal PRL levels varied between 17-5000 ng/ml in forty-seven as yet untreated pa-
tients, and between 17-27000 ng/rnl in fifteen treated patients. In the untreated patients 
a positive correlation existed between (log) sellar plus EST area and (log) basal PRL 
(Fig. 2; n = 47, r = +0-68, P < 0-0005). The same applied to the (log) volume and 
(log) basal plasma prolactin (n = 24, r = +0-66, P < 0-0005). 
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Fig. 2. Correlation between (log) tumour size (=lateral area of the sella plus extrasellar tissue) and (log) ba-
sal prolactin level in forty-seven untreated patients (r = 0·68, P < 0·0005). Closed symbols repre-
sent female patients. 
TSH 
Basal TSH (log) showed a negative correlation with (log) sellar plus EST size (P < 
0-025). In forty-one untreated patients a negative correlation was shown between (log) 
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sellar plus EST size and (log) .6. TSH (P < 0-01; Fig. 3). At sellar plus EST sizes of 
3 cm2 or more twelve of the sixteen patients (75%) had an impaired response in relation 
to normal males and females (Table 2) in contrast to six of twenty-five patients with a 
value less than 3 cm2 (24%). Taking a value of .6. TSH of 5 mU/1 as the normal lower 
limit (Hershman, 1978; McLaren et al., 1974) subnormal responses occurred in eight 
of sixteen patients (50%) with a sellar plus EST size of 3 cm2 or more against in only 
one of twenty-five patients (4%) with an area of less than 3 cm2 (P < 0-0025). 
In this group of patients a tumour size of 3 cm2 also appeared critical with respect of 
the circulating thyroid hormone concentrations in plasma (Klijn et al., 1979). Decreased 
or low normal values of T4 and T3 occurred only in patients with a tumour size above 
3 cm2 (57 and 62% respectively). 
J: 
(f) 
1-
<l 
.. 
0 
• 
~· ... 
•• 0 ~ 
. . ...... 
••• • 0 •• 
0 
• 
0 
0 0 
0 
Tumour size (cm2 ) 
Fig. 3. Relationship between (log) tumour size (=lateral area of the sella plus extrasellar tissue) and (log) 
.::1 TSH in the TRH test in forty-one untreated patients (r = 0·36, P < 0·01)". Closed symbols repre-
sent female patients. 
Gonadotrophins 
Basal plasma LH and FSH levels (log) showed a negative correlation with (log) sellar 
plus EST size (both P < 0-005). A negative correlation existed also between (log) .6. 
LH as wel as (log) .6. FSH (Fig. 4A) and (log) sellar plus EST size: P < 0·0005 and 
P < 0-005, respectively. In the female patients, (log) oestradiol was negatively correla-
ted with (log) sellar plus EST size (n = 21, r = -0-45, P < 0·025). The partial correla-
tion coefficient for the relationship between sellar plus EST size and .6. LH after 
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T ABEL 2. R~lationship between tumour size ( = sella+ extrasellar tissue size) and the prevalence 
of endocrine deficiencies 
< 3 cm2 ;;.: 3 cm2 
Decreased Ll TSH 6/25 (24%) 12/16 (75%) 
(in relation to matched controls) 
Decreased LlTSH ( < 5 mUll) 1/25 (4%) 8/16 (50%) 
Decreased LlLH 5/25 (20%) 8115 (53%) 
Decreased LlFSH 4/25 (16%) 11/14 (79%) 
Impaired metyrapone test 1/30 (3%) 7/16 (44%) 
* Significance of difference assessed using x2-test 
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Fig. 4. A. Relationship between Oog) tumour size (lateral area of the sella plus extrasellar tissue) and Oog) 
A FSH in the LHRH test in thirty-eight untreated patients (r = -0·47, P < 0·005). Closed symbols 
represent female patients. B. A histogram concerning the relationship between tumour size and the 
incidence of an impaired FSH response to LHRH. Solid boxes indicate an impaired response. Diffe-
rence between patients with a tumour size above and below 3 cm2 : P < 0·0025 (x2-test). 
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Fig. 5. Relationship between (log) ,::1 FSH and ,::1 LH in thirty-nine untreated patients with hyperprolactinae-
mia and a pituitary tumour (r = +0·79, P < 0·0005). 
exclusion of the influence of oestradiol was -0·63 (P < 0·005). On the other hand the 
partial correlation coefficient for the relationship between sellar plus EST size and 
oestradiol after exclusion of the influence of~ LH was -0·1171 (n.s.). 
A subnormal increase of LH after administration of 100 p,g LHRH i. v. was seen in eight 
out of fifteen patients (53%) with a sellar plus EST size of 3 cm2 _or more against five 
out of twenty-five patients (20%) with a sellar plus EST size of less than 3 cm2 (Table 
2 3 4 5 6 7 8 9 10 II 12 13 14 15 25 26 
Tumour size (cm 2 ) 
Fig. 6. Frequency distribution of impairment of the metyrapone test in forty-six untreated patients in relation 
to tumour size (lateral area of the sella plus extraseliar tissue). Solid boxes indicate an impaired mety-
rapone test. 
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2, x2-test, P < 0·05). A subnormal response of FSH was observed in eleven out of four-
teen patients with a sellar plus EST size of 3 cm2 or more (79%) against four out of 
twenty-five (16%) patients with a sellar plus EST size below this value (Fig. 4B, x2-test 
P < 0-0025). At tumour sizes between 2 and 3 cm2 a decreased LH and FSH response 
occurred in three and two out of the five patients respectively. A very close relationship 
was noted between (log) A LH and (log) A FSH (Fig. 5; P < 0·0005). 
Hyper-responses of FSH and LH occurred only in women with a sellar size of less than 
2·5 cm2 (50 and 60% respectively). The mean age of these female patients with a hyper-
response (29 years) was not significantly different from that of the other female patients 
(33 years). 
ACTH 
A negative correlation was also observed between sellar plus EST size and plasma de-
soxycortisol after metyrapone in thirty-six patients (P < 0·025). Of the forty-six patients 
in whom the integrity of the pituitary-adrenal axis was judged either by the plasma de-
soxycortisollevel or the increase of urinary 17-0HCS after metyrapone or both, sixteen 
patients had a sellar plus EST size of 3 cm2 or larger (Fig. 6). Seven of these patients 
(44%) had an impaired response, in contrast to only one patient with a slight impairment 
of the metyrapone test in the thirty patients with a sellar size below 3 cm2 (x2-test, P 
< 0·0025). 
DISCUSSION 
In patients with hyperprolactinaemia and a pituitary tumour we investigated the relation-
ship between morphological and functional indices of the pituitary and the tumour. Al-
though an exact volume measurement of the pituitary tumours would be ideal, we have 
used the largest lateral area of the sella turcica plus EST as an estimate of the tumour 
size, instead of a volume measurement. A planimetric area determination is more accura-
te than measuring two linear dimensions (Di Chiro & Nelson, 1962; Hurxthal, 1947). 
Although in patients without a pituitary tumour a small lateral area of the sella turcica 
can be accompanied by a large width of the sella (Fischer & Di Chiro, 1964) and al-
though in 'normal' adults there is a tendency to an inverse correlation between the area 
and the width of the sella turcica (Seki, 1965), in our patients with a pituitary tumour 
we found a significant positive correlation between lateral sellar or tumour area and sel-
lar width. In a number of the patients it was ultimately not possible to calculate the sellar 
and tumour volume with Di Chiro's formula. In those patients in whom a calculation 
of sellar EST volume could be performed an excellent correlation between both indices 
was found. So, in patients with a pituitary tumour the area of the sella (+EST) is a useful 
measure for tumour size. 
In the literature a distinction is generally made between micro- and macroadenomas, 
with and without extrasellar extension (Hardy et al., 1978; Chang et al., 1977; Wilson 
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& Dempsey, 1978; Jaquet et al., 1978). Microadenomas are defmed as adenomas having 
a diameter ofless than 10 mm. Newton (1978) found that in 100 patients with suspected 
prolactin-secreting pituitary adenomas, all patients with intracapsular adenomas of more 
than 10 mm in diameter (at operation) had abnormal sellar volume and all patients with 
intracapsular tumours less than 10 mm in diameter had normal sellar volume. Venzina 
(1978) never found suprasellar extension in patients with grade 1 microadenomas (that 
is exhibiting discrete modifications of the sellar floor only). Studying the incidence of 
extrasellar extension in relation to the accurately measured tumour area in patients with 
a pituitary tumour and hyperprolactinaemia, we found that an area of 3 cm2 is rather 
critical. Below this value (microadenomas and smaller macroadenomas) extrasellar ex-
tension of the tumour (either supra- or infrasellar) rarely occurs. When tumour size ex-
ceeded 3 cm2, however, the chance of extrasellar extension by radiological and 
perimetrical examination, increased sharply to 92% of the patients. Looking at the area 
of the sella only, the presence of extrasellar extension increases already at sellar sizes 
between 2 and 3 cm2 (namely to five out of fifteen). Below a sellar size of 2 cm2 the 
incidence is two out of twenty-seven patients. Extrasellar extension of the tumour is un-
common in patients with a normally sized sella with localized alterations or a double 
contour. 
Therefore, we have now decided to omit air-encephalography in this group of patients 
with hyperprolactinaemia, provided a CAT -scan is normal, excluding the presence of a 
suprasellar tumour. However, at sellar sizes above 2 cm2 (or when plasma prolactin le-
vels exceed 400 ng/rnl) we judge an examination with regard to suprasellar extension 
(CAT-scan, potentially followed by a AEG) necessary. When the sellar area exceeds 3 
cm2 we consider air-encephalography on a routine base. 
With regard to the relationship between the size of the sella turcica and plasma prolactin 
levels, Child et al. (1975) described a positive correlation between (log) sellar area ( < 
3 cm2) and (log) basal prolactin level ( < 1000 ng/rnl). Our data confirms this correlation 
for a larger group of untreated patients with a wider variation in tumour size (1-25 cm2) 
and in basal prolactin level (17-5000 ng/rnl). A practical consequence of this finding 
is the urge to look carefully for extrasellar extension when PRL levels are disproportio-
nately high in relation to the size of the sella. In the group of patients with a microadeno-
ma plasma prolactin levels varied between 17 and about 400 ng/rnl and no correlation 
between sellar size and prolactin levels was found. This might be explained by the discre-
pancy between sellar and adenoma size and relative importance of peaks of secretion 
from normallactotroph cells or adenoma cells in this category of patients. In cases, ho~ 
wever, where the size of the microadenomas had been established (Bernasconi et al., 
1978) after surgical intervention (diameter 5-10 mm) there was no observed correlation 
between this size and prolactin levels. This may also be explained by difference in secre-
tory activity of the adenoma cells from patient to patient. 
We also studied the relationship between sellar plus EST size and the occurrence of se-
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condary endocrine deficiencies. We found that a tumour size of 3 cm2 is not only impor-
tant with regard to the incidence of extrasellar extension of the tumour but also with 
regard to the incidence of loss of pituitary functional reserve. We demonstrated that abo-
ve a sellar plus EST size of 3 cm2 disturbances in the responses to TRH, LHRH and 
metyrapone occur with a rather striking increase in frequency. Pituitary insufficiency 
may be associated with intrasellar as well as with suprasellar processes. In our series, 
a diminished hormonal reserve could be found in patients without suprasellar extension 
of the tumour, whereas a normal reserve was not uncommon in patients with suprasellar 
extension. This makes the evaluation of the relative importance of anterior lobe cell 
destruction on the one hand, and of destruction of the hypothalamo-pituitary connection 
on the other hand, very difficult as causes of function loss. 
The TSH response to TRH is related to age and sex (Snyder & Utiger, 1972; Sowers 
et al., 1976; Hershman, 1978). In comparison with a control group matched with respect 
to age and sex, marginally low responses of TSH occurred both above and below a sellar 
plus EST size of3 cm2 , but definite abnormal responses ofTSH (less than 5 mU/1) main-
ly occurred above a sellar plus EST size of 3 cm2• 
In patients with pituitary tumours accompanied with hyperprolactinaemia the response 
.of LH and FSH to LHRH may either be normal, excessive or subnormal (Zarate et al., 
1973; Mortimer et al., 1973; Thorner et al., 1974; Glass et al., 1975; Franchimont et 
al., 1975; Archer et al., 1976; Chang et al., 1977; Campenhout et al., 1977). We found 
a significant difference between the incidence of an impaired response of LH and FSH 
to LHRH in patients with a sellar plus EST size above and below 3 cm2 , respectively. 
Above a sellar plus EST size of 2 cm2 the incidence of an impairment of the pituitary-
gonadal axis increases (LH and FSH, P < 0·05 and < 0·0025, respectively). The signi-
ficant partial correlation between tumour size and Ll. LH, after exclusion of the influence 
of oestradiol-17 (3, shows that tumour size, not lack of oestradiol-17 (3, is the causal factor 
in this diminished Ll. LH. 
According to several authors the response of FSH to LHRH tends to be more exaggera-
ted than the LH response (Asfour et al., 1977; Lachelin et al., 1977; Kletzky et al., 
1977). However, Healy et al. (1977) found hyper-responses of both FSH and LH not 
only in patients with hyperprolactinaemic secondary amenorrhoea but also in patients 
with normoprolactinaemic secondary amenorrhoea. We observed parallel hyper-
responses of FSH and LH to LHRH only in female patients, and only when tumour size 
is less than 2·5 cm2 . An increased incidence ofFSH hyper- responsitivity relative to that 
of LH was not found. 
With regard to the pituitary-adrenal axis we found that the ACTH reserve was preserved 
somewhat better than TSH and gonadotrophin reserve. Impairment was almost totally 
restricted to patients with sellar plus EST size of more than 3 cm2 • 
In patients with a pituitary tumour and hyperprolactinaemia, the rather sharply increased 
incidence of supra- or intrasellar extension of the tumour and of anterior lobe hormone 
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deficiencies at sellar plus EST sizes above 3 cm2, is of great importance for determining 
the correct management of these patients. We have previously showed that an impaired 
response ofLH and FSH to LHRH in patients with prolactin secreting pituitary tumours, 
greatly diminishes the possibility of obtaining ovulatory cycles after normalization of cir-
culating PRL levels by bromocriptine therapy (Lamberts et al, 1978). We consider a sel-
lar (+EST) area of more than 3 cm2 as 'high risk' and a sellar area between 2 and 3 
cm2 as 'potential risk'. On the basis of the data presented here it appears necessary to 
perform a trans-sphenoidal adenomectomy before the sellar size has exceeded 2-3cm2 • 
With respect to the problems that may arise during pregnancy, an increased incidence 
of extrasellar extension and hormonal insufficiency during pregnancy is to be expected 
in female patients with a sellar size above 2-3 cm2 before pregnancy. 
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CHAPTER ,IV 
INTERRELATIONSHIPS BETWEEN TUMOUR SIZE, 
AGE,. PLASMA GROWTH HORMONE AND 
INCIDENCE OF EXTRASELLAR EXTENSION IN 
ACROMEGALIC PATIENTS 
J.G.M. Klijn, S.W.J. Lamberts, F.H. de Jong, K.J. van Dongen and 
J.C. Birkenhager 
Department of Medicine (III) and of Clinical Endocrinology, University Hospital 
'Dijkzigt', Erasmus University, Rotterdam, the Netherlands 
SUMMARY 
In 44 consecutive acromegalic patients we studied the interrelationships between tumour 
size, age, incidence of extrasellar extension, growth hormone levels and 'tumour 
growth'. These parameters were compared with results from a previous study in 62 pro-
lactinoma patients. It appeared that the incidence of extrasellar extension in acromegalic 
patients was lower than in the prolactinoma patients (32 versus 44%). In acromegalic 
patients extrasellar extension occurred on the average at a lateral sellar and tumour area 
of almost 1 cm2 larger than in prolactinoma patients (with respect to sellar size generally 
above 3 cm2 versus 2 cm2 , with respect to tumour size generally above 4 cm2 versus 
3 cm2). 
Log tumour size and log basal growth hormone level were positively correlated 
(P < 0·0005). In the acromegalic patients there was a negative correlation between the 
size of the pituitary tumour and the age of the patient (P < 0-005) in contrast to the 
absence of such a relationship in the prolactinoma patients. In the group of acromegalic 
patients mean tumour size decreased gradually from the third to the sixth decade (5.0, 
3.8, 3.0 and 2.3 cm2 , respectively). The interval between the time of appearance of 
symptoms and the time of diagnosis was significantly shorter in younger patients and in 
women. The restriction of large tumours Oateral area > 5 cm2) to young patients ( < 
35 year) and the short period between the appearance of symptoms and the time of diag-
nosis in these patients indicate that growth hormone secreting pituitary tumours generally 
grow more rapidly in younger patients. 
Reprinted from Acta Endocrinologica 95:289-297 (1980) 
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In patients with a pituitary tumour extrasellar extension of the tumour constitutes one of 
the major complications. In a previous study we demonstrated that in 62 patients with 
hyperprolactinaemia and a pituitary tumour a sellar size or a 'tumour size' of 2-3 cm2 
-as measured directly with a planimeter on the lateral X-ray of the skull- represented 
a critical limit for the presence of extrasellar extension of the pituitary adenoma (Klijn 
et al. 1980b). A positive correlation between tumour size and the plasma prolactin (Prl) 
level was found. In acromegalic patients such a correlation between tumour size and ba-
sal growth hormone (GH) level is not well established up to now (Quabbe 1980; Giova-
nelli et al. 1980). Pituitary tumours occur at all ages from puberty onwards, but little 
is known about the influence of age on tumour size and growth. 
The aim of the present study was to answer the following questions. 1) Is the incidence 
of extrasellar extension in acromegalic patients different from that in patients with Prl 
secreting tumours? 2) Are tumour size and basal plasma GH concentration related? 3) 
What is the influence of the age of the individual on tumour growth rate in acromegaly 
and on the chance of extrasellar extension? 
MATERIALS AND :METHODS 
Patients 
Forty-four consecutive acromegalic patients (21 women and 23 men) were investigated. 
They were referred to our endocrine cliiric by specialists in internal mediCine 
(n = 16), gynaecology (n = 5), neurology or neurosurgery (n = 6), ophthalmology (n 
= 2), rheumatology or orthopaedy (n = 6), urology (n = 3) or - incidentally - other 
specialists. All patients were untreated at the time of study. In 32 of them the presence 
of a pituitary tumour was proven by surgery. The others were not operated upon. The 
results of this study were compared with those of a previous investigation of 62 patients 
(38 women and 24 men) with hyperprolactinaemia and a pituitary tumour without growth 
hormone excess (Klijn et al. 1980b and in press). 
Methods and materials 
All patients were investigated by plain radiography, lateral polytomography (hypocycloi-
dal, sections of 2 mm) and complete ophthalmological evaluation, including perimetry. 
Further radiological examination consisted of air-encephalography (AEG) and - in most 
cases - carotid angiography. As a measure of tumour size we have chosen the largest 
lateral area of the sella in combination with that of extrasellar tissue (EST), if present. 
The largest lateral area of the sella +EST was measured on a plain lateral X-ray after 
verification of the true sellar and extrasellar tissue outlines by means of lateral polytomo-
graphy and the lateral tomograms of the AEG. Direct surface measurements were car-
ried out with a planimeter as described in detail before (Klijn et al. 1980b). Normal 
values for sellar size are between 0.7and 1.4 cm2 (95% range in 100 patients without 
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TABLE 1. Referred pattern and clinical features in 44 consecutive acromegalic patients. 
Mode of Overall 
presentation prevalence 
n % n % 
Change of appearance/soft tisue swelling/ 
acral growth 6 14 44 100 
Weight gain 20 45 
Gigantism 2 
Acroparaesthesias 3 7 31 70 
Facial neuralgias 3 7 
Arthropathy 2 5 13 30 
Back pain 1 2 9 20 
Tiredness 2 25 57 
Hyperhidrosis 2 36 82 
Thirst (without diabetes insipidus) 6 14 
Hypertrichosis 14 32 
Ear/nose/throat complications 2 14 32 
Hypertension 4 9 9 20 
Cardiac complications 2 5 10 23 
Impaired glucose tolerance 13 30 
Manifest diabetes mellitus 2 
Abdominal pain 3 7 14 32 
Inguinal or umbilical hernia 10 23 
Renal stones 3 7 8 18 
Goitre 18* 41 
Headache 6 14 23 52 
Hypersornnolence 4 9 
Loss of concentration and/or memory 4 9 
Visual impairment 2 5 6 14 
CSF-rhinorrhoea 2 
Oligo-, amenorrhoea/infertility 5 24** 11 52** 
Impotence 4*** 10 43*** 
Loss of libido 11 25 
Galactorrhoea 2 10 48** 
Cystic mastopathy 4 19** 
Diagnosis by chance 2 5 2 5 
* One patient with a papillary carcinoma. 
** Percentage of the female patients. 
*** Percentage of the male patients. 
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-pituitary pathology). The area of the sella (+EST) was also measured by means of 
square mm paper. 
Plasma GH levels were measured by a homologous radioimmunoassay (IRE, Belgium), 
and Prl according to Kwa et al. (1973). Normal basal Prl values are up to 15 and 12 
ng/ml for women and men, respectively. The biochemical diagnosis of acromegaly was 
made on the basis of the absence of a suppression of plasma GH concentrations to less 
than 5 ng/ml in response to an oral glucose load (100 g). 
Statistical analysis of the data was performed using regression analysis, two-tailed Stu-
dent's t-test or X2-test. 
D. extension into 
sphenoid sinus 
GO 0 0 .. 
c. visual field 0 .. ... 0 0 
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B. suprasellar 
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-
•:. 0 0 
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Fig. L Tumour size (=lateral area of the sella+ extrasellar tissue) in relation to the presence of extrasellar 
extension by radiological and perimetrical criteria in 44 untreated acromegalic patients. There is some 
overlap of the groups of patients represented in the upper three panels (B, C, D). A patient may be 
represented in one. two or three of these panels. Closed symbols represent female, open symbols 
male patients. 
RESULTS 
Epidemiological and clinical evaluation 
The mean age of the 21 female patients was 39 years (median 40 years, range 19-74 
years) and of the male patients 40 years (median 41 years, range 21-71 years). There 
was a preponderance of patients between 20 and 50 years. Histological examination of 
tumour material of the 32 operated patients revealed the presence of a chromophobe ade-
noma in ten cases, an acidophil adenoma in nine cases and a mixed adenoma in nine ca-
ses. In four patients a precise histological diagnosis was not obtainable. 
The referral pattern and clinical features are summarized in Table 1. One of the acrome-
galic women menstruated regularly, nine were (post) menopausal and 11 had secondary 
oligo- or amenorrhoea. The mean duration of the secondary menstrual disorder was 4.5 
years (range 1,4-15 years). Amenorrhoea occurred in three patients after cessation of oral 
contraceptive treatment and in one patient after childbirth. In 10 of these 11 patients with 
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Fig. 2. Correlation between log tumour size (=lateral area of tbe sella + extrasellar tissue) and log basal 
growth hormone in 44 untreated acromegalic patients (r = 0.59, P < 0.0005). Closed symbols 
represent female patients. 
oligo- or amenorrhoea the plasma Prl level was estimated. Three of them had a high 
basal Prllevel (137, 174 and 183 ng/ml, respectively), six a mild hyperprolactinaernia 
(range 19-43 ng/ml) and one a normal Prllevel (4 ng/ml). Galactorrhoea occurred in 
10 out of 44 patients, all women (mean age 30 years, none of them older than 50 years). 
All but one had hyperprolactinaernia. 
Radiological and ophthalmological evalution 
In all patients the sella turcica was enlarged. The lateral area of the sella +EST varied 
between 1.5 and 13.6 cm2 with a mean of 3.64 cm2• There was no difference in tumour 
size between women and men (3.50± 1.69 cm2 versus 3.76±2.63 cm2 ; mean ±SD). In 
14 patients (32 %) extrasellar extension of the tumour was present radiologically (mean 
sellar +EST size: 5.9 cm2). Ten patients (23%) had suprasellar extension, six (14%) 
of them with visual field defects and one of them with infrasellar extension. Four patients 
showed infrasellar extension of the tumour only (Fig.1). In the 30 patients without extra-
sellar extension mean sellar size was 2.6 cm2 • Extrasellar extension occurred only at tu-
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mour sizes of more than 3 cm2 , namely in 14 out of 22 patients with a tumour size of 
more than 3 cm2 (64%). However, only two out of nine patients with a tumour size be-
tween 3 and 4 cm2 showed extrasellar extension, while at a tumour size of above 4 cm2 
extrasellar extension was present in 12 out of 13 patients (92%). Besides the increase 
in size the sella turcica of 37 patients was more or less asymmetrical. In 20 cases the 
left side was larger, in 17 cases the right side. 
When we take into consideration the size of the sella only (i.e. without the area of EST, 
if present) two patients with a tumour size of more than 3 cm2 turned out to combine 
extrasellar extension with a sellar size of less than 3 cm2 (2.5 and 2.4 cm2). This means 
that of the 23 patients with a sellar size of less than 3 cm2 only two had evidence of extra-
sellar extension (9%) in contrast of 12 out of 21 patients with a sellar size exceeding 
3 cm2 (57%). Taking the group of patients with a sellar size between 2 and 3 cmz only 
two out of 16 patients had extrasellar extension (13%). 
There was good agreement between the results of the two different methods of area mea-
surements of tumour (n = 44; r = +0.993; P < 0.0005). The slope of the regression 
line was 1.004, the intercept -0.14 cm2• 
Endocrinological evaluation 
Growth hormone was measured in all 44 patients before treatment. The basal GH level 
(mean of 2 or more estimations) varied between 7 and 720 ng/rnl with a mean of 81 
ng/rnl in the female patients and 59 ng/rnl in the male patients. There was a positive cor-
relation between the logarithm of the sellar +EST area and the logarithm of the (avera-
ge) basal GH level (Fig. 2). Furthermore a positive correlation was found between log 
tumour volume (lh x H x D x W according to Di Chiro & Nelson 1962) and log basal 
GH in those patients in whom the width of the sella floor was measurable on an antero-
posterior plain X-ray (n = 36, r = 0.48; P < 0.01). A good correlation appeared to 
exist between the area and volume measurements of the tumours (n = 36, r = 0.955, 
P < 0.0005) as previously also found in patients with hyperprolactinaemia and a pituita-
ry tumour (Klijn et al. 1980b). 
Hyperprolactinaemia was observed in 13 (54%) out of 24 untreated patients. Prolactin 
levels of more than 100 ng/rnl were found in only three of these patients. 
Data with regard to pituitary-target organ function in these patients before treatment have 
been published before (Klijn et al., in press). Hypothyroidism was encountered in only 
one patient. This is to be compared to the occurence of a low TT4level ( < tlg/100 rnl) 
in 31 % of prolactinoma patients with the same range of tumour size as found in the acro-
megalic patients (~ 1.5 cm2). An abnormal metyrapone test was found in four out of 
the 36 investigated acromegalic patients (11%; tumour sizes: 2. 7, 4.1, 6.9 and 7.0 cm2). 
In the group of prolactinoma patients with an enlarged sellar area ( ~ 1.5 cm2) an impai-
red metyrapone test was found in eight out of 33 patients (24%). A decreased gonado-
trophin secretion was present in 12 out of 42 (29%) investigated acromegalic patients 
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(in contrast to about 50% of the prolactinoma patients with the same range of tumour 
size). All these 12 patients had tumour sizes of more than 2.5 cm2 (only two of them 
below 3 cm2). 
Acromegaly 
A tumour size 
3 
n= 14 n=9 n= 11 n=5 n=5 
10 20 30 40 50 60 70 year 
tumour size 
(cm2) 
0 
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• 
7 0 0 
• 
• • 
00 
5 • 
• 
0 0 
3 • • 
0 • 
0 0 
• 
10 15 20 25 :.jo 35 40 45- 50 55 60 65 70 year 
age 
Fig. 3. Correlation between age and tumour size ( = lateral area of the sella + extrasellar tissue) in 44 un-
treated acromegalic patients (r = 0.48, P < 0.005). In panel A the arrows represent SEM. Closed 
symbols indicate female patients. 
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Relation of age to tumour size and tumour growth rate 
In the acromegalic patients we found an evident negative relationship between tumour 
size and age (Fig. 3A and B). The mean tumour size decreased gradually from the third 
to the sixth decade (4.98 ± 3.04; 3.82 ± 1.89; 3.02 ± 0.92; 2.30 ± 0.75; mean 
± SD). This contrasts with the fmdings in our group of prolactinoma patients (Fig. 4). 
The nine acromegalic patients with the largest tumours ( > 5 cm2) were all younger than 
35 years. Likewise 10 out of the 14 patients with extrasellar extension were less than 
35 years old. On the other hand 15 out of 18 patients with a tumour size below 2.5 cm2 
were more than 35 years old. All three histological tumour types (acidophil, chromopho-
be, or mixed) were present in the group of patients with large tumours. 
As to the mean period between the time of onset of symptoms of acromegaly and the 
time of diagnosis, two points are remarkable (Table 2). Firstly this delay was found to 
be shorter in younger patients and secondly there was a significant difference between 
women and men of all ages (4.1 year and 8.6 year, respectively, P < 0.001.). 
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Fig. 4. Relationship between age and tumour size in 62 untreated patients with hyperprolactinaernia and a 
pituitary tumour (without GH excess). Closed symbols represent female patients. 
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TABLE 2. Mean delay (in years) between start of symptoms and time of diagnosis. 
Age group 
(years) Women n Men n Total n 
19 - 30 2.1 8 4.2 5 2.9 13 
31 - 40 5.0 3 9.3 7 8.0 10 
41 -50 7.2 5 10.1 6 8.8 11 
51 - 70 3.6 5 10.4 5 7.0 10 
All patients 4.1 +3.1 *years 21 8.6+5.1*years 23 6.5 years 44 
* P< 0.001 
DISCUSSION 
The frequency of the various clinical manifestations of acromegaly in our patients is on 
the whole in reasonable agreement with previous reports (Davidoff 1926; Davis 1941; 
Kellgren et al. 1952; Wright et al. 1970; Hirsch et al. 1969; Daughaday 1974). The high 
frequency of tiredness without hormonal insufficiency might be explained by myopathy 
(Mastaglia et al. 1970), abnormal joint mechanics (Kellgren et al. 1952), peripheral neu-
ropathy caused by soft tissue swelling and perineural or endoneural fibrous proliferation 
(Daughaday 1974) and/or cardiac disease (Hirsch et al. 1969). Remarkable was a relati-
vely high frequency of inguinal hernia in our acromegalic men (30%). 
The incidence of extrasellar extension in the acromegalic patients (32%) was lower than 
in the prolactinoma patients (44%), whose data we reported before (Klijn et al. 1980b). 
With respect to pituitary tumour size extrasellar extension is uncommon below a size of 
3 cm2 in both groups of patients. However, above a tumour size of 3 cm2 the frequency 
of extrasellar extension is lower in the acromegalic (64%) than in the prolactinoma 
patients (92%), as there appears to be a cluster of acromegalies with a tumour size of 
between 3 and 4 cm2 without extrasellar extension (Fig. 1). However, at tumour sizes 
of more than 4 cm2 extrasellar extension occurred in 92% of the acromegalic patients 
also. 
Using the lateral sellar area (i.e. without the area of EST) a lower incidence of extrasel-
lar extension of the tumour was again observed in acromegaly as compared to prolactino-
ma patients. In the patients with a sellar size of less than 3 cm2 radiological evidence 
of extrasellar extension was found more frequently in the prolactinoma patients than in 
the acromegalies (17% versus 9%), as especially reflected in the relatively high inciden-
ce of extrasellar extension in prolactinoma patients with a sellar size between 2 and 3 
cm2 (33% versus 13%). In the patients with a sellar size of more than 3 cm2 the frequen-
cy of extrasellar extension was also higher in the prolactinoma patients than in the acro-
megalies (90% versus 57%). In summary it appeared that on the average in acromegalic 
patients extrasellar extension occurred at sellar and tumour sizes of 1 cm2 larger than 
in prolactinoma patients (for tumour size 4 cm2 versus 3 cm2 , for sellar size 3 cm2 versus 
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2 cm2). In our experience ballooning of the pituitary fossa occurred frequently in acro-
megaly as also reported by Pribram & du Boulay (1971). We think that the lower fre-
quency of extrasellar extension and the occurrence of this complication at larger tumour 
sizes in acromegalic patients may be caused by a (indirect) GH effect on the sella turcica 
wall itself. Growth hormone was found to be 'the most effective bone growth stimulating 
pituitary hormone' (Thorngren & Hansson 1977). We propose the following hypothesis. 
Acromegalic patients have an increased bone tissue turnover rate with increased peri-
osteal bone formation (Roelfsema 1972; Daughaday 1974). The pituitary fossa bone wall 
may therefore adapt more easily to the pressure of an expansive pituitary tumour than 
when a pituitary tumour is present without GH excess. It is also possible that in acrome-
galic patients the pituitary fossa tends to increase in size anyhow just as the frontal, 
mastoid and ethmoid sinuses may enlarge considerably. However, with further increa-
sing tumour size the intrasellar pressure will ultimately be sufficiently high to cause ex-
trasellar extension, but at larger tumour sizes in acromegalic patients than in patients 
with other pituitary tumour types. 
Hypothyroidism, decreased gonadotrophin secretion and insufficient pituitary adrenal 
function occurred also less frequently in the acromegalic patients than in our group of 
patients with hyperprolactinaemia and a pituitary tumour, especially when the same ran-
ge of tumour size is considered (i.e. after exclusion of the microprolactinomas). In acro-
megalic patients, however, a high incidence of an impaired TSH response to TRH has 
been noted (Hallet al. 1972; Klijn et al., in press) and a discrepancy between LH and 
FSH secretion (Lindholm et al. 1977). This might be explained by an effect of GH on 
thyroid, gonads and adrenals (for example development of goitre with suppression of 
TSH secretion) or on hypothalamic function. 
We found a positive correlation between tumour size and basal plasma GH level, as we 
reported before for tumour size and the basal plasma Prllevel in patients with a prolacti-
noma (Klijn et al. 1980a,b). Iri the group of acromegalic patients with a small adenoma 
( < 3 cm2) such a relationship was not present. This is in agreement with the findings 
of Giovanelli et al. (1980), who found no significant correlation between plasma GH 
concentration and tumour size in 57 acromegalic-patients with small intrahypophyseal 
GH-secreting tumours (less than 13 mm in diameter at operation). It is noteworthy that 
is our group of patients there may be a wide range of plasma GH levels for a certain 
tumour size. Quabbe (1980) found also that small tumours may be accompained by rela-
tively high plasma GH concentrations, while larger tumours may have relatively low se-
cretory activity. However, our data indicate that plasma GH levels of more than 50 
ng/ml are associated predominantly with a tumour size of more than 2.5 cm2 • 
Pituitary tumours may become manifest at an early age or later in life. The declining 
incidence of microprolactinomas in older patients (Fig. 4) may be explained by a lack 
of symptomatology. The true incidency may however be inferred from the frequency of 
microadenomas in routine autopsies, reported as 2.7% (Hardy 1978), 9% (McCormick 
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& Halmi 1971), and 22.5% (Costello 1935), the frequency of microprolactinomas 6% 
(Kovacs et al. 1979) and the observation of Kovacs et al. (1979) that 8% of a group of 
geriatric patients had an elevated plasma Prl level. 
We know of no previous data concerning a negative correlation between pituitary tumour 
size and age. In our series of patients with acromegaly large tumours above 5 cm2 appea-
red to be uncommon in older patients but were frequent (about 50%) in patients younger 
than 35 years. A second interesting finding is the relatively short period intervening be-
tween the onset of symptoms of acromegaly and the time of diagnosis in the younger 
patients. These two observations indicate that on the whole GH-secreting pituitary tu-
mours grow more rapidly in the younger than in the older patients. Gonadal steroids 
might be implicated in this respect. The longer delay between the clinical appearance 
of acromegaly and the time of diagnosis found in men as compared to women might be 
explained by the fact that men are not so rapidly alarmed by changes in their appearance 
than women. One the other hand photographs taken over the year often show that hyper-
somatotropism must have been present years before complaints are noted. Therefore, 
some of the GH secreting pituitary tumours, arisen in younger patients, grow rapidly 
and others grow more slowly as tumours do in older people. On the basis of our fmdings 
treatment of acromegaly should be more aggressive in younger than in older patients. 
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CHAPTER V 
THE VALUE OF THE 1HYROTROPIN-RELEASING 
HORMONE TEST IN PATIENTS WITH 
PROLACTIN-SECRETING PITUITARY TUMORS AND 
SUPRASELLAR NON-PITUITARY TUMORS 
JAN G.M. KLIJN, M.D.* STEVEN W.J. LAMBERTS, M.D. 
FRANK H. DEJONG, PH.D., JAN C. BIRKENHAGER, M.D. 
Department of Internal Medicine III and of Clinical Endocrinology, 
University Hospital Dijkzigt, Erasmus University, Rotterdam, The Netherlands 
SU1\1MARY 
The prolactin (PRL) response to thyrotropin-releasing hormone (IRH) (t:.PRL) was nor-
mal in 7 (I8%) of 38 patients with clinical evidence of a prolactinoma. A negative per-
centage correlation between basal PRL and t:.PRL was found (P < 0.05), but a 
percentage correlation between tumor size and t:.P RL was absent. In a survey of literatu-
re concerning 548 patients, t:.PRL after 1RH administration amounted to I 00% or more 
of the basal value in II % of patients with clinical evidence of a prolactinoma and in 
9% with an adenoma proven by surgery. Hyperprolactinemia was also present in 12 of 
our 2I patients (57%) with suprasellar tumors not related to pituitary tumors. In 7 of 
11 of these hyperprolactinemic patients (64%) the PRL response to 1RH was decreased. 
In conclusion, the 1RH test may be helpful but is not decisive in the diagnostic work-up 
of hyperprolactinemic patients. 
Fertil Steril 35:I55, I98I 
The diagnostic value of the thyrotropin-releasing hormone (TRH) test in the differential 
diagnosis of hyperprolactinemia is still under discussion. I-S Hyperprolactinemic patients 
with a normal sella turcica or only minor alterations as shown by sellar tomography, re-
ferred to previously as "functional hyperprolactinemia," have been found to harbor mi-
Reprinted from Fertility and Sterility 35:155-161 (1981) 
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croprolactinomas at operation. 8-10 A distinction has been made between patients with 
microprolactinomas (prolactin [PRL]-secreting pituitary tumors less than 1 em in diame-
ter, sella not enlarged) and macroprolactinomas (tumors more than 1 em in diameter, 
enlarged sella). Some authors have reported a diminished PRL response to TRH (.llPRL) 
in all patients with micro- or macroadenomas,2• 5· 8· 10-15but other authors have reported 
a normal response in a minority of their patients (in larger series ranging between 6% 
and 33%).4• 7• 16-20 We investigated the relationship between the response of PRL to 
TRH and the lateral area of the sella or of the pituitary tumor (in case of extrasellar ex-
tension) in 38 patients with clinical evidence of a PRL-secreting pituitary tumor. The re-
lationships between LlPRL and basal PRL, sex, age, thyroid-stimulating hormone (TSH) 
response to TRH, T4, T3, and suppressibility of PRL by bromocriptine, respectively, 
were evaluated. Furthermore, the incidence of a decreased PRL response to TRH was 
investigated in patients with hypothalamic disorders caused by suprasellar non- pituitary 
tumors. 
MATERIALS 
Patients. The PRL response to TRH (400 p.g intravenously) was measured in 38 untrea-
ted hyperprolactinemic patients (28 women) with radiologic evidence of a pituitary tumor 
with the exception of 4 women with a normal sella turcica but with the typical 
galactorrhea-amenorrhea syndrome. In 11 patients (8 women) the presence of a pituitary 
adenoma was subsequently proven by surgery. Plasma PRL levels were also measured 
in 21 patients (13 women) with suprasellar tumors not arising from the pituitary (5 with 
an ectopic pinealoma or germinoma, 4 with a craniopharyngioma, 4 with a dermoid cyst, 
6 with a meningioma, one with an astrocytoma, one with leukemia). In 18 of these pa-
tients a TRH test was carried out. Patients with primary hypothyroidism, renal insuffi-
ciency, or liver disease or who were undergoing drug treatment were excluded. 
Diagnostic Testing. In eight patients with hyperprolactinemia and an abnormal sella (five 
women), in seven acromegalic patients (three women) with normal or slightly increased 
PRL level ( < 35 ng/ml), and in eleven infertile oligospermic men (only one with a 
slightly increased PRL level) TRH tests were performed with two different doses (400 
and 200 p.g intravenously) in an at-random order. The two tests were conducted at an 
interval of 2 to 5 days. In all patients, plain radiography, lateral polytomography of the 
sella, and complete ophthalmologic evaluation, including assessment of the visual fields, 
were performed. Additional radiologic examinations, when indicated, consisted of air 
encephalography, and/ or computerized tomography, and/ or carotid arteriography. The 
largest lateral areas of the sella and of extrasellar tissue, if present, were used as a mea-
sure of pituitary tumor size. Estimation of plasma PRL levels and direct measurements 
of the surface of the sella turcica were carried out as described previously.21 Normal 
values for sellar size ranged from 0. 7 to 1.4 sq em (in 95% of 100 patients without pitui-
tary abnormalities). 
218 
PRL Response. The PRL response to TRH was measured in untreated patients only. 
Blood samples were obtained through an indwelling venous catheter before and 10, 20, 
30, 60 and 120 minutes after the intravenous administration of 400 p,g ofTRH (Hoechst). 
The differences between the highest value for PRL during the test and the basal value 
(..:1PRL), and the percentage increase in plasma PRL above the baseline level (%..:1PRL), 
were used as indices of response. The maximal TSH response to TRH (..:1TSH), plasma 
T4, the free T4 index, and plasma T3 were also estimated, the latter not in all patients. 
In 15 patients with a PRL-secreting pituitary tumor, plasma PRL levels were measured 
every hour for 12 hours and again 24 hours after an oral dose of 2.5 mg of bromo-
criptine. 
Statistical analysis of the data was performed using regression analysis. 
Normal Values. Normal basal plasma PRL values are ~ 15 ng/ml in women (mean 7.1 
ng/ml) and ~ 12 ng/ml in men (mean 4.6 ng/ml). In 22 female control subjects we found 
a range for ..:1PRL between 11.2 and 86.4 ng/ml (mean ± standard deviation 43.6 ± 
20.7 ng/ml) and in 7 normal men a range between 8.6 and 57.6 ng/ml (mean± standard 
deviation 22.9 ± 17.6 ng/ml). In all controls ..:1PRL was more than 100% (for women, 
mean 741%, range 361% to 2260%; for men, mean 638%, range 102% to 1646%). The 
peak PRL value occurred in 7 cases at 10 minutes, in 17 at 20 minutes, in 4 at 30 minu-
tes, and in 1 at 60 minutes after the injection of TRH. 
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RESULTS 
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Fig. 1. Log-log plot of basal PRL levels against absolute PRL responses to TRH in 38 untreated patients 
with clinical evidence of a prolactinoma. • , Female patients. No correlation was demonstrated. 
Patients with Hyperprolactinemia and a Pituitary Tumor. The highest plasma PRL valu-
es were observed in six cases at 0 minute, in eight at 10 minutes, in eleven at 20 minutes, 
in eight at 30 minutes, in two at 60 minutes, and in three at 120 minutes after TRH admi-
nistration. In 11 of 38 patients (29%) the maximal increment of PRL in response to TRH 
was more than 100% of the basal value (Figs. 1 and 2). A normal PRL response on per-
centage basis (in relation to our control population) occurred in 7 of the 38 patients 
(18%). The range of tumor size in these patients varied between 1.0 and 3.8 sq em. In 
16 patients ( 42%) with a wide range in basal PRL levels a PRL response of less than 
20% occurred (Fig.2). Of the 11 patients with a surgically proven pituitary adenoma, 
3 had a APRL of more than 100%. There was no correlation between basal PRL levels 
and APRL as expressed in nanograms per milliliter (Fig. 1), but there was a negative 
correlation between the basal PRL level and the percentage APRL (Fig. 2; P < 0.05). 
No correlation was found between percentage APRL and tumor size (Fig. 3) or ATSH. 
Also no correlation was found between APRL or percentage APRL and age, T4 or T3. 
One dose of 2.5 mg of bromocriptine suppressed the basal PRL level in all 15 patients 
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tested to 15.2% ± 3.2% (mean ± standard error of the mean) of the basal value with 
a range between 4% and 38% (maximal suppression after 7 hours). There was no corre-
lation between the extent of the PRL response to TRH and the decrease in PRL response 
to bromocriptine. 
Patients with Suprasellar Tumors Not Arising from the Pituitary. Of the 21 patients with 
primarily suprasellar tumors, 12 (57%) had elevated basal plasma PRL levels (range 22 
to 182 ng/ml). In 11 of these 12 patients a TRH test was carried out. In seven of them 
( 64%), .::lPRL was less than 100% . In contrast, in only one of seven normoprolactinernic 
patients of this group (14%) in whom a TRH test was carried out, the PRL response 
was decreased. No hyper-responders (.::lPRL > 2000%) were present. Six of the twelve 
hyperprolactinemic patients and six of the nine normoprolactinemic patients had an en-
larged sella. 
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Fig. 2. Relationship between basal PRL levels and the percentage increase in PRL levels after TRH admi-
nistration (both in log scale) to 38 untreated patients with clinical evidence of a prolactinoma (r = 
-0.38; P < 0.05). •, Female patients. 
Comparison of the Effects of 200 and 400 p,g of TRH 
Good agreement between the PRL responses to 200 and 400 p,g of TRH was found in 
seven acromegalic patients and eleven oligospermic infertile men (Fig. 4: r = +0.80, 
P < 0.001). However, in eight patients with a prolactinoma no statistically significant 
correlation between the two responses was observed. In six patients the first test resulted 
in the highest response to TRH regardless of the dose used. One patient did not show 
a response in either test and in one patient (with the largest tumor of all) the second dose 
of 200 p,g of TRH resulted in a higher response than the first one. 
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DISCUSSION 
The diagnostic value of the TRH test in the differential diagnosis of hyperprolactinernia 
has been uncertain. In general, two groups of reports can be distinguished: those recor-
ding an impaired PRL response in all patients with a prolactin-secreting pituitary adeno-
ma and those describing a normal (mostly low-normal) percentage A.PRL in only a 
minority of patients suspected of having a prolactinoma and also in patients with a surgi-
cally proven adenoma (Table 1). 
Most authors have reported a mean A.PRL in normal women 3 to 6 times the mean basal 
value and approximately 3 times the mean basal value in normal men. Although the lo-
wer limit of the normal range for APRL after TRH administration varies from author 
to author, in general the lower limit of the normal increment is taken as 100% of the 
basal value. Our lower limit of the percentage A.PRL in normal women largely exceeded 
100%. 
We found normal responses in 18 % of our patients and a response of more than 100% 
in 29%. Comparable observations have been reported by Ayalon et al.,6 Jeske,7 and 
Guinet et al. 16 We compiled individual data on hyperprolactinernic patients with 
normal-sized (rnicroadenomas) or enlarged sellas (macroadenomas) from 35 reports in-
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No correlation was demonstrated. 
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acromegaly, or a prolactinoma. ~1 , Response to the first test; ~2, response to the second test. 
sofar as these data were presented (Table 1). Of 548 patients investigated we counted 
61 patients (11%) with a APRL of more than 100%; such a PRL response was also found 
in 13 of the 144 patients (9%) with a surgically proven pituitary adenoma. The fact that 
some authors found only blunted responses in their patients with a prolactinoma whereas 
others observed normal responses in a minority of their patients may be explained by 
the selection of patients and/or the size of the group of patients investigated. On the basis 
of the data on these 548 patients it may be concluded that roughly 1 of 10 patients with 
clinical evidence of a prolactinoma will have a PRL response to TRH of more than 2 
times the basal value ("false- positive responder"). 
The dosage of TRH used in the various studies was 200 p,g or more, whereas with 100 
p,g a maximal PRL response is found in normal subjects.37 In our patients with a prolac-
tinoma in whom we carried out a TRH test with 400 p,g as wel as with 200 p,g of TRH, 
the flrst test performed resulted in the highest response to TRH regardless of the dose 
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used. It is known that, in vitro, the secretion of PRL by pituitary tumor cells is much 
higher than the secretion by normallactotrophs and is also higher in relation to the PRL 
content of the cells. 38 The chromophobe aspect of the tumor cells is probably caused by 
a low hormone storage39; thus exhaustion of the cells may be the cause of the lower or 
absent PRL response to TRH in the second test performed. This conclusion is further 
underlined by the observations by Lachelin et al., 10 who also showed that in patients 
with a prolactinoma the basal plasma PRL concentration was diminished after repeated 
administration of TRH. 
Values for APRL lower than 100% after TRH administration have also been reported 
in some normal hyperprolactinemic women during pregnancy and after delivery40• 41 
and in several patients with hyperprolactinemia caused by drugs42 or during hypoglyce-
mia induced by an insul-intolerance test.31 Therefore, in hyperprolactinemic states cau-
sed by stimuli in the presence of a normal PRL-secreting system, a decreased percentage 
response of PRL to TRH in relation to that of a control group is also possible. 
In contrast to Ayalon et al.,6 we found a negative correlation between the basal PRL le-
vel and the percentage APRL. This finding may be explained by the higher incidence 
of positive responders in our patients with only slightly increased basal plasma PRL le-
vels. Jeske,7 Ayalon et al.,6 and Kleinberg et alY also reported a higher incidence of 
positive responses in patients with only slightly increased basal PRL levels and a normal-
sized sella. However, positive responses may also occur in patients with macroadeno-
mas. Indeed, in our series a correlation between tumor size and the percentage APRL 
could not be demonstrated. 
The use of L-dopa or dopaminergic agonists as a test in the differential diagnosis of hy-
perprolactinemia appears to be of no value because these agents invariably cause sup-
pression of plasma PRL levels.7• 8· 12• 16· 17 The absence of an increase in the PRL level 
after the administration of dopamine antagonists (chlorpromazine, metoclopramide, or 
sulpiride) as well as the absence of a nocturnal PRL increase are of diagnostic value in 
addition to the TRH test, 6-8• 28· 33 but normal responses to antagonists 16 and normal noc-
turnal increases in PRL levels have been reported in patients with a prolactinoma. 
In the differential diagnosis of hyperprolactinemia with an impaired response of PRL to 
TRH, hypothalamic disorders not caused by suprasellar extension of a pituitary tumor 
must be considered. 1• 25 Snyder et al. 1, Schwinn et al.,25 and Woolf et al.44 together re-
ported a lowered PRL response ( < 100%) in nine of seventeen hyperprolactinemic pa-
tients with hypothalamic disorders. We found also a decreased PRL response to TRH 
in seven of eleven cases. Thus in approximately 60% of hyperprolactinemic patients with 
suprasellar disorders, a blunted PRL response to TRH is present ("false-negative 
responders"). 
We conclude that the TRH test may be a useful adjunct in identifying hyperprolactinemic 
patients with a prolactinoma. However, a positive response does not exclude the presen-
ce of a prolactinoma, whereas a negative response with or without an abnormal sella tur-
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cica does not exclude primarily suprasellar abnormalities. It is advisable to carry out a 
computerized tomographic scan (or air encephalography) in most if not all patients with 
unexplained hyperprolactinemia. 
/ 
TABLE 1. Survey of 35 Reports Concerning 548 Hyperprolactinemic Patients with Gonadal 
Insufficiency (with Enlarged or Normal-Sized Sellas) 
Reference Year TRH Microadenoma Macroadenoma Total Reported surgically 
dose proven adenoma 
p.g No. a % No.a % No. a % No. a % 
Jacobs and 
Daughaday22 1973 400 1/7 14 1/7 14 
Del Pozo23 1973 250 0/6 0 1/6 17 1/12 8 
Snyder et al.I 1974 400 2/11 18 
Archer et al. 24 1974 500 3/5 60 3/5 60 
Schalson et al.9 1975 1/8 12 1/8 12 1/8 12 
Schwinn et al.25 1975 500 015 0 0/5 0 0/5 0 
Guinet et al.I6 1975 3/9 33 3/9 33 
Zarate et al.26 1975 400 017 0 0/7 0 0/1 0 
Aono et al.27 1976 500 1/10 10 1/10 10 
Hirvonen et al. 3 1976 200 1/10 10 0/1 0 1/11 9 
Fossati et al. 28 1976 200 0/4 0 0/2 0 0/6 0 
Jacobs et al. 2 1976 200 0/17 0 0/12 0 0/29 0 
Glass et ai.29 1976 200 0/9 0 
Lamberts et al. 4 1976 400 3/8 37 4/14 29 7/22 32 3/10 30 
Antunes et al. 30 1977 500 0/4 0 
Kleinberg et al. !7 1977 500 2/6 33 1/16 6 3/22 14 
Lachelin et al. 10 1977 200 0/18 0 0/18 0 0/5 0 
Boyd et al.I8 1977 500 0/7 0 2/7 29 2/14 14 2/5 40 
Kletzky et al.31 1977 500 2/15 13 
Healy et al. 5 1977 200 0/16 0 0/2 0 0/18 0 
Samaan et al.32 1977 500 3/4 75 3/4 75 3/4 75 
Tolis 11 1977 0/11 0 0/2 
L 'Hermite et a1.12 1977 200 0/41 0 
Faglia et al.I3 1977 200 0/29 0 0/25 0 
L'Hermite et al.I9 1978 200 3/10 30 3/10 30 
Jaquet et al. 33 1978 200 2/14 14 2/14 14 
Silvestrini et ar_34 1978 200 3/33 9 0/16 0 
Cowden et al. 8 1979 200 017 0 0/14 0 0/14 0 
Barbarino et ar_I4 1979 200 0/20 0 0/20 0 
Ayalon et al. 6 1979 200 6/18 33 0/2 0 
Jeske7 1979 200 4113 31 3/18 17 7/31 23 
Eversmann et al. 35 1979 200 0/8 0 0/3 0 0111 0 
Assies20 1979 200 3/21 14 5/26 19 8/47 17 2/11 18 
Murray et al. 15 1979 500 0/4 0 0/6 0 0/10 0 
Volpe et al. 36 1979 200 2/13 2/13 15 
Total 23/191 12 23/145 16 61/548 11 13/144 9 
a Number to the left indicates number of patients with a positive TRH test (.<iPRL > 100%); 
to the right, number of patients investigated. 
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CHAPTER VI 
THE FUNCTION OF THE PITUITARY-THYROIDAL 
AXIS IN ACRO:MEGALIC PATIETS V. PATIENTS 
WITH HYPERPROLACTINAEMIA AND A 
PITUITARY TUMOUR 
J.G.M. KLUN, S.W.J. LAMBERTS, R. DOCTER, F.H. DEJONG, 
K.J. VAN DONGEN AND J.C. BIRKENMGER 
Departments of Medicine (111), Division of Clinical Endocrinology and 
Department of Neuroradiology, University Hospital 'Dijkzigt', Erasmus 
University, Rotterdam 
SUMMARY 
The function of the pituitary-thyroidal axis was examined in fifty-three of sixty-two pa-
tients with hyperprolactinaemia and a pituitary tumour and in forty of forty-four acrome-
galic patients, in whom one or more indices of the pituitary-thyroid function were 
determined before treatment. In the patients with hyperprolactinaemia and a pituitary tu-
mours, sellar + extrasellar tissue (EST) size showed a significant negative correlation 
with the response of TSH to TRH (.:lTSH) as well as with the circulating T4 and T3 
levels. These correlations were not present in the acromegalic patients. In the prolactino-
ma group a sharp decrease in mean serum T4 and T3 levels was found at sellar + EST 
sizes exceeding 3 cm2 • In twenty-three patients with a sellar + EST size of 3 cm2 or 
more, thirteen (57%) showed a T4level ofless than 6 jtg/dl against none of twenty-eight 
patients with a sellar + EST size ofless than 3 cm2 • For T3, using a limit of 120 ng/dl, 
the corresponding numbers were eight out of thirteen (62%) and none of ten patients 
respectively. A positive correlation was observed between .:1 TSH and the T3 levels but 
not between .:lTSH and T4, while in the acromegalic patients there was no correlation 
between TSH reserve and T3 or T4. In the patients with hyperprolactinaemia and a pitui-
tary tumour positive correlations between basal TSH and .:lTSH as well as between T4 
Reprinted from Clinical Endocrinology 13, 577-585 (1980) 
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I 
and T3 levels were observed. These correlations were not found in the acromegalic pa-
tients. 
In conclusion: (1) Thyroid function appears to be independent of pituitary tumour size 
in patients with acromegaly but not in patients with hyperprolactinaemia and a pituitary 
tumour. (2) In acromegalic patients the high incidence of an impaired TSH response 
(without hypothyroidism and independent of tumour size) may be caused by suppression 
of TSH secretion rather than by destruction of thyrotrophic cells. 
In a previous study (Klijn et al., 1980) we showed that in patients with hyperprolactinae-
mia and a pituitary tumour, a sellar size or a 'tumour size' [area of sella + extrasellar 
tissue (EST), if present, on the lateral X-ray of the skull] of 2-3 cm2 is a critical value 
with regard to the incidence of extrasellar extension of the tumour and loss of anterior 
pituitary hormone reserve. The TSH response to TRH (ATSH) was negatively correlated 
with tumour size, while in patients with tumour sizes exceeding 3 cm2 a sharply increa-
sed incidence of an impaired TSH response was seen. Since the importance of the pituita-
ry TSH reserve with respect to the thyroid function in patients with a pituitary tumour 
is not clear, we examined the significance of tumour size and ATSH in relation to circu-
lating thyroid hormone levels in the group of patients we reported on before (Klijn et 
al., 1980), comparing the results to those obtained in a group of acromegalic patients. 
PATIENTS, MATERIALS AND METHODS 
Patients 
Sixty-two patients (thirty-eight women) with hyperprolactinaemia and a pituitary tumour 
(without growth hormone excess) were investigated as well as forty-four patients 
(twenty-one women) with acromegaly. In the group of patients with hyperprolactinaemia 
and a pituitary tumour the mean age of the female patients was 32 years (median 29 
years, range 16-67 years) and of the male patients 35 years (median 35 years, range 
15-59 years). In the acromegalic patients the mean age of the women was 39 years (me-
dian 40 years, range 19-74 years) and of the men 40 years (median 41 years, range 21-71 
years). All patients were untreated. 
Radiological and ophthalmological examination 
All patients were investigated by plain radiography, lateral polytomography (hypocycloi-
dal, section of 2 mm) and complete ophthalmological evaluation, including visual fields. 
Further radiological examination consisted of air-encephalography (AEG) and in most 
cases angiography of the carotid artery. As a measure of tumour size we have chosen 
the largest lateral area of the sella in combination with that of extrasellar tissue (EST), 
if present (Klijn et al., 1980). 
Endocrine investigations and assays 
In forty-one untreated patients with a pituitary tumour and hyperprolactinaemia (thirty 
230 
females, eleven males, age range 15-67 years; the age of only one patient exceeded 44 
years) and in twenty-seven untreated acromegalic patients (fifteen women, twelve men, 
age range 19-65 years; six patients above 50 years) the TSH response to TRH (400 p.,g, 
Hoechst) was measured as described before (Klijn et al., 1980). 
Before any treatment basal thyroxine and triiodothyronine levels were determined in 
fifty-two and twenty-three of the sixty-two patients with hyperprolactinaemia and a pitui-
tary tumour as well as in forty and eighteen of forty-four acromegalic patients, respecti-
vely. (ln this retrospective study T4 and T3 were not determined before operation in a 
number of patients). In addition, in most of the patients, thyroxine binding proteins were 
assessed by means of the resin-uptake test (triosorbkit Abbott Laboratories). Prolactin, 
thyroxine (T4), triiodothyronine (T3) and TSH were measured using previously descri-
bed radioimmunoassay techniques (Kwa et al., 1973, Visser et al., 1975, Docter et al., 
1972, Klijn et al., 1980). Plasma GH levels were measured by a homologous radioim-
munoassay (IRE, Belgium). Thyroid antibodies were investigated in forty-four patients 
with hyperprolactinaemia and a pituitary tumour and in twenty-seven acromegalic pa-
tients, especially when T4 was low or basal TSH at the upper limit of normal. Circula-
ting thyroid antibodies were found in a 28-year-old acromegalic woman (T4 = 9.5 p.,g/dl, 
basal TSH = 4.2 mu/1, ATSH = 13.8 mu/1) and in a 64-year-old acromegalic man (T4 
= 9.7 p.,g/dl, basal TSH = 1.6 mu/1, ATSH = 4.7 mu/1). 
Normal values 
Normal values for sellar size are between 0.7 and 1.4 crri2 (95% range in 100 patients 
without pituitary pathology). Normal basal values of TSH are less than 4.9 mu/1 (95% 
range of71 controls). In our laboratory the maximal increment of plasma TSH in respon-
se to stimulation with 400 p.,g TSH is between 8.1 and 38.7 mu/1 in eleven females aged 
20-40 years, between 7.1 and 16.0 mu/1 in eight females aged 40-60 years and between 
4.9 and 14.0 mu/1 in seven females aged 61-72 years. In eight normal men ATSH varied 
between 6.1 and 13 .1 mu/1. The mean value ± SD of T 4 is 8. 6 ± 1. 95 p.,g/ dl in fifty 
controls (95% between 4.7 and 12.5 p.,g/dl). The mean value ± SD of T3 is 145 ± 30 
ng/dl (95% range in 180 controls between 85 and 205 mg/dl). There was no sex differen-
ce in the thyroid hormone concentrations. 
Statistical analysis 
Statistical analysis of the data was performed using regression analysis, two-tailed Stu-
dent's t test or x2-test. Partial correlation coefficients were calculated according to 
Snedecor & Cochran (1967). 
RESULTS 
Relationship between tumour size and ATSH 
In contrast to observations made in patients with hyperprolactinaemia and a pituitary tu-
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mour there was no correlation between sellar + EST size and ~ TSH in acromegalic 
patients (n = 27, r = 0.03). Impaired TSH responses to TRH appeared to be indepen-
dent of tumour size (Fig. lb, Table 1), age, basal GH (n = 21, r = 0.19) or GH respon-
se to TRH (n = 13, r = 0.35). The first finding is in sharp contrast with the significantly 
increased incidence of a subnormal TSH reserve in patients with hyperprolactinaemia 
and a pituitary tumour at sellar + EST sizes of 3 cm2 or more (Fig. 1a). This was true 
using control groups divided according to sex and age (see normal values) as well as 
using a standard lower limit of ~TSH of 5 mu/ml (Table 1). 
No correlation between basall7j)-estradiol and ~TSH was present in the amenorrhoeic 
patients with a prolactinoma (n = 13, r = -0.32) or acromegaly (n = 7, r = +0.13). 
Relationship between tumour size and circulating thyroid hormone levels 
In the patients with hyperprolactinaemia and a pituitary tumour, sellar + EST size sho-
wed a negative correlation with the circulating T4 and T3 levels in serum (Figs. 2a and 
3a, both P < 0.005). A sharp decrease in mean plasma T4 and T3 levels was found 
at sellar+ EST sizes exceeding 3 cm2 • Lowered or low normal levels ofT4 ( < 6 p.g/dl) 
and T3 ( < 120 ng/dl) were present only in patients with a sellar + EST size of 3 cm2 
or more (57% for T4 and 62% for T3; P < 0.005 and P < 0.01 respectively). Slight 
(~TSH: 5-7 mu/1; n = 5) or more marked lowering (~TSH < 5 mu/1; n = 1) of TSH 
reserve in patients with tumours smaller than 3 cm2 was never accompanied by low T4 
or T3 levels. 
In contrast to these fmdings we observed no correlation between sellar + EST size and 
circulating plasma T4 or T3 levels in the acromegalic patients (Figs. 2b and 3b). Low 
values of T4 (less than 6 p.g/dl) were not found. However, one patient had a borderline 
free thyroxine index on the basis of a decrease in T3 resin uptake. 
Relationship between ~TSH and circulating thyroid hormone levels 
Although in the patients with hyperprolactinaemia and a pituitary tumour a tendency to 
lower T4 levels existed with decreasing values of ~TSH, no significant correlation be-
tween ~TSH and serum T4levels was found (Fig. 4a). A positive correlation, however, 
was observed between ~TSH and the circulating T3 levels (Fig. 5a, P < 0.01). In the 
group of patients with hyperprolactinaemia and a pituitary tumour partial correlation 
coefficients were calculated for the relationships between tumour size, ~TSH and T4 or 
T3. The partial correlation coefficient for the relationship between tumour size and T4 
after exclusion of the influence of ~TSH (n = 39) was -0.4018 (P < 0.05); between 
~TSH and T4 after exclusion of the influence of tumour size 0.1213 (not significant= 
n.s.) and between ~TSH and tumour size after exclusion of T4 -0.4508 (P < 0.01). 
The partial correlation coefficients for the same relationships with T3 instead of T4 
(n = 19) were -0.3387 (n.s.), 0.4041 (n.s.) and -0.3775 (n.s.) 
In the acromegalic patients T4 as well as T3 was not correlated to ~TSH (Figs. 4b and 
5b). 
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Fig. 1. Frequency distribution of impairment of the TSH response to 400 p.g TRH in forty-one untreated 
patients with hyperprolactinaemia and a pituitary tumour (a) and in twenty-seven untreated acromega-
lic patients (b) with respect to tumour size. Solid boxes indicate an impaired TSH response (.6. TSH 
< 5 mull). a Difference between patients with a tumour size above and below 3 cm2 : P < 0.0025 
(x2test). b: n.s. 
Relationship between T4 and T3 
In the patients with hyperprolactinaemia and a pituitary tumour a positive correlation be-
tween T4 and T3 levels was found (n = 23, r = +0.42, P < 0.05), but low levels 
of T3 can be accompanied by normal levels of T4 and vice versa. In the acromegalic 
patients a correlation between T4 and T3 was absent (n = 16, r = +0.23, n.s.). 
TABLE 1. Incidence of pituitary-thyroid hypofunction in untreated patients with pituitary tumours 
(% of cases investigated). 
Prolactinoma Acromegaly 
Whole Whole 
<3 cm2 >3 cm2 group <3 cm2 >3 cm2 group 
.D.TSH t ( <5 mu/1) 4 50 22 50 46 48 
.D.TSH t (control groups) 24 75 44 57 54 56 
T4 <6 J.tg/dl 0 57 25 0 0* 0* 
* One patient with a borderline value of the F. T .I. 
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Fig. 2. Relationship between (log) tumour size and serum T4 levels in fifty-two untreated patients with 
hyperprolactinaemia and a pituitary tumour (a: r = -0.50; P < 0.0005) and in forty untreated acro-
megalic patients (b: r = +0.14, n.s.). • = Women; o = men. 
Significance of basal TSH 
In the patients with hyperprolactinaemia and a pituitary tumour a negative correlation 
was found between log sellar + EST size and log basal TSH (P < 0.025). There was 
a positive correlation between log basal TSH and log .::lTSH (P < 0.001; Fig. 6a). Only 
one out of twenty-six patients with a basal TSH of 1 mu/1 or more showed a .::lTSH of 
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Fig. 3. Relationship between Oog) tumour size and serum T3 levels in twenty-three untreated patients with 
hyperprolactinaemia and a pituitary tumour (a: r = -0.60; P < 0.005) and in eighteen untreated 
acromegalic patients (h: r = +0.80; n.s.). • = Women; o = men. 
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Fig. 4. Relationship between (log) 11 TSH and serum T4 levels in forty untreated patients with hyperprolacti-
naernia and a pituitary tumour (a: r = +0.31; 0.10 > P > 0.05) and in twenty-seven untreated 
acromegalic patients (b: r = +0.02; n.s.). • = Women; o = men. 
less than 5 mu/1. In the acromegalic patients correlations between basal TSH and sellar 
+ EST size (n = 27, r = 0.006) or ATSH (Fig. 6b) were absent. 
In both groups of patients correlations between the basal TSH level and circulating levels 
of T4 or T3 were absent because of the incidence of normal T4 and T3 levels in the 
presence of undetectable basal TSH. 
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Fig. 5. Relationship between Oog) llTSH and serum T3levels in twenty untreated patients with hyperprolac-
tinaernia and a pituitary tumour (a: r = +0.62; P < 0.01) and in sixteen untreated acromegalic 
patients (b: r = +0.01; n.s.). o = Women; o = men. 
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untreated acromegalic patients (b: r = +0.35; P < 0.10). • = Women; o = men. 
DISCUSSION 
In patients with hyperprolactinaemia and a pituitary tumour we have previously shown 
that there is a sharply increased incidence of loss of anterior pituitary hormone reserve 
above a radiological sellar + EST area of 3 cm2 (Klijn et al., 1980). The results of the 
present study indicate that in these patients an area of 3 cm2 might also be critical with 
regard to the function of the target organ, the thyroid gland. It is not clear to what extent 
the TSH secretion has to be impaired before secondary hypothyroidism ensues. In pa-
tients with hyperprolactinaemia and a pituitary tumour we did not find a positive correla-
tion between LlTSH and serum T4 levels. Such a relationship could be absent because 
of the possible inclusion of patients with tertiary hypothyroidism: low normal or slightly 
decreased T4 levels in combination with a normal or a hyper-response of TSH to TRH. 
Another cause might be the production of an abnormal TSH molecule which could be 
responsible for subnormal or low normal thyroid function (Faglia et al., 1975; Petersen 
et al., 1978). A third mechanism could be an increased sensitivity of the thyroid to TSH 
in partial pituitary failure (Sluiter, 1979). The fmding of the combination of low thyroid 
hormone levels and decreased TSH reserve (instead of the expected increased TSH reser-
ve in the case of an intact pituitary-thyroidal axis) indicates destruction of thyrotrophs 
in at least some of the patients with hyperprolactinaemia and a large pituitary tumour. 
In cases with extensive pituitary destruction an impaired conversion of T4 to T3 may 
also be involved (Balsam et al., 1978). 
In the acromegalic patients the lack of correlation between tumour size, basal TSH, 
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.6.TSH, T4 and T3 is striking. The discrepancy observed between the very low incidence 
of hypothyroidism and the frequent occurrence of a decreased TSH reserve (independent 
of tumour size) which is in contrast to the fmdings in our prolactinoma patients, indicates 
suppression of TSH secretion rather than destruction of thyrotrophs in some acromegalic 
patients. This suppression of TSH secretion may be caused by an autonomous thyroid 
function (as in hyperthyroidism ) as suggested by Hall et al. (1972). Goitre has been 
found in a considerable number (25-50%) of acromegalic patients (Davidoff, 1926; 
Davis, 1941; Daughaday, 1974). Our fmdings in acromegalic patients show a certain 
similarity to those patients with euthyroid multinodular goitre in whom .6. TSH is inverse-
ly related to thyroid weight and not related to basal serum T4 or T3 concentrations 
(Smeulers et al., 1977). The observation that GH administration may reduce the TSH 
response to TRH in pituitary dwarfs (Kanatsuka et al., 1979) as well as the fmding that 
the TSH reserve improved after blocking the release of GH in acromegaly (Fanghanel-S 
et al., 1978) suggest increased somatostatin secretion in response to high GH levels as 
an alternative cause of suppressed TSH secretion. However, in our acromegalic patients 
we found no relationship between GH levels on the one hand and TSH reserve on the 
other. 
In is concluded that the cause of an impaired TSH response to TRH in acromegalic 
patients may differ from that observed in patients with prolactinomas. 
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CHAPTER Vll 
THE ROLE OF PROLACTIN IN THE INmBITORY 
ACTION OF BROMOCRIPTINE ON GROWTH 
HORMONE SECRETION IN ACROMEGALY 
S.W.J. Larnberts1, J.G.M. Klijn1, C.C.J. van Vroonhoven2 , S.Z. Stefanko2 and 
A. Liuzzi3 
Department of Medicine and of Clinical Endocrinologyl, Erasmus University, 
Rotterdam, Department of Pathology, Erasmus University, Rotterdam, 
The Netherlands and Endocrine Unit3, Ente Ospedaliero Niguardo, Milano, Italy 
SUMMARY 
Abstract. Bromocriptine treatment results in clinical improvement and inhibition of 
plasma GH levels in only part of the acromegalic patients. The possible role of the simul-
taneous presence of Prl and GH in GH-secreting pituitary adenomas was investigated 
with regard to the inhibitory action of bromocriptine on GH secretion and the paradoxi-
cal increase of GH release in reaction to TRH. 
Surgically obtained pituitary tumour tissue from 35 consecutive acromegalic patients was 
studied immunohistochemically. In 21 patients no Prl was present in the tumour tissue. 
These patients had normal plasma Prl levels. In the other 14 patients Prl was present 
in the tumour tissue. Hyperprolactinaemia was found in 10 of these 14 patients. Plasma 
GH levels from 2 till 10 h after the administration of 2.5 mg bromocriptine measured 
before operation were significantly more suppressed in the patients with mixed GH/Prl-
containing than in those with pure GH-containing pituitary adenomas, being 38 ± 4% 
and 65 ± 4% of basal values, respectively (P < 0.01). The response of GH to TRH, 
however, did not differ significantly between the two groups. Conclusions: 1. In about 
70% of patients with 'mixed' GH/Prl containing adenomas, hyperprolactinaemia is pre-
sent. 2. The simultaneous presence of Prl and GH in a GH-secreting pituitary tumour 
increases the sensitivity of GH secretion to bromocriptine. 3. The plasma Prl level is 
of value to predict which patients with acromegaly are likely to respond to bromocriptine 
with an inhibition of GH secretion. 
Reprinted from Acta Endocrinologica 103: 446-450 (1983) 
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Acute administration of dopaminergic drugs paradoxically suppresses growth hormone 
(GH) secretion in part of the patients with acromegaly (Liuzzi et al. 1972, 1974a,b). 
Chronic bromocriptine therapy was reported to lower plasma GH levels and to have be-
neficial clinical effects in a lot of acromegalic patients (Sachdev et al. 1975; Belforte et 
al. 1977; Wass et al. 1977). In other studies however, no or hardly any positive effect 
was reported (Summers et_al. 1975; Dunn et al. 1977; Lindholm et al. 1981). No clear 
explanation for the discrepancy between these results of the treatment with bromocriptine 
has been offered so far (Thorner et al. 1981; Kobberling et al. 1982). 
We recently studied the relationship between the plasma prolactin (Prl) concentration of 
79 untreated acromegalic patients and the response of GH to bromocriptine (Lamberts 
et al. 1982). Hyperprolactinaernia was present in 42% of these patients, and it was shown 
that an increased plasma Prl level is accompanied in most acromegalic patients by high 
sensitivity of GH secretion to bromocriptine in the acute test (Lamberts et al. 1982), but 
also during chronic therapy (Lamberts et al. 1979). 
In the present study the immunohistochemical presence or absence of Prl in pituitary tu-
mour tissue of 35 transsphenoidally operated acromegalic patients was correlated with 
the in vivo sensitivity of GH secretion to bromocriptine and TRH. 
PATIENTS AND :METHODS 
Thirty-five untreated acromegalic patients (16 males and 19 females) aged 23-62 years 
"" 
were studied. The diagnosis of acromegaly was made by the combination of the presence 
of clinical signs and symptoms of increased GH secretion with elevated fasting plasma 
GH levels, which could not be suppressed to less than 5 ng/ml after oral administration 
of 100 g of glucose. Plasma levels of GH were determined by a double antibody radioim-
munoassay method using the C.E.A. kit (CIS, France). Normal values in both sexes are 
1-5 ng/ml. Plasma Prllevels were determined by the same method with a kit from IRE 
(Antwerp, Belgium). In both assay systems 1 ng of the standard employed is equivalent 
to 1 ng of the standard VLS = 1 of the NIH. The upper limit of normal plasma Prllevels 
is 12 ng/ml in men ai1.d 15 ng/ml in women. Inhibition curves of standard human GH 
were repeatedly compared with inhibition curves of patient plasma and were always 
found to be paralleL No cross- reactivity of GH was found in the Prl-assay under GH 
levels of 150 ng/ml and vice versa. 
In the study of GH secretion in response to bromocriptine, the patients were studied in 
the morning in basal conditions. All studies were done between 3-14 days before opera-
tion. Serial blood specimens were collected through an indwelling polyethylene catheter 
placed in an antecubital vein. At least 4 blood samples were taken before 2.5 mg bromo-
criptine was administered at 8 a.m. and additional samples were drawn hourly up till 
12 h following the drug and after 24 h. The TRH test was carried out on a separate day 
at 2 p.m. Four-hundred p.,g TRH (Hoechst, Wiesbaden, Germany) was administered iv 
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for 30 s, and apart from at least two baseline blood samples, additional samples were 
obtained at 20, 30, 60 and 120 min. 
In these patients no medication that might account for an elevated plasma Prl level was 
taken and the existence of primary hypothyroidism was excluded. Suprasellar extension 
of the pituitary tumour was investigated by CT -scanning of the suprasellar region. 
Paraplast-embedded tissue blocks from pituitary adenomas of acromegalic patients obtai-
ned by transsphenoidal surgery were investigated by light microscopic and immunohisto-
chemical methods. Pathological investigations were done blindly, without knowledge 
about the endocrine characteristics of these patients. All tissues had been fixed for 6-8 
h in 4% phosphate-buffered neutral formaldehyde and processed routinely. Tumour 
histology was studied by haematoxylin and eosin, PAS and Masson staining methods. 
For the immunohistochemical identification of GH and Prl producing cells in the adeno-
matous tissues, an direct immunohistoperoxydase method (Nakane & Pierce 1967) was 
used as described in detail elsewhere (Nieuwenhuijzen Kruseman et al. 1975). The rabbit 
anti-human GH antibodies were purchased from Behring Werke (Western Germany; lot 
no. 1896, OTXIX) and Wellcome (Beckenham, England). The rabbit anti-human Prl 
antibodies were a kind gift from Dr. P .K. Nakane (Denver, USA) or were obtained from 
Calbiochem- Behring Corp. 
Statistical evaluation was done by analysis of variance. 
RESULTS 
Specimens of pituitary tumour tissue obtained at transsphenoidal operation from 35 con-
secutive acromegalic patients were investigated (Table 1). In all patients immunoreactive 
GH was present in the tumour tissue, while no Prl immunoreactivity was observed in 
the tumour tissue of 21 patients ('pure GH containing pituitary adenomas'). In 14 pa-
tients both immunoreactive GH and Prl were present in the tumour tissue ('mixed 
GH/Prl containing pituitary adenomas'). The prevalence of acidophilic, chromophobic 
and mixed acidophilic/ chromophobic staining pattern was similar in both groups of 
patients (Table 1). 
In 10 of the 14 patients in whom Prl was shown to be present in the pituitary tumour, 
elevated circulating plasma Prl levels were present, while no additional hyperprolacti-
naemic acromegalies were found in the group of patients with 'pure GH- containing ade-
nomas' (Table 1). Suprasellar extension of the pituitary tumour was present in 10 
patients (5 patients with pure GH- and 5 with mixed GH/Prl- containing adenomas; 
Table 1). 
No statistically significant difference was seen between plasma GH concentrations 
between both groups of patients (Table 1). The percentage inhibition of GH levels after 
bromocriptine as measured over 24 h (Fig. 1) was from 2 till 10 h after a dose of 2.5 
mg statistically significantly more pronounced in the 14 patients with mixed tumours than 
in the 21 patients with pure GH-containing tumours (P < 0.01 after 3, 4, 5, 6, 7, 8 
241 
TABLE 1. Histology, immunohistochemistry, circulating GH and Prl levels in 35 acromegalic 
patients operated transsphenoidally _ 
Patient M/F Age Risto- Immuno- Plasma Plasma Plasma GH Plasma GH Suprasellar 
years logy histo- pr)l GH1 after bro- after TRH3 extension 
chemistry (ng/ml) (ng/ml) mocriptinel % of the 
Prl present % tumour 
M 33 acid+chrom 4±3 80±6 90±2 -(122) + 
2 M 36 acid 10±3 23±8 57±3 +(366) 
3 M 57 acid 9±1 24±3 80±5 +(356) 
4 M 33 acid+chrom 7±3 69±5 71±3 -(80) + 
5 M 48 acid 8±2 33±8 51±3 +(129) 
6 M 23 acid 6±3 43±4 60±4 +(1500) 
7 M 47 acid 8±2 57±13 57±4 +(252) 
8 F 52 acid 11±3 12±3 96±7 -(10) 
9 F 32 acid+chrom 10±1 35±6 65±6 -(27) 
10 M 55 acid 9±4 15±4 62±5 -(8) 
II M 61 acid+chrom 9±1 23±4 82±5 +(225) 
12 M 50 acid 11±3 16±3 78±6 -(72) 
13 F 46 acid+chrom 7±2 28±2 52±3 -(67) 
14 F 47 acid 3±2 51±6 91±4 -(0) 
15 F 63 acid+chrom 12±1 11±2 36±7 +(412) 
16 F 47 acid+chrom 2±1 102±10 49±4 +(144) + 
17 M 45 acid 6±2 29±2 84±3 -(50) 
18 F 47 acid 10±3 17±4 52±3 -(67) 
19 F 52 acid 4±2 8±3 102±2 -(0) + 
20 M 37 acid 3±4 11±1 86±4 -(40) 
21 F 28 acid+chrom 9±2 107±12 79±5 -(44) + 
22 F 44 acid+chrom + 160±39 16±3 17±5 +(2300) 
23 F 36 chrom+acid + 69±6 54±7 50±1 not done 
24 M. 50 chrom + 145±46 244±63 33±2 +(135) + 
25 M 62 acid+chrom + 173±16 88±5 35±5 +(ll8) + 
26 F 31 acid+chrom + 141±21 142±47 33±7 +(183) + 
27 M 53 acid+chrom + 27±4 24±3 40±3 -(67) 
28 F 49 acid + 9±2 44±4 52±6 +(800) 
29 M 49 acid + 5±2 18±3 31±4 +(414) 
30 M 42 acid + 2±3 35±4 31±2 -(75) 
31 F 26 acid+chrom + 19±3 247±11 58±20 -(13) + 
32 M 62 acid+chrom + 175±36 117±22 19±4 +(1350) + 
33 F 31 acid + 24±8 36±5 37±6 -(18) 
34 F 53 acid+chrom + 20±3 12±2 27±2 +(963) 
35 F 56 acid + 5±2 18±4 44±3 +(525) 
Plasma Prl and GH are mean ± SEM of at least 5 determinations on different days. 
2 Plasma GH measured in 8 samples taken hourly from 2 till 10 h after the administration of 
2.5 mg bromocriptine as a percentage of two basal values. 
3 Maximal increment of plasma GH after TRH as percentage of the basal level ( + = increment) 
of more than 100%; the percentage maximal increase is given in parentheses. 
acid = acidophilic; chrom = chromophobic. 
and 9 hand P < 0.05 2 and 10 h after bromocriptine). The individual responses of GH 
secretion in these 35 patients are shown in Table 1. Bromocriptine induced an inhibition 
of GH release of more than 50% in 2 of 21 patients with pure GH-containing tumours 
and in 11 of 14 patients with mixed tumours. 
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Fig. 1. The response of plasma GH to the administration of 2.5 mg bromocriptine at 8 a.m. followed for 
24 h in 21 acromegalic patients ( o) with 'pure' GH-containing pituitary ademonas and 14 acromega-
lic patients (e) with presumably 'mixed' GH/Prl containing adenomas. A significantly higher sup-
pression of plasma GH was observed in the latter group from 2 till 10 h after administration of 
bromocriptine: P < 0.01 after 3, 4, 5, 6, 7, 8 and 9 hand P < 0.05 after 2 and 10 h. The vertical 
bars represent SEM. 
A paradoxical increment of plasma GH after TRH administration of more than 100% 
of the basal value was seen in 9 of the 21 patients with pure GH-containing adenomas 
and in 9 of the 13 patients examined with mixed tumours. This difference is not statisti-
cally significant. A homogeneity in the responses of GH to bromocriptine and TRH (i.e. 
the presence or absence of both a decrease of GH of more than 50% after bromocriptine 
and an increase of GH of more than 100% of the basal value after TRH) was observed 
in 23 of the 34 acromegalic patients (68% ). This homogeneity in responsiveness of GH 
to TRH and bromocriptine in patients with acromegaly was also present if the percentage 
increase of GH after TRH was correlated with the percentage decrease of GH from 2-8 
h after bromocriptine (r = 0.48; P < 0.01 in the whole group of 34 patients and r = 
0.59; P < 0.05 in the 13 patients with mixed GH/Prl containing tumours). 
DISCUSSION 
Medical treatment with dopaminergic drugs of patients with acromegaly is still contro-
versial, because of the differences reported in the sensitivity of GH secretion to bromo-
criptine and the variability of the clinical improvement (Belforte et al. 1977; Dunn et 
al. 1977; Lindholm et al. 1981; Sachdev et al. 1975; Summers et al. 1975; Wass et al. 
1977). Liuzzi et al. (1974b) showed that in general those acromegalic patients whose GH 
levels are inhibited by dopaminergic drugs also react to TRH with a paradoxical increase 
of GH secretion, while patients unresponsive to dopaminergic stimuli were also un-
responsive to TRH. This homogeneity in the responsiveness of GH to bromocriptine and 
TRH in acromegaly was seen in 86% (Liuzzi et al. 1974b), 76% (Lamberts et al. 1982) 
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and 68% (present study) of the patients. This resemblance between the characteristic 
qualities of GH secretion in some acromegalies with those of normal Prl secretion, led 
several groups to suggest a role for Prl in the response of acromegalies to bromocriptine 
(Chiodini et al. 1974; Lamberts et al. 1976, 1979; Werner et al. 1978). In a recent study 
(Lamberts et al. 1982) elevated plasma Prl levels were found in 42% of 79 untreated 
acromegalic patients. Bromocriptine (2.5 mg) inhibited GH secretion by more than 50% 
in 22 % of the normoprolactinaemic patients and in 70% of the hyperprolactinaemic 
patients (P < 0.001). 
Elevated plasma Prllevels were found in 32% of 73 untreated acromegalic patients ih 
another report (De Pablo et al. 1981). A subject of speculation has been whether normal 
or tumour cells are reponsible for the hypersecretion of Prl. The GH- producing tumour 
may interfere in the transport of hypothalamic Prl-inhibting factor (PIF) resulting in hy-
persecretion of Prl by the normallactotroph which is no longer restrained by hypothala-
mic PIF. The immunohistochemical investigation in the present study indicates, 
however, that in the majority of the cases the elevated plasma Prllevel is a result of se-
cretion of Prl by a mixed GH/Prl containing adenoma. Histological examination of pitui-
tary tumour tissue from our acromegalic patients did not allow a prediction as to the 
presence or absence of Prl in the GH- secreting pituitary adenoma, because histological 
staining procedures are not specific for the nature of the hormones present in the cells. 
There was suprasellar extension of the pituitary adenoma in 5 of the 14 patients with 
mixed tumours and in 5 of the 21 patients with pure GH-secreting adenomas. This series 
of patients seems too small to exclude a role of tumour mass in hyperprolactinaemia 
observed in the 5 patients with mixed tumours. 
From the results observed in this group of 35 acromegalic patients and the 79 patients 
reported before (Lamberts et al. 1982) we conclude that the plasma Prl concentration 
may be of value in the prediction of which patients would be likely to react with a para-
doxical inhibition of GH secretion to bromocriptine. A parallel was observed between 
the presence of clearly increased circulating Prl concentrations and the presence of Prl 
in the tumour in only 10 of 14 patients. So hyperprolactinaemia cannot be used as the 
sole parameter in order to predict whether an acromegalic patient is likely to react to 
bromocriptine with an inhibition of GH secretion. We suggest that the findings in the 
present study might explain at least in part the discrepant results in the medical treatment 
of acromegaly (Belforte et al. 1977; Dunn et al. 1977; Lindholm et al. 1981; Sachdev 
et al. 1975; Summers et al. 1975; Wass et al. 1977). 
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Introduction 
Surgery, medical treatment and radiation therapy are the three main types of therapy for 
pituitary tumors. Radiation therapy was first applied in the management of acromegaly. 
In 1907 successful radiotherapy w~s carried out by Gramegma (1) in a 45-year-old acro-
megalic female and by Beclere (2) in a 16-year-old girl with gigantism. After 75 years 
of experience, there is no longer doubt that radiotherapy plays a major role in the mana-
gement of pituitary adenomas especially because of its efficacy in longterm tumor control 
(3-7). External radiotherapy can be used as a single therapy or after surgery as an additi-
onal treatment and for preventing tumor recurrences. However, there are hardly any data 
on the long-term effects of radiotherapy (without or with surgery) especially on survival. 
Therefore, the aim of the present retrospective study was measurement of the long-term 
effects of conventional external radiotherapy in combination with surgery or as a single 
treatment. Patients (n = 336) with a pituitary tumor treated since 1950 in Rotterdam 
were studied with regard to 1) hypersecretion, especially growth hormone secretion; 2) 
anterior pituitary functions; 3) recurrence rate and 4) survival. 
Reprinted from Trends in Diagnosis and Treatment of Pituitary Adenomas (eds. S.W.J. 
Lamberts, T.J.H. Tilders, E.A. van der Veen, J. Assies), Free University Press, 
Amsterdam, pp 359-372 (1984). 
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PATIENTS AND :METHODS 
The records of 336 patients (169 women) with a pituitary tumor treated since 1950 were 
reviewed. It concerns 117 patients with acromegaly (group I) and 219 patients with a 
macroprolactinoma or a "non-functioning" tumor (group II). Of group II 47 were cer-
tain macroprolactinomas and in 172 cases it was impossible to retrospectively decide 
whether it concerned a "non-functioning" or a prolactin (PRL) secreting tumor. The 
mean age of group I was 43 year (range 14-72 year) and of group II 46 year (range 16-82 
year). The cumulative percentage to age is nearly the same in both groups of patients 
(fig. 1). Thirty patients in group I and 33 in group II needed a second surgical and/or 
radiotherapeutical treatment because of recurrence or a disturbing residue of the tumor. 
The occurrence o.f a recurrence was determined by radiological (pneumoencephalograp-
hy, computertomography), ophthalmological and/or hormonal examinations. 
Eighty two patients were treated with orthovoltage (40 as a single therapy and 42 in com-
bination with surgery) and 238 patients with megavoltage (53 as a single therapy and 
185 in combination with surgery) irradiation, while 16 did not receive any kind of radio-
therapy. In total 111 patients were operated by the transsphenoidal route. 
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Fig. 1. The cumulative percentage to age for group 1 (xxxx) and group II (oooo): see text. 
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Plasma concentrations of GH, PRL, TSH, thyroxine, gonadotropins, sex steroids, corti-
sol and 11-desoxycortisol as well as urinary 17-0HCS were determined as described 
before (8). De~ermination of plasma GH was available since 1965, while most of the 
other hormones were measured in plasma since the beginning of the seventies. For 
measurement of normal pituitary function we have used also the TRH-, LHRH- and me-
tyrapone test. 
Statistical analysis of the data was performed using two-tailed students t-test or x2- test. 
Radiotherapeutic procedure 
Radiotherapy was given within 1-2 months after operation in 23 doses of 200 rad, four 
to five doses a week. Before 1966 the patients were irradiated with an orthovolt appara-
tus of 250 KV (3000 rad in 18-22 days, 200 rad per dose). After 1966 the patients have 
been treated with 4 or 6 MV linear accelerator. A coronal arc rotation technique was 
used with an arc angle of220° through the top of the skull and with a radiation source-to-
skin distance of 80-100 em. The isodose curves were computer- generated with the tu-
morvolume (indicated by the neurosurgeon on the x-rays) within the 95% isodose line. 
In the case of very large tumors radiation therapy was carried out with a parallel 
opposed-field technique via a pair of temporal fields. In this set-up the total dose was 
also 4600 rad, 5 doses of 200 rads per week. 
RESULTS 
Acromegaly 
In a study concerning 64 acromegalic patients, which were examined in a more detailed 
manner after 1969 we have investigated the effects of conventional external radiotherapy 
as a single treatment (n = 19) in comparison with those of combined treatment with 
transsphenoidal surgery (n = 45) on plasma GH levels and anterior pituitary function. 
I) Single treatment with radiotherapy 
The individual results of primary conventional radiotherapy in 19 patients are shown in 
fig. 2. In general a satisfactory decrease of GH levels was obtained during the years after 
irradiation. Nine patients (47%) reached a plasma GH level of less than 10 ng/rnl; 7 of 
them of (less than) 5 ng/rnl. Especially the patients with a pretreatment plasma GH level 
of less than 50 ng/rnl reached in general the normal range. 
Five patients subsequently underwent transsphenoidal surgery and four were treated with 
bromocriptine because of an insufficient decrease of plasma GH levels. 
2) Combined treatment 
The individual short-term effect of transsphenoidal surgery on basal plasma GH levels 
and the effect of additional radiotherapy in 45 operated patients is shown in fig. 3. In 
seven out of 43 patients (16%) with preoperative GH levels above 5 ng/rnl plasma GH 
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levels were normalised (GH < 5 ng/ml) after transspehnoidal surgery. However, four 
out of five of these 7 "cured" patients, in whom a TRH test was carried out after opera-
tion, showed a persisting pathological response of GH to TRH, while the fifth patient 
without increase of the GH level after TRH postoperatively had shown also no response 
to TRH before surgery. Ten out of the 39 patients (26%) with preoperative GH levels 
above 10 ng/rnl had postoperatively GH levels ofless than 10 ng/rnl. The results of trans-
sphenoidal surgery appeared dependent on preoperative GH levels. Patients with preope-
rative GH levels of more than 31 ng/rnl never reached GH levels of less than 5 ng/rnl 
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Fig. 2. The individual results of primary conventional radiotherapy in 19 patients with acromegaly. 
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postoperatively, while patients with GH levels of less than 10 ng/ml after operation, al-
ways had GH levels of less than 42 _ng/ml preoperatively. However, in the years after 
postoperative radiotherapy the majority of the patients reached normal plasma GH levels. 
In fig. 4 the same results are presented in chronological order as a percentage of the pre-
operative GH leveL In 11 patients the decrease in GH level was not more than 30%. 
In the first 15 patients the results were worse (six without important decrease in GH le-
vel) than in the remaining 30 patients. Additional radiotherpy caused a substantial further 
decrease in plasma GH. 
3) Comparison of single radiotherapy with combined surgical and radiotherapy 
By surgery alone the mean plasma GH level decreased immediately to 52% of the preo-
perative value (fig. 5). After postoperative irradiation mean plasma GH level decreased 
gradually further to 5-10% of the preoperative value with a maximal decrease after 7 
years; subsequently mean plasma GH remained constant. 
Radiotherapy alone caused a decrease in plasma GH levels of 40% in the first year (fig. 
5). After llfz-2 years the same effect as by transsphenoidal surgery (a decrease of about 
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50%) was reached. After 3 years of treatment no significant difference was seen between 
the decrease in the GH levels after irradiation alone or after transsphenoidal surgery fol-
lowed by irradiation. However, a subgroup of 34 patients (76%) with a relatively suc-
cessful surgical intervention showed over 7 years a significantly larger percental 
decrease of plasma GH levels than a subgroup of the remaining 11 (24%) unsuccessfully 
operated patients (decrease of plasma GH < 30%). This last group with the same mean 
plasma GH level pre- and postoperatively - showed the same curve of percental decre-
ment as the patients treated with radiotherapy alone (fig. 6). 
4) Effect on basal plasma prolactin in acromegalic patients 
Hyperprolactinemia was found in 54% of our acromegalic patients. In these hyperprolac-
tinemic patients the mean plasma PRL level decreased by surgery to 47% of the preope-
rative value .In the normoprolactinemic patients the mean decrease was only to 82% of 
the preoperative value. In general, radiotherapy caused in the hyperprolactinernic acro-
megalic patients, a decrease of the plasma PRL concentration by about 50%. 
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5) Overall effect 
Virtually all the patients treated with orthovoltage irradiation had their primary treatment 
before the time (1965), that the radioimmunological plasma GH estimation was availa-
ble. So, it is impossible to compare the results of this type of radiotherapy with that of 
megavoltage irradiation.- The overall cumulative "curation" rate in 84 evaluable acro-
megalic patients, treated with MeV radiation therapy (with or without surgery) was 
found to be 74% using 10 ng/ml and 60% using 5 ng/ml as the normal upper limit for 
plasma GH after 10 years (fig. 7). In 79 patients surgery in combination with radiothera-
PY (N = 47) appeared more effective in causing "curation" (GH < 5 ng/ml) than radio-
therapy alone: 78% versus 43% after 10 years of follow up (fig. 8). In parallel it can 
be stated that complaints concerning hyperhydrosis, acroparaesthesias and soft tissue 
swelling disappeared quicker after surgery in combination with irradiation than after 
irradiation alone. 
Macroprolactinomas and hormonally inactive tumors 
In 16 transsphenoidally operated patients with a macroprolactinoma the mean plasma 
PRL concentration decreased directly by surgery to 67 ± 9% (mean ± SEM) of the pre-
operative value. Postoperative irradiation exerted a great variation in response; the mean 
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Fig. 7. Overall "curation" rate in 84 acromegalic patients treated with MeV radiation therapy (with or 
without surgery). 
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plasma PRL level decreased to 62 ± 17% after one year and to 27 ± 11% of the presur-
gical value after two years. The maximal decrease was reached after 3 years (to 10 ± 
3%). However, some of the patients were excluded for evaluation later on during the 
follow up because of additional treatment with bromocriptine. 
Only four patients were treated with radiotherapy alone. One_ patient reached normal 
PRL levels seven years after the radiotherapy and menses returned spontanously. 
In the patients with "non-functioning" tumors there is no valuable tumor marker. Objec-
tive response to treatment or recurrence of the pituitary tumor can only be evaluated by 
radiological and sometimes by ophthalmological examinations. Therefore it was difficult 
to differentiate between complete or partial (residue) "curation". 
Side effects 
1) In general 
Locally loss of hair was sometimes a short-term side effect. The incidence of persisting 
side effects is indicated in Table I. Headache occurred in 15% of the patients without 
headache before treatment; this varied between a heavy feeling on the head and severe 
migrainic pain. On the other hand in patients with headache before treatment this com-
plaint sometimes disappeared after treatment. Ten percent of the patients complained 
about memory loss during the follow up. Pituitary hypofunction, caused by radiotherapy 
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alone, occurred in up to 21% of the patients (see below). There were no deaths or pituita-
ry sarcomas in the follow up. One patient, who was overtreated elsewhere after normal 
conventional treatment, became blind. 
TABLE 1. Persisting side effects of radiation therapy. 
start or increase of headache 15% 
Partly loss of memory 10% 
Loss of normal pituitary function up to 21% 
Visualloss* 0% 
* with the exception of one patient, treated additionally with 4700 R (10 doses) in an 
other hospital (1959) after conventional treatment with 3000 R Yz year before. 
2) Effect on pituitary function 
In 3 groups of patients with a pituitary tumor the effect of surgical and/or radiotherapeu-
tical treatment on normal pituitary function was studied. Group A consisted of 45 acro-
megalic patients treated by transsphenoidal surgery and radiotherapy, group B consisted 
of 22 acromegalies treated with radiotherapy alone, group C consisted of 37 operated 
(25 x transsphenoidal, 12 x subfrontal) and subsequently irradiated patients with a pro-
lactinoma as well as 28 patients with a "non-functioning" tumor treated in the same way 
(21 x transsph., 7 x subfrontal). 
In groups A and C surgical treatment did not cause a significant decrease of basal TSH, 
LH and FSH or the reaction of desoxycortisol to metyrapone. In contrast, a significant 
decrease of the pituitary reserve of TSH (p < 0.002), LH (p < 0.01) and FSH (p < 
0.01) occurred. A recovery of the pituitary adrenal axis has been observed in 4 out of 
9 acromegalic patients with a disturbed metyrapone test before operation. In case of nor-
mal pituitary function before therapy surgical treatment disturbed most frequently gona-
dotropin secretion (23%), while the pituitary-adrenal function was frequently disturbed 
by irradiation both as single treatment as well as postoperatively (Table ITA, fig. 9). 
Hypothyroidism did not occur after radiotherapy alone, but did after postoperative irra-
diation. In group C a significant increase of L1 TSH (p < 0.02) in the presence of a signi-
ficant decrease of plasma T4 (p < 0.01) was remarkable after postoperative 
radiotherapy indicating hypothalamic insufficiency. The cumulative incidence of hormo-
nal insufficiency before and after both kinds of therapy is shown in Table liB. 
Recurrence-free interval and survival 
1) Recurrence rate 
The cumulative recurrence rate is indicated in Fig. 10. After 20 years of follow-up 88% 
(zie 2 en 3) of the acromegalies was recurrence-free and 76% of the patients with a ma-
croprolactinoma or a "non-functioning" tumor. 
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TABLE 2A Incidence of hormonal insufficiency caused by therapy (group A and B) 
Function Caused by Caused by radiotheraphy 
surgery only after surgery radiother. only 
(=group A) (= group A) (= group B) 
- Hypothyroidism 5% 17% 0% 
- Gonadotropin secretion t 23% 13% 8% 
- Corticotropin secretion t 12% 44% 21% 
TABLE 2B Cumulative incidence of hormonal insufficiency before and after surgery, and after 
subsequent radiotherapy in 45 acromegalic patients (group A). 
Before After After 
surgery surgery radiotherapy 
- Hypothyroidism 7% 11% 29% 
- Gonadotropin secretion t 42% 54% 61% 
- Corticotropin secretion t 20% 21% 59% 
2) Survival 
Ten years after treatment 83% of the acromegalies were alive and 82% of the patients 
with macroprolactinomas or "non-functioning" tumors. This contrasts with 92% and 
90% respectively for 2 control groups matched for sex and age and living in the time 
period between 1965-1969 (Fig. 11). Twenty years after treatment 71% of group I and 
66% of group II were alive. The overall survival after therapy appeared better in the 
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group of patients treated with the combined surgical and radiotherapeutical therapy than 
with radiotherapy alone (Fig. 12). In general, the difference in survival is about 10% 
from the third year onwards. 
3) Causes of death 
Cardiovascular- and cerebrovascular disease, respiratory insufficiency and malignant 
tumors occurred more frequently in the acromegalic patients (Table III). Also in 3 other 
acromegalic patients benign polyps in the colon were found. In the group of patients with 
macroprolactinomas and "non-functioning" tumors death by postoperative complica-
tions was more frequent than in the group acromegalies, possibly because of the fact that 
the mean tumor size and the incidence of suprasellar extension was larger in this group 
of patients. 
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TABLE 3. Causes of death. 
Macroprolactinomas Acromegaly 
and "non-functioning" (n = 117) 
tumors (n = 219) 
n % n % 
-- cardiovascular disease 8 17 6 26 
-- cerebrovascular disease 4 8 4 17 
-- respiratory -- insufficiency 2 2 9 
--embolism 4 8 0 0 
-- malignant neoplasms 
--stomach 0 
-- colon 0 2 
-- renal 0 4 8 1+1 5 22 
--breast 2 1 
-- skin 1 0 (1)* 
--thyroid 0~ 0 (1)* 
-- tumor progression 3 7 0 0 
-- postoperative 5 11 4 
radiation damage 0 0 4 
accident 1 2 0 0 
others 4 8 2 9 
unknown 14 29 2 9 
total 48 100% 23 100% 
* Present tumors not related to death. 
DISCUSSION 
Conventional external radiotherapy is an important part of the therapy of pituitary adeno-
mas especially because of its efficacy of long-term tumor control (3-7). A disadvantage 
of irradiation is the delayed effect. On the other hand surgery is rarely curative in macro-
adenomas and even in 30-40% ofmicroadenoms (9-12). Recurrences occur in the majo-
rity of macroadenomas (3, 5, 7) and in some microadenomas if surgery is not combined 
with radiotherapy (13). Medical treatment with dopamine agonists as bromocriptine is 
effective in the majority ofprolactinomas (12, 14), but these tumors recur shortly after 
stopping the treatment (14); so long-term medical treatment is often necessary. 
Although the combination of surgery and radiotherapy is as effective as radiotherapy 
alone in preventing recurrences (5), the combined treatment causes a more rapid decrea-
se of GH and PRL secretion and a higher "curation" rate. In this study it appeared for 
the first time that the combined treatment was also superior to radiotherapy alone with 
respect to long-term survival. The better survival may at least partly be caused by a shor-
ter time period of exposure to high plasma GH levels in the acromegalic patients. The 
causes of death in our patients are in general comparable with those found in the studies 
_ of Wright (15) and Alexander (16). 
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A disadvantage of the combined therapy is the higher incidence of hormonal insufficien-
cy compared with the direct effect of surgery and the long-term effect of radiotherapy. 
However, the gain of preventing recurrences, a higher chance of more rapidly occurring 
curation with less complaints and longer survival seems more important than life long 
medical treatment of hypopituitarism. Even with respect to fertility the possibilities of 
treatment are improving. On the other hand, in old patients with small tumors and/or 
relatively low plasma levels of GH - which small tumors indeed occur more frequently 
in older patients than in young ones as we reported before (17) - treatment with external 
radiotherapy alone will be sufficient in most of them. 
In conclusion 
1) Conventional external radiotherapy plays a major role in the management of pitui-
tary (macro) adenomas, especially with respect to efficacy of long-term tumor 
control. 
2) Combined surgical and radiotherapeutic treatment is more effective then single 
therapy with respect to "curation" and survival. 
3) a After radiotherapy or the combined therapy the corticotrophic function was more 
frequently disturbed than the other functions. 
b Pituitary insufficiency caused by radiotherapy occurred more frequently after 
postoperative irradiation than when irradiation was used as a single treatment. 
4) The overall survival of treatment patients with pituitary (macro )adenomas is about 
10% less than that of a normal control group (about 80 vs about 90% after a follow 
up of 10 years), which means a death rate of twice the expected number. 
ACKNOWLEDGEMENTS 
We are very grateful to dr. W.L.J. van Putten and Mr. P. van Assendelft for comm~nts 
and excellent help in preparing the curves of the epidemiological study, to Mrs. C. Th. 
Hoeijmans-van Haasteren for expert administrative help, and to the audiovisual service 
for preparing the prints. 
REFERENCES 
1. GRAMEGNA, A. (1909) un cas d'acromegalie traite par Ia radiotherapie. Rev Neurol 17:15. 
2. BECLERE, A. (1909) The radio-therapeutic treatment of tumours of the hypophysis, gigantism, and acro-
megaly.Arch Roentg Ray 14:142. 
3. HENDERSON, W.R. (1939) The pituitary adenomata: a follow-up study of the surgical results in 338 
cases (Dr Harvey Cushing's series) Brit J Surg 26:811. 
4. ELKINGTON, S.G., McKISSOCK, W. (1967) Pituitary adenoma: Results of combined surgical and radio-
therapeutic treatment of 260 patients. Brit Med J 1:263. 
260 
5. ERLICHMAN, C. MEAKIN, J.W., SIMPSON, W.J. (1979) Review of 154 patients with non- functioning 
pituitary tumors. Int J Rad Oncol 5:1981. 
6. EASTMAN, R.C., GORDON, P., ROTH, J. (1979) Conventional supervoltage irradiation is an effective 
treatment for acromegaly. J Clin Endocrinol Metab 48:931. 
7. AMENDOLA, B.E., THRALL, J.H., AMENDOLA, M.A., KANELLITSAS, C. (1981) Pituitary adeno-
mas: when is radiation therapy indicated? Int J Rad Oncol 7:1286. 
8. KLIJN, J.G.M., LAMBERTS, S.W.J., DEJONG, F.H., DOCTOR R., VAN DONGEN, K.J., BIR-
KENHAGER, J.C. (1980) The importance of pituitary tumour size in patients with hyperprolactinaemia 
in relation to hormonal variables and extrasellar extension of tumour. Clin endocrinol 12:341. 
9. FAHLBUSCH, R., (1980) Surgical failures in prolactinomas. In: Derome PJ, Jedynak CP, Peillon F (eds). 
Pituitary Adenomas, Biology, Physiopathology and Treatment, Asclepias Publishers, Paris, p 273. 
10. PEARSON, O.H., ARAFAH, B., BRODKEY, J. (1981) Management of acromegaly. Ann Int Med 
95:225. 
11. LAWS, E.R., RANDALL, R.V., ABBOUD, C.F. (1982) Surgical treatment of Acromegaly: results in 
140 patients. In: Givens JR (ed) Hormone-Secreting Pituitary Tumors, Year Book Medical Publishers, 
Chigaco: p 225. 
12. VON WERDER, K., (1982) Therapy of Prolactinomas in: Fliickiger E, del Pozo E, von Werder K (eds) 
Prolactin, Physiology, Pharmacology and Clinical Findings, Springer-Verlag Berlin, p 184. 
13. SERRl, 0., RASIO, E., BEAUREGARD, H., HARDY, J., SOMMA, M. (1983) Recurrence ofhyper-
prolactinemia after selective transsphenoidal adenomectomy irt women with prolactinoma. New Eng! J Med 
309:280. 
14. THORNER, M.O., PERRYMAN, R.L., ROGOL, A.D., CONWAY, B.P., MACLEOD, R.M., 
LOGIN, I.S., LEON MORRIS, J. (1981) Rapid changes of prolactinoma volume after withdrawal and 
reinstitution of bromocriptine. J Clin Endocrinol Metab 53:480. 
15. WRIGHT, A.D., HILL, D.M., LOWY, C., RUSSEL FRASER, T. (1970) Mortality in acromegaly. 
Quarterly J Med New Series XXX1X 39:1. 
16. ALEXANDER, L., APPLETON, D., HALL, R., ROSS, W.M., WILKINSON, R. (1980) Epidemiology 
of acromegaly in the Newcastle region. Clin Endocrinol 12:71. 
17. KLIJN, J.G.M., LAMBERTS, S.W.J., DEJONG, F.H., VAN DONGEN, K.J., BIRKENHAGER, J.C. 
(1980) Interrelationships between tumour size, age, plasma growth hormone and incidence of extrasellar 
extension in acromegalic patients. Acta Endocrinol (KBh) 95:289. 
261 
CHAPTER IX 
SUMMARY AND CONCLUSIONS 
The main aims of this thesis were to investigate l) the value of 
diagnostic procedures 2) the relationship between symptoms, tumour 
size, age, hormonal hypersecretion, hormonal insufficiency, and 
extrasellar extension of tumour 3) the results of surgery, irradiation 
and medical treatment. 
After a historical introduction in chapter I, our results are 
reported and discussed together with recent literature data in chapter 
II with reference to our own publications (chapter III-VIII). 
The occurrence of pituitary 
symptomatology has been recognized 
radiotherapeutical treatment started 
gland tumours with different 
long before 1900. Surgical and 
in the first decade of this 
century. Prominent pioneers were especially Hirsch and Cushing. Later 
on in the 1960s Guiot and Hardy acquired fame by the introduction of 
microsurgical techniques for transsphenoidal surgery. In the 1960s 
also the irradiation techniques improved. The endocrinology of the 
pituitary and its target organs started really in the 1920s, but the 
unraveling of the structure of most pituitary and hypothalamic 
hormones with the introduction of numerous radioimmunoassays in the 
1970s caused a break-through in the diagnostics of pituitary tumours. 
These revolutionary developments in endocrinologic evaluation together 
with important advances in neuroradiological techniques have made 
possible early diagnosis of small pituitary tumours since 1970 
resulting in improvement of therapeutical results. With respect to 
medical treatment major achievements have been made by the development 
of dopaminergic drugs as bromocriptine and of somatostatin analogues 
as Sandostatin, apart from developments of substitution therapies in 
case of hormonal insufficiency. With respect to the latter therapies 
the discovery in 1950 of adrenal steroids for pre-, intra- and 
postoperative care is one of the important historical events because 
it strikingly decreased the death rate related to pituitary surgery. 
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Symptoms and patient characteristics are described in Chapter II 
section C.l., and Chapters III and IV. The main symptoms in patients 
with prolactinomas are gonadal dysfunction and galactorrhoea caused by 
the hyperprolactinaemia per se. Microprolactinomas are mainly found in 
young women, while postmenopausal women and men have predominantly 
presenting symptoms caused by macroprolactinomas (hypopituitarism, 
neurologic and visual disturbances). In patients with acromegaly the 
spectrum of symptoms is much broader than in patients with 
prolactinomas '· because hypersecretion of GH and . indirectly of 
somatomedin C affects all organs and tissues. Most frequent symptoms 
are soft tissue swelling, acral growth, hyperhidrosis, 
acroparaesthesias and headache. Cardiovascular complications, and 
maybe a slightly increased incidence of malignant tumours, are causes 
of a decreased life-expectancy. In general, young acromegalic patients 
have larger and more rapidly growing tumours than older patients 
necessitating more agressive treatment in younger patients. Patients 
with non-functioning tumours generally have very large tumours and 
symptoms of local tumour extension resulting in destruction of 
surrounding tissues. 
Radiological and ophthalmological evaluation is described in 
Chapter II, section C.2.a. and Chapters III and IV. In our material 
the incidence of extrasellar extension was lower in acromegalic 
patients than in patients with prolactinomas (32 vs 44%). It appeared 
that extrasellar extension occurred at a critical size of the 
pituitary tumour and sella turcica. In acromegalic patients 
extrasellar extension occurred on the average at a lateral sellar and 
tumour area of almost 1 cm2 larger than in prolactinoma patients (with 
respect to sellar size generally above 3 cm2 versus 2 cm2 , with 
respect to tumour size generally above 4 cm2 versus 3 cm2). We found a 
striking negative correlation between pituitary tumour size and age in 
acromegalic patients in contrast to the absence of such a relationship 
in the prolactinoma patients. 
Endocrine diagnosis is described in chapter II, section C.2.b., and 
Chapters III-VII. Although for a certain tumour size basal plasma PRL 
and GH concentrations will vary and vice versa, there appeared a 
strong correlation between tumour size and PRL or GH levels (Chapter 
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III and IV, respectively). A number of dynamic tests are available for 
the diagnosis of hypersecreting pituitary tumours. The TRH-test is 
most commonly used in patients with prolactinomas and acromegaly in 
addition to an oral glucose tolerance (suppression) test in 
acromegaly. Patients with prolactinomas show a decreased response of 
PRL (by less than 100% of the basal value) to TRH in 90% of the 
patients (Chapter V). In contrast acromegalic patients show a 
paradoxical increase of GH secretion in reaction to TRH. 
Hyperprolactinaemia was also present in 57% of patients with 
suprasellar tumours not arising from the pituitary with a PRL response 
of less than 100% to TRH in 64% of these patients (Chapter V) • In 
acromegaly a paradoxical increase of GH to TRH (by more than 100% of 
the basal value) was observed in 44% of the normoprolactinaemic, in 
59% of the midly hyperprolactinaemia and in 75% of the clearly 
hyperprolactinaemic patients (Chapter II, section C.3.b.3.a.3., and 
Chapter VII). 
The occurrence of hormonal insufficiency is related to pituitary 
tumour size and type of pituitary tumour (Chapter II section C.2.b.2., 
Chapters III, IV and VI). In patients with prolactinomas we found a 
negative correlation between tumour size and basal as well as 
stimulated pituitary functions. A prolactinoma size of 3 cm2 turned 
out to be a critical value not only for the occurrence of extrasellar 
extension, but also for the occurrence of hypopituitarism (Chapter 
III). Decreased pituitary hormone reserve was observed in 3-24% of the 
patients with a tumour size less than 3 cm2 in contrast to 44-79% in 
2 . patients with a tumour size of more than 3 em • Acromegal1c patients 
show much less frequently hormonal insufficiency than prolactinoma 
patients (Chapter IV and VI). Hypothyroidism is rare in acromegalic 
patients, but we found a high incidence (about 50%) of an impaired TSH 
response to TRH independent of tumour size. These observations suggest 
that an impaired TSH response may be caused by suppression of TSH 
secretion rather than by destruction of thyrotrophic cells (Chapter 
VI). 
Hyperprolactinaemia occurs in 40-55% of acromegalic patients. We found 
a clear relationship between the basal PRL level, the presence of a 
defined GH response to TRH and the presence of a defined GH response 
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to a test dose of 2.5 mg bromocriptine (Chapter II section 
C.3.b.3.a;3. and Chapter VII). Acromegalic patients with hyper-
prolactinaemia show a higher sensitivity to TRH (increase of GH) and 
one dose of bromocriptine (more pronounced decrease of GH) than 
normoprolactinaemic patients. A homogeneity in the responses of GH to 
TRH and bromocriptine was observed in 74% of all acromegalic patients 
and in 92% of hyperprolactinaemic acromegalic patients, but there was 
no significant correlation between the percentage increase of GH after 
TRH and the percentage decrease after bromocriptine. On the basis of 
immunohistochemical examination of pituitary tumours (Chapter VII) 
hyperprolactinaemia appeared to be present in 70% of the patients with 
mixed GH/PRL containing adenomas. Plasma GH levels were significantly 
more suppressed by bromocriptine in patients with mixed GH/PRL-
containing than in those with pure GH-containing adenomas, but the 
response of GH to TRH did not differ significantly between the two 
subgroups of acromegalic patients. The plasma PRL concentration and 
the GH response to TRH and one test dose of bromocriptine appeared of 
predictive value with respect to the result of chronic treatment with 
bromocriptine. Acromegalic patients with hyperprolactinaemia and/ or 
with a high response of GH to TRH and/or with especially a strong 
suppression of GH in the acute bromocriptine test, showed more 
pronounced suppression of GH during chronic bromocriptine treatment 
than other patients. 
Unfortunately, no single form of therapy is uniformly successful in 
all patients. Therefore an multidisciplinary approach is important. In 
patients with acromegaly, Cushing's disease and non-functioning 
tumours surgery mostly in combination with irradiation postoperatively 
is generally the first choice of treatment, while primary medical 
therapy has become generally accepted in patients with prolactinomas. 
Medical treatment with bromocriptine is often given as an adjunctive 
therapy in patients with acromegaly. Somatostatin analogues maybe 
applied in the near future as a first-line treatment in these 
patients, especially when slow-release depotpreparations will be 
available. Conventional external irradiation is sufficiently effective 
in strongly lessening tumour recurrences and in long-term control of 
tumour growth, but not for obtaining rapid therapeutic effects. 
265 
However, it has to be stated that, although more sophisticated 
hormonal and radiological diagnostic procedures have resulted in the 
detection of pituitary tumours at an earlier stage, and despite 
important improvement in operative, irradiation and drug therapy in 
the last 15 years, complete permanent cures can still not achieved in 
some patients with prolactinomas and in a sifnificant number of 
patients with acromegaly or Cushing's disease. 
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SAMENVATTING EN CONCLUSIES 
De belangrijkste doelstellingen van dit proefschrift waren te 
onderzoeken, ten eerste de waarde van diagnostische technieken, ten 
tweede het verband tussen symptomen, tumorgrootte, leeftijd, hormonale 
hypersecretie, hormonale insufficientie en extrasellaire ui tbreiding 
van de tumor, ten derde de resultaten van chirurgische, 
radiotherapeutische en medicamenteuze behandeling. 
Na een inleiding betreffende de historie in hoofdstuk I, 
beschrijven en bediscussieren wij de eigen resultaten in het licht van 
recente literatuurgegevens in hoofdstuk II met verwijzing naar onze 
eigen publikaties (hoofdstuk III-VIII). 
Het voorkomen van hypophysetumoren met verschillende 
symptomatologie is reeds lang voor 1900 herkend. De toepassing van 
chirurgische en radiotherapeutische behandeling begon in de eerste 
decade van deze eeuw. Vooraanstaande pioniers waren vooral Hirsch en 
Cushing. Later in de 60-er jaren verwierven Guiot en Hardy roem door 
de introduktie van microchirurgische technieken voor de 
transsphenoidale operatie. In de 60-er jaren vond ook een verbetering 
plaats van de bestralingstechnieken. De endocrinologie van de 
hypophyse en zijn doelorganen begon feitelijk in de 20-er jaren maar 
de ontrafeling van de struktuur van de meeste hypophysaire en 
hypothalame hormonen tezamen met de introduktie van talrijke 
radio-immunoassays in de 70-er jaren veroorzaakte een doorbraak in de 
diagnostiek van de hypophysetumoren. Deze revolutionaire 
ontwikkelingen in endocrinologische evaluatie tezamen met belangrijke 
verbeteringen in neuroradiologische technieken heeft een vroege 
diagnose van kleine hypophysetumoren mogelijk gemaakt sinds 1970, 
resulterend in verbetering van de behandelingsresultaten. Met 
betrekking tot medicamenteuze therapie werd belangrijke vooruitgang 
geboekt door de ontwikkeling van dopamine-agonisten als bromocriptine 
en van somatostatine-analogen, zoals Sandostatine, los van 
ontwikkelingen betreffende substitutietherapie, in geval van hormonale 
insufficientie. Met betrekking tot deze laatste vorm van therapie, kan 
gesteld worden dat de ontdekking van corticosteroiden in 1950 en de 
toepassing bij de peri-operatieve zorg een van de belangrijkste 
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historische gebeurtenissen is geweest omdat de sterfte bij en na 
operatie daardoor sterk afnam. De symptomen en kenmerken van de 
patienten zijn beschreven in hoofdstuk II sec tie C. 1., en de hoofd-
stukken III en IV. De belangrijkste symptomen in patienten met 
prolactinomen zijn gonadale dysfunktie en galactorrhoe, veroorzaakt 
door de hyperprolactinaemie als zodanig. Microprolactinomen worden 
voornamelijk gevonden in jonge vrouwen terwijl postmenopausale vrouwen 
en mannen zich overwegend presenteren met symptomen veroorzaakt door 
macroprolactinomen (hypophysaire insufficientie, neurologische en 
visus-stoornissen). In patienten met acromegalie is het spectrum van 
symptomen veel uitgebreider dan in patienten met prolactinomen omdat 
hypersecretie van groeihormoon en indirekt van somatomedine-C alle 
organen en weefsels aantast. De meest voorkomende symptomen zijn weke 
delen zwelling, groei van de lichaamsuiteinden, abnormaal sterke 
transpiratie, tintelingen en hoofdpijn. Cardiovasculaire complicaties, 
en misschien een licht toegenomen incidentie van maligne tumoren, zijn 
oorzaken van een verminderde levensverwachting. Jonge acromegale 
patienten hebben in het algemeen grotere en sneller groeiende tumoren 
dan oudere patienten, hetgeen een meer aggressieve therapie bij jonge 
patienten noodzakelijk maakt. Patienten met niet-functionerende 
tumoren hebben over het algemeen zeer grote tumoren en symptomen 
veroorzaakt door lokale uitbreiding van de tumor resulterend in 
destructie van omgevende weefsels. 
Bet radiologisch en oogheelkundig onderzoek is beschreven in 
hoofdstuk II, sectie C.2.a., en hoofdstukken III en IV. In ons 
patientenbestand kwam extrasellaire uitbreiding van de hypophysetumor 
bij acromegale patienten minder frequent voor dan bij patienten met 
prolactinomen (32 vs 44 %) • Bet bleek dat extrasellaire uitbreiding 
optrad bij een kritische grootte van de hypophysetumor en sella 
turcica. Bij acromegale patienten trad extrasellaire uitbreiding 
gemiddeld op bij een lateraal oppervlak van sella en tumor van 
ongeveer 1 cm2 grotere omvang dan bij patienten met prolactinomen (met 
2 2 betrekking tot sellagrootte over het algemeen boven 3 em vs 2 em , 
2 
met betrekking tot tumorgrootte over het algemeen boven 4 em , vs 
2 3cm ). Wij vonden een opvallend negatieve correlatie tussen de grootte 
van de hypophysetumor en de leeftijd bij acromegale patienten in 
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tegenstelling tot de afwezigheid van zo'n relatie bij de patienten met 
prolactinomen. 
De endocriene diagnostiek is beschreven in hoofdstuk II, sectie 
C.2.b. en in hoofdstukken III-VII. Hoewel voor een bepaalde 
tumorgrootte de basale plasma prolactine en groeihormoonconcentraties 
varieren en omgekeerd, bleek er een sterke correlatie te bestaan 
tussen tumorgrootte en de plasmaconcentraties van prolactine of 
groeihormoon (resp. hoofdstuk III en IV). Een aantal testen met 
stimulatie of remming van de hormoonsecretie zijn beschikbaar voor het 
diagnostiseren van hypersecernerende hypophysetumoren. De TRH-test 
wordt veelvuldig toegepast bij patienten met prolactinomen en 
acromegalie tezamen met een glucose-tolerantie-test bij patienten met 
acromegalie. Patienten met prolactinomen vertonen een verminderde 
respons van prolactine (minder dan 100% van de basale waarde) op TRH 
in 90% van de patienten (hoofdstuk V). Daarentegen vertonen acromegale 
patienten een paradoxe toename van groeihormoonsecretie in reactie op 
stimulatie met TRH. Hyperprolactinaemie was ook aanwezig bij 57% van 
de patienten met suprasellaire tumoren niet van hypophysaire origine 
en een prolactine respons van minder dan 100% kwam voor bij 64% van 
deze patienten. Bij acromegalie werd een paradoxe toename van 
groeihormoon op stimulatie met TRH (meer dan 100% van de basale 
waarde) waargenomen bij 44% van de normoprolactinaemische, bij 59% van 
de licht hyperprolactinaemische en bij 75% van de duidelijk 
hyperprolactinaemische patienten (hoofdstuk II, sectie c.3.b.a.3., en 
hoofdstuk VII). 
Het voorkomen van hormonale insufficientie staat in verband met de 
grootte van de hypophysetumor en het type hypophysetumor (hoofdstuk 
II, sec tie C. 2. b. 2., hoofdstukken III, IV en VI). Bij patienten met 
prolactinomen vonden wij een negatieve correlatie tussen tumorgrootte 
en zowel de basale als de gestimuleerde hypophysefuncties. 
tumorgrootte van 3 cm2 bleek bij prolactinomen niet alleen 
Een 
een 
kritische waarde te zijn ten aanzien van het voorkomen van 
extrasellaire uitbreiding maar ook met betrekking tot het voorkomen 
van hypophysaire insufficientie (hciofdstuk III). Verminderde 
hypophysaire hormoonreserve werd vastgesteld bij 3 tot 24% van de 
patienten met een tumorgrootte minder dat 3 cm2 , in tegenstelling tot 
269 
44-79% bij patienten met een tumorgrootte van meer dan 3 cm2 • 
Patienten met acromegalie vertonen veel minder frequent hormonale 
insufficiE!ntie dan patienten met een prolactinoom (hoofdstuk IV en 
VI). Hypothyreoidie komt zelden voor bij acromegale patienten, maar 
wij vonden een hoge frequentie (ongeveer 50%) van een verminderde 
TSH-respons op TRH onafhankelijk van de tumorgrootte. Deze 
waarnemingen suggeren dat een verminderde TSH respons eerder wordt 
veroorzaakt door suppressie van de TSH-secretie dan door destructie 
van thyreotrope cellen (hoofdstuk VI). 
Hyperprolactinaemie komt voor bij 40-55% van acromegale patienten. 
Wij vonden een duidelijke relatie tussen de basale prolactine-
concentratie in het plasma, de aanwezigheid van een gedefinieerde 
groeihormoon-respons op TRH en de aanwezigheid van een gedefinieerde 
groeihormoon-respons op een testdosis 
(hoofdstuk II, sectie C.3.b.3.a.3. en 
van 2.5 mg bromocriptine 
hoofdstuk VII). Acromegale 
patienten met hyperprolactinaemie vertonen een grotere gevoeligheid 
voor TRH (in de zin van een toename van groeihormoon) en voor een 
eenmalige dosis van bromocriptine (meer uitgesproken daling van 
groeihormoon) dan normoprolactinaemische patienten. Een homogeniteit 
in de response van groeihormoon op TRH en bromocriptine werd 
waargenomen bij 7 4% van alle acromegale patienten en bij 92% van de 
hyperprolactinaemische acromegale patienten maar er was geen 
significante correlatie tussen de percentuele toename van groeihormoon 
na TRH en de percentuele afname na toediening van bromocriptine. Bij 
70% van de patienten met gemengde (groeihormoon- en prolactine-
bevattende) adenomen (hoofdstuk VII) bleek hyperprolactinaemie 
aanwezig. Plasma groeihormoon-concentraties werden bij patienten met 
gemengd groeihormoon/prolactine-bevattende adenomen significant 
sterker onderdrukt met behulp van bromocriptine dan bij patienten met 
alleen groeihormoon-bevattende adenomen, maar de respons van 
groeihormoon op TRH verschilde niet significant tussen de 2 subgroepen 
van patienten met acromegalie. De plasma prolactine-concentratie, de 
groeihormoon-respons op TRH en op een tes tdosis van bromocriptine 
bleken van voorspellende waarde met betrekking tot de resultaten van 
chronische behandeling met bromocriptine. Acromegale patienten 
vertoonden een meer uitgesproken onderdrukking van de groeihormoon-
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secretie tijdens 
vergelijking tot 
chronische behandeling 
andere patienten wanneer 
met 
er 
bromocriptine 
sprake was 
in 
van 
hyperprolactinaemie en/of een sterke respons van groeihormoon op TRH 
en/ of met name een s terke daling van groeihormoon tijdens de acute 
bromocriptine-test. 
Helaas bestaat er geen enkelvoudige vorm van behandeling welke op 
uniforme wijze effectief is bij alle patienten. Daarom is een 
multidisciplinaire benadering belangrijk. Bij patient en met 
acromegalie, de ziekte van Cushing en niet-functionerende tumoren, is 
operatie, meestal in combinatie met post-operatieve bestraling 
gewoonlijk de eerste keuze van therapie, terwijl bij patienten met 
prolactinomen over het algemeen medicamenteuze therapie met 
bromocriptine wordt toegepast als primaire behandeling. Bij patienten 
met acromegalie wordt deze medicamenteuze therapie dikwijls toegepast 
als een aanvullende behandeling. In de nabije toekomst zullen mogelijk 
somatostatine-analogan worden aangewend als een eerste vorm van 
behandeling bij deze patienten, vooral wanneer depotpreparaten 
beschikbaar zullen komen. Conventionele uitwendige bestraling is 
voldoende effectief met betrekking tot het drastisch verlagen van het 
aantal recidieven en het remmen van de tumorgroei op lange termijn, 
maar deze therapie is niet geschikt voor het verkrijgen van een snel 
therapeutisch effekt. Opgemerkt moet echter worden dat, hoewel meer 
geavanceerde endocriene, radiologische en diagnostische technieken 
hebben geresulteerd in opsporing van hypofysetumoren in een vroegere 
fase, complete definitieve genezing nog steeds niet kan worden bereikt 
bij sommige patienten met prolactinomen en bij een belangrijk aantal 
patienten met acromegalie of met de ziekte van Cushing, ook ondanks de 
belangrijke verbeteringen in operatieve, radiotherapeutische en 
medicamenteuze behandeling in de laatste vijftien jaar. 
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PART II 
MANIPULATION OF CANCER WITH 
HYPOTHALAMIC HORMONES 

CHAPTER X 
LONG-TERM PEPTIDE HORMONE TREATMENT 
WITH LHRH-AGONISTS 
IN METASTATIC BREAST CANCER: A REVIEW 
JAN G.M. KLIJN AND JOHN A. FOEKENS 
Department of Endocrine Oncology (Endocrinology and Biochemistry), 
The Dr Daniel den Hoed Cancer Center, Rotterdam, The Netherlands 
1. Introduction 
Different steroid hormones, peptide hormones, growth factors and other 
trophic substances are involved in growth regulation of breast cancer 
cells (23). Endocrine therapy of breast cancer consists of a variety 
of both medical and surgical treatment modalities including 
ovariectomy and hypophysectomy. In general medical treatment usually 
concerns (anti)steroidal agents. Recently, a new approach in the 
treatment of hormone-dependent tumors has been applied, namely 
manipulation of the hypothalamic-pituitary function by analogs of 
hypothalamic hormones. Neuropeptides might play a more important role 
in cancer treatment because of the absence of serious side effects. 
Especially analogs of LuteinizingHormone-Releasing-Hormone (LHRH) are 
of great interest (33). In addition, recently we observed also breast 
cancer growth inhibitory effects of an analog of another hypothalamic 
hormone i.e. somatostatin (21,35). Moreover analogs of these both 
neuropeptides appear to act also directly on breast cancer cells in an 
inhibitory fashion (1,2,18,26,27). 
Since the unravelment of the structure of LHRH and elucidation of its 
physiology by Schally and Guilemin (1971), numerous analogs with 
Reprinted from Proceedings of the Symposium on "Endocrine-Dependent 
Breast Cancer, Critical Assessment of Recent Advances" (ed. R. 
San ten), 14th Int. Cancer Congress, 20-27 August 1986, Budapest, in 
press (1987). 
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pronounced and long-term effects have been synthesized and tested 
(3,8,32,33). Most of these agents appeared to have a paradoxical 
antifertility effect during long-term treatment with sufficiently high 
(supraphysiological) doses. ·The most potent ones of these agents have 
been applied in experimental and clinical studies. In 1976 De Sombre 
et al. reported for the first time regression of rat mammary tumors 
effected by a LHRH analog (5). Since then a number of experimental 
studies on endocrine and growth inhibiting effects in rodents with 
different kinds of tumors have been published (3 ,8, 33). Summarizing 
these data, chronic LHRH agonist treatment with pharmacological doses 
appears to cause: 1) "partial hypophysectomy" with decreased 
gonadotropin and prolactin secretion, 2) "chemical castration" with a 
striking fall in plasma sex steroids followed by a reduction in weight 
of accessory sex organs, 3) inhibition of enzymes involved in 
steroidogenesis, 4) direct effects on extrapituitary tissues such as 
gonadal tissue and both breast and prostate tumor cells. LHRH-like 
receptors have been found in a prostate tumor (33) and in breast 
cancer cells (6,26,27). Inhibition of tumor growth by LHRH analogs 
have been observed in rats with experimental mammary, prostate, 
pituitary, bone and pancreatic tumors (33). 
Since 1981 a large number of clinical phase II and a few compar-
ative studies have established the value of LHRB agonists in prostate 
cancer treatment (22,31,32,33), as also in our hands (4,16,17,34). 
With respect to breast cancer, in 1982 we reported for the first time 
tumor regression in premenopausal patients with metastatic breast 
cancer using the LHRH agonist buserelin (12). From October 1981 till 
January 1985 we have treated 32 premenopausal patients with a minimal 
follow-up of 1.5 year. In this report we will present a summary of our 
updated results and those reported in the literature during the last 
few years. Furthermore we will present some data on our experimental 
studies in vitro (MCF-7 cells) and vivo (DMBA rat mammary tumor). 
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2. Mechanism of action 
The possible mechanisms of action of LHRH analog treatment are 
summarized in Figure 1. There are both indirect 
POSSIBLE IIECHANISMS OF ACTION OF LHRH-ANALOGS 
LHRH-AGONIST 
/ ! high ~ chronic dose administration I PITUITARY I I PITUITARY I ' ' desensitization of L~e LH0 . gonadotrophic cells 
ADS I GONADS I I GO:ADS I 
I ~ LH receptor 
' !OOGENESIS 0 down regulation STEROIDOGENESIS 0 
I ' STEROIDOGENESIS 0 IIAIOIARY/PROSTATE TUJIOUR GROWTH 
STERO 
INHIBITION 
acute and chronic endocrine effects via the pituitary and ovaries as 
well as direct effects on tumor cells. The main mechanism of action is 
medical castration as a result of suppression of the 
hypothalamo-pituitary-gonadal function. This is a consequence of 
desensitization via down-regulation of pituitary LHRH receptors (32) 
while also gonadal gonadotropin receptor levels decrease after a short 
peak of plasma gonadotropin concentration on the first day of 
treatment. Furthermore, besides pituitary and gonadal desensitization 
a direct effect of LHRH analogs on gonadal tissue of animals has been 
described while there is no agreement about such effect occurring in 
humans. Ultimately, these effects on pituitary and gonads lead to 
decrement of LH secretion and inhibition of steroidogenesis and thus 
to castrate plasma concentrations of estradiol and progesterone during 
chronic treatment. The importance of the direct growth inhibitory 
effects on tumor cells observed in vitro is not clear but is probably 
277 
minor compared to those of medical castration. We will describe the 
reported direct and indirect effects below. 
2.a. Direct antitumor effects 
Dose-dependent effects of the LHRH agonist buserelin on human breast 
cancer cells (MCF-7) have been described by us (1,2,7,18) and by 
others (26,27,37). Especially the stimulated growth with low doses of 
estradiol (E2) appears to be inhibited. These doses of E2 used in in 
vitro studies are comparable with castrate or postmenopausal E2 plasma 
concentrations. With higher E2 doses the inhibitory effect of the LHRH 
agonist decreased. This suggests that a certain balance between E2 and 
buserelin concentrations is a prerequisite to obtain inhibiting 
effects of buserelin at the cellular level. Furthermore, Wiznitzer and 
Benz (37) observed also direct inhibition of the prolactin stimulated 
growth of other mammary carcinoma cells (T47D). In contrast to their 
experience with this cell line, we found that the addition of 
tamoxifen to buserelin abolished partly the inhibitory effects of 
buserelin on E2 induced growth of MCF.:_7 tumor cells and vice versa 
(7). The inhibitory action of LHRH agonists is specific because little 
effects are observed in cultures of other breast cancer cell lines and 
a "normal" breast cell line (27). 
In search for the mechanism of action we found that, with 30 pmol/1 
E2 as mitogen, buserelin did not change the patterns of secreted 
proteins (analyzed by SDS-PAGE followed by fluorography) or amounts of 
secreted polypeptides with epidermal growth factor (EGF)-like activity 
(7). Interestingly, while we did not observe effects of buserelin 
administration on MCF-7 cytoplasmic and nuclear E2 receptor (ER) 
levels, the E2-induced progesterone receptor (PgR) synthesis was 
strongly (87%) inhibited. Interference of buserelin and tamoxifen on 
E2-induced PgR synthesis might partly explain their antagonistic 
effects in vitro as mentioned above. 
2.b. Receptors for LHRH and steroids 
As in an experimental prostate tumor (33) LHRH-like receptors have 
been demonstrated in experimental and primary human breast carcinoma 
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(6,26,27). LHRH agonists may, however, exert their direct effects not 
only via LHRH receptors but also via modulation of steroid and peptide 
hormone receptors (see section 2a) or via influencing secretion of 
autocrine or paracrine glycoproteins and growth factors. 
In clinical studies the most beneficial effects of LHRH agonist 
therapy have been observed in patients with ER-positive tumors (53% 
response), while tumor regression was observed in only a few patients 
withER-negative tumors (20). During chronic LHRH agonist treatment of 
rats with mammary tumors, ER and PgR levels were strongly decreased as 
was observed after surgical castration (19). 
2.c. Indirect (endocrine) antitumor effects 
The influences of chronic LHRH agonist treatment on gonadotropin, 
prolactin and steroid hormone secretion in patients with metastatic 
breast cancer are extensively described by us (12-15, 18-20) and by 
others (9,24,28,29). 
After a short-term increase during a few hours on the first 
treatment day plasma gonadotropin levels decreased below pretreatment 
levels within 2-3 weeks for LH and within 3 days for FSH (14,15). 
Thereafter plasma gonadotropin concentrations can be kept low 
(especially biologically active LH) for many years during treatment. 
No ovulatory peaks were observed. 
Anovulation as indicated by persisting low plasma progesterone 
levels occurred in all patients even with low doses of LHRH agonists 
intranasally (i.n.) (13-15,18). During treatment with relatively low 
doses (see section 3) recurrent peaks of E2 may occur followed by 
menstruation. However, with high doses subcutaneously (s.c.) (~ 1 mg 
per day) complete suppression of ovarian follicular function can be 
reached in all patients with a striking fall of plasma E2 
concentration to castration values within 2-4 weeks (Figure 2) as 
observed for plasma testosterone in men with prostate cancer 
(4,16,17). 
Similarly serum estrone and estrone sulfate are profoundly suppressed, 
whereas no constant changes were observed in the serum levels of 
androstenedione and cortisol (9, 24). On the first treatment day a 
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Figure 2. Mean plasma E2 concentrations during chronic single 
treatment with decreasing dosages of buserelin sub-
cutaneously (s.c.) in 11 patients. 
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small rise in plasma prolactin occurs, but disappears during 
continuing treatment (18). All authors found no significant effect on 
basal prolactin levels. However, we observed a decrease of the natural 
night peak of prolactin during chronic subcutaneous treatment (18). 
3. Which dose for use? 
There appeared a great interindividual variation in endocrine response 
(13-15,18). While there is relatively less difference in potency 
between the commonly used LHRH analogs, some patients need 100 times 
higher dosages than others to reach complete medical castration. In 
general, amenorrhea has been observed in 15-20% of the patients 
treated with a daily dose of 400-600 ug i.n. (N8-12 ug s.c.), in 40% 
treated with 1200 ug i.n. ( N 25 ug s.c.), in ::!:_ 75% treated with 
100-1000 ug s.c. and in 100% of the patients treated with 1000 ug s.c. 
or more respectively. In our study (20), decreasing gradually the 
initial dose of 3 mg to 0.4 mg s.c. per day, we observed 
that plasma E2 can increase to above castrate levels when dosages 
below 1 mg were used (Figure 2). Therefore we advice a dose of at 
least 1 mg per day, as is also used by others (9,24). Relatively lower 
daily dosages between 50-300 ug can reach medical castration in nearly 
all (90-100%) patients when administered continuously per infusion or 
slow release formulations. Furthermore, the highest dosages have the 
advantage of potential direct antitumor effects in vivo. 
4. Clinical treatment results 
In 9 (39%) out of 23 premenopausal patients with metastatic breast 
cancer we observed an objective tumor response (20). Four other 
studies (9,10,11,24,25,28,29) with a shorter followup show response 
rates (CR+PR) varying between 31 and 47% (Table 1). Overall an 
objective remission was found in 44 out of 116 patients (38%). The 
reported durations of remission are comparable with those occurring 
during common kinds of endocrine therapy. The longest duration of 
remission until now is more than 54 months (20). An objective response 
has been observed in 30 out of 57 patients with an ER-positive 
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Table l 
RESULTS Of LHRH-AGONIST TREATMENT IN PREMENOPAUSAL 
METASTATIC BREAST CANCER ---
(Updated 1986) 
Author LHRH-agonist 
.!! 
1) Klijn et al. Buserelin 23 
2) Nicholson et al. Zoladex 45 
3) Harvey et al. Leuprolide 25 
* 4) Mathe et al. D-Trp-6-LHRH 8 
5) Hoffken et al. Buserelin 15 
In total 116 
* pretreated 
Overall response rate of ER-positive tumors: 30/57 (53%) 
Table 2 
CR + PR 
9 (39%) 
14 (31%) 
11 (44%) 
3 (38%) 
7 (471'0) 
44 (38%) 
RESULTS OF LHRH-AGONIST TREATMENT IN POSTMENOPAUSAL 
METASTATIC BREAST CANCER 
(Updated 1986) 
Author LHRH-agonist ~ CR + PR 
1) Harvey et al. Leuprolide 41* 4 (10%) 
2) Mathe et al. D-Trp-6-LHRH 15* 3 (20/~) 
3) Plowman Zoladex 10 2 (20%) 
4) Waxman Buserelin 18 0 ( 0%) 
In total 84 9 (11%) 
* pretreated 
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tumor (53%) while remissions in patients with ER-negative tumors occur 
rarely. The median survival appeared in our study 3 years (Figure 3), 
which is at least as good as has been reported for other kinds of 
endocrine therapy. In another study (29) responding patients showed a 
clear longer survival than the failures As shown in Table 2 
objective remissions are also observed in a minority (11%) of 
postmenopausal patients with breast cancer (9,10,25,30,36). Because no 
change in plasma postmenopausal steroid hormone concentrations has 
been found (28,36), these tumor regressions might be explained by the 
reported (see section 2.a.) direct antitumor effects of LHRH analogs. 
Figure 3. SURVIVAL OF 23 PATIENTS WITH METASTATIC BREAST 
CANCER TREATED WITH BUSERELIN ALONE ANO 
5. Side effects 
9 PATIENTS TREATED WITH BUSERELIN + TAM OR MA 
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No side effects occurred with the exception of those caused by the 
intended hypogonadism, especially hot flushes (20). A few patients 
treated with subcutaneous injection had more or less short-term 
urticarial skin irritation which did not cause pain or discomfort. 
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6. Combination treatment 
In analogy to the intended complete androgen blockade by combination 
therapy in patients with metastatic prostate cancer (17,22), complete 
estrogen blockade by using LHRH analogs in combination with 
antiestrogens may cause more rapid relief of complaints (during single 
LHRH agonist treatment it takes several weeks) and hopefully an 
improvement in response rate, duration of response and survival. 
Potential disadvantages of this combination might be both abolishment 
of the suppressive effect of LHRH analogs on pituitary-ovarian func-
tion by the stimulating effect of tamoxifen, at least during 
intranasal buserelin therapy (13-15,18) and abolishment of the direct 
inhibitory effect of LHRH analogs on tumor cells (see section 2.a) 
(7). On the other hand we observed objective responses in 5 of 9 
patients during combination therapy with buserelin and tamoxifen or 
megestrol acetate (20). The survival of these 9 patients appeared 
slightly better than the group of patients treated with buserelin 
alone (Figure 3), but the numbers are too small for analysis and for 
making definite conclusions. 
7. Treatment strategy in endocrine dependent breast cancer 
Because of the absence of serious side effects and the observed 
efficacy which is comparable to that of surgical castration or 
tamoxifen treatment, LHRH analogs are suitable first-line agents in 
the treatment of premenopausal breast cancer. Especially when 
long-acting sustained release formulations (injected once per month) 
indeed will appear to be as effective as daily administration of the 
drug (29), this kind of treatment may be of great advantage. 
Ovariectomy as second line treatment after LHRH agonist treatment 
seems less effective (29) and mainly effective in a few patients with 
insufficiently suppressed ovarian function. Tamoxifen can be effective 
in patients not responding to LHRH agonist therapy ( 13,14), but its 
value for these patients is not clearly defined. More logical is the 
use of progestins in the second line (after LHRH agonist therapy) 
because of their antigonadotropic properties, their continuous 
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suppression of ovarian function, and their potential antitumor effects 
in patients with ER-negative tumors. However, this kind of treatment 
causes more side effects. 
In postmenopausal patients LHRH agonist treatment is of less value 
because of the low response rate and short-term duration of response 
(9,24). Maybe, in very old patients with low drug compliance and 
slowly growing tumors, the use of long-acting depot preparations might 
be of any value. 
8. Conclusions 
1. In premenopausal metastatic breast cancer chronic LHRH agonist 
treatment appears as effective as other common kinds of endocrine 
therapy with respect to response rate, duration of response and 
survival. 
2. No serious side effects have been observed. 
3. Although intranasal administration appeared to be a pleasant and 
sufficiently effective way of treatment in some patients, high 
subcutaneous dosages of LHRH-agonists (at least 1 mg per day) are 
needed for reaching optimal and rapid suppression of the 
pituitary-gonadal function within 3 weeks in all patients. Probably 
sustained release formulations administered once per month will be 
sufficient in most patients too. 
4. The reported tumor remissions in some postmenopausal patients (10%) 
and the demonstration of LHRH binding sites in some human breast 
cancers may support the occurrence of direct antitumor effects in 
vivo as observed in vitro. 
9. Future prospects 
Controlled randomized prospective studies with LHRH agonists versus 
ovariectomy or tamoxifen or other LHRH agonist formulations have to 
be performed in the near future. 
Application of more long-acting sustained release preparations, 
which can be injected once per month, and later possibly once per 
3-6 months. 
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Use of LHRH antagonists which may cause medical castration within 
one day and thus a more rapid tumor response. 
More effective combination treatments. 
Application in old postmenopausal patients? 
Use of adjuvant therapy? 
Application in hormonal synchronization regimens before 
chemotherapy. 
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CHAPTER XI 
EFFECTS OF SOMATOSTATIN ANALOG 
(SANDOSTATIN) TREATMENT 
IN EXPERIMENTAL AND HUMAN CANCER 
J.G.M. KLIJN, B. SETYONO-HAN, G.H. BAKKER, 
M.S. HENKELMAN, H. PORTENGEN AND J.A. FOEKENS 
Department of Endocrine Oncology (Endocrinology and Biochemistry), 
The Dr Daniel den Hoed Cancer Center, Rotterdam, The Netherlands 
INTRODUCTION 
New approaches to the therapy for some known hormonedependent but also 
unknown "hormone-dependent" tumors are being developed on the basis of 
experimental studies in animal models. For instance such a new 
approach is the use of recently produced analogs of hypothalamic 
hormones, especially of Luteinizing-Hormone-Releasing-Hormone (LHRH) 
and somatostatin (30,31). In the last few years the value of LHRH 
analog treatment has been established by a number of clinical studies 
concerning metastatic breast and prostate cancer (see this book). 
However, only a few studies are reported about the application of 
somatostatin analogs in the treatment of malignant tumors 
(2,24,25,28,31,36). 
Somatostatin is a cyclic tetradecapeptide and was first isolated by 
Brazeau et al. (1973) from the hypothalamus (5). It is believed that 
somatostatin acts primarily locally, with paracrine effects, but it 
Reprinted from Proceedings of the International Symposium on "Hormonal 
Manipulation of Cancer, Peptides, Growth Factors, and New 
(Anti)Steroidal Agents" (eds. J.G.M. Klijn, R. Paridaens, J.A. 
Foekens), Raven Press, New York, pp 459-469 (1987). 
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can act also endocrine, autocrine and as a lumone (9,26,27). The 
natural hormone has a short half-life and a short duration of action. 
To circumvent this short duration of action and to develop 
organ-selective compounds, extensive attempts to synthesize analogs 
have been made (1,24-28, 31). Several somatostatin analogs have been 
shown in experimental animals to possess greater potency, longer 
duration of action and a different spectrum of biological actions 
compared to the parent somatostatin molecule. They appeared to 
suppress the secretion of pituitary hormones (GH, PRL, TSH), insulin, 
glucagon and several other gastrointestinal hormones, some of which 
(gastrin, secretin, cholecystokinin) being involved in the growth 
regulation of gastrointestinal tumor cells (15,20, 25,27,34,35, Lamers 
this book). Furthermore, plasma concentrations of some growth factors 
as somatomedin C (IGF-1) (16, 17) and epidermal growth factor (EGF) 
(10), which factors stimulate the growth of some types of tumor cells 
(mammary, pancreatic), may decrease during chronic treatment. On the 
basis of the mechanism of actions as mentioned above, it is 
conceivable that somatostatin analogs may have direct and indirect 
inhibiting actions even on the growth of unknown "endocrine-related" 
tumors as showed by Redding and Schally (24,25,31). Very recently, 
sufficient quantities of somatostatin analogs came available for 
long-term (pre)clinical studies. In this article we will summarize our 
results of chronic somatostatin analog treatment in various tumor 
models using the analog Sandostatin (SMS-201-995), kindly provided by 
Sandoz, Basel. Furthermore we will present preliminary data of a 
clinical study in patients with malignant gastrointestinal tumors. 
RESULTS 
Pancreatic tumors 
A number of pancreatic tumors appears to contain high levels of 
steroid hormone receptors and enzymes involved in steroid metabolism 
(14, Johnson this book) indicating potential hormone dependency. 
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Furthermore the secretion of some gastrointestinal hormones, which are 
involved in the growth regulation of pancreatic (tumor) cells, can be 
suppressed by somatostatin. These data and those reported by Redding 
and Schally (25) prompted us to examine the effects of Sandostatin, a 
new potent somatostatin analog, in rats with a transplantable 
pancreatic acinar tumor (Prof. Longnecker). We have investigated the 
characteristics of this tumor(model) and the mechanism of action of 
Sandostatin. Furthermore we have compared the effects of different 
dosages of Sandostatin on tumor growth and plasma concentrations of 
some hormones and growth factors with those of other endocrine 
measures. 
Tumors were kindly provided by Dr. A.G. Bogden, E,G. and Mason 
Research Institute. About 100 microliter of tumor suspension was 
injected subcutaneously (s.c.) in the left- and right side of male 
inbred Lewis rats. Two weeks after the tumor transplantation 95% of 
the rats already had a detectable tumor mass. With respect to other 
tumor characteristics we have demonstrated in these tumors the 
presence of EGF receptors and low levels of progesterone receptors 
(PgR) in the absence of estradiol receptors (ER), while Reubi and 
Maurer (Sandoz, Basel) were able to show the presence of specific 
binding sites for the somatostatin analog by autoradiography. 
Subcutaneous treatment was usually started right from tumor trans-
plantation (prophylactic treatment) or 2 weeks after transplantation 
(treatment groups). The treatment groups (n=8) were compared with 
control groups with tumor and supercontrols without tumor. The rats 
were treated twice daily with 5 dosages of Sandostatin (0.05, 0.2, 
1.0, 5.0, and 20 ug), the LHRH agonist buserelin (5 ug), and the 
aromatase inhibitor aminoglutethimide (0.5 and 2.0 mg). 
Tumor bearing control rats showed lower body weight than rats 
without transplanted tumors (32). Somatostatin analog treatment had no 
or minor effect on the body weight of tumor 
bearing rats. Untreated tumor bearing rats had lower plasma concen-
trations of GH, IGF-1 and EGF compared to rats without tumors. This 
might be explained by the worse condition of rats with tumors 
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accompanied by delayed body growth. In tumor bearing rats treatment 
with Sandostatin decreased plasma concentrations of GH (~40%), IGF-1 
(~15%), EGF (20-80%), and tumor PgR levels (30-50%). Rats treated 
right from time of tumor inoculation showed pronounced inhibition of 
tumor growth after 2 weeks (4.1. ~6.6 mm2 (s.d.) vs. 45.8 ~ 34.4 mm2 
in controls) and 55% inhibition after 6-9 weeks. In the average a 
growth inhibition of 35% was reached in the non-prophylactic treatment 
groups after 6-9 weeks of treatment with the different dosages of 
Sandostatin used. A dose of 1. 0 ug twice daily seems slightly more 
effective than the other dosages when used prophylactically, but we 
did not observe a difference in growth inhibiting effects between the 
5 different dosages of Sandostatin used in the treatment groups with 
tumors. Treatment with 2x2 mg aminoglutethimide caused comparable 
tumor growth inhibition (50%) while buserelin appeared somewhat less 
effective (Fig. 1). 
Fig. 1 
PANCREATIC TUMOR LOAD 
0 50 100 % of control (x :1: SEM) 
n = 32 control 
n = 22 Sandostatin 2x1 JJ9 proph. 
n = 8 Sandostatin 2x5 JJ9 proph. 
n = 8 Sandostatin 2x0.05 pg 
n = 8 Sandostatin 2x0.2 }J9 
n = 32 Sandostatin 2x1 JJ9 
n = 24 Sandostatin 2x5 JJ9 
n = 16 Sandostatin 2x10 }J9 
n = 8 Busserelin '2x5 }J9 
n = 16 Sandostatin 2x1 JJ9 + Bus 2x5 }J9 
n = 8 Sandostatin 2x5 Jl9 + Bus 2x5 JJ9 
n = 8 Aminoglut. 2x0.5 mg 
n = 8 Aminoglut. 2x2 mg 
·= p 0.05 **= p 0.005 
Tumor growth inhibiting effects of different kinds of 
treatment in rats with transplantable pancreatic tumors. 
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Rhabdomyosarcomas 
The observation that some sarcomas can produce growth factors as 
insulin-like growth factor II (IGF-2) and secondly that IGF-1 is 
involved in the growth regulation of muscle cells, led us to study the 
effect of Sandostatin treatment on the growth of transplantable 
rhabdomyosarcomas in WAGRIJ rats. However, no growth inhibiting effect 
could be observed (Fig. 2). 
800 
MM 2 4 weeks after 
tumour inoculation 
600 
400 
200 
0 
0 
, 
. 
, 
, 
2 3 
WEEKS 
TREATMENT GROUPS: 
SMS: 2x5 ug/day 
2x1 ug/day 
2x0.2 ug/day 
2x0.2 ug/day 
(prophylaxis) 
CONTROL 
(n = 8 per group) 
Fig. 2. No effect of various dosages of Sandostatin on tumor load in 
rats bearing rhabdomyosarcoma on the back (results are mean 
values with indication of the maximal S.D. values 
calculated). 
DMBA rat mammary tumors 
Rats with DMBA induced mammary tumors were treated twice daily with 
the same 5 dosages of Sandostatin as described before (i.e. 0.05, 0.2, 
1.0, 5.0, and 20 ug) for 3 weeks. We observed a bell-shaped curve of 
dose-respo-nc:e relationship for single Sandostatin treatment (Fig.3, 
Table 1). Maximal tumor growth inhibition (82% as compared to controls 
i.e. 10% vs. 57% growth) was reached with a dose of 2 x 0.2 ug per 
day. Lower and higher dosages of Sandostatin appeared to cause less or 
no growth inhibition. There was even a tendency to an increased tumor 
growth rate in rats treated with the highest dose. 
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Treatment with buserelin showed equal results as ovariectomy 
causing clear tumor regression, while single somatostatin analog 
treatment caused only inhibition of tumor growth. The best results 
were obtained with the combination of LHRH and somatostatin agonists 
i.e. 77% regression (Table 1). 
Sandostatin treatment with the highest dosages caused no 
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Fig. 3. Effects of different dosages of Sandostatin on rat mammary 
tumor growth in vivo (upper part) and on MCF-7 tumor cell 
growth in vitro (lower part). 
effects on the weight of the pituitary, adrenals, ovaries and uterus. 
Using the lowest dosages sometimes a small but significant decrement 
of the weight of these organs was observed. Treatment with Buserelin 
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caused highly significant decrement of the weight of the uterus and 
ovaries. Plasma hormone studies are in progress. No binding sites for 
Sandostatin could be demonstrated by autoradiography (Maurer and 
Reubi, Basel) using a technique described in detail before (29). 
Human breast cancer cells (MCF-7) 
Looking for possible direct effects at the level of tumor cells we 
have studied the effects of 9 different concentrations 
Table 1. Comparison of the relative effects on rat mammary tumor load 
of various doses of Sandostatin compared to those of other 
endocrine treatments 
CHANGE 
(%) 
CONTROL +57/+57 
2x o.o5llg SMS +38 
2x 0.2p.g SMS +10 
2x lpg SMS(L) +38/+42 
2x 5}lg SMS +76 
2x 20\lg SMS(H) +94 
2x 5J.lg Busere1in -40/-49 
Buserelin + SMSL -77 
Buserelin + SMSH -27 
ovariectomy 
-51 
-6 -10 
of Sandostatin between 10 and 10 M in cultures of MCF-7 tumor 
cells both in the absence and presence of estradiol and/ or insulin. 
The known stimulating effects of estradiol and insulin were confirmed. 
But, we showed for the first time that a somatostatin analog directly 
inhibits the growth of breast cancer cells in vitro. In all four 
conditions tested Sandostatin appears to inhibit tumor cell growth. 
Based on 3 consecutive experiments the most profound inhibition (73 ± 
18%; x ± SEM) measured by cell number (Fig.3), DNA and protein content 
of the cultures was observed in cultures with insulin and without 
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added estradiol (p < 0.005). With respect to dose response 
relationship, strikingly again a bell-shaped curve was observed as in 
the in vivo experiments with rat mammary tumors. Maximal suppression 
of the growth of the cultures was obtained at a sharply defined amount 
of Sandostatin (10-8 mol); at lower and higher dosages the inhibition 
of cell growth was less striking. 
The observation that Sandostatin had a direct inhibitory effect in 
vitro on MCF-7 cell growth prompted us to investigate the possible 
presence of somatostatin receptors. We have measured the kinetics of 
uptake of the Sandostatin derivative 125r-SMS 204-090 in MCF-7 cell 
4 
cultures and indeed specific binding was observed namely 3 x 10 
molecules per cell (32). 
Patients with pancreatic and gastrointestinal adenocarcinomas 
Patients with metastatic pancreatic (n=7), gastric (n=2) and 
colorectal tumors (n=9) were chronically treated with 3 x 200 ug 
Sandostatin s.c. per day. Plasma IGF-I decreased in nearly all 
patients. IGF-1 concentrations in plasma (measured directly and by 
acid extraction) decreased both in patients with pancreatic tumors and 
colorectal tumors but an increase occurred to pretreatment levels 
after 8-13 weeks of treatment (Fig.4). 
Acid-extracted IGF-1 concentrations were much lower in pancreas 
carcinoma patients than in colorectal carcinoma patients and appeared 
in the first group not different from direct assayable IGF-1 plasma 
concentrations. This might be explained by the fact that most patients 
with (liver) metastases of pancreatic cancers were cachectic and had 
no appetite. 
With respect to possible antitumor effects, no objective remissions 
were observed but 3 patients with metastatic colorectal tumors showed 
stable disease during 3-9 months. No serious side effects were 
observed. Nearly all patients had increased fecal fat loss, but 
significant loss of body weight did not occur. 
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3 0 Pancreatic carcinomas (n= 7) 
• Gastro-interstina1 carcinomas (n=9) 
- Direct assay 
-- ~ Assay in acid-ethanol-extracted serum 
2 
0 
0 3 7 2 4 813 16 
DAYS WEEKS 
DURATION OF TREATMENT 
Fig. 4. Mean serum IGF-1 concentrations during chronic treatment with 
Sandostatin in patients with metastatic pancreatic and 
gastrointestinal carcinomas. 
DISCUSSION AND CONCLUSIONS 
Somatostatin analog treatment appeared to cause clear (dose dependent) 
growth inhibiting effects in experimental pancreatic and breast 
cancer. From our experience the dose used appeared very critical. 
Higher dosages than the optimally suppressive dose are less effective, 
maybe as a consequence of desensitization of the cells during 
treatment. 
With regard to mechanism of action somatostatin analogs have direct 
and indirect effects on tumor cells. In Lewis rats with pancreatic 
tumors growth inhibition might be caused both via the demonstrated 
somatostatin receptors and/or decrement of hormone and growth factor 
secretion especially of EGF. 
Sandostatin can act on mammary tumor cells also by different ways. 
Based on our observation of growth inhibition in vitro of tumor cells 
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(MCF-7) bearing binding sites for Sandostatin and of mammary tumors in 
vivo without somatostatin receptors the presence of direct and 
indirect effects is probable. Somatostatin and analogs may exert their 
action directly by interacting with its specific receptor or by 
modulation of other hormone receptors, and indirectly by a decrease in 
the secretion of pituitary hormones (GH, PRL) and growth factors such 
as IGF-1 and EGF. With respect to indirect actions Murphy et al. (23) 
described that human GH may be a potent ligand for the lactogenic 
receptor in human breast cancer cells, while Shiu and Iwasiow (33) 
observed induction of specific proteins by GH and prolactin (PRL) in 
human breast cancer cells. The observations that increased plasma GH 
levels in breast cancer patients occur (8) and that hyperprolactinemia 
is an unfavorable prognostic factor (6) might be of importance. 
In addition somatostatin may act as a paracrine or autocrine 
regulator of tumor cell proliferation by influencing secretion of 
autocrine or ·paracrine growth factors. Recently IGF-1 appeared to be 
one of the autocrine growth factors for various breast tumor cell 
lines and to stimulate the growth of MCF-7 tumor cells (18,19). The 
interaction of mammogenic peptide hormones (GH, PRL, insulin), 
steroids and EGF with modulation of their respective receptors 
(7 ,11-13,22,23) in addition to the possible inhibiting effects of 
Sandostatin on the secretion of EGF and IGF-1, suggests a very complex 
mechanism through which somatostatin and its analogs act in vivo and 
in vitro. It is interesting to note that analogs of LHRH (3,4,21) and 
somatostatin (this report) have direct inhibitory effects on tumor 
cell growth antagonizing in vitro biological effects of those steroid 
(estradiol) and peptide hormones (GH, insulin) which secretion in vivo 
is suppressed by pharmacological doses of the same neuropeptide 
analogs. 
In conclusion 
1. In experimental pancreatic and breast cancer models somatostatin 
analog treatment appears to cause clear tumor growth inhibitory 
effects in vivo and in vitro. 
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2. With respect to dose-response relationship a bell-shaped curve was 
observed. 
3. Specific binding sites for a iodinated derivative of Sandostatin 
appear to be present in MCF-7 cells and pancreatic tumors. 
4. No antitumor effect was observed in rats with rhabdomyosarcomas. 
5. In the majority of patients with gastro-intestinal tumors chronic 
Sandostatin treatment decreased plasma IGF-1 levels; the clinical 
data with respect to tumor growth inhibition are thus far too 
scarce for definite conclusions. 
6. More studies are needed to define the optimal dose and mode of 
administration in patients with carcinomas. 
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SOMATOSTATIN ANALOG TREATMENT IN RATS WITH TRANSPLANTABLE PANCREATIC TUMORS. 
J.G.M. KLIJN, B. SETYOND-HAN, G.H. BAKKER, H. PoRTENGEN AND J.A. FoEKENS. DR DANIEL DEN HOED CANCER CENTER. THE NETHERLANDS 
Somntoatatin han mninly boon detected in tho central Uf!rvoua 
syutem and the gaatt"ointentinal tract. Somntontntin and its 
nnnloga inhibit the secretion of grovth hormone (GH), 11omc 
growth factors, and mc>at gnntrointeatinnl hormonca, of which 
llomc arc involved in tho grovth regulation of pnncrcntic 
cella. Futthormorc, a nwnber of pancrentic tumors nppcatu to 
contain a high content of steroid hormone receptors and 
enzymen involved in atcroid metnboliam indicnting potential 
hormone dependency. Thone data and thono prcviounly reported 
by Schnlly ot al. led us to ~UHI\lti!O that aomntoatntin nnnlogn 
may influence the growth of different experimental pancrentic 
AIMS OF THE STUDY 
1) To test \lhcth"r the aomntoatatin analog SMS 201-995 
(Sandostntin) inhibita tho gro11th of a tranaplnntnblc 
acinar pancreatic tumor in rata (Prof. Longnecker). 
2) Determination of tho characteristicn of the tumor (model). 
3) Investigation of the mechaniom of action of the 
SoiiUltontatin analog. • 
4) Invcatigation of the offocta of comblu.,U treatment: and 
comparison \lith other .,ndocrine mcaaurcu. 
Anillw.ln 
~w"r" kindly provid"d by Dr. A. E. Bogden, Eg & G Mason 
Research Inntitute. About 100 microliter of tumor uuop.,nnion 
van injected n.c. in the left-and rfght Side of the hind 
flankn of mnlc inbred Levin rata. The rata vcrc divided into 
groupa of 8 animals. After randomi::ation each group had about 
the DDl!IC overage body ~omight. Tlolo \leoko llfter tho tumor 
transplantation 95% of the rots already had a detectable 
tumor mans. Subcutuneouu treatment lolllS us=lly ntnrtcd right 
from tumor trsnupluntntion (prophylactic trcut:mont) or t\lo 
'\locka after trannplantntion (treat:mcnt groupu). The treatment 
groupa \olore compared \lith control groups (lolith tumor) and 
supercontrola (\olithout tumor). 
Treatment - diffor<.!nt dosagm1 Snndoutatin (0.05, 0.2, 1, 5, 
--- - ;~!e!~rf~~ ~:~~a;;~~iat (2 x 5 1us per day). 
- Amiooglutcthimide (2 x 0.5 nnd 2 x 2.0 mg/dny). 
Hormones : GH and IGF-1 (SoiiUltomedin C) by rndioimmuoonnllllY• 
-- EGF like nativity by rndiorccoptor aasny. 
Hormone receptora : - ER and Pg:R according EORTC guidelincn. 
- EGFr by acntchnrd n=lyaia. 125 
- Somntoatntin rcceptorn with J 
Sandootntin nod autoradiography 
(by Maurer nod Rcubi, Buscl). 
CHARACTERISTICS OF THE PANCREAS TUMOR 
Rintology : acinar adenocarcinoma 
Progcaterone receptor : 
EGF receptor 
Somatoutatin receptor : 
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EFFECT OF SOMATOSTATIN ANALOG TREATMENT ON BODY WEIGHT 
OF RATS WITH TRANSPLANTABLE PANCREATIC TUMORS 
PLASMA LEVELS OF GROWTH HORMONE 
SOMATOMEDINE C IN RATS WITH PANCREATIC TUMORS 
PLASMA EGF IN RATS WITH PANCREATIC TUMORS 
PROGESTERONE RECEPTOR CONTENT CX ± SEM) 
Sandostatln2><1,1lOJII"CIIIII.' 
Sandastatln2><1)1Q+DUI21<5,110 
~ 300 •SUPER CONTROL• 
~ 
~ 
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~ 
> 250 
0 g 
~ 
~ 200 
150 
0~0~--~~--~~~--~~ 
WEEKS AFTER TUMOR INOCULATION-
EFFECT OF SOMATOSTATIN ANALOG TREATMENT ON MEAN 
TUMOR LOAD OF TRANSPLANTED PANCREATIC TUMORS IN RATS 
0 
< g 
/ ....... •••• COOTROL (Q.9tNACLl 
g 5.0 i /l\ ~ 
z 
;1i 
/~~~--_;-:· SHS MEOI!J1 2x5 IJG 
i// .-·.\. SMSHIGH2x10UG 
//,'./ 'SMSLOW 2x1 UG 
:l: 2.5 ~jl SMSPROPHYLACTIC2x11JG 
........ -···· 
0
o 1 3 4 6 
WEEOKS AFTER TUMOR INOCULATION 
PANCREATIC TUMOR LOAD 
1) Tumor bonring rata showed lower body weight than rata 
\lithout tranaplanted tumors. Somntontatin nnnlog 
trontmcnt had no or minor effect on tho body \oleight of 
tumor bearing rata. 
2) - Tumor bearing rnto had lo\olor plaama.conccntrationa of 
GH, Somatomedin C (IGF-1) and EGF compared to ratn 
W'ithout tumor. 
- Som.nto11tntin analog treatment dccrenaed plaamn 
concentrationa of GH (+ 40%), Somntomedin C (+ 15%}, 
EGF (2G-80%). nod tumor PgR content (30-50%).-
- Somatostatin analog treatment (6-9 \oleeka) inhibited 
pancreatic tUlllor groW'th (35%) vith the bo11t reaulta (55% 
inhibition} vhen uacd directly from tumor inoculation. 
APPENDIX PAPER 1. 
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side-effects! This safety is believed to be due to the drug's 
selective dopaminergic blocking action in the limbic 
forebrain with virtually no such effect in the nigrostriatal 
system, 9 although it is also possible that its high inherent 
anticholinergic activity may protect against parkinsonian 
side-effects. 10 
Although extrapyramidal side-effects with melleril are 
alleged to be caused only by high doses, 5 severe parkinsonism 
developed in patient3 when he was taking only 25 mg daily. 
We detected that patients 1 and 2 were taking thioridazine 
only after some time and after apparently effective levodopa 
therapy had been introduced. In patient 4 prochlorperazine 
therapy was discovered only at a systematic review of current 
medication at a home visit by the geriatrician. These cases 
amply confirm the statement by Lader11 that the more 
diligent the search, the greater will be the yield of adverse 
drug reactions. 
In all cases of apparent drug-induced parkinsonism it is 
uncertain whether the condition is entirely iatrogenic or 
whether mild parkinsonism has been aggravated by the 
dopamine antagonism of the offending drug.< In this small 
series all four patients returned to normal when treatment 
with the phenothiazine was stopped. Duvoisin 12 has 
emphasised, however, that subclinical parkinsonism may 
become oven during a period of psychotropic therapy and 
may apparently subside when the offending therapy is 
stopped, only to re-emerge in the ensuing year or two. 
The practical lessons of these findings are clear. 
Phenothiazines, even the "safe" thioridazine, may cause 
severe parkinsonism in elderly patients. Parkinsonism thus 
induced may persist for a considerable time. C. D. Marsden 
(personal communication) maintains that it may persist for up 
to 2 years. Even with good standards of general practice and a 
specific inquiry about current medication, it may be difficult 
to determine accurately whether a patient is receiving (or has 
recently received) a phenothlazine. Special inquiry is 
necessary. Phenothiazines should therefore be prescribed as 
seldom and as sparingly as possible, and a most meticulous 
check should be made of drugs being taken (or recently taken) 
in all patients diagnosed as having parkinsonism. Perhaps the 
only foolproof safegnard is a careful "drug holiday" every 6 
months in parkinsonian patients in whom a drug effect is 
seriously considered. This time off therapy would reveal 
whether the condition had been entirely or partly drug 
induced (Marsden: personal communication). 
Correspondence should be addressed to J. W., Department of Geriatric 
Medicine, City Hospital, Greenbank Drive, Edinburgh EH 10 SSB. 
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Preliminary Communication 
TREATMENT WITH A LUTEINISING·HORMONE· 
·RELEASING-HORMONE ANALOGUE 
(BUSEREUN) IN PREMENOPAUSAL PATIENTS 
WITH METASTATIC BREAST CANCER 
JAN G. M. KLIJN FRANK H. DEJONG 
Departments of Internal Medicine and Clinical Endocrinology, 
Rotterdamsch Radio-Therapeutisch Insuiuut, Dr Daniel den Hoed 
K/iniek, and Department of Internal Medicine III and Clinical 
Endocrinology, Erasmus University, Rotterdam, Netherlands 
Summary Four premenopausal women with 
metastatic breast cancer were treated with a 
potent luteinising-hormone-releasing-hormone (LHRH) 
analogue as a single first-line agent. Buserelin 
(6-D-ser-(bu')-LHRH-(1-9)-ethylamide) was given in very 
high dos~s intravenously and then imranasally; ovarian 
function did not decrease within 1-2 weeks, but after this 
period low to very low (postmenopausal) plasma oestradiol 
levels were reached in all patients, accompanied by flushes. 
Two patients, however, subsequently showed transient peaks 
of plasma oestradiol, probably due to a persistent follicle, 
which lasted for some weeks without a rise in plasma 
luteinising hormone, follicle-stimulating hormone, or 
progesterone. In two patients there was no significant change 
in the tumour, whereas in the other two patients there was 
remarkable improvement. 
INTRODUCTIOK 
MANY luteinising-hormone-releasing-hormone (LHRH), 
analogues with pronounced and long-term effects have been 
synthesised and tested_ 1- 4 Most of these agents have a 
paradoxical antifertility effect in male and female rats during 
long-term treatment with sufficiently high (supra-
physiological) doses. Inhibition of steroidogenesis is followed 
by weight loss of the gonads and secondary sexual organs. 
Plasma oestradiol levels fall to the concentrations found in 
oophorectomised r:its; 3 thus LHRH analogues can elicit 
chemical oophorectomy. 
In human beings administration of LHRH analogues 
initially leads to stimulation and subsequently to suppression 
of pituitary and gonadal function. 5 Short-term treatment 
both during the follicular phase' and after midcycle shortens 
the menstrual cycle with luteolysis. 7•8 When an LHRH 
analogue was administered throughout the menstrual cycle 
there was no ovt.ilation. 9 This hormonal oophorectomy might 
be important in the treatment of hormone-dependent 
tumours. No results of treatment with LHRH analogues in 
patients with metastatic breast cancer have yet been reported, 
but several studies in animals indicate that LHRH agonists 
produce regression of spontaneous or dimethylbenz-
(a)anthracene-induced mammary tumours. 4•10. 12 The results 
are similar to those obtained with oophorectomy10•1' and 
tamoxifen studies. 12 No serious side-effects have been 
reported. 9 We have treated four premenopausal women with 
metastatic breast carcinoma with one of the most potent 
LHRH analogues, buserelin (6-D-ser [bu']-LHRH [ 1-9] 
ethylamide), as a single first-line agent; we initially gave very 
high doses intravenously and then smaller doses intranasally. 
PATIENTS AND METHODS 
Four premenopausal women (aged 44, 41, 48, and 44, 
respectively) with metastatic breast carcinoma gave informed 
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consent for this new form of hormonal treatment. All menstruated 
regularly once every 4 weeks. They had undergone surgical 
treatment and (with the exception of patient 2) local radiotherapy 
for primary breast cancer 1112, 5, 1112, and 3'h years previously. 
Patients 1-3 were treated with an 8 h infusion of 3 mg buserelin 
from 9.00 A.M. until 5.00 P.M. on 7 successive days. Blood samples 
for measurement of luteinising hormone (LH) and follicle-
stimulating hormone (FSH) were taken by way of an intravenous 
catheter twice before, then 30 min, 1 h,2h, 3 h,4h, 6 h,and8hafter 
the start of the infusion. Patient 4 was treated with a continuous 
infusion of3 mg/day buserelin for three days, and blood samples for 
LH and FSH measurement were taken every 4 h. In all patients 
plasma oestradiol and progesterone were measured every day before 
the infusion and on days 1 and 7 in the Hrst three patie:1ts 1 h, 4 h, 
and 8 h after the start of the infusion. After the intravenous 
treatment the daily therapy was changed to three doses per day of 
200 t-tg buserelin intranasally (3X400 t-tg in patient 4). During this 
treatment blood samples were taken weekly for measurement of 
LH, FSH, oestradiol·l7[J, and progesterone. Each patient was asked 
to make a basal temperature curve. 
LH, FSH, oestradiol·l7fJ, 13 and progesterone 14 concentrations 
were measured as reported previously. Results for LH are now 
expressed in terms of the World Health Organisation standard 
68/40 rather than standard 69/104. The normal range for basal Ui: 
is 3·5-12·6 IU/1. andforbasa!FSH 1·2-4·2 IU/1. 
RESULTS 
Endocrine E Jfects 
Patient I had, before treatment, high basal plasma 
concentrations ofLH and FSH and low plasma oestradiol and 
progesterone levels, suggesting that she was perimenopausal 
(see accompanying figure). In patients 2 and 3 basal plasma 
LH and FSH were high, but oestradiol levels were also high 
(figure). Ovulation bad probably occurred I or 2 days earlier 
as shown by rising plasma progesterone concentrations. In 
patient 4 (figure) basal LH and FSH were normal before 
treatment, and plasma progesterone showed only a small and 
slow increase during the week after treatment started. 
On the first treatment day peak values for plasma LH and 
FSH were reached after 3 to 8 h. In patients 2 and 3 plasma 
LH and FSH fell to the starting level within I day, whereas in 
patients I and 4 high plasma levels persisted for more than I 
week (figure). Ultimately, plasma gonadotropin levels fell 
below the pretreatment values in all patients. 
Patients 2, 3, and 4 began menstruating on days 24, 28, and 
25, respectively, of the cycle in which therapy was started, but 
patient I did not menstruate. The duration of the luteal phase 
was normal in patients 2 (14 days) and 3 {at least 12 days). 
After 2 weeks' therapy plasma oestradiol concentrations were 
66-206 pmol/1, whereas plasma progesterone was low and 
remained low (<1·5 nmol/1) in the next few weeks of follow-
up. The basal temperature curves showed an irregular 
(patients I and 3) or monophasic panern (patients 2 and 4). 
Within 7 weeks all patients bad very low plasma oestradiol 
concentrations (33-103 pmol/1) and experienced hot flushes 
for the first time in their lives. However, patients 1 and 3 
subsequently showed transient peaks of plasma oestradiol 
without increases in plasma LH, FSH, or progesterone. 
The very high doses of buserelin caused no side-effects 
which the four patients could recall or which could be shown 
by physical and routine laboratory examinations. 
Effects on Tumour Growth 
Patient 1 had cytologically proven costal-bone metastases 
which were causing bone pain. During treatment the pain 
varied and decreased after 7 weeks. Radiographic 
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examination of the skeleton showed no change. Physical and 
laboratory examinations also showed no signs of progression. 
Patient 2 had increasing bone pain and sciatica with 
immobility caused by a partially destroyed and compressed 
lumbar vertebra (L2) due to progressive metastatic disease. 
This patient, who asked for active euthanasia I week after the 
start of therapy, improved remarkably. She is now free of pain 
and works full-time. A suspect hard axillary lymph-node 
(1·8X 1·5 em) disappeared completely. 
Patient 3 bad cytologically proven skin, lymph-node, and 
bone metastases. Mter 7 weeks' treatment there was no 
significant change in the extent of the metastases, although 
there was a tendency to progression of the skin metastases. 
Patient 4 had a pleural effusion histologically proven to be 
carcinomatous. The effusion disappeared in 6 weeks without 
intrapleural cytostatic therapy or discharge of the pleural 
effusion, and her complaints of coughing ceased. 
DISCUSSION 
Long-term treatment with large doses of LHRH agonists 
causes pituitary exhaustion and desensitisation, 2.4-6 
inhibition of prolactin secretion, 11 •15•16 and down·regulation 
of gonadal gonadotropin receptors with decreased 
steroidogenesis;2.4,l7,IS a direct effect ofLHRH analogues at 
the ovary has also been demonstrated. 19•20 Inhibition of 
oestradiol secretion seems to be the major determinant for an 
antitumour effect in animals with mammary tumours. 4 Also, 
the recently reported ability of LHRH analogues to 
antagonise the biological actions of sex steroids21 ,22 may be 
important for hormone~dependent tumours such as breast 
cancer. 
Plasma LH and FSH fell below pretreatment values after 
about 2 weeks' treatment and then rose slightly in some of our 
patients. Very low plasma LH levels (I or 2 IU/1) were not 
reached. The paradoxical reaction of plasma LH to the 
LHRH analogue in patient I during the I st week of treatment 
is interesting. From the 2nd day plasma LH fell, after a slight 
rise, during the infusion period, but during the night LH 
levels rose. This finding indicates increased release and 
production ofLH outside the period ofintravenous therapy. 
Although shortening of the menstrual cycle with luteolysis 
has been reported when treatment was started after 
midcycle,7•8 in patients 2 and 3 the duration of the luteal 
phase of the cycle in which treatment began was normal. 
Patient 2 menstruated 4 days early probably because of an 
early ovulation rather than luteolysis. In patient 4 corpus 
luteum insufficiency is a plausible cause of the moderate 
increment in plasma progesterone and the early onset (3 days) 
of menstruation. 
All four patients became anovulatory after the 
menstruation at the end of the menstrual cycle in which 
buserelin treatment began. Plasma oestradiol decreased 
funher to postmenopausal values 6-7 weeks after treatment 
started. The high plasma level of oestradiol (without a rise in 
progesterone) for some weeks in patient 1, possibly due to a 
persistent follicle, was disappointing in terms of the aims of 
this therapy. It seems the pituitary is not able to respond to 
the increased levels of oestradiol by releasing the mid-cycle 
peak ofLH and FSH (i.e., the positive feed-back is disturbed). 
Follow-up was short for the determination of effects on the 
tumours. In patients 1 and 3 after 7 weeks' treatment there 
were no significant clinical, chemical, or radiological signs of 
regression or progression of the tumour. However, in 
patients 2 and 4, who showed the most favourable endocrine 
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M =menstruation. Hatched area represents pericxl of intravenous treatment. 
effects of treatment, there was remarkable improvement. 
The results of this therapy with the LHRH analogue 
buserelin are not the best but offer hope. The problem of 
inhibiting luteal steroidogenesis within a few days remains, 
but most hormonal treatments for breast cancer need 1 or 2 
weeks before they are effective. Also we must be aware that a 
persistent follicle or a number of active small follicles may 
develop. We believe, however, that LHRH analogues will 
ultimately be useful in the treatment of metastatic breast 
cancer, certainly in combination with other hormonal 
treatment. 
ADDENDUM 
14 and 9 weeks respectively after the stan of the treatment 
patients 2 and 4 were still in remission with continuous 
"oophorectomised" levels of plasma oestradiol (about 45 
pmol/1), while patient l's condition was stable at 14 weeks 
with very low plasma oestradiol (about 45 pmol/1). Because of 
slowly growing metastases in the skin and because of a second 
oestradiol peak, we decided to add anti-oestrogenictherapy in 
patient 3. 
We thank the medical department, Hoechst Pharma Holland, for supplies of 
the LHRH agonist, our colleagues of the hospital breast cancer group, the 
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LH and FSH, H. Portengen, D. M. van Goal, and H. G, Bierings (or technical 
assistance, C. Hoeijmans and G. van den Bos for administrative help, and J. 
Marselje for preparing the prints. 
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CHOLERA AND ESTUARINE SALINITY IN 
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RICHARD G. FEACHEM 
Ross Institute and Department of Medical Microbiology, 
London School of Hygiene and Tropical Medicine, 
Keppel Street, LonMn WCIE 7HT 
Summary Laboratory investigation has shown 
that Vibrio cholerae requires a salinity of at least 
0 · 01 o/o to survive beyond 24 h. This requirement, when 
coupled with the observation that water becomes unpalatable 
at salinities above approximately 0 · 1 o/o, suggests that 
waterborne transmission of cholera is unlikely to take place 
when water salinity falls outside the range 0 · 01-0 · 1 o/o. A 
hypothesis is proposed that this constraint on waterborne 
transmission, together with the seasonal fluctuations of 
estuarine salinities, may explain the seasonality of cholera in 
estuarine cities. 
INTRODUCTION 
UNTIL the mid-1970s Vibrio cholerae was regarded as an 
organism with only a limited ability to survive in the 
environment.' However, isolation of the 01 serotype of V. 
cholerae from aquatic environments in areas believed to be 
free of clinical cholera has challenged this view and raised the 
possibility that the organism is a normal inhabitant of specific 
aquatic habitats. 2•3 Even if this is not the case, these 
environmental isolations suggest that V. cholerae can survive 
for lengthy periods in certain aquatic environments. 4 
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V. CHOLERAE SURVIVAL AND SALINITY 
All of the recent isolations of the 0 1 serotype of V. cholerae 
in areas non-endemic for cholera have been made from 
brackish waters. In Chesapeake Bay, U.S.A., for example, V. 
cholerae was only isolated from waters of salinity of 
0 · 4-1 · 7%.5 We have measured the effect of salinity on V. 
cholerae survival to explore whether salinity might be a 
dominant controlling factor in the aquatic distribution of the 
organism. 
Six Bangladesh isolates ofO 1 V. cholerae El Tor Inaba were 
suspended in a range of sea salt solutions prepared from 
sterile distilled water and natural sea salt containing no 
additives. The pH was standardised at 8 · 0 and the solutions 
were stored in the dark at room temperature (about 25°C). 
Bacterial counts were made by means of a spread plate 
technique. We inoculated 0 · 1 ml of log10 dilutions of the 
bacterial suspension on to trypticase soy agar plates. The 
plates were incubated overnight at 37°C and the dilution 
chosen for the count was that which gave between 30 and 300 
colonies. Each count was carried out in duplicate. 
The minimum level ofsaltrequired for survival for 1 day at 
25 o C was 0 · 01 o/o, whilst the optimum level for survival fell in 
the range 0·5-3·0% (fig. 1). This may explain the 
discrepancy between the reported short survival of V. 
cholerae in potable water and the extended survival of the 
vibrio in estuarine waters of appreciably higher salinity.' 
SALINITY OF DRINKING WATER 
Water becomes unpalatable at salinities above 0·1 %.6 
Therefore, if cholera in man is associated with drinking water 
in which there is a V. cholerae population, transmission is 
most probable when water salinities fall ·in the range 
0 · 01-0 · 1 o/o. This may in part explain the historical 
association beriveen human cholera and cities with poor 
sanitation located on estuaries. 
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APPENDIX PAPER 2. 
LONG-TERM LHRH-AGONIST TREATMENT IN METASTATIC BREAST CANCER 
AS A SINGLE TREATMENT AND IN COMBINATION WITH OTHER 
ADDITIVE ENDOCRINE TREATMENTS 
JAN G. M. KLIJN 
Dr. Daniel den Hoed Cancer Center/Rotterdam Radio-Therapel!tiC Institute, Groene Hilledijk 301, 
3075 EA Rotterdam, The Netherlands 
(Received for publication 13 July 1983) 
:twenty-one premenopausal patients with metastatic breast cancer (unselected for receptor status) were 
treated during 3-14 months with the potent LHRH-agonist Buserelin (Hoe 766) as a first-line therapy. In 
one-third of 12 patients treated with Buserelin alone an objective tumour response was observed in the 
absence of side effects. The longest duration of response occurred in 2 patients with complete remissions 
(14+ and 13+ months). After addition and in combination with tamoxifen this LHRH-agonist treatment 
caused an objective response in about half (8/17) of the patients. A problem appears to be the great varia-
tion in hormonal response especially during the combination treatment with tamoxifen, which was not 
found during combination treatment with megestro1 acetate in 4 patients. Ultimately, of the whole group 
of 21 patients, 9 patients (43%) showed an objective remission, 6 stable disease and 6 progression of 
tumour growth. 
Key words: Breast cancer, LHRH. 
INTRODUCTION 
Many analogues of luteinizing-hormone-releasing-
hormone (LHRH) with marked and prolonged effect in 
comparison with the natural hormone have been syn-
thesized and tested.1- 4 A lot of them appeared to have 
a paradoxical antifertility effect in male and female rats 
during chronic treatment in sufficiently high (supra-
physiological) doses. Such long-term treatment with 
large doses of LHRH-agonists causes: (1) 'partial hypo-
physectomy' with decreased gonadotrophin1- 5 and 
prolactin secretion;4- 7 (2) 'chemical castration' with 
decreased steroidogenesis and reduction in weight of the 
gonads and of secondary sexual organs;1• 4- 8 (3) Possibly 
a direct antisteroidal effect at the target organs!-11 
These endocrine effects are important with regard to 
the treatment of hormone-dependent tumours. In experi-
mental studies such chronic LHRH-agonist treatment 
appeared to inhibit the growth of mammary,'· 6• 12• 13 
prostate14 and pituitary tumours.7 
In view of these findings we started in 1981 a study 
in premenopausal patients with metastatic breast carci-
noma. Recently the preliminary results have been pub-
lished.15• 16 Meanwhile we have experience with long-
term endocrine and anti-tumour effects of chronic 
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lreatment with the LHRH-agonist Buserelin (Hoe 766) 
as a first-line agent in a larger group of patients. The 
longest duration of treatment is by now more than 
14 months. Further we studied the effects of combina-
tion therapy with the LHRH-agonist and tamoxifen as 
well as megestrol acetate. 
PATIENTS, METHODS AND TREATMENT 
Twenty-one premenopausal patients with metastatic 
breast cancer gave informed consent to be treated with 
the potent LHRH-agonist Buserelin as a single agent or 
in combination with other additive hormonal treatment. 
All patients had not previously been treated for their 
metastatic disease and were unselected for receptor 
status. Twelve patients were treated with Buserelin alone 
(1) and totally 14 patients with the combination of the 
LHRH-agonist with 2 X 20 mg tamoxifen (2) as indicated 
in Table I. In addition, we treated recently 4 other 
patients with the combination ofBuserelin and 4 X 45 mg 
megestrol acetate per day (3). 
Blood samples for the measurement of LH, FSH, 
·oestradiol (E2) and progesterone (prog) were taken daily 
in the first week and later on weekly during chronic 
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Table I. Data of 17 patients treated with Buserelin alone or in combination with tamoxifen 
Group A 
I. Twelve patients (median age = 40 yr) treated with a daily dose of 3 mg Buserelin per infusion or subcutaneously 
during 3-7 successive days followed by 3 X 400 flg per day intranasally. 
2. In 9 of these patients tamoxifen 20 mg twice daily was added later on because of tumour progression or recurrent 
peaks of plasma oestradiol 
Group B 
Five patients (median age= 37 yr) treated with the combination of Buserelin and tamoxifen from the start of treatment 
Disease-free interval: x = 2.5 yr (range 0.5-5.0 yr) 
Oestradiol receptor: 4 X positive; 2 X negative; II X unknown 
Start of treatment during the luteal phase: II X 
intranasal therapy. Plasma concentrations of these 
hormones were measured by radioimmunoassay as 
described previously. 17 The normal range for basal LH 
is 3.5-12.6 I.U./1 and for basal FSH 1.2-4.2 I.U./1. 
Measurements of tumour response were performed 
according to UICC criteria. 
RESULTS 
1. Single treatment with Buserelin 
An objective tumour response occurred in 4 patients 
and stable disease in 4 further patients, while progression 
was shown in the remaining 4 patients (Table 2). The 
longest duration-of response is more than 14 months. No 
side effects were observed with the exception of hot 
flushes. 
An ovulation as indicated by persisting low plasma 
progesterone levels was reached in all patients during 
chronic treatment with Buserelin alone, but recurrent 
peaks of oestradiol occurred in 6 out of I 0 evaluable 
patients (Table 3). In 4 patients a complete castration 
effect with persisting postmenopausal values for plasma 
oestradiol was found (for instance Fig. 1). In 2 patients 
the chronic effect on ovarian function could not be 
evaluated because the treatment had to be changed 
witbin 6 weeks due to rapid progression in tumour growth. 
Objective remissions occurred especially in patients with 
complete 'chemical castration' (3X), but it appeared also 
in one patient with recurrent peaks of oestradiol. 
2. Combination therapy with Buserelin and tamoxifen 
In 9 of the 12 patients, treated with Buserelin alone, 
tamoxifen. was added later on because of recurrent peaks 
of oestradiol or tumour progression. In addition to the 4 
Table 2. Anti-tumour effects during treatment with Buserelin alone and in 
combination with tamoxifen 
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Group 
A (I) 
Type of responsea 
CR: 2X} 
4/12 
PR:2X 
NC:4X 
F:4X 
A (2) After addition of TAM: 2X PR 
B 
In total 
CR: IX 
PR: !X 
NC: IX 
F:2X 
CR: 3X } 
8/17 
PR: 5X 
NC:4X 
F: 5X 
Duration (months) 
3-5 
4.5-3-3+-3 
acR = complete remission, PR = partial remission, NC no change, 
F =failure. 
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Table 3. Endocrine effects in 17 patients treated with Buserelin alone and in combination with 
tamoxifen 
Sex steroids 
1. Buserelin alone 
(n= 12) 
2. Buserelin +TAM 
(group A+ group B = 9 + 5 = 14) 
Effect 
(a) 'Castration' 
(b) Rec. E2 peaks 
Not evaluable 
(a) 'Castration' 5 + 1 = 
(b 1) Rec. E2 peaks 
without progesterone 
(b2) Rec. E2 peaks with progesterone 
secretiom 3 + 4 = 
Complete 'chemical castration' in 40% of the patients. 
L.H. ,,~ ocooccc """"''" 
Occurrence 
4X 
6X 
2X 
6X 
!X 
7X 
8X 
, "I" ~I 
l,...:,;..,::.:.~,::;:::;:, :;:,:;:,:;,;?;,::;::;~~;:;=;,;:::,;::;:::, ,;:;:::, ~~ ,;:;::, ,;::,;=;::, ;:, ;=, r1 r•,r•:·;:,-..............-;o, f', ;:,,;:~;:, ;:;;:;;:;J;:~;:, ;;=~;::;:~;:;=;:;:r;.,:;:;:: =;:,:;:,.,r~2nt 1 
60dayo of'zme~str~~l ~Yet~- ~eeks ~f treatm';nt 20 
F.S.H. 1 
(U/
1
) '"l~~~~~~~~~,,~·l~i?iri~T?~i~i97~1~i~i?ii~7~i~l~i~IT<~i·ri~l ni·?~l~i~iTI~i~lrrtrn~i9<~1TITi~<r<r<~< <n<~<~<T<T<r<~Oi 
E2 '" ~ (pmo1/1):~, 
I I I 
Prog. no 
, ..• ;'':l A 
II I I I I I I I fl I I I 1.1 I I I I I I I I I II I I l I l I tl I I I I I II I il II I I I II 
P.R.L. 
(llg/1) 
Fig. 1. Changes of plasma hormone concentrations during chronic LHRH-agonist treatment in a patient with chemical 
castration (group A). 
objective responders during chronic Buserelin treatment 
two more patients showed a partial response during the 
combination therapy (one had stable disease and one 
progression during Buserelin treatment). So, in total, 6 of 
the 12 patients of group A reached ulthnately an objective 
response. 
In the 5 patients (group B), treated with the combina-
tion therapy from the start of treatment, we observed two 
objective remissions, one stable disease and two failures 
(Table 2). 
The endocrine response during the combination 
therapy was strongly variable. Addition of tamoxifen to 
Buserelin treatment can cause disappearance of oestradiol 
peaks, but also recurrence of ovarian progesterone secre· 
tion (Table 3, Fig. 2). In one case hypersthnulation of 
the ovaries was observed (without progression of tumour 
growth). 
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Fig. 2. Changes of plasma hormone concentrations during combination therapy with Buserelin and tamoxifen in a 
patient of group B. 
3. Combination therapy with Buserelin and megestrol 
acetate 
Recently we treated 4 patients with this drug combina· 
tion from the start of treatment. All patients showed a 
complete castration effect with continuously post-
menopausal values for plasma oestradiol (Fig. 3). With 
regard to tumour response we observed one objective 
remission, two times stable disease and one progression. 
Relationship with receptor status 
In only 6 of the 17 patients of group A + B was the 
receptor status of the primary tumour known (Table 4), 
so it is very difficult to make conclusions. Four patients 
with an ER-positive tumour showed 3X an objective 
response and IX stable disease during combination treat-
ment, while 1 of the 2 patients with an ER-negative 
tumour showed a partial remission during Buserelin treat-
ment and the othe:- ~regression. 
DISCUSSION 
In this study chronic single treatment with the LHRH-
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agonist Buserelin has been proven to be effective in one-
third (4/12) of unselected premenopausal patients with 
metastatic breast cancer without causing side effects. 
After addition of tamoxifen an objective response has 
been ulthnately observed in about half of the patients 
(8/17). Thus, the response rate of tumour growth inhibi-
tion appears as good as other types of ablative or additive 
endocrine therapy. Although direct antisteroidal actions 
of LHRH-agonists•-u are described and prolactin secre· 
tion decreased,4 - 7 the main mechanism of anti-tumour 
action seemed to be a ~chemical castration' .4 • 18 Also in 
our study the patients with a castration effect showed 
the best responses. So, another advantage of LHRH-
agonist treatment together with the absence of side 
effects might be the possibility for the future to select 
patients, who will respond to oophorectomy. 
However, the problem remains the great variation in 
hormonal response during treatment with Buserelin alone 
(as well as in combination with tamoxifen), which is in 
contrast with the fmdings in rats1- 8 and with the 
relatively uniform endocrine response in patients treated 
with LHRH-analogues for prostate carcinoma.19 - 21 In 
our patients with breast cancer unpredictable recurrence 
of plasma peaks of oestradiol was found in 60% of the 
LHRH in breast cancer 12 7 
LHRH-A 
Megestrol ac. l.H. '" (U/1)'~ 
"' 
"" 
____ l 
/; -. ~- ;--; ' ' -; =;-
day of menstrual cycle weeks of treatment 
F.S.H., 
(U/1) lL~~~~~~p~:,#,:~.~.~=;-=~~:~~~~.~.~:=7~~=r~~~:~,-T~~ 
Prog. 
(nmol/1) 
P.R.L. 
(!19/1) 
I l 
' ' : ; ' ; ' 
day of menstrual cycle 1 weeks of tr~atment 
Fig. 3. Changes of plasma hormone concentrations during combination therapy with Buserelin and megestrol acetate. 
Table 4. Relationship with receptor status in 17 patients treated with 
Buserelin alone and in combination with tamoxifen 
E2-receptor Treatment 
LHRH-A alone 
(group A) 
LHRH-A+TAM 
(group A+B) 
n = 14 
ER+ CR+PR 
NC 
F 
ER- CR+PR 
NC 
F 
ER unknown CR + PR 
NC 
F 
patients. The reason for this variation in endocrine 
response is unclear and has to be resolved. Maybe even 
higher dosages of Buserelin are necessary to reach a 
castration effect in ali patients. 
During treatment with the combination with 
tarnoxifen an (in)sufficient corpus luteum function was 
found in half of the patients (7/14, Table 3) as proven by 
postovulatory plasma progesterone levels. This indicates 
n = 12 
1/2 
1/2 
1/2 
1/2 
3/8 
3/8 
2/8 
3/4 
1/4 
2/2 
1/8 
2/8 
5/8 
that tarnoxifen may overcome the suppressive effect on 
hypothalarno·pituitary function by chronic LHRH· 
agonist treatment. Therefore we combined Buserelin 
with high-dose megestrol acetate treatment because of 
its antigonadotropic properties. From the endocrine 
point of view this combination appeared more suitable 
than the combination of Buserelin with tarnoxifen. How· 
ever, not all patients responded with tumour growth 
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inhibition, and side effects as body weight increase with 
a cushingoid face occurred after about 3 months of 
treatment. 
In conclusion. chronic intranasal Buserelin treatment 
was shown to be effective in premenopausal women with 
metastatic breast cancer without causing side effects. 
Further clinical investigations are necessary to find the 
most suitable dose and drug combination. 
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Anti-tumor and endocrine effects of chronic LHRH agonist treatment (Buse-
relin) with or without tamoxifen in premenopausal metastatic breast cancer 
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Blonk-van der Wijst" and Steven W.J. Lamberts'. 
a Departments of Internal Medicine, Clinical Endocrinology, and Biochemistry, Dr Danii'l den Hoed Cancer 
Center! Rotterdamsch Radio- Therapeutisch Instituut; and' Department of Internal Medicine Ill and Clinical 
Endocrinology, Erasmus University, Rotterdam, The Netherlands 
Keywords: breast cancer, Buserelin, LHRH agonist, premenopausal women, tamoxifen 
Summary 
Seventeen premenopausal women with metastatic breast cancer were treated with the potent Luteinizing 
Hormone Releasing Hormone (LHRH) agonist Buserelin as a first-line agent. Twelve patients (group A) 
were treated with Buserelin alone and five patients (group B) with the combination of Buserelin and 
tamoxifen from the start of treatment. In nine patients of group A tamoxifen was added to Buserelin later on 
because of tumor progression or recurrent peaks of plasma estradi'ol (E2). Chronic intranasal therapy with 
Buserelin alone, preceeded by parenteral administration, caused an objective remission in four patients 
(2 x C.R., 2 x P.R.) and stable disease in four further patients without causing side effects. The longest 
duration of response until now is more than 29 months. After addition of tamoxifen a partial response 
occurred in two more patients of group A. Anovulation with suppressed progesterone secretion was reached 
in all patients treated with Buserelin alone, but transient peaks ofE, occurred in. the majority (60%) of the 
patients. Addition of tamoxifen to Buserelin treatment caused disappearance of E, peaks in 2 patients, but 
also reappearance of progesterone secretion with recurring E2 peaks in 3 other patients; in one case 
hyperstimulation of the ovaries was observed without progression of tumor growth. In group B only one 
woman showed a complete castration effect, while in four patients progesterone secretion was not (com-
pletely) suppressed. In two of these five patients an objective response occurred. In conclusion, Buserelin 
appears effective in the treatment of premenopausal women with metastatic breast carcinoma, but with the 
regimen used close control of endocrine parameters is necessary because of the variation in hormonal 
response with a risk of (hyper)stimulation of the ovaries, especially during combination therapy with 
tamoxifen. 
Introduction 
In animals chronic treatment with supraphysiologi-
cal doses of LHRH agonists causes: 1) 'partial hy-
pophysectomy' with decreased gonadotropin (1, 2) 
and prolactin secretion (2-5); 2) 'chemical castra-
tion' with a striking fall in plasma sex steroids 
followed by a reduction in weight of secondary 
sexual organs (1-6); and 3) inhibition ofthe biolog-
ical actions of sex steroids at their target organs 
(7-9). At least some of these endocrine effects have 
been suggested to be important in the treatment of 
Address for offprints: Jan G.M. Klijn. M.D .• Dr Daniel den Hoed Cancer Center/Rotterdamsch Radio~Therapeutisch Instituut, 
Groene Hilledijk 301. 3075 EA Rotterdam, The Netherlands. 
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hormone-dependent tumors such as breast (3, 5, 
10-12) and prostatic cancer (12, 13) induced in 
animals. 
Recently the preliminary results of treatment 
with LHRH agonists in patients with advanced 
breast (14, 15) and prostatic cancer (1~19) have 
been reported. The aim of the present study was 
the evaluation of long-term effects of single treat-
ment with the LHRH agonist Buserelin (Hoe 766; 
6-D-Ser-(bu')-LHRH-(1-9)-ethylamide) on tumor 
growth and hormone secretion in premenopausal 
patients with metastatic breast cancer treated dur-
ing a period of 3-20 months after our 'Preliminary 
Communication' (15) on 2 months follow-up. In 
addition, the effect of a combination therapy ofthe 
LHRH agonist with tamoxifen was investigated, 
especially with respect to the endocrine response. 
It was not our intention to compare the anti-tumor 
efficacy of the two treatments. 
Patients, methods and treatment 
Patients 
Seventeen consecutive menstruating women (un-
selected for receptor status; mean age 40 yr, range 
28-53 yr) with previously untreated metastatic 
breast carcinoma gave informed consent for this 
new form of hormonal treatment. The mean dis-
ease-free interval between treatment of primary 
and secondary breast cancer was 2.5 years (range 
0.5-5.0 yr). The receptor status of the primary 
tumor was known in 6 patients (Table 1). Various 
kinds of metastases occurred in this group of pa-
tients (Table 1); patients with clear liver metastasis 
were excluded from this study. 
Before treatment all patients were examined ra-
diologically by total skeletal survey, bone-scan, 
and scintigraphy or CT-scan of the liver. Physical 
and routine laboratory examinations (hematology 
and chemistry) were performed. The patients were 
Table 1. Pretreatment data and outline of the treatments in 17 premenopausal patients with metastatic breast cancer. 
Patient Age 
(yr) 
Group A 
I 44 
2 41 
48 
44 
44 
43 
40 
35 
35 
10 44 
II 35 
12 35 
Group B 
13 53 
14 28 
15 30 
16 41 
17 37 
Parenteral LHRH agonist 
treatment 
daily dose 
3mg 
3mg 
3mg 
3mg 
3mg 
3mg 
3mg 
3mg 
3mg 
3mg 
3mg 
3mg 
3mg 
3mg 
3mg 
3mg 
3mg 
by 
R hr in f. 
Shr inf. 
Shr inf. 
24hr inf. 
24hr inf. 
24hr inf. 
3 X I s.c. 
days 
7 
3 X I S.C. 7 
3 X I S.C. 7 
3 X 1 S.C. 
3 X I S.C. 
3 X 1 S.C. 
24 hr in f. 
24hr inf. 
24hr inf. 
24hr inf. 
24hr inf. 
3' 
3' 
3' 
3' 
3'' 
Dose of Menstrual cycle Localization of ER PR 
chronic i.n. day at start of metastasis (fmollmg) 
treatment treatment 
3 X 400,ug 11 B 
3 X 400,ug II B. Ln 
3X400,ug 16 B. Ln. S 20 so 
3 X 400,ug 12 p 
3 X 400,ug 24 L 
3x400,ug 12 Lu, S 
3 X 400,ug 26 s 
3 X 400,ug 15 B, P. Lu, Li. Ln 
3 X 400,ug 25 Ln. (B"). thyroid 
3X400,ug post ovulatory S. (Ln"?) 
3 X 400,ug 9 Ln.P 
3 X 400,ug 21 B. P, Ln 23 
3 X 400,ug' 16 Ln. S 25 
3 X 400,ug''' 18 B 
3X400,ug' 9 B 40 
3 X 400,ug' 15 B 
3 X 400,ug'' P. Lu, Ln 
B =bone: P =pleura: Lu =lung: Li =liver: S =skin: Ln =lymph nod.e: inf. =infusion: s.c. =subcutaneously: i.n. =intranasal: 
* = plus 2 X 20 mg tamoxifen daily. 
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seen every three weeks after the start of treatment 
for recording of complaints, physical examin-
ations, and routine laboratory investigations. Bone 
or lung metastases were evaluated every 3--6 weeks 
during the first half year of treatment (later on at 
least every 3 months in case of long-term regression 
or stable disease). Total skeletal survey and bone-
scan were repeated at least once every half year; 
echosound or/and CT-scan or/and scintigraphy of 
the liver were repeated if indicated. Measurements 
of tumor response were performed according to 
Ul CC criteria. 
Treatment 
Twelve patients (group A) were treated with Bus-
erelin as a first-line single agent; in 9 of these 
patients tamoxifen 20 mg twice daily was added 
later on because of tumor progression or recurrent 
peaks of plasma estradiol. A second group (group 
B) of 5 patients was treated with the combination 
of Buserelin with tamoxifen from the start of treat-
ment. 
After parenteral (intravenous or subcutaneous) 
administration of 3mg Buserelin per day for 3-7 
days, the therapy was changed to three doses of 
400 t-Lg Buserelin per day intranasally (Table 1). In 
eight patients of group A and in three of group B 
the treatment was started during the luteal phase. 
Hormone and receptor measurements 
During the parenteral treatment period, blood 
samples for the measurement of luteinizing hor-
mone (LH), follicle stimulating hormone (FSH), 
and prolactin (PRL) were taken frequently ( 6-9 
times per day). Plasma estradiol-17/3 (E2) and pro-
gesterone were measured daily during this period. 
During intranasal therapy blood samples were 
taken weekly for measurement of LH, FSH, PRL, 
E,, and progesterone. Plasma concentrations of 
these hormones were measured by radioim-
munoassay as described previously (15, 20). The 
normal range for basal LH is 3.5-12.6 IU/1, for 
basal FSH 1.2-4.2 IU/1, and for basal PRL up to 
15 t-Lgll. Luteal phase plasma progesterone concen-
trations exceed 3 nmol/1 while follicular phase E2 
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levels are larger than 150 pmol/1. Steroid receptors 
were assayed in the primary tumors by the method 
recommended by the EORTC Breast Cancer Co-
operative Group (21). 
Significances of differences between mean val-
ues at various time points within treatment groups 
were assessed by Student's paired t-test. 
Results 
The individual endocrine effects concerning the 
presence or absence of chemical castration and 
effects on tumor growth are listed in Table 2. Typi-
cal examples of endocrine responses to treatment 
with these doses of Buserelin are shown in Figs. 
lA-D. 
Endocrine effects 
Gonadotropins 
Group A. On the first day of treatment, peak val-
ues for plasma LH (186. 7 ± 20.3 IU/1; mean ± 
SEM) and FSH (31.8 ± 5.0 IU/1) were reached 
about 4--6 hours after Buserelin administration. 
Within one day LH and FSH dropped rapidly (Fig. 
2). Mean plasma LH concentrations decreased be-
low pretreatment levels after 2-3 weeks and con-
tinued to decrease slowly. Mean plasma FSH con-
centrations fell to the pretreatment level within 3 
days, decreased below the pretreatment level dur-
ing the first week, and remained thereafter at the 
same level (2.0-3.0 IU/1) during more than one 
year (Fig. 2). No ovulatory peaks were observed. 
Subnormal levels occurred rarely. 
After addition of tamoxifen in 9 patients, later 
on during treatment, mean plasma LH and FSH 
did not change significantly. Mean plasma LH did 
tend to increase 6-7 weeks after the addition of 
tamoxifen, but this might be caused by incidental 
peaks of LH and FSH in two of the patients. In 
patient 5 a clear increase of plasma LH and FSH 
was observed after discontinuation of hormone 
therapy (Fig. 1C), maybe caused by the following 
chemotherapy. 
Group B. The mean plasma LH and FSH concen-
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Tah/e 2. Summary of endocrine and anti-tumor effect:-; of chronic Buscrclin treatment with or without tamoxifcn. 
Effects of Buscrdin treatment only E!Tccts of Buscrclin + tamoxifcn 
Patient Chemical E, peaks Prog. Tumor Duration Chemical E, peaks Pro g. Tumor Dumtion 
castmtion ·peaks response or castration ·peaks' response of 
(>3.0 response (>3.0 response 
nmol/1) (months) nmol/1) (months) 
Group A 
I + N.C. 4.5 + + P? 
+ C.R. 211" 
3 + N.C. 3 + P.R. Ill 
4 + C.R. 19 1 
+ p + p 
+ P.R. + N.C. 
+ N.C. 3+ + + N.C. I+ 
+ N.C. + p 
y + P.R. + p 
10 + p 
II p + p 
12 p + + P.R. 
Group B 
13 + + P.R. 5+ 
14 + + C.R. 3+ 
15 + N.C. 5+ 
16 + + p 
17 + + p 
C.R. =complete remission: P.R.= partial remission (decrease of more than 501Xl of size of tumor lesions): N.C.= no change: 
P =progression: Prog =(cyclic) ovarian progesterone :-occrction: E~ = cstr:.tdiol-17/'). 
tration showed the same curve during combination 
therapy as during long-term treatment with the 
LHRH agonist alone (Figs. 3A and 3B). After two 
weeks of treatment there was a tendency to some-
what higher levels in group B, but a significant 
difference was found only at 5 weeks for LH 
(p<O.Ol). 
During the combination therapy with Buserelin 
and tamoxifen we observed 5 times (3x in group 
A, 2x in group B) a plasma LH peak between 27 
and 44 IU/l. In 3 cases (patients 1, 7 and 14) such a 
peak was followed by a clear increase of plasma 
progesterone, indicating corpus luteum function. 
Other patients showed increased progesterone se-
cretion though peaks of secretion of LH and FSH 
were not detected (Table 2). 
Sex steroids 
Group A. In the first weeks of treatment no in-
316 
crease of plasma progesterone concentrations was 
detected in patient 1 (perimenopausal) and patient 
12 (one month hospitalization and treatment with 
morphine and metoclopramide causing hyper-
prolactinemia before Buserelin therapy). Nine pa-
tients finished their ongoing cycle after normal du-
ration of the luteal phase with normal plasma 
progesterone levels. Only in patient 4 (Fig. lB) 
there was an indication of corpus luteum insuffi-
ciency. 
During chronic therapy with 3 x 400 JJ-g Bus-
erelin intranasally, anovulation occurred in all pa-
tients as indicated by persisting low progesterone 
levels (Table 2). In four of the 10patients who were 
treated with Buserelin alone for a period long 
enough for evaluation of the effect on ovarian func-
tion, a complete 'chemical castration' was found 
with persisting low plasma estradiolleveis between 
<20 and 75 pmol/1 during follow-up periods of 3 to 
LHRH-analogue treatment in breast cancer 213 
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(Prog). and prolactin (PRL) in patients 3 (A). 4 (B). 5 (C). and 7 {D). M = mcn~truation: ov =ovariectomy: 1111 = intravcnou" 
Buscrclin trc<Jtmcnt~ l ! l ! l =subcutaneous injections with Bu~crclin: ! -! =period of intranasal Bu~erclin treatment: 
DO= period of oral treatment with tamoxifcn. 
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Fig. 2. Acute and chronic effects of long-term treatment with Buserelin alone on plasma LH (0--0) and FSH ( •--•) concentra-
tions in 12 patients (group A). 
A 
LH 
U/1 
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50 
"' 
30 
-· 
20 
lO 
* p< 0.01 
l 2 3 10 12 
d~;~ys WI!Ck; 
Fig. 3. Acute and chronic effects of long-term treatment with 
Buserelin alone (0--0) on plasma LH (Fig. 3A) and FSH 
(Fig. 3B) concentrations compared with those during chronic 
20 months (for example patient 4, Fig. lB). How-
ever, the remaining six patients showed transient 
peaks of plasma estradiol without increases in 
plasma LH, FSH, or progesterone (Table 2). 
Hyperstimulation of the ovaries occurred in one 
patient (patient 7, Fig. 1D). One week after ad-
B 
FSH 
U/1 
32 
2B 
" 
20 
" 
l2 
l 2 3 
days 
..... J..,r. .. ·l· .. L.T...r....1 LHRH-A +TAM 
10 12 14 
w<reks 
treatment with the combination of Buserelin and tamoxifen 
( • ...... •) in 8 and 4 patients respectively. all of them treated for 
at least 12 and 8 weeks respectively. 
dition of a high dose of tamoxifen (80mg daily) 
ovulatory progesterone secretion preceded by a 
small LH peak returned in this patient. Although 
the histologically proven skin metastases showed 
no change either before or after addition of tamox-
ifen to Buserelin treatment, we decided to perform 
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surgical castration. At operation both ovaries 
showed multiple follicles with a ruptured follicle 
containing blood in one ovary. Tumor size showed 
no change before or during more than 9 months 
after the ovariectomy. 
In 9 patients tamoxifen was later added to Bus-
erelin treatment because tumor progression or 
plasma estradiol peaks occurred. Four patients 
(Table 2) still showed estradiol peaks during the 
combination therapy. and in 3 of these 4 patients 
even ovarian progesterone secretion returned at l. 
4 and 7 weeks after the addition of tamoxifen (see 
also Fig. ID). On the other hand, the estradiol 
peaks which occurred during treatment with Bus-
erelin alone were no longer observed after addition 
oftamoxifen in patient 3 and patient 5 (Fig. lA and 
!C). 
In summary, the endocrine response to Bus-
erelin alone (with the doses used). as well as in 
combination with tamoxifen, is very variable. Ul-
timately 'chemical castration' was reached in 7 pa-
tients (58%). In 3 (maybe 4) of 6 patients con-
secutively treated with combined chemotherapy 
(CMF), plasma estradiol and progesterone re-
mained low after discontinuation of hormonal 
therapy (with exception of continuing tamoxifen in 
patient 10 and 12). 
Group B. In three patients (13, 15 and 17) we 
observed a clear corpus luteum insufficiency with 
short-term and decreased progesterone secretion, 
while two patients (14 and 16) showed normal cor-
pus luteum function. Ovulation occurred about 1 
and 3 weeks later than normal in patients 15 and 17 
during the ongoing cycle at the start of treatment. 
After the end of the ongoing cycle only patient 15 
showed a complete castration effect subsequently, 
while in the other fciur patients estradiol peaks 
occurred in the presence of progesterone secretion 
(Table 2); low luteal progesterone secretion was 
observed in 3 of these patients. 
Prolactin secrefion 
In general, during long-term treatment there were 
no impressive changes in plasma prolactin concen-
trations (Fig. !A-D). Detailed data during parent-
eral and intranasal therapy will be published 
separately. 
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Effects on tumor growth 
Single freatment 
Buserelin alone appeared effective in four patients 
(two complete and two partial remissions) and 
caused stable disease in four more, while pro-
gression occurred in the remaining four patients 
(Table 2). The longest remission until now is more 
than 20 months. This patient had a pleural effusion 
histologically proven to be carcinomatous. The 
effusion disappeared in 6 weeks without intra-
pleural cytostatic therapy or discharge of the 
pleural effusion. Her complaints of coughing ceas-
ed and she is still normally functioning as housewife 
without any complaints or side effects of the treat-
ment except a few flushes per day. In three of the 
four patients in whom a 'chemical castration' was 
attained, we observed an objective response. while 
in the fourth patient (patient 8 with stable disease) 
temporary improvement occurred with less com-
plaints. The fourth objective response occurred in 
patient 6 in spite of recurrent peaks of estradiol. 
Combination therapy with tamoxifen 
Group A. After addition of tamoxifen to the treat-
ment with Buserelin, two more patients (patient 3 
and 12) showed an objective response. In patient 3 
extensive diffuse skin metastases disappeared com-
pletely, while bone pain disappeared and plasma 
alkaline phosphatase decreased. However, after 10 
months a pleural effusion developed, in which tu-
mor cells were found. She showed again an objec-
tive response during treatment with megestrol ace-
tate, indicating hormone sensitivity. Although in 
patient 5 (Fig. 1C) a complete chemical castration 
was reached after addition of tamoxifen. further 
progression of lung metastases occurred indicating 
the possibility of a hormone-independent tumor. 
These lung metastases disappeared after chemo-
therapy, but they recurred after seven months. 
Group B. Two patients showed an objective re-
sponse, one stable, and two progressing disease 
(Table 2). Patient 13 had a partial regression of skin 
and lymph node metastases; patient 14 showed re-
calcification of osteolytic bone lesions although 
chemical castration was not obtained. 
Relationship with receptor status 
It appears very difficult to make conclusions be-
cause receptor measurements were performed in 
only 6 tumors.· One of the 2 patients with a recep-
tor-negative tumor showed a partial remission for 5 
months during treatment with Buserelin alone (pa-
tient 9, Table 2). 
Side effects 
Hot flushes and decreased libido occurred in the 
patients with 'complete chemical castration·. Hot 
flushes occurred also in other patients between 
peaks of estradiol. In 3 of 6 patients who were 
treated in the first week with subcutaneous injec-
tions of Buserelin, urticarial skin irritation oc-
curred a few minutes after injection at the injection 
site lasting 1-2 hours. Antibodies against Buserelin 
could not be identified in plasma obtained between 
a few weeks and a few months after the start of 
treatment (estimations performed by the Depart-
ment of Pharmacology Hoechst. Frankfurt). Other 
side effects such as cardiovascular complications 
were not observed. 
Discussion 
In animal studies. LHRH analogues have been 
shown to act directly and indirectly at the levels of 
the pituitary (1, 7, 22, 23), the gonads (1. 7. 22-31), 
and target organs of sex steroids (7-9). In this study 
the response of metastatic breast carcinoma to Bus-
erelin alone or in combination with tamoxifen was 
investigated. The effect of Buserelin alone might 
be ascribed to its castrating and possibly intrinsic 
anti-estrogenic effect, while by the combination 
therapy the castration effect of Buserelin might be 
enhanced by inhibition of the effect of the already 
low plasma estradiol concentration on the tumor by 
tamoxifen. Chronic intranasal Buserelin therapy 
was shown to be effective in one third ( 4/12) of 
premenopausal women with metastatic breast can-
cer without causing side effects (except hot flushes 
or decreased libido). In total, in 8 of 17 patients an 
objective response was observed after treatment 
with Buserelin, alone or in combination with tam-
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oxifen. One patient (no. 9) with an estrogen recep-
tor (ER)-negative tumor showed an objective re-
sponse. Similar observations were made in rats 
withER-negative mammary tumors (11). although 
in the latter system the effect might be mediated 
through decreased prolactin levels. 
The main problem to be resolved remains the 
great variation in hormonal response to treatment 
with Buserelin alone as well as in combination with 
tamoxifen. The hormonal response varied from a 
complete castration effect to ovarian hyperstimula-
tion. Treatment with tamoxifen alone has been 
found also to cause a great variation in hormonal 
response (32-34). Plasma E, concentrations varied 
between postmenopausal levels and a three-fold 
increase as compared to normal menstrual cycles. 
In contrast to treatment with tamoxifen. treatment 
with the LHRH agonist alone prevents the de-
velopment of corpora lutea (as indicated by the 
absence of progesterone secretion in all patients) 
probably by suppression of the positive feedback of 
estradiol on the preovulatory LH and FSH peak. 
With regard to the effects of tamoxifen on gonad-
otropin secretion, the reported results are conflict-
ing. Sherman et a!. (34) found no significant in-
crease of plasma gonadotropin levels during two 
cycles. but Manni and Pearson (32) observed an 
increase of plasma gonadotropin levels during 
longer treatment. In our study, long-term treat-
ment with Buserelin alone caused suppression of 
gonadotropin secretion to about 40--50% of the 
pretreatment value, while addition of tamoxifen 
did not increase the plasma concentrations signifi-
cantly. However, during the combination therapy 
we sometimes observed peaks of LH and FSH. 
followed in some patients by ovarian progesterone 
secretion, so that the stimulatory effect of tamox-
ifen on the pituitary gonadal axis (32) may over-
come the suppressive effect of the doses of LHRH 
agonist used. A point of concern is the potential 
fertility of patients on this combined endocrine 
treatment; addition of tamoxifen may annihilate 
the advantage of contraception caused by single 
treatment with Buserelin (35-37). unless the endo-
metrial changes caused by long-term tamoxifen 
treatment (34) prevent gravidity. 
Ovarian 'hyperstimulation' was not reported to 
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occur during treatment with tamoxifen alone (in 
contrast to treatment with clomid (33)), but in our 
study the combined tamoxifen and LHRH agonist 
treatment caused clear ovarian 'hyperstimulation' 
with enlarged ovaries containing multiple follicles 
in one of our patients (patient 7). Nevertheless, 
tamoxifen appeared able to cause an objective re-
mission of the tumor in spite of recurring peaks of 
estradiol as observed in patients 12, 13 and 14, 
which observations confirm the findings of Manni 
and Pearson (32). 
Intriguing is the phenomenon that in two pa-
tients estradiol peaks disappeared after addition of 
tamoxifen without a clear change in basal gonado-
tropin levels. This might be caused by a direct 
effect of tamoxifen on the ovary via ovarian 
estradiol receptors, which have been demonstrated 
in normal ovaries (38). 
In order to find the most effective way to start 
treatment we have used several schemes of parent-
eral therapy in subgroups of patients (Table 1). We 
did not find a clear difference in endocrine re-
sponse between the subgroups. After an initial 
peak of plasma gonadotropins we observed an ab-
sent or reduced pituitary responsiveness ( desensi-
tization) during chronic treatment with the LHRH 
agonist Buserelin, which might be explained by a 
decrease or abnormal breakdown of pituitary 
LHRH receptors (22). In contrast with the com-
plete suppression of ovarian estradiol secretion in 
rats (5), an unpredictable recurrence of plasma 
peaks of estradiol was found in the majority ( 60%) 
of our patients during chronic treatment with a 
moderately high dose of 1200 J.Lg Buserelin intran-
asally. Nevertheless, ovulation did not occur in 
these patients, as indicated by the absence of pro-
gesterone secretion. The recurrence of estradiol 
secretion was also found in about 75-85% of the 
women in studies where the efficacy of lower doses 
of LHRH analogues was investigated with respect 
to contraception (35-37). In those studies pro-
gesterone secretion appeared not completely sup-
pressed in all women (10-15% of treatment cycles) 
during chronic treatment with lower intranasal 
doses of 400-600 J.Lg per day. Suppression of gona-
dal function may have been caused both indirectly 
via the initial LH burst with subsequent down-
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regulation of gonadal receptors and interference 
with enzymes involved in steroid biosynthesis, as 
well as by a direct effect on the ovary (1, 7, 22-31). 
In animals, LHRH binding proteins are found in 
ovarian tissue (25, 29, 30), while LHRH analogues 
also appear to have a direct in vitro effect on gran-
ulosa cells in the presence of gonadotropins (28, 
31). However, in women a direct effect on the 
gonads is uncertain (39-41). The possible absence 
of a direct effect of LHRH and its analogues on the 
human ovary could be a cause for the difference in 
gonadal response between rats and women. An-
other cause might be the change of the very high 
parenteral dose of 3 mg per day after the first week 
to a relatively low dose of about 25 J.Lg resorbed 
intranasally (about 2% resorption of the total in-
tranasal dose of 1200 J.Lg). This dose might be at the 
lower limit of the effective range, causing complete 
castration in only some of the women. Possibly 
higher doses are necessary for complete inhibition 
of ovarian function in all patients. Indeed, prelimi-
nary data of an ongoing study about the effects of 
very high subcutaneous doses of LHRH agonist 
indicate that complete chemical castration can be 
reached in all patients with sufficiently high doses 
(J.G.M. Klijn eta!., unpublished data). 
Recently some authors found that LHRH analo-
gues inhibit the action of sex steroids on their target 
organs (7-9); these observations are in conflict with 
those of Furr and Nicholson in castrated immature 
rats (5). An indication for a direct temporary anti-
tumor action of LHRH analogues was found by 
Corbin (12), who showed a direct dose-related 
effect on the growth of mouse mammary tumor 
cells in vitro after 4 days of treatment. Also we 
found a weak anti-estrogenic effect of Buserelin on 
MCF-7 cells (42). Further, the finding of an objec-
tive response after 10 weeks in 16% of postmeno-
pausal women (14) treated chronically with very 
high doses of a LHRH analogue after prior other 
therapy, may be an argument for a direct anti-
tumor effect, because ovariectomy is not effective 
in postmenopausal patients. In our clinical study 
we found no clear indication for a direct anti-tumor 
effect of the Buserelin dose used, because the best 
responders had a complete castration indicating 
that 'pharmacological castration' may be the main 
mechanism of action in inhibiting tumor growth. 
However, one patient (6) showed an objective par-
tial response in spite of the presence of peaks of 
estradiol. 
In conclusion, Buserelin was shown to be effec-
tive in the treatment of premenopausal women 
with metastatic breast cancer, but with the doses 
used the hormonal response appeared not uniform 
as found in patients with prostatic carcinoma. It is 
not possible to predict the type of hormonal re-
sponse for an individual patient. So, although the 
response rate of tumor growth inhibition appears 
as good as that of other types of endocrine therapy 
(for instance ovariectomy) in the absence of side 
effects, further investigations with other dose regi-
mens and modes of application or combinations 
with other drugs are necessary to show that LHRH 
agonists will be valuable in treating patients with 
breast cancer. 
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Abstract-Three patients with metastatic prostatic cancer were treated for 10, 6and 
2 months with the potent LHRH-agonist Buserelin (Hoe 766) as a first-line agent. 
A II showed a fall of elevated prostatic acid phosphatase levels (nearly undetectable 
after treatment in 2 patients) parallel to plasma testosterone with a relief of 
complaints after 3-4 weeks of treatment. Two patients had an increment of appetite 
and body weight. In one patient radiological evidence for objective tumour 
regression was found by CT scan of the prostate (decrease of 41% in prostate 
volume), skeletal X-rays and bone scan. In this patient plasma alkaline 
phosphatase showed a transient increase parallel to disappearance of osteolytic 
bone lesions (indicating new bone formation) followed by a normalization. It is 
concluded that LHRH-agonist treatment is effective in patients with metastatic 
prostatic ca:_cinoma in the absence of serious side-effects. 
INTRODUCTION 
LUTEINIZING- hormone- releasing- hormone 
(LHRH) is a hypothalamic decapeptide that 
induces release of luteinizing hormone (LH) and 
follicle-stimulating hormone (FSH) from the 
pituitary. These gonadotropins stimulate gonadal 
steroid production. However, LHRH has a short-
lived effect on gonadotrophin secretion. It is 
therefore not suitable for long-term therapy. To 
date, many LHRH analogues with marked and 
prolonged effect have been synthesized and tested 
[1-4]. A lot of them appeared to have a 
paradoxical antifertility effect in male and female 
rats during chronic treatment with pharmaco-
logical doses. Effects observed were at the level of 
the pituitary [1-7], gonads [8, 9] and the target 
organs of sex steroids [10-12]. 
Firstly, in the pituitary such long-term 
treatment with large doses of LHRH analogues 
causes exhaustion and desensitisation of the 
gonadotrophic cells [1-4] and further inhibition 
of prolactin secretion [5-7]. Secondly, after a 
short-term increase of gonadotrophin secretion 
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down-regulation of gonadal gonadotrophin 
receptors with decreased steroidogenesis occurred 
[2, 4, 13, 14]. Further, a direct extrapituitary effect 
of LHRH at the gonad has also been demonstrated 
[8, 9]. Clayton et al. found a direct inhibition of 
testicular function by LHRH receptors in 
interstitial cells [9]. Locally produced LHRH-like 
peptides in the testis appear to have a regulating 
function for the testosterone secretions [15, 16]. A 
third possible important way of action is the 
recently reported ability of LHRH analogues to 
antagonize the biological actions of sex steroids 
[10-12]. The antiandrogenic action of LHRH-
agonists appears to be different from cyproterone 
acetate [II]. Sundaram et al. [10] demonstrated 
that these peptides could block the growth-
promoting effect of testosterone on the rat 
prostate and seminal vesicles. An in vitro study 
suggests that the antiandrogenic activity of 
LHRH analogues is not due to its ability to 
compete with androgens for their intracellular 
receptors [II]. On the other hand, F urr and 
Nicholson have been unable to show anti-
androgenic effects of two analogues in castrated 
immature rats [17]. 
The striking fall in plasma sex steroid levels to 
post-castration values and reduction in weight of 
secondary sexual organs during chronic treat-
ment with LHRH-analogues [2, 4, 7, 18, 19] 
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suggested a treatment for hormone-dependent 
tumours [4, 17]. In animals a regression of 
prostatic [18], mammary [4, 5, 17, 20], pituitary 
[7] and cartilage tumours [21] (chondrosarcoma) 
has been shown. 
Recently, the first data of LHRH-agonist 
treatment in small series of patients with prostate 
[22-28] and breast cancer [29, 30] have been 
published. After our reports about the results in 
patients with breast cancer [29, 30], we present in 
this study detailed data about the effects of long-
term LHRH-agonist treatment in three patients 
with prostate cancer. 
MATERIALS AND METHODS 
Three patients with metastatic prostate 
carcinoma gave informed consent to be treated 
with an LHRH-agonist (Buserelin =Hoe 766). 
Their relevant data are summarized in Table 1. 
Patient 3 had received primary radiotherapy and 
total body irradiation (6 Gy) 3 yr before the 
occurrence of metastasis, but the patients had 
undergone no further treatment for either 
primary or metastatic disease. 
They were treated with 3 X 0.5 mg Buserelin 
subcutaneously for 6 days followed by 3 X 400 p.g 
daily per intranasal spray. In the first week blood 
samples were taken frequently (Figs I and 2) for 
measurement of LH, FSH, prolactin (PRL), 
testosterone (T), oestradiol (E2 ), alkaline phos-
phatase, acid phosphatase and specific prostatic 
acid phosphatase (PAP). Blood sampling has 
been performed daily before the morning 
rreatment injection, and for LH, FSH and PRL 
on some days (2-5) 4 hr after the injections. 
During the follow-up (10, 6 and 2 months 
respectively) they were measured weekly during 
the first months, later every 3 weeks. Plasma 
hormone concentrations were measured by 
radioimmunoassay as described previously [29, 
31]. Alkaline phosphatase was assayed in 
glycine-NaOH buffer of pH 9.6 at 37°C (normal 
values 15-38 U/1) and total acid phosphatase in 
acetate buffer of pH 5.5 at37°C(normal up to 12.0 
U/1). PAP was determined using a solid-phase 
enzyme immunoassay [32] (normal up to 1.6 U/1). 
Before treatment all patients were examined 
radiologically by total skeletal survey, bone scan 
and abdominal CAT scan apart from physical and 
routine laboratory examinations. They were seen 
every 3 weeks after the start of treatment for 
physical examinations and recording of com-
plaints. Local bone lesions were evaluated every 
6-12 weeks by X-rays and by skeletal survey after6 
months. CT scan of the prostate was repeated after 
3 and 6 months. 
RESULTS 
Endocrine effects 
After ·stimulation of gonadotrophin secretion 
on the first treatment day plasma LH and FSH 
levels decreased gradually to below pretreatment 
values with a plateau level after about 5-8 weeks. 
After the second treatment day there was no 
increase of the gonadotrophins in the plasma 4 hr 
after the subcutaneous Buserelin injections, 
indicating desensitisation of the pituitary. 
Plasma testosterone showed a slight increment 
in the first week (with peak levels of 158, 148 and 
122% of the basal value after 2-3 days of 
treatment) followed by a clear decrease to near 
castration levels in 3-9 weeks (1.1-2.4 nmol/1) 
(Fig. I). Plasma oestradiol concentration showed 
changes in parallel with those of plasma 
Table l. Pretreatment patient dates 
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Patient 1 
Age (yr) 72 
Stage of tumour T~N'"M 1 
Tumour differentiation 
Symptoms at disturbed diabetes 
presentation 
Weight loss (kg) 
Prostatic acid 
phosphatase (ll'l) 
Alkaline phosphatase 
(ll 1) 
Bone scan 
mellitus, bone pain, 
prostatism 
32.2 
abnormal 
metastasis 
Patient 2 
65 
T 2N 0M 1 
high 
prostatism 
3.2 
23 
abnorm.ll 
arthrosis, metastasis? a skeletal-survey 
CT sran (abdomen) hydronephrosis. enlarged no lymph nodes 
lymph nodt>s 
Duration of treatment 10 months 6 monthS 
Patient 3 
82 
T:!-:iN\M 1 
moderate to poor 
bone pain, pancytopenia 
27.6 
43 
abnormal 
metastasis 
no lymph nodes 
2 months 
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Test 
1•••>/1):1~. 
o-o 
t I 
1 2 J 4 5 6 7 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 
Test P 3 
(nmol/1) 10 i 
·~, 
1 2 3 4 5 6 7 2 3 4 5 6 7 10 
doy of treatment weeks of treatment 
Fig. 1. Changes of plasma testosterone le·vels in 3 patients during chronic LHRH-agonist {!I of 766) treatmrnt 
(p =patient). 
testosterone. Mean plasma oestradiol decreased 
from 117 before treatment to 14 pmol!l after 2 
months of treatment. In patient I, whose detailed 
data are shown in Fig. 2, plasma prolactin 
increased in the first week with only a slight 
decrease later on; the other two patients did not 
show a decrement. 
It has to be noted that patient 3 already had 
subnormal plasma testosterone values before 
treatment (5.7 and 7.2 nmol/1) in the presence of 
elevated LH (54 IU/1) and FSH (43 IU/1) levels. 
During treatment plasma testosterone decreased 
to 2.0 nmol/1 and the gonadrotrophins to 12.4 and 
14.6 respectively. 
Antitumour effects 
Patient I. Complaints of prostatism diminished 
dramatically within 3-4 weeks of treatment. He 
was again able to make long trips by coach 
without stopping every half-hour as before 
treatment. Bone pain and the disturbance of the 
regulation of his diabetes disappeared; it was no 
longer necessary to use analgesics. During 
treatment the appetite increased followed by an 
increase of 13 kg in body weight. 
An objective response has been proven by 
recalcification of an osteolytic lesion (after 3 
months) in the right femur neck (Fig. 3), a clear 
improvement of the bone scan (Fig. 4), rapid 
normalisation of acid phosphatase and PAP (Fig. 
2), and a decrement in prostatic volume with 41% 
from 76.0 to 44.6 cm3 after 3 months (Fig. 5 ). 
Thereafter no further significant decrease was 
observed. Enlarged parailiacal lymph nodes 
decreased in size. A cloudy osteoblastic vertebral 
lesion disappeared. On the other hand, a sharp 
round osteoblastic lesion became visible in the 
neck of the left femur (Fig. 3), while before 
treatment the bone scan showed a hot spot locally. 
Patient 2. This patient had a more gradual 
improvement of his prostatism-probably in 
relation with the slower decrease in plasma 
testosterone levels-although the CAT scan 
showed no significant decrement of the prostate 
volume. A slightly increased PAP before treat-
ment became nearly undetectable (from 3.2 to 
0.1 U/1) during treatment, with a normalisation 
within 6 weeks. The bone scan showed an 
improvement without changes of the X-rays, 
which also showed spondylarthrosis of the 
vertebral column. Faint muscle pain disappeared. 
His appetite improved and his weight increased 
by 3.3 kg. He is now free of complaints and feeling 
well. 
Patient 3. This very arteriosclerotic patient had 
extensive bone metastasis, as indicated by 
multiple bone lesions and severe pancytopenia. A 
bone marrow aspiration showed tumour cells. An 
operation was contraindicated. Buserelin spray 
was administered every day by his wife or 
daughter. The acid phosphatase activity in the 
serum decreased within 9 weeks without signifi-
cant changes on the X-rays. Concomitantly, the 
activity of PAP decreased from 27.6 to5.7 U/1. An 
elevated plasma LDH activity decreased from 
1160 to 459 U /1 in the presence of normal plasma 
bilirubin. He needed a lot of analgesics (aspirin, 
indomethacin) because of bone pain, which 
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Fig. 2. Changes of plasma hormone levels, and serum alkaline and acid phosphatase acti1rities in patient l. 
Ul =injections,· r =intranasal administration. 
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Fig. 3. (A) (upper part) An osteolytic lesion with an osteosclerotic surrounding in the right femur neck of 
patient I before treatment; a minimal scl(trotic lesion in the head of the left femur; (b) (lower part) clear 
improvement in the right femur neck and the appearance of a dense sharp osteoblastic lesion in the left femur 
head after 3 months of treatment. 
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Fig. 4. Bone scintigraphy before treatment (left) and 6 months after start of treatment (right) in patient 1. 
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Fig. 5 CAT scan of the prostate before (upper part) and 3 months after start of treatment (lower part) m 
patient I. 
489 
331 
LHRH-agonist Treatment in Metastatic Prostate Carcinoma 491 
diminished slightly after 8 weeks. At this time he 
developed pain in the gastric area. which might 
have been caused by the analgesics. After 9 weeks 
he died subacutely, possibly by a gastrointestinal 
bleeding caused by the analgesics in combination 
with thrombocytopenia. 
Side effects 
Patient I experienced an increase of libido 
during the first week (no increase of bone pain) 
followed by a sharp decrease after 3 weeks. Also, in 
patient 2 libido and potency decreased. Both 
patients got hot flushes. Patient 3 already had a 
low sexual activity before treatment. None of the 
patients showed cardiovascular side-effects in the 
sense of hypertension, oedema, dyspnoea or 
thrombosis. 
DISCUSSION 
Several hormones are involved in the regula-
tion of growth and functions of the prostatic 
gland. but androgens are the most important ones 
[33]. The most important androgen is testosterone, 
mainly (95%) produced in the testis. Other 
androgens such as androstenedione and dehydro-
epiandrosterone are also derived from the 
adrenals. 
The major part of prostatic carcinomas are 
'hormone-dependent' for their growth [34]. 
Bilateral orchidectomy appeared effective in the 
treatment of prostate cancer as well as high-dose 
oestrogens. The latter treatment, however, caused 
cardiovascular side-effects in about 40% of the 
patients [35]. The first preliminary studies with 
LHRH analogues have shown that this new kind 
of hormonal treatment, administered sub-
cutaneously or intranasally, decreases plasma 
testosterone to (nearly) castration levels [22, 23, 27, 
28]. Response rates of 70-90% are reported in the 
absence of serious side-effects. The main mech-
anism of action is probably a 'chemical castration' 
[17], but intrinsic antisteroidal effects [10, II] and 
inhibition of enzymes (17-hydroxylase, 17-
desmolases) involved in steroid synthesis are 
described [4]. Recently, chronic treatment with 
LHRH-agonist appeared superior to bilateral 
orchidectomy in regressing metastatic bone 
lesions and decreasing plasma PAP in spite of the 
absence of a significant difference in plasma 
testosterone levels [36]. This superior effect might 
be caused by the possible additional antisteroidal 
properties of LHRH-agonists or by decreased 
adrenal androgen synthesis. Further, a direct 
effect of the LHRH-agonist on the tumour cells 
cannot be excluded since LHRH-receptors were 
found to be present in an experimental prostatic 
tumour [37]. 
All our patients showed subjective improve-
ment and decrement of serum acid phosphatase 
and PAP, of which the enzyme activity has been 
shown to be related with tumour mass [38]. 
Patient I also showed radiological evidence for 
objective tumour regression. Improvement with 
respect to prostatism can be explained by 
decrement of primary tumour size, but might be 
partly due to shrinkage of normal prostate tissue. 
Remarkable is the close relationship between 
plasma testosterone and PAP levels. In this 
patient bone scintigraphy appeared superior in 
early detection of bone lesions (head of left femur, 
ribs and spines). Plasma alkaline phosphatase 
showed a transient increase parallel to the 
disappearance of osteolytic lesions (indicating 
new bone formation) followed by a normalisation 
(Fig. 2). In the head of the left femur a 
circumscript pronounced osteoblastic lesion, 
which was scarcely visible on the X-ray before 
treatment, appeared at the same place as a hot spot 
was shown on the bone scan before treatment. 
This can be explained as an abnormal bone 
reaction that ·can occur after inhibition of the 
growth of a spot tumour cells. This sharp, round 
osteoblastic lesion did not change after 3 months 
of treatment. So, the events in this patient indicate 
that an increase of plasma alkaline phosphatase 
and/or appearance of new osteoblastic bone 
lesions during the first period of treatment are not 
a proof for tumour progression. 
In conclusion, long-term treatment with the 
LHRH-agonist Buserelin appeared effective in 
patients with hormone-dependent metastatic 
prostate cancer without causing any serious side-
effects. Our results are comparable with those 
reported by other centres using the same or other 
analogues. After the end of ongoing phase II 
studies in different countries phase III studies will 
be needed to indicate which treatment modality 
will be the most suitable one as a first-line 
therapy. 
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Letters to the Editor 
COMBINED TREATMENT WITH BUSERELIN AND 
CYPROTERONE ACETATE IN METASTATIC 
PROSTATIC CARCINOMA 
SIR,-Since establishment of the value of LHRH (luteinising 
hormone releasing hormone) agonists in prostatic cancer1- 5 clinical 
interest has focused on different formulations, on LHRH 
antagonists, and on combination treatments. Labrie et al4 reported 
excellent results with a combination of an LHRH agonist and pure 
(non-steroidal) antiandrogens, both in preventing disease flare and 
in terms of survival, the effect of this treatment being "complete 
blockade1' of testicular and adrenal androgens. Until now these 
promising results have not been confirmed. 
W'e have treated thirteen previously untreated patients with 
metastatic prostatic cancer with the steroidal antiandrogen 
cyproterone acetate (CPA) at a dose of 3x50 mg daily, in 
combination with the LHRH agonist buserelin at a dose of 
3X0· 5 mg subcutaneously for 7 days followed by 3X0·4 mg daily 
intranasally. Plasma testosterone, LH, and cortisol concentrations 
and prostatic acid phosphatase (PAP) activity were compared with 
results infifty-eightunselected patients being treated with buserelin 
alone in a multicentre study. 
During the first week the addition of the steroidal antiandrogen 
CPA to LHRH agonist therapy prevented the LHRH-agonist-
induced rise in PAP despite a temporary increase in plasma 
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testosterone (figure). Thus the risk of"flare-up"2.4 is remote with 
combination therapy. Furthermore, the addition of CPA to chronic 
LHRH agonist treatment seemed to cause a significantly more 
pronounced suppression of mean plasma testosterone 
concentration from the second week of treatment (decrease to 18% 
of pretreatment value, compared with 39% during treatment with 
buserelin alone after 2 weeks; p <O · 05) and this difference was 
sustained for at least 3 months (figure). However, this difference in 
plasma testosterone levels did not lead to differences in plasma PAP 
activity in the longer term. Basal LH secretion and stimulated LH 
secretion (LHRH test) was more suppressed during combination 
therapy than it was in patients on buserelin done. We observed no 
difference and no significant change in basal and corticotropin 
stimulated cortisol concentration between those treated with 
buserelin alone and those given the combination, either before or 
after 3 months of treatment. 
Whether complete blockade of androgens not only prevents the 
LHRH-agonist induced disease flare but also greatly improves 
survival remains uncertain. Indeed, besides two non-cancer 
(treatment) related deaths we have seen progressive disease in four 
out of thirteen patients treated with buserelin/CPA(mean follow-up 
9 months, range 7-13 months). Twenty-four out of fifty-eight 
patients treated with buserelin alone have shown tumour 
progression within one year. Our preliminary data accord with 
those ofFaure et al, who used a combination ofbuserelin with a pure 
anriandrogen. 5 We recommend more comparative studies, and with 
that in view we have started a randomised study within the EORTC 
to investigate the possible advantages of the addition of an 
antiandrogen (CPA) to medical castration with an LHRH agonist. 
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TRANSIENT NEONATAL HYPOTHYROIDISM IN VERY 
LOW BIRTHWEIGHT INFANTS: IS TREATMENT 
NECESSARY? 
SrR,-Routine neonatal screening for hypothyroidism was 
introduced in the West of Scotland in 1979. Thyrotropin (TSH) is 
measured on Guthrie blood spots by an immunoradiometric 
rnethod1 on or soon after the lOth day oflife. Preterm babies in our 
neonatal units are also screened by the same method irrespective of 
gestational age, although testing may be delayed beyond the lOth 
day until milk feeding is well established for the correct diagnosis of 
phenylketonuria and galactosaemia (which is included in the 
Guthrie test). 
In both healthy and sick preterm infants low T3 and T4 values, 
which progressively increase to approach normal term values by 
5-7 weeks, are well documented.2•3 A high TSH is thought to 
distinguish those infants with congenital hypothyroidism. 
However, in the sick very low birthweight infant this type of 
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LHRH-AGONIST TREATMENT IN CLINICAL AND 
EXPERIMENTAL HUMAN BREAST CANCER 
J. G. M. KLIJN*:i:, F. H. DE JONGt, S. W. J. LAMBERTSt and M. A. BLANKENSTEIN* 
*Departments of Internal Medicine, Clinical Endocrinology and Biochemistry, Dr Daniel den Hoed 
Cancer Center/Rotterdam Radio-Therapeutic Institute, Rotterdam and tDepartment of Internal Medi-
cine III and Clinical Endocrinology, Erasmus University, Rotterdam, The Netherlands 
Summary-Thirty-one premenopausal patients with metastatic breast cancer were treated for 3-33 months 
with the potent LHRH~agonist Buserelin (Hoe 766) as a first-line therapy. Twelve women (group !A) were 
treated with a daily dose of3 x 400 jlg Buserelin intranasally and 10 women (group IB) with a daily dose 
of 2 x 1 mg subcutaneously after parenteral treatment with 3 mg per day in the first week. Nine patients 
(group II) were treated chronically with 3 x 400 J1g Buserelin intranasally in combination with 2 x 20 mg 
tamoxifen (n = 5, group IIA) or 4 x 45 mg megestrol acetate (n = 4. group liB). A great variation in 
hormonal response with recurrent peaks of E2 in about half of the patients was observed in groups IA 
and liA, while in group IB and liB a "chemical castration" was reached in all patients with the most 
pronounced suppression ofE2 secretion in group IB. An objective tumour response was found in 13 (42%) 
and stable disease in 7 (23%) out of 31 patients. Nine out of 22 patients (41 %) treated with Buserelin 
alone showed an objective response. In 8 of 17 patients (48%) with an estradiol receptor-positive tumour 
and in one of 2 patients with an ER-negative tumour we observed an objective remission. In an 
experimental study we found that Buserelin has a weak direct anti-estrogenic effect on the growth of 
human mammary tumour cells (MCF-7) in vitro. In conclusion medical treatment with high doses of 
Buserelin appears as effective as surgical castration in premenopausal metastatic breast cancer with an 
absence of serious side effects. 
INTRODUCTION 
Analogues of luteinizing-hormone-releasing-hormone 
(LHRH) are of increasing importance and of great 
promise in the treatment of different kinds of 
tumours [1-6]. In animals chronic treatment with 
pharmacological doses have been reported to cause 
exhaustion and desensitization of gonadotroph cells 
in the pituitary, inhibition of prolactin secretion, 
"chemical castration" with a striking fall in plasma 
sex steroids followed by a reduction in weight of 
accessory sex organs, inhibition of enzymes involved 
in steroidogenesis, and antagonism of biological ac-
tions of sex steroids [7, 8]. Furthermore, the findings 
of both LHRH-like receptors in an experimental 
prostate tumour [9] and the observation of an in-
hibitory effect of a LHRH analogue on the growth of 
mouse mammary tumour cells in vitro [2] suggest a 
possible direct effect of LHRH analogues at the level 
of hormone dependent tumour cells. 
During the last 2-3 years analogues of LHRH have 
been shown to cause long-term remissions of prostate 
tumours in a number of clinical studies [1, 10--12]. 
However, reports on the effects in patients with breast 
cancer are limited [13]. Since 1981, we have been 
working on the antitumor effects of LHRH-agonist 
Buserelin (Hoe-766) for the treatment of metastatic 
breast cancer. In addition, the effect of a combination 
therapy of this LHRH agonist with tamoxifen and 
+Correspondence address: Dr J. G. M. Klijn; Dr Daniel 
den Hoed Cancer Centre/Rotterdam Radio-Therapeutic 
Institute, Groene Hilledijk 301. Rotterdam, The Nether-
lands. 
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megestrol acetate was investigated especially with 
respect to the endocrine response. Based on our 
previous reports [13-16] we present this review on 
long-term LHRH agonist treatment (3-33 months) in 
31 patients and describe results of laboratory experi-
ments on the effect of Buserelin on a human mam-
mary tumour cell line (MCF-7). 
PATIENTS, TREATMENT AND METHODS 
Clinical studies 
Thirty-one premenopausal patients with metastatic 
breast cancer gave consent for treatment with the 
potent LHRH-agonist Buserelin (Hoe 766) as a single 
agent or in combination with other agents like tam-
oxifen (TAM) or megestrol acetate (MA). All pa-
tients had not been treated previously for their meta-
static disease. In total, 17 patients had an estradiol 
receptor (ER)-positive and two an ER-negative tu-
mour, while in 12 patients the receptor status was 
unknown. 
During the first week all subgroups of patients 
were treated with a daily dose of 3 mg Busere1in 
parenterally (for 3-7 successive days) as described 
before [15, 16]. Subsequently 12 patients (group IA) 
were treated chronically with 3 x 400 11g Buserelin 
intranasally (i.n_) and I 0 patients (group IB) with 
2 x I mg Buserelin subcutaneously (s.c.) decreasing 
this dose after 2 months with 2 x 0.1 mg per day for 
1 month. Ultimately the patients in this subgroup IB 
have been treated with doses between 800 and 
2000 p.g per day s.c. Five women (group IIA) were 
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Fig. 1. Changes of plasma hormone concentrations during chronic LHRH~agonist treatment in a patient 
with chemical castration and a complete tumour remission during 2 years. 
treated with 3 x 400 Jlg Buserelin i.n. in combination 
with 2 x 20 mg tamoxifen from the start of treatment. 
while in 9 out of the 12 patients of group IA 
tamoxifen was added later because of tumour 
progression or recurrent peaks of plasma estradiol 
(E2 ). Four patients (group liB) were treated with 
3 x 400 11g Buserelin i.n. in combination with 
4 x 45 mg megestrol acetate s.c. 
Blood sampling, measurement of plasma lutein-
ising hormone (LH) follicle stimulating hormone 
(LH) follicle stimulating hormone (FSH), estradiol, 
progesterone (Prog) prolactin (PRL) and estradiol 
receptor were done as described previously [17, 18]. 
Measurement of tumour response were performed 
according to the UICC criteria. 
Significances of differences between mean values at 
various time points within treatment groups were 
assessed by Student's paired t-test. 
Experimental studies 
MCF-7 cells cultured at 37'C in an atmosphere of 
5% C02 were trypsinized and seeded in T-25 flasks 
in "fully supplemented medium" to allow attachment 
of the cells to the culture flasks [19, 20]. Additions to 
the medium included estradiol, the LHRH agonist 
Buserelin, and synthetic LHRH (Relefact, Hoechst 
AG). These additives were given either alone or in 
combination at various concentrations. 
In some experiments dextran-coated charcoal 
treated foetal calf serum (DCCFCS) was used. After 
the desired culture period the medium was removed 
and the cells were washed twice with 0.154 M NaCI. 
Thereafter, cells were dissolved in I ml I M NaOH at 
50'C for I h. The protein concentration of the re-
sulting solution and the DNA content were measured 
as described elsewhere [20]. An excellent correlation 
between DNA and protein contents was observed 
(0.863, p < 0.001). 
RESULTS 
Clinical studies 
Endocrine effects 
Gonadotropins. On the first treatment day peak 
values for plasma gonadotropins were reached about 
4--{) h after the start of single treatment with Busere-
lin. Thereafter plasma LH and FSH dropped rapidly 
in spite of continuous infusion with Buserelin while 
during the following days no significant increase was 
observed (Fig. I) indicating pituitary exhaustion and 
desensitisation. 
In group IA mean plasma LH concentrations 
decreased below pretreatment levels after 2-3 weeks 
and continued to decrease slowly (Fig. 2). Mean 
plasma FSH concentration fell to the pretreatment 
level within 3 days, decreased further during the first 
week and remained thereafter at the same level during 
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Fig. 2. Mean plasma concentrations ofLH during chronic intranasal (group lA) and subcutaneous (group 
IB) treatment with Buserelin as a single treatment and in combination intranasally with tamoxifen (group 
IIA). 
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more than I year. During chronic subcutaneous 
treatment (group IB) the suppression of plasma LH 
(Fig. 2) and FSH (Fig. 3) was more pronounced than 
during intranasal administration. No ovulatory 
peaks were observed in both subgroups, while sub-
normal gonadotrophin levels occurred rarely. 
During combination therapy with tamoxifen 
(group IIA) mean plasma gonadotrophin concen-
trations were slightly higher than during single treat-
ment with Buserelin (Fig. 2) while preovulatory peaks 
of LH and FSH were observed in some patients. In 
group liB (Buserelin s.c. + MA) plasma gonado-
trophin concentrations were comparable with those 
observed in group IB. 
During single intranasal therapy with Busereiin 
"complete medical castration" with persistent post-
menopausal plasma E2 concentrations, was reached 
in only 4 out of I 0 evaluable patients, e.g. in the 2 
patients with a complete tumour remisson during 24 
(Fig. I) and 33+ months. In the other, 6 evaluable 
patients had recurring E2 peaks of various sizes. 
During chronic subcutaneous treatment plasma E2 
concentrations showed a striking fall to castration 
Sex steroids. Anovulation as indicated by persis-
ting low plasma progesterone levels occurred in all 
patients of groups IA, IB and liB (Table I); however, 
sub-normal peaks of progesterone were observed in. 
7 out of 14 patients treated with Buserelin intra-
nasally in combination with tamoxifen. 
30 
' 
20 
::> 18 
I 16 
(f) 14 
lL 12 
10 
8 
6 
4 
2 
123456782. 4 
Table 1. Relative changes in plasma hormone (LH. 
FSH, E~. Prog) concentrations during single LHRH 
agonist treatment with Buserelin (group lA + IB) and in 
combination with tamoxifen (TAM) or megestrol ace-
tate (MA) (i.e. groups IIA and liB respectively) 
LH/FSH E, Prog. 
lA LHRH-A i.n. 
JB LHRH-A S.C. 
!IA LHRH-A i.n.+TAM 
liB LHRH-A i.n. + MA 
! !~1 0 
w w 0 
!~1 1~1 !~O 
u u 0 
!-reduced, T-increased, =-equal, 0-no change. 
10 12 14 16 18 
Days Weeks of treatment 
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Fig. 3. Mean plasma concentrations (±SEM) ofFSH during chronic intranasal (i.n.) and subcutaneous 
(s.c.) treatment with Buserelin alone (group !A and !B). 
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Fig. 4. Mean plasma E2 concentrations during single treatment with Buserelin and in combination with 
tamoxifen (TAM) and megestrol acetate (MA); groups lA, IB, IIA and liB. 
levels within 2-3 weeks in all I 0 patients (group IB) 
with a mean concentration of 19 pmol/1 ( = 5 pg/ml) 
during long-term treatment (Fig. 4). 
The response of E2 concentrations during combina-
tion therapy with tamoxifen was very variable; from 
complete medical castration level to hyperstimulation 
level. Recurrent peaks of E2 occurred in 8 out of 14 
treated patients. In contrast, during combination 
therapy with megestrol acetate no peaks of E2 were 
observed, while plasma E2 concentrations were sup-
pressed to a mean value of 45 pmol/1 (Fig. 4). 
Prolactin. On the first treatment day a moderate 
rise of plasma PR was seen in 10 out of II patients 
of group IA. Peak values between 7 and 51 Jl.g/1 were 
reached mostly at 6 h after start of parenteral treat-
ment. The mean basal value of 7.5 ± 1.12 Jl.g/1 in-
creased to a mean peak value of 18 ± 3.9 Jl.g/1 
(P < 0.05). On the last day of parenteral single 
treatment with Buserelin plasma PRL levels remained 
unchanged and equivalent to the pretreatment values 
in 9 examined patients. 
During parenteral therapy the mean night peak of 
PRL at 0100 decreased from 27.2 ± 4.6 to 
15.9 ± 3 Jl.g/1 (n = 6, P < 0.05). During chronic 
intranasal treatment with 3 x 400 }lg Buserelin the 
day-uight rhythm remained intact (Fig. 5). Pituitary 
35 
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PRL reserve, as measured by the TRH-test, showed 
an increase in 7 of 9 investigated patients after I week 
of treatment (n = 9, 58.7 ± 13.3 to 76.6 ± 14.1, 
P < 0.05). After 3 months there was no significant 
difference with pituitary PRL reserve as measured 
before the start of treatment. 
In the group of patients treated with Buserelin in 
combination with tamoxifen (group IIA) only a 
temporary small rise in plasma PRL was seen on the 
first treatment day (8.4 ± 1.98 to 13.5 ± 1.93 }lg/1, 
P < 0.05), which did not occur on the last day of 
parenteral treatment. During chronic treatment the 
day-night rhythm was not present in 3 investigated 
patients (Fig. 5). In group IIB there was a tendency 
to an increase in basal plasma PRL levels probably 
caused by megestrol acetate, which was shown to 
increase prolactin secretion [21]. 
Effects on tumour growth 
In group IA an objective tumour response was 
found in 4 out of 12 patients with a mean duration 
of 16+ months (Table 2). The longest duration of 
response occurred in the 2 patients with a complete 
remission (CR). One had a recurrence of tumour after 
24 months of treatment and did not respond to 
tamoxifen as a second line agent; the other patient is 
(BI 
.-·~ . ..-::~. 
·-·-==·-· .'J""C"-. 
-·--- . 
9 13 17 21 
o'clock 
9 
Fig. 5. 24-Hour profile of plasma prolactin (PRL) concentrations during intanasal therapy with Buserelin 
alone (A) and in combination with tamoxifen (B)~ groups IA and IIA. 
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Table 2. Antitumour effects in 31 premenopausal patients with metastatic breast cancer 
during single LHRH agonist treatment with Buserelin (group lA + IB) and in combination 
with tamoxifen (TAM) or megestrol acetate (MA) 
Group Treatment CR + PR No change Failure 
!A Hoe 766 i.n. 4 x (X= I6+m) 4x (3-5m) 4x 12 
IB Hoe 766 s.c. 5 x (X=S+m) 1 x (5m) 4 x (2 x mixed) 10 
IIA Hoe 766+TAM 3 x (X= to+m) Ox 2x 5 
liB Hoe 766+MA I x (t9+m) 2 X (17,20+) lx 4 
Total l3 X (42%) 7 X (23%) II X (35%) 31 
Objective response rate during single Hoe 766 treatment (IA +B)= 9/22 (41 %). Longest 
duration of response: 33 + months. 
still in complete remission after 33 months of treat-
ment without any side effects. In group IB, with a 
relatively short mean duration of follow up, an 
objective response was observed in 5 out of I 0 
patients (2 x CR) with a longest duration of response 
of 9 months. 
In the 5 patients treated with Buserelin in combina-
tion with tamoxifen (group IIA) 3 objective re-
missions were observed; the longest duration of re-
sponse until now is more than 22 months. In the 4 
patients treated with Buserelin in combination with 
megestrol acetate (group liB) one partial response 
(19+ months) and two times stable disease (Table 2) 
occurred. On the whole an objective tumour response 
was observed in 13 of all 3.1 patients (42%) and in 9 
of 22 patients (41 %) during single treatment with 
Buserelin (group IA +B). No side effects occurred 
with the exception of those caused by the intended 
hypogonadism. 
Antitumour effects in relation to receptor status 
Only the patients of group IB were selected for 
receptor status. Five of these ten patients (50%) with 
an ER-positive tumour showed an objective response. 
In total, 17 out of the 31 patients had an ER-positive 
tumour and 8 of them (47%) showed an objective 
response. Of the 2 patients with an ER-negative 
tumour I had a partial remission during 5 months, 
0.6 
~ 
0.4 
0 
--... 
c 
.. 
~ 0.2 
~ 
E2 (nmo!/1) 
Bus (nmol/1) 
LHRH ( nmol/1) 
80 800 0 80 800 0 
0 400 
while 4 of the other 12 patients with an ER-unknown 
tumour showed an objective response also. 
EXPERIMENTAL STUDIES 
At concentrations of 80 and 800 nmol/1, Buserelin 
did not affect the growth of the MCF-7 cells 
significantly (Fig. 6). Although the stimulatory effect 
of estradiol on the cells is rather small, addition of 
Buserelin combined with estradiol results in a 
significantly lower protein and DNA content than 
addition of estradiol alone. The inhibitory effect of 
Buserelin on the protein content of MCF-7 cultures 
in the presence of estradiol was dose dependent. 
Moreover, LHRH itself also showed a slight anti-
estrogenic effect. In medium containing 10% 
DCCFCS Buserelin appeared to inhibit the estradiol-
induced increase in cellular protein and DNA. In our 
experience this anti-estrogenic effect of Buserelin can 
be counteracted by an equimolar amount of a LHRH 
antagonist. 
DISCUSSION 
In our studies with the LHRH agonist Buserelin, 
the response rate of tumour growth inhibition ap-
pears at least as good as other known types of 
ablative or additive endocrine therapy with 50% 
60 
40 
0 80800 0 80 BOO 0 
0 400 
Fig. 6. Protein and DNA content ofMCF-7 cultures grown in fully supplemented medium after five daily 
additions of estradiol (E2 ) alone or combined with 80 or 800 nM Buserelin (Bus) or 400 nM synthetic 
LHRH. Results are given as means± SD~ n = 8-9; "'P < 0.01 vs cultures kept in the presence of estradiol 
· alone. · 
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objective remissions in the ER-positive patients. Two 
recent preliminary reports concerning two studies 
with a relatively short follow-up confirmed our data. 
Harvey et a/. [22] found an objective remission in II 
out of 25 premenopausal patients (44%) treated with 
1-10 mg of the LHRH agonist Leuprolide by daily 
subcutaneous injection. Further, Walker et a/.[23] 
reported an objective tumour response in 3 of 16 
premenopausal patients treated with 250--1000 flg of 
the LHRH agonist Zoladex by daily subcutaneous 
injection. 
The main mechanism of antitumour action of 
LHRH is probably by "chemical castration". In our 
clinical study the patients with a castration effect 
during single treatment with Buserelin showed the 
best responses, but it is still unclear how "complete" 
the chemical castration has to be. Our experimental 
studies with MCF-7 mammary tumour cells indicate 
that there may be an additional direct antitumour 
effect based on antagonism of the stimulatory action 
of estrogens remaining in the circulation after in-
complete chemical castration by this new form of 
endocrine therapy. 
With respect to the endocrine effects. the occur-
rence of complete chemical castration and sup-
pression of gonadotrophin secretion appeared dose 
dependent. During intranasal treatment with 
3 x 400 f1 g Buserelin (2% resorption, i.e. comparable 
with 25 f1g subcutaneously) a chemical castration 
occurred in 4 out of 10 evaluable patients (40%) as 
found by Hardt and Schmidt-Gollwitzer[24] in 5 out 
of 9 premenopausal women (55%). Hence, in total a 
chemical castration was reached in 9 out of 19 
patients (47%). However, high doses of Buserelin 
subcutaneously (800--2000 flg daily) appeared to 
cause very low mean plasma E2 concentrations (as 
after castration) in all 10 patients (100%). During 
treatment with the combination of Buserelin and 
tamoxifen an insufficient corpus luteum function was 
found in half (7/14) of the patients as proven by 
post-ovulatory plasma progesterone levels. In some 
patients pre-ovulatory LH and FSH peaks were ob-
served. This indicates that Tamoxifen may overcome 
the suppressive effect on hypothalamo--pituitary 
function following chronic intranasal LHRH-agonist 
treatment. Therefore we combined Buserelin with 
high-dose megestrol acetate treatment because of its 
antigonadotropic properties. From the endocrine 
point of view this combination appeared more suit-
able than the combination of Buserelin with tam-
oxifen. However. side effects such as body weight 
increase with a cushingoid face occurred after about 
3 months of treatment. 
In conclusion treatment with high doses of busere-
lin appears as effective as surgical castration in 
premenopausal patients with metastatic breast can-
cer. Apart from the absence of serious side effects 
another advantage of LHRH-agonist treatment 
might be an additional weak anti-estrogenic effect as 
observed on MCF-7 mammary tumour cells. A dose 
of 3 x 400 flg Buserelin i.n. (comparable with 25 flg 
s.c. per day) caused anovulation in all patients but 
suppression of follicular maturation occurred in only 
about half of the patients. However, high doses of 
Buserelin subcutaneously (2000--8000 flg) appeared 
to cause a striking suppression of E2 secretion within 
2-3 weeks in all patients. 
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Direct Inhibitory Effect of a Luteinizing 
Hormone-releasing Hormone Agonist on MCF-7 
Human Breast Cancer Cells* 
M.A. BLANKENSTEIN,tt M.S. HENKELMANt andJ. G. M. KLIJN§ 
Departments oft Biochemistry and §Internal Medicine, The Dr Daniel den Hoed Cancer Center, P. 0. Box 520 I, 3008 AE Rotterdam, 
The Netherlands 
Abstract-The iffect of the LHRH agonist Buserelin on the M CF-7 human breast cancer cell 
line was studied. Cells were cultured in medium containing 1 0°/o untreated foetal calf serum or 
I 0% steroid-depleted serum. In both media the DNA and protein content of cultures kept for 3--5 
days in the presence <if80-SOO nM Buserelin and I nM oestradiol were 8-27% lower than those 
off/asks cultured in the presence of oestradiol alone (P < 0.05). LHRH itself (400 nM) also 
displayed an antiproliferative iffect on the MCF-7 cultures. At an equimolar concentration, the 
LHRH antagonist ORG 30093D abolished the antiproliferative effect of Buserelin. MCF-7 cells 
did not specifically take up radioiodinated LHRH. Our data are the first to indicate that LHRH 
analogues may inhibit the growth <if M CF-7 cells to a limited extent. The anti tumour activi!Ji <if 
these compounds in vivo may, then, be due to the main pituitary and gonadal ejftcts, resulting in a 
decrease of the concentration of oestrogen in the circulation and, in addition, a direct effect at the 
target cell level. 
INTRODUCTION 
ANALOGUES of LHRH are currently being evalu-
ated for use in the treatment of advanced breast [I, 
2] and prostate cancer [3--5]. When administered 
over a long period and at a sufficiently high dose, 
these compounds elicit antifertility effects [6]. Two 
mechanisms have been suggested which would 
lead to 'medical gonadectomy'. Firstly, prolonged 
stimulation with pharmacological doses of LHRH 
agonists results in exhaustion and/ or desensitiza-
tion of the gonadotropic cells in the pituitary, 
which in turn leads to a reduced gonadotropin 
output [7, 8] and, hence, a decreased steroidogene-
sis. Secondly, direct effects of analogues of LHRH 
at the gonadal level may also cause a decreased 
steroidogenesis [9, 10]. In this respect it has been 
suggested that gonadal cells use a locally synthe-
tized LHRH-like peptide for communication [11]. 
The direct effects of LHRH-like peptides at the 
gonadal1evel have been extensively investigated in 
the rat. They are thought to be mediated by 
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receptors for LHRH on the membranes of the 
gonadal cells [9, 12-14]. By analogy with the rat, 
an LHRH agonist has been reported to inhibit the 
secretion of progesterone by cultured human gra-
nulosa cells [15]. In another study, however, no 
such effect was observed [16]. Similarly, the pre-
sence of receptors for LHRH-like peptides in the 
human gonads is still a matter of debate [ l 7, 18]. 
In addition to causing medical gonadectomy, 
analogues of LHRH have been suggested to inter-
fere with the action of steroid hormones on their 
target cells [19-21]. LHRH analogues can inhibit 
oestrogen-induced growth of the rat uterus [21, 
22], oestrogen-induced increases in the activity of 
enzymes associated with uterine cell proliferation 
[23], androgen-induced growth of rat seminal vesi-
cles and ventral prostate [22] and f3-glucuronidase 
activity in the mouse kidney [20]. From these 
observations, the working hypothesis has been 
derived that, apart from impairing ovarian ster-
oidogenesis, LHRH agonists may exert an addi-
tional antitumour effect based on interaction with 
the remaining (adrenal) steroids at the target cell 
level. The preliminary results of Corbin [19], who 
reported an inhibitory effect of an LHRH analogue 
on the growth of mouse mammary tumour cells in 
vitro, support this hypothesis. By contrast, Furr and 
Nicholson [24] did not observe an anti oestrogenic 
effect of an LHRH analogue in ovariectomized 
immature rats. 
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The present study was designed to study the 
existence of direct antitumour effects of LHRH 
agonists. In this respect, effects of Buserelin and 
oestradiol on the human breast cancer cell line 
MCF-7 and the binding of radioactive LHRH to 
these cells have been investigated. 
MATERIALS AND METHODS 
The human breast cancer cell line MCF-7 was 
obtained from EG&G Mason Research Institute, 
Worcester, MA, U.S.A., in its 219th passage. Cells 
were cultured at 37°C in an atmosphere of5% C02 
and air in Falcon T-75 culture flasks in RPMI-
1640 medium, supplemented with 10% heat-
inactivated FCS, 100 U/ml penicillin, 0.1 mg/ml 
streptomycin (Gibco, Grand Island, NY, U.S.A.) 
and 10 ng/ml insulin (Organon, Oss, The Nether-
lands). This medium will be referred ta as 'fully 
supplemented medium'. For experiments the cells 
were trypsinized and seeded in T -25 flasks in fully 
supplemented medium to allow attachment of the 
cells to the culture flasks. After one day the 
medium was changed for the experimental 
medium, which was changed daily unless indicated 
otherwise. 
Experimental media 
Additions to the medmm included oestradiol, 
(Merck, Darmstadt, F.R.G.), tamoxifen (ICI-
Farma, Rotterdam, The Netherlands), the LHRH 
agonist Buserelin (Hoechst-Pharma, Amsterdam, 
The Netherlands) and the LHRH antagonist 
[NAc-p-Cl-(D)Phe-1,2, (D)Trp-3, (D)Phe-6, 
(D)Ala-lO]LHRH (ORG 30093D Organon Inter-
national, Oss, The Netherlands) [25]. These addi-
tives were given either alone or in combination at 
concentrations indicated at the individual experi-
ments. Oestradiol and tamoxifen were added to the 
medium as concentrated solutions in ethanol. The 
final concentration of ethanol in the medium never 
exceeded 0.2% (v/v). Corresponding amounts of 
ethanol were added to media which did not contain 
oestradiol or tamoxifen. Working solutions of 
Buserelin were prepared in Dulbecco's phosphate-
buffered saline (Gibco, Grand Island, NY, 
U.S.A.), which was also added to the media which 
lacked Buserelin. A concentrated solution of the 
LHRH antagonist was prepared in 70% ethanol. 
Working solutions were prepared by dilution with 
phosphate-buffered saline. In one experiment 
synthetic LHRH (Relefact, Hoechst AG, Frank-
furt-am-Main, F.R.G.) was used. This compound 
was used directly as supplied. In some experiments 
FCS was treated for 30 min at room temperature 
with 0.5% (w/v) Norit and 0.05% dextran T-70. 
Charcoal was removed by centrifugation for 30 min 
at 10,000 g. The supernatant is referred to as 
dextran-coated charcoal-treated FCS (DCCFCS). 
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Termination of experiments 
After the desired culture period the medium was 
removed and the cells were washed twice with 
0.154 M NaCI. Thereafter, cells were dissolved in I 
ml 1 M NaOH at 50°C for 1 hr. The protein 
concentration of the resulting solution was esti-
mated by the method of Bradford [26] using the kit 
from Bio-Rad (Richmond, CA, U.S.A.) and hu-
man serum albumin (KABI, Stockholm, Sweden) 
as a standard. DNA was measured with a 
fluorimetric assay [27]. Diaminobenzoic acid 
(Merck, Darmstadt, F.R.G.) and herring sperm 
DNA (Schuchardt, Munich, F.R.G.) were used as 
reagent and standard respectively. Cell numbers 
were not counted since it has been described that 
for the MCF-7 cell line changes in cell number 
show a consistent correlation with changes in DNA 
mass [28]. 
Binding studies with LHRH 
Radio-iodinated LHRH was purchased from 
New England Nuclear (Dreieich, F.R.G.). 
Radiochemical purity was verified by thin-layer 
chromatography on cellulose plates (Merck, 
Darmstadt, F. R. G.) in the system n-
butanol:water:ethyl acetate = 11:2:1 (v/v/v). In 
binding studies the cells were washed twice and 
incubated for 90 min at 4°C with approximately 
300,000 cpm of tracer in 10 mM Tris-HCI buffer, 
pH 7 .8, containing I mM dithiothreitol and 0.1% 
bovine serum albumin as described by Loumaye et 
al. [29]. After the incubation, cells were washed 
twice and dissolved in 1 M NaOH as described 
above. For comparative purposes, the binding of 
radioactive LHRH to 25,000 gmembrane prepara-
tions [17] of rat pituitary and human breast and 
ovarian carcinoma tissue was also studied. 
In the figures results are given as means ± 
standard deviation. The number of replicate 
observations is represented by n. Statistical analy-
sis was performed with Wilcoxon's test. Differences 
were considered to be statistically significant when 
a P value of less than 0.05 was found. 
RESULTS 
Effects of Buserelin and tamoxifen 
In early experiments we studied the effect of a 
single administration of Buserelin on the growth of 
MCF-7 cells. At concentrations of 10 and 100 
ng/ml, Buserelin did not affect the protein content 
of the cells which were cultured for 1-3 days after 
addition of the drug. In further experiments the 
medium was changed daily in order to reduce the 
possibility that putative effects of Buserelin on the 
cells remain undetected as a result of rapid meta-
bolism (and inactivation) of the peptide. The re-
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Fig. 1. Protein content of MCF-_7 cultures grown in fully supplemented 
medium at different times during dai{y administration of 80 nM 
Buserelin and! or 1000 nM tamoxifen. Data are given as means± S.D.; 
n = 5; "'P < 0.05 vs corresponding control. 
suits in Fig. 1 demonstrate that under the condi-
tions used, i.e. in fully supplemented medium and 
after daily administration, Busereli~ has no effect 
on the growth of the cells. Tamoxifen, on the other 
hand, significantly decreased the growth rate of the 
cells (P < 0.05), as evidenced by a lower protein 
content of the cultures. Buserelin did not alter the 
response of the cells to tamoxifen. 
Comparison of protein and DNA content 
To justifY the use of the protein content of the 
cultures for the evaluation of the results of the 
present experiments, this parameter was compared 
to the DNA content of the cultures. An excellent 
correlation was found between these parameters. 
In 36 sets of data originating from four different 
experiments a correlation coefficient of 0.863 (P < 
0.001) was found. The intercept of the regression 
line [DNA = 0.22 X protein - 2.02] was statisti-
cally not distinguishable from zero. Moreover, 
changes in the protein content of the cultures as a 
result of experimental manipulation of the cultures 
also showed a significant correlation with changes 
in the DNA content of the cultures (r = 0.849; P < 
0.001). Again, the intercept of the regression line 
was not different from zero. 
Combined effects of Buserelin and oestradiol 
Subsequently, the possibility that the LHRH 
analogue interferes with the action of oestradiol on 
the cells was investigated. The results presented in 
Fig. 2 show that although the stimulatory effect of 
oestradiol on the cells is rather small, addition of 
Buserelin combined with oestradiol results in a 
significantly lower protein and DNA content than 
addition of oestradiol alone. The inhibitory effect of 
Buserelin on the protein content of MCF-7 cul-
tures in the presence of oestradiol was dependent 
on the dose of the peptide (Fig. 3). Moreover, 
LHRH itself also showed a slight anti-proliferative 
~ffect (Fig. 3). 
-a 6oo 
~ 
l40o 
200 
120 ~ -" 0 ;:;:: 80 --.... <( z 0 C[b ~ 40 
Oestradiol- + + + + 
Buserelin 
- - + + 
Time (d) 
Fig. 2. Protein and DNA content of MCF-7 cultures grown in fully 
supplemented medium at different times during daily administration of 1 
nM oestradiol alone or in combination with 80 nM Bus_ertlin. Results are 
means± S.D.; n = 4-6: *P < 0.02 vs cultures kept in the presence of 
0.6 
-" 
0.4 
0 
0:: 
--.... 
·~ 
0 
o': 0.2 
~ 
E2 (nmol/1) 
Bus (nmol/1) 
LHRH (nmol/1) 
oestradiol only. 
80 800 80 800 
000400 
Fig. 3. Protein content of MCF-7 cultures grown in fully supplemmted 
medium after five daily administrations of oestradiol (E<J) alone or 
combined with 80 or 800 nM Buserelin (Bus) or 400 nM synthetic 
LHRH. Results are given as means± S.D.; n = 8-9; *P < 0.01 vs 
cultures kept in the presence of oestradiol alone. 
Effect of an LHRH antagonist and steroid-depleted 
medium 
The data in Fig. 4 demonstrate that the effect of 
Buserelin on oestrogen-stimulated MCF-7 cells 
can be counteracted by an equimolar amount of 
the LHRH antagonist ORG 30093D. This com-
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Fig. 4. Protein content of MCF-7 cells kept for 5 days in fully 
suppLemented medium containing oestradiol (1 nM), Buserelin (800 
nM) or the LHRH antagonist ORG 30093D (800 nM), either alone or 
in combination. Culture medium was changed daily. Results are given as 
means± S.D.; n = 10; "'P < 0.05; **P < 0.01. 
pound also appeared to be able to stimulate the 
growth of the MCF-7 cells. 
Effects of oestradiol and Buserelin may have 
been reduced by interference from compounds 
present in FCS. The results in Fig. 5 show that in 
medium prepared with steroid-depleted FCS 
Buserelin also inhibits the oestradiol-induced in-
creases in cellular protein and DNA. 
LHRH binding studies 
The binding of radio-iodinated LHRH to MCF-
7 cells and rat pituitary membranes is shown in 
Fig. 6. Pituitary membranes readily bound the 
tracer, which could be displaced from its binding 
sites by an excess of radio-inert LHRH or 
Buserelin. Scatchard plot analysis of the binding of 
radioactive LHRH to rat pituitary membranes 
revealed a binding capacity of 40 fmol/mg mem-
brane protein and a dissociation constant of 0.06 
nM. By contrast, the tracer bound to the MCF-7 
cells to a much smaller extent, and the binding 
observed could not be displaced by an excess of 
radioinert ligand. No binding was observed to 
membranes prepared from solid human mammary 
and ovarian tumours. 
DISCUSSION 
The results described in the present paper are 
the first to demonstrate that a'} LHRH agonist can 
directly interfere with the proliferation of human 
breast cancer cells in culture. It appears from our 
data that Buserelin can antagonize the stimulatory 
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Fig. 6. Binding of [1 251]-LifRH to rat pituitary membranes and 
MCF-7 cells and displacement by a lOOO:fold excess of radioinert 
LHRH or an SOOO:fold excess of Buserelin. Results are given as means ± 
S.D.; n = 3for the pituitary membranes; n = 5for the MCF-7 cells. 
action of oestrogens on these cells. LHRH itself 
was also capable of inhibiting the oestradiol-
induced proliferation of the cells, whereas the 
LHRH antagonist ORG 30093D counteracted the 
effect of Buserelin. The limited magnitude of the 
effects of Buserelin on the cells, however, supports 
the current consensus that the main anti-tumour 
effect of LHRH analogues is exerted via a suppres-
sion of circulating levels of oestrogens. 
The reason why only relatively small effects of 
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Buserelin were observed may very well reside in 
the fact that oestradiol also had limited effects. Yet 
the magnitude of the stimulatory effect of oestra-
diol on our MCF-7 cells is not different from that 
in other reports [30-32]. Other investigators have 
shown that the effect of oestradiol on these cells 
may depend on the source of serum [33]. It is 
conceivable that the. anti-proliferative action of 
Buserelin is more pronounced in cells which show a 
higher increase in growth rate in response to 
oestradiol. Therefore the use of other sera is cur-
rently under investigation. 
One attempt to increase the sensitivity of the 
cells to oestradiol was already undertaken in the 
present series of experiments. The presence of FCS 
in the culture medium may result in an oestrogen 
concentration which already causes a maximal or 
near-maximal proliferation rate of the cells. Alier-
natively, other mitogens present in FCS may 
stimulate the proliferation of the cells to such an 
extent that they cannot respond to addition of 
oestradiol with an increase in the rate of prolifera-
tion. Therefore experiments were also done with 
medium in which the FCS was replaced with 
DCCFCS. The rates of both the basal and the 
oestradiol-induced proliferation in medium pre-
pared with DCCFCS (Fig. 5) decreased only mar-
ginally as compared with medium prepared with 
untreated FCS (Fig. 2), which led us to conclude 
that other factor(s) present in FCS and resistant to 
charcoal treatment must be responsible for main-
taining the proliferation rate of the cells on a 
relatively high level. It could be argued that the 
action of Buserelin on the MCF-7 cells is directed 
against the stimulatory action of these other 
mitogens, rather than oestradiol. In our opinion, 
however, this possibility is not very likely since 
Buserelin had no effect in the absence of oestradiol. 
Our data are in agreement with those of Corbin 
[19], who found that daily administration of the 
LHRH agonist Wy 40,972 temporarily retarded 
the growth of mouse mammary tumours cells in 
culture. In contrast to our results, however, Corbin 
observed an effect already I day after the first 
administration, and after 6 days cell numbers in 
cultures treated with the analogue were equal to 
those in control cultures. In our study the first 
effects could be shown only after 3-4 days. In view 
of the relatively high growth rate of the cells, effects 
could not be investigated for more than 6 days. 
Therefore we can offer no data on the duration of 
the suppression of cell growth. From the data in 
Figs 2 and 5, however, it appears that the effect of 
Buserelin on the MCF-7 cells is also transient. In 
the experiment reported in Fig. 2, for example, the 
protein content of control cultures and cultures 
kept in the presence of oestradiol or oestradiol plus 
Buserelin all increased by a factor of 2. 7 between 
days 3 and 5. The inhibitory action of Buserelin 
thus appears to be manifested only after initial 
exposure of the cells to the peptide. The most 
obvious explanation for this observation is in-
activation of the peptide by degradative enzymes. 
To circumvent this possibility, the culture medium 
was replaced daily in the present series of experi-
ments. To further evaluate this possibility, an 
experiment was done in which the culture medium 
was not changed. Medium which is conditioned by 
MCF-7 cells for more than 5 days can still stimu-
late the secretion of LH and FSH by rat pituitary 
cells in culture. In this respect there was no 
difference between fresh and conditioned medium 
[F.H. de Jong, ·personal communication]. The 
presence of biological LHRH activity after pro-
longed exposure of the medium to MCF-7 cells 
virtually rules out the possibility that the transien-
cy of the effect ofBuserelin on the cells is caused by 
exhaustive degradation of the peptide. 
Other explanations for this phenomenon include 
transient effects on cell attachment, changes in the 
uptake of the peptide by the cells, the existence of 
several populations of cells, of which only a minor-
ity is sensitive to Buserelin, or the secretion of an 
LHRH-like peptide by the cells. The secretion of 
an endogenous LHRH-like regulatory peptide 
may, of course, obscure effects of exogenously 
added peptides. The presence of high concentra-
tions of LHRH-like immunoreactive ma"terial has 
been documented in human milk [34, 35] and in 
ductal mammary carcinoma [36]. It remains to be 
investigated which, if any, of these possibilities 
accounts for the present observations. 
In the present study the growth-inhibiting effect 
of Buserelin was tested at only one, relatively high 
concentration of oestradiol, i.e. I nM. This concen-
tration was chosen because it is known to induce 
maximal stimulation ofMCF-7 cells. It remains to 
be investigated whether t-he growth-inhibiting 
effect of Buserelin is dependent on the concentra-
tion of oestradiol. To answer this question it may 
be essential to use a system in which the response 
of the cells to oestradiol is much more pronounced. 
Our observation that Buserelin and LHRH itself 
can act directly on MCF-7 cells is highly sugges-
tive for the presence of specific receptors for 
LHRH-like peptides in these cells. A similar situa-
tion appears to prevail for the Dunning R 3327H 
rat prostatic carcinoma. This transplantable 
tumour regresses following administration of 
LHRH analogues [25]. Recently, this tumour was 
also found to contain receptors for LHRH-like 
peptides [37]. We have used commercially avail-
able iodinated LHRH in the search for the pre-
sence of such receptors in MCF-7 cells. No satur-
able binding of labelled LHRH to the cells was 
observed. By contrast, rat pituitary membranes 
showed specific binding of the peptide. This vir-
tually rules out the possibility that the LHRH lost 
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its biological act1v1ty upon iodination, but indi-
cates that the putative receptors for LHRH-like 
peptides in MCF-7 cells may have a very low 
affinity for LHRH itself. Alternatively, the 
observed effects of LHRH on the MCF-7 cells 
(Fig. 3) need not be mediated through receptors, or 
putative receptors may be occupied with endoge-
nous LHRH-like material [34-36]. After submis-
sion of this paper, data were published by Miller et 
al. [38], which support the suggestion that the 
putative receptors for LHRH-like material have a 
low affinity for native LHRH. These authors found 
that iodinated LHRH-agonist was able to bind to 
MCF-7 cells, but that LHRH itself showed only a 
very limited cross-reactivity with this binding. 
paper support the hypothesis that LHRH agonists, 
apart from their main anti tumour activities which 
are mediated by the pituitary and the gonads, may 
have an additional antitumour effect excerted 
directly on the tumour cells. 
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SUMMARY The growth-stimulation of MCF-7 human breast cancer cells in vitro 
induced by 30 pM estradiol was inhibited both by the LHRH-agonist Buserelin 
and the anti-estrogen Tamoxifen used as single agents. Combined administration 
of both drugs was less effective in this respect. In the presence of estradiol 
Buserelin had no effect on the pattern of [35s]methionine labelled secretory 
proteins when examined with one-dimensional gel electrophoresis, whereas the 
estrogen-induced progesterone receptor synthesis was inhibited. Thus with 
estradiol concentrations comparable to plasma values in medically castrated 
patients, the LHRH-agonist Buserelin can directly inhibit breast cancer cell 
growth in Vitro • © 1986 Academic Press. Inc. 
Chronic treatment with pharmacological doses of LHRH agonists causes sup-
pression of the pituitary-gonadal axis resulting in decreased gonadal ster-
oidogenesis (1). This kind of therapy appeared to be effective in the treat-
ment of hormone dependent tumors as breast (1-7) and prostatic cancer (1,8-
li). Apart from its action on the pituitary-gonadal axis also direct effects 
of LHRH analogs on gonadal tissues have been observed (see for review ref. 
12). Moreover, direct effects on extra-gonadal tissue as breast cancer. cells 
have been previously reported by us and by others (5,13-16). Recently, 
specific binding sites for LHRH-agonists have been demonstrated in breast 
cancer cells (16,17). In search for the mechanism of action and to evaluate 
the possible clinical significance of direct anti-tumor effects of Buserelin, 
an LHRH agonist, we have studied the growth of human breast cancer cells in 
culture in the absence and presence of Tamoxifen with estradiol concentrations 
as found in vivo following medical castration. 
MATERIALS AND METHODS 
The human breast cancer cell line MCF-7 was obtained from EG&G Mason Research 
Institute, Worchester, MA, USA, in its 219th passage. Cells were maintained in 
0006-291 X/86 SI.50 
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culture in a humidified atmosphere of 5% CO and air at 37°C in RPMI-1640 
medium supplemented with 10% heat-inactivated ~etal calf serum (FCS), 100 U/ml 
penicillin, 0.1 mg/ml streptomycin and 10 ng/ml insulin. Jor experiments to 
study growth the cells were trypsinized and seeded in 25 em flasks. After one 
day the medium was changed for the experimental medium which was refreshed at 
day 3 and day 5. 
Experimental media consisted of RPMI-1640 medium supplemer:ted with 10% 
steroid-depleted male human serum (DC-MRS), 100 U/ml penicillin and 0.1 mg/ml 
streptomycin. Male human
0
serum was obtained from healthy donors and heat-inac-
tivated for 30 min at 56 c. Removal of sex steroids from sera was performed by 
0.5% charcoal-0.05% dextran T-70 (w/v) absorption for 20 h at 4°C under con-
tinuous stirring. Additions to the medium included estradiol (Merck, Darm-
stadt, FRG), Tamoxifen (ICI-Farma, Rotterdam, The Netherlands), Buserelin 
(Hoechst-Pharma, Amsterdam, The Netherlands), and Org 30093D (Organon, Oss, 
The Netherlands). 
After culturing for 7 days the experiments were terminated as described 
before (15), and protein or DNA-content of the cell cultures, which were shown 
to be equally applicable, were used as parameter to study the growth of the 
cultures. 
Preparation of cytosol and nuclear extract 
2For measurement of estrogen and progesterone receptors cells grown in 75 
em flasks were harvested with a rubber policeman in 5 ml phosphate buffered 
saline (PBS), pooled, and centrifuged for 5 min at 100xg. Pellets were resus-
pended in 3 ml 10 mM Tris-HCl buffer, pH 7.4, containing 1.5 mM EDTA, 10 mM 
monothioglycerol, and 10% (v/v) glycerol. Cells were homogenized with a Dounce 
glass-glass homogenizer with 30 strokes of a tight-fitting pestle. The super-
natant obtained after centrifugation for 10 min at 800xg was further centri-
fuged for 40 min at 100,000xg. The lOO,OOOxg supernatant fraction was defined 
as cytosoL The residual 800xg pellet was washed twice with 10 mM Tris-HCl 
buffer, pH 8.0, containing 3 mM MgCl , 1 mM monothioglycerol and 0.25 M su-
crose, and following centrifugation tor 10 min at· 800xg nuclear extract was 
prepared as follows. Nuclear pellets were resuspended in 0.5 ml 10 mM Tris-HCl 
buffer, pH 8.0, containing 1.5 mM EDTA, 1 mM monothioglycerol, 10% glycerol 
and 0.6 M NaCl (buffer A), sonicated for ~xS s with a MSE PG-104 sonicator at 
setting low 3, incubation for 1 h at 4 C and centrifugation for 15 min at 
lS,OOOxg. 
Labelling and measurement of steroid receptors 
for cy1t8os~li;t e:J~o:~h ane~ th:~ge~~e~ne [ r~l~~~~:~i~~re0;a~~ll= ~y Hi]~~~ba~6~~ 
(Amersham, Houten, The Netherlands) in the absence and the presence of a 
100-fold excess non labelled competitor to correct for non-specific binding. 
Nuclear receptors were labelled by incubation for 18 h at 4 C, followes by a 
further 3 h at 30°C for the estrogen receptor, and a further 3 h at 17 C for 
the progesterone receptor. Bound and free ligand were separated by G-25 
gel-filtration on Sephadex PD-10 columns in buffer A, and 8-drop fractions 
were collected and counted for radioactivity. Specifically bound radioactivity 
in the void-volume fractions was considered to be receptor-bound. 
RESULTS AND DISCUSSION 
The LHRH-analog Buserelin appeared to have direct inhibitory effects on the 
growth of MCF-7 cells when cultured in medium supplemented with fetal calf 
serum (15, 16). Since in our experiments the estradiol-stimulated growth was 
only approximately 10% (15), we have replaced fetal calf serum by male human 
serum, as applied by De Vleeshouwer et aL (18). In experiments in which 
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Figure 1. Effect of estradiol and Buserelin on the protein content of MCF-7 
cell cultures gro"'l in medium supplemented with DC-MRS. Results 
represent the mean ± SD of six incubations. 
Figure 2. Effects of estradiol (30 pM), the LHRH-agonist Buserelin (0.8 )lM) 
the LHRH-antogonist Org 30093D (0.6 )lM) on the DNA content of MCF-7 
cell cultures. Results represent the mean ± SD of six-fold incu-
bations. 
*Significantly different from all the other incubation conditions 
(2p < 0.05; Wilcoxon) 
medium was supplemented with 10% DC-MHS, 10-100 pM estradiol already resulted 
in maximal stimulations (4-6 fold) of MCF-7 cell cultures when compared to 
cultures grown in the absence of estradiol (not shown). Similar observations 
were made in studies in which medium was supplemented with 10% female human 
serum (19). 
When premenopausal patients are treated chronically with Buserelin a medi-
cal castration can be reached resulting in circulating concentrations of 
estradiol ranging from 5 to 50 pM (5). Postmenopausal women also have castrate 
values of estradiol. Therefore, we have used a comparable concentration of 30 
pM estradiol in the first series of experiments looking for the effects of 
increasing dosages of Buserelin. It appeared that a dose-response relationship 
existed resulting in an almost complete inhibition (96%) of the stimulated 
growth with 0.8 VM Buserelin (Fig.l). Although it appeared that in subsequent 
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experiments, with different batches of male human serum used for the cultures, 
this effect was variable, the observed inhibitory effect of Buserelin could be 
blocked completely by addition of the LHRH-antagonist Org 30093D (Fig.2). This 
suggests the presence of specific receptors for LHRH on membranes of MCF-7 
cells in culture (16). Combined effects of estradiol, Tamoxifen and Buserelin 
on the growth of MCF-7 cells were studied and it appeared that at different 
concentrations of estradiol (30 and 80 pM), an approximately 500-fold excess 
of Tamoxifen inhibited the estrogen-induced growth with 87% and 92%, respect-
ively (Table 1). The additional presence of Buserelin during culturing result-
ed in less growth inhibition (32% and 67%) than was observed for Tamoxifen 
alone (Table 1). 
To study whether the observed inhibitory effect of Buserelin on the growth 
of MCF-7 cell cultures might in some way be related to changes in steroid 
receptor concentrations, experiments were performed in which the cytosolic and 
nuclear estrogen and progesterone receptors were measured after culturing of 
the cells in the absence and the presence of 30 pM estradiol and 0.8 pM Buser-
elin. Buserelin appeared to have no effect on the amount of cytosolic estrogen 
receptors while a 380% increase in the amount of progesterone receptors, 
induced by estradiol, could be blocked for 87% when Buserelin was present 
TABLE 1 
INHIBITION OF ESTROGEN-STIMULATED GROWTH 
BY TAMOXIFEN AND BUSERELIN 
additions inhibition of estrogen-
stimulated growth (%) 
Tamoxifen (13 nM) 87 6 
experiment Buserelin (270 nM) 87 
(30 pM e.J Tamoxifen + Buserel1n 32 6 
Tamoxifen (40 nM) 92 4 
experiment 2 Buserelin (825 nM) 66 14 
(80 pM Eo) Tamoxtfen + Buseretin 67 14 
Effects of Tamoxifen and Buserelin on the estradiol-stimulated growth 
of MCF-7 cell cultures. The growth-stimulations in experiments 1 
(3.6-fold) and 2 (8.3-fold) were set at 100% for the calculation of 
the percentages inhibition by Tamoxifen and/or Buserelin. Data are 
obtained from the protein values of six-fold incubations. 
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TABLE 2 
CYTOSOL.IC AND NUCLEAR STEROID RECEPTORS 
estrogen receptor progesterone receptor 
Conditions cytosol nucleus cytosol nucleus 
(pmol/mg P) (pmol/mg DNA) (pmol/mg P) (pmol/mg DNA) 
Control 1.8 2.9 1.0 2.2 
Buserelin 2.1 2.9 1.5 2.0 
Estradiol 0.8 2.6 4.8 2.9 
Estradiol + 0.8 3.1 1.5 0.8 Buserelin 
Effects of estradiol (30 pM) and Buserelin (0.8 pM) on the amounts of 
cytosolic and nuclear estrogen and progesterone receptor. 
(Table 2). Also the progesterone receptor content measured in high salt nu-
clear extracts after stimulation with estradiol was reduced from 2.9 to 0.8 
pmol/mg DNA by Buserelin (Table 2). It has been reported that although Tamoxi-
fen below a concentration of 0.1 pM (20) and some other anti-estrogens (C1628M 
and U23 ,469M) (21) were able to increase cytoplasmic progesterone receptor 
levels, they as yet inhibited the growth of MCF-7 cell cultures. It is there-
fore uncertain whether the direct growth-inhibitory action of Buserelin can be 
attributed solely to its inhibiting effect on the estrogen-induced progester-
one receptor synthesis, but interference at this level might explain why 
Tamoxifen and Buserelin partly abolish their mutual effects on MCF-7 tumor 
cell growth. 
Apart from its effect on the synthesis of the progesterone receptor, estra-
diol affects the synthesis of specific secretory proteins (22) of which the 
most abundant (MW:52K) is believed to act as an autocrine mitogen (23). We 
have therefore investigated whether Buserelin could affect the synthesis of 
specific secretory proteins. Although estradiol at a concentration of 30 pM 
already significantly stimulates the synthesis of [35s]methionine labelled 
specific secretory proteins, measured by fluorograms obtained after one-dimen-
sional SDS-PAGE, we could not observe any effect of the addition of Buserelin 
(not shown). Effects on posttranslational events can not be excluded yet, 
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together with possible effects on the secretion of estrogen stimulated growth 
factors (24,25). 
In conclusion, the LHRH-agonist Buserelin directly inhibits the estradiol-
stimulated growth of MCF-7 human breast cancer cells in vitro. The direct 
anti-tumor effects are observed at concentrations of estradiol that prevail 
in chemically (as by LHRlJ. agonist) castrated premenopausal breast cancer 
patients and in postmenopausal women. Use of LHRH-agonist therapy in clinical 
practice with the aim to obtain (additional) direct anti-tumor effects, may 
however depend on the availability of drug preparations which result in main-
tenance of sufficiently high plasma concentrations of circulating LHRH agon-
ist. In this respect the observation of Miller et al (16) that concentrations 
of as low as 1 nM Buserelin, which can currently be obtained in vivo, already 
resulted in a net decrease of breast tumor cell growth in vitro, and secondly, 
the observation of objective tumor remissions in about 10% of postmenopausal 
patients (7 ,26-28) support the clinical significance of direct anti-tumor 
effects. 
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INTRODUCTION 
Different steroid and peptide hormones, growth factors and 
other trophic substances are involved in the growth regulation 
of breast cancer cells (17). Especially oestrogens play an im-
portant role. Since the observation of tumour growth remission 
after surgical castration by Beatson (1896) various treatment 
modalities have been developed, which suppress gonadal, adrenal 
or peripheral oestrogen production or antagonize the stimula-
tory effects of oestrogens at the level of the tumour cells. 
Apart from castration by surgical and radiotherapeutical means 
it appeared possible to suppress pituitary-gonadal function by 
different kinds of medical treatment. During the last 5 years, 
it became apparent that LHRH analogues are of interest for sup-
pression of pituitary gonadotrophin secretion and for reaching 
"medical castration", especially because of the absence of side 
effects (25). The effectiveness of this type of treatment has 
been established in patients with prostate cancer by a large 
number of investigators (see previous chapters and review, 25) 
as well as by our group (13,14,26) and the number of studies in 
breast cancer patients has been increasing since our first re-
port in 1982 (9). Since that time we have treated 32 premeno-
pausal patients with metastatic breast cancer with at present a 
minimal follow-up of 1.5 years. Part of the endocrine and cli-
nical results have been published before in detail (9-12, 15, 
16). In this report we present our updated results and a review 
on this subject in the literature. 
PATIENTS, TREATMENT AND METHODS 
Thirty-two premenopausal patients with metastatic breast 
cancer gave consent for treatment with the potent LHRH-agonist 
Buserelin (Hoe 7 66) as a single agent or in combination with 
other agents like tamoxifen or megestrol acetate. The charac-
teristics of this group of patients with respect to age, 
disease-free interval, oestradiol receptor status and follow-up 
are indicated in Table 1. All patients were unselected with the 
exception of the patients in group IB (see treatment scheme), 
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TABLE 1. 
PATIENTS 
32 premenopausal patients with metastatic breast cancer 
mean age: 40 yr (range 30 - 53 yr) 
disease-free interval: x = 2.5 yr (range 0.5 5.0 yr) 
oestradiol receptor: 18 x pas., 2 x neg., 12 x unknown 
mean follow-up: 3.5 yr (range 1.5 4.5 yr) 
who were selected on the basis of having an oestradiol receptor 
positive tumour. 
During the first week all subgroups of patients were treated 
parenterally (Table 2) with a daily dose of 3 mg Buserelin as 
described before (11). Subsequently 12 patients (group IA) were 
treated chronically with 3 x 400 ).lg Buserelin intranasally 
(i.n.) and 11 patients (group IB) with 2 x 1 mg Buserelin sub-
cutaneously (s.c.), decreasing this daily dose after 2 months 
with 2 x 0.1 mg for every next month and switching to intra-
nasal administration in the presence of continuous medical 
castration after one year of treatment. Ultimately the patients 
in this subgroup IB have been treated with doses between 2 x 
1000 IJg s.c. and 3 x 400 ug i.n. ( "-'25 flg s.c.) per day (Table 
2). Five women (group IIA) were treated daily with 3 x 400 ug 
TABLE 2. 
PATIENTS AND TREATMENT SCHEME 
Hay 1986 
Group n first week I long-term treatment 
lA 12 3 mg Hoe 766 i.v. 3 x 400 1-19 i.n. 
I 
or s.c. 
IB 11 3 mg Hoe 766 i.v. I 2000 --- 100 pg s.c. __ ,_. i.n. 
I * IIA 5 3 mg Hoe 766 i.v. 3 x 400 ~g i.n. + 2 x 20 mg TAM 
* liB 4 3 mg Hoe 766 i.v. I 3 x 400 ~g i.n. + 4 x 45 mg HA 
I 
* Total 32 patients TAM = tamoxifen 
* HA = megestrol acetate 
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Buserelin i.n. in combination with 2 x 20 mg tamoxifen from the 
start of treatment, while in 9 out of the 12 patients of group 
lA tamoxifen was added later because of tumour progression or 
recurrent peaks of plasma oestradiol. Four patients (group IIB) 
were treated with 3 x 400 ~g Buserelin i.n. in combination with 
4 x 45 mg megestrol acetate s.c. 
Blood sampling, measurement of plasma luteinising hormone 
(LH), follicle stimulating hormone (FSH), oestradiol (E2), 
progesterone (Prog), prolactin (PRL) and oestradiol receptor 
(ER) were done as described previously ( 4,8). Measurement of 
tumour response were performed according to the UICC criteria. 
Significances of differences between mean values at various 
time points within treatment groups were assessed by Student's 
paired t-test. 
RESULTS 
Endocrine effects 
Gonadotrophins 
Results have been described in detail before (11,12,15). 
During chronic subcutaneous treatment the suppression of gona-
dotrophin secretion was more pronounced than during intranasal 
administration. No pre-ovulatory peaks were observed with the 
exception of data in a few patients treated with Buserelin plus 
tamoxifen (group IIA), while subnormal immunoassayable gonado-
trophin levels occurred rarely. 
Sex steroids 
Anovulation as indicated by persisting low plasma progeste-
rone levels occurred in all patients of group IA, IB and IIB; 
however, subnormal peaks of progesterone were observed in 7 out 
of 14 patients treated with Buserelin i.n. in combination with 
tamoxifen (10,11). 
During chronic subcutaneous treatment plasma E2 concen-
trations showed a striking fall to castration levels within 3 
weeks with a mean concentration of 19 pmol/1 (5 pg/ml) during 
1-4 months after start of treatment (Fig.l). During subcu-
taneous treatment mean plasma E2 was much more suppressed than 
during intranasal treatment, during which a great variation in 
plasma E2 concentrations was observed as expressed by a large 
SEM. During intranasal treatment some patients ( 40%) reached 
medical castration values, others showed recurrent peaks of E2. 
During gradual decrement of the daily subcutaneous dose, 
mean plasma E2 slowly increased after 5-12 months of treatment 
using Buserelin dosages of 0.6 - 1.4 mg per day. Plasma E2 le-
vels reached the same range as observed in patie~ts with medi-
cal castration during intranasal therapy (Fig.l) i.e. between 
20 and 60 pmol/1. One patient (Fig.2) showed a clear escape of 
pituitary-gonadal suppression after 32-40 weeks of treatment 
s.c. while after 20 weeks plasma E2 levels were already 
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FIG. 1. Mean plasma E2 concentrations during chronic single treatment with Buserelin intranasally (i.n.) and subcutaneously 
(s.c.) in 23 patients. 
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FIG. 2. Dose dependent effects on plasma E2 and prog levels and 
lymph node metastasis (lnn) of subcutaneous treatment with Hoe 
766 in the same patient. 
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slightly increased using dosages of L 4 - 0. 6 1]1g per day. 
Ultimately a small peak of progesterone occurred. After in-
crement of the dose to 2 x 1 mg s.c. per day a medical cas-
tration was reached again. This patient showed a complete 
remission of her cervical lymph node metastases within 5 weeks 
after start of treatment, but a recurrence of these lymph node 
metastases occurred after 9 months, about 7 weeks after the 
time that plasma E2 increased above levels of 100 pmol/1. When 
medical castration was reached for the second time after dose 
increment a complete tumour remission occurred again indicating 
that the tumour was still hormone dependent. However, after one 
year of treatment hormone independency occurred with tumour 
progression in the presence of castration levels of plasma E2. 
On the other hand, in another patient it appeared possible to 
decrease the daily dose from 2000 ]J.g s.c. to 1200 ]J.g i.n. ( rv25 
]J.g s.c.) in the course of 1 year. In this patient continuous 
medical castration and nearly complete tumour regression for 
more than 2 years were observed. 
Prolactin 
Detailed data were reported in a previous report (15). The 
main observations were that basal and stimulated (TRH) plasma 
PRL levels increased during the first day and after one week of 
treatment respectively. Thereafter there appeared no signi-
ficant difference with pretreatment values. During parenteral 
therapy the mean nig.ht peak of PRL, however, decreased signi-
ficantly from 27.2 + 4.6 to 15.9 ~ 3 ]J.g/1 (p < 0.05). 
Antitumour effects 
The effects on tumour growth are summarized in Table 3. In 
the whole group 14 patients (44%) showed an objective remission 
with a mean duration of response of more than 19 months. Three 
patients are still under treatment. In addition 6 patients 
(19%) showed stable disease. An objective response during 
single Buserelin treatment was found in 9 out of 23 patients 
(39%) and in 5 out of 11 (45%) patients selected on the basis 
of an ER-positive tumour treated subcutaneously. Until now the 
longest duration of response is more than 53 months. At 
present, this patient has been treated with an LHRH analogue 
for the longest period reported. In total, 8 out of 18 patients 
with an ER-positive tumour responded objectively (44%). 
Survival 
The overall survival of the whole group of 32 patients is 
shown in Fig.3. Median survival is 3 years. Eight patients 
(25%) died within 1.5 years after start of treatment. Thirteen 
(54%) out of 24 patients, all of them with a follow-up of at 
least 3 years survived longer than 3 years. The 9 patients with 
combination treatment showed a somewhat better survival curve 
than the other patients, but the number is too small for 
definite conclusions. In general, these results are as good or 
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better than those reported in the literature. 
TABLE 3. 
ANTITUMOR EFFECTS IN 32 PATIENTS 
May 1986 
I I 
Group Treatment CR + PR I No Change I failure n 
IA Hoe 766 i.n. 4 x (x = 2l+m) I (3-5m) I 4 X 4x 12 
IB Hoe 766 s.c. 5 x (x = l4+m) I 1 X (5m) I 5x(2x mixed) 11 
IIA Hoe 766 + TAM 3 X (x = 15+m) I 0 X I 2x 5 
liB Hoe 766 + MA 2 X ( 22,4l+m) I 1 X (14m) I lx 4 
I 
Total 14 X (44l'O) I 6 X (19l'O) I 12x 32 
- Objective response rate during single Hoe 766 treatment (IA+B) = 9/23 (39~) 
- Objective response rate in patients with ER + tumors: 45% 
- longest duration of response: 53+ months 
Side effects 
No side effects occurred with the exception of those caused 
by the intended hypogonadism, i.e. hot flushes, decreased li-
bido and in a few patients mental depression. Hot flushes were 
experienced 3-4 weeks after start ' : treatment at the time of 
medical castration. The frequency t-:C the flushes varied between 
3-30 times per day. During the years of treatment the intensity 
decreased. Some patients (about 15%) showed short-term (10-60 
minutes) urticarial skin irritation at the injection site with-
out pain or itching. 
DISCUSSION AND CONCLUSIONS 
In our study the objective response rate in premenopausal 
metastatic breast cancer is 39% during single LHRH agonist 
treatment. Recently, in 4 other studies (5-7,18,19,23) with a 
shorter follow-up and with application of 4 different LHRH 
agonists comparable response rates (between 31 and 47%, Table 
4) have been reported. In total, an objective response was 
found in 44 (38%) out of 116 patients. The overall response 
rate in patients withER-positive tumours appeared 53% (30/57). 
So, chronic LHRH-agonist treatment seems as effective as other 
common kinds of endocrine treatment in premenopausal breast 
cancer in the absence of serious side effects, but randomised 
. 362 
% 
100 
90 
80 
70 
60 
50 
40 
0 6 12 18 24 30 36 42 48 
MONTHS 
FIG. 3. Survival of 32 premenopausal patients with metastatic 
breast cancer treated with Buserelin (9 in combination with TAM 
or HA). 
studies have still to be performed. On the basis of our experi-
ence and that of others (21,22), an escape of suppression of 
pituitary-ovarian function or non-complete medical castration 
may occur in some women treated with daily dosages of an LHRH 
agonist lower than 1 mg subcutaneously, especially after ini-
tiation of therapy during either the mid-cycle or luteal phase 
according to Nicholson et al. (21, 22). Therefore we advise a 
daily dose of at least 1 mg s.c. to reach safely medical cas-
tration in all patients as also observed by Harvey and Manni et 
al. (5 ,6, 18~ 
Although the main mechanism of action of LHRH agonist treat-
ment is medical castration, direct antitumour effects at the 
level of tumour cells cannot be excluded. We reported before 
(1,2,15) and in this book (Foekens et al.) on direct antitumour 
effects of Buserelin using oestrogen stimulated breast cancer 
cell growth (MCF-7) in vitro in the presence of E2 concentra-
tions as found in castrated or postmenopausal patients. Prolac-
tin stimulated growth of breast cancer cells appeared inhibited 
too as found by Wiznitzer and Benz (28) using a prolactin res-
ponsive cell line (T-47-D). Direct effects were also observed 
by Miller et al. ( 20, this book) but not on all cell lines 
investigated. The suggestion of direct effects of the LHRH 
agonists in vitro is supported by the in vivo observation that 
LHRH agonist treatment can cause objective remission in post-
menopausal metastatic breast cancer (5,6,19,24, Table 5) and by 
the presence of (low affinity) binding sites for LHRH agonists 
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TABLE 4. 
RESULTS Of LHRH-AGONIST TREATMENT IN PREMENOPAUSAL 
METASTATIC BREAST CANCER 
(Updated 1986) 
Author LHRH-agonist 
.!! 
l) Klijn et a1. Busere1in 23 
2) Nicholson et al. Zoladex 45 
3) Harvey et al. Leuprolide 25 
4) ~lathe et al. * D-Trp-6-LHRH 8 
5) Hoffken et al. Buserelin 15 
In total 116 
* pretreated 
Overall response rate of ER-positive tumors: 30/57 (53ll:) 
TABLE S. 
CR + PR 
9 (39ll:) 
14 (3lll:) 
11 (44ll:) 
3 (38l'O) 
7 (47ll:) 
44 (38ll:) 
RESULTS OF LHRH-AGONIST TREATMENT IN POSTMENOPAUSAL 
METASTATIC BREAST CANCER 
(Updated 1986) 
Author LHRH-agonist n CR + PR 
-
1) Harvey et al. Leuprolide 41* 4 ( 10~~) 
2) Hathe et al. D-Trp-6-LHRH 15* 3 c2o~n 
3) Plo'Wlllan Zoladex 10 2 czo~n 
4) H'axman Buserelin 18 0 < o~n 
In total 84 9 (11%) 
* pretreated 
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in breast cancer cells (3, 20). However, the in vivo results 
could not be reproduced by all authors (27), and the relatively 
low overall response rate (11%) indicates that this kind of 
treatment will be of less value in postmenopausal patients. 
Maybe in some patients with bad drug compliance slow release 
preparations injected once per 1-3 months may be useful in the 
future. 
In conclusion 
1. In premenopausal metastatic breast cancer chronic LHRH-ago-
nist treatment appears as effective as other common kinds of 
endocrine treatment in the absence of serious side effects. 
2. Although intranasal administration appeared to be a pleasant 
and sufficiently effective way of treatment in some 
patients, high subcutaneous dosages of LHRH-agonists (at 
least 1.0 - 1.5 mg per day) are needed for reaching optimal 
and rapid suppression of the pituitary-gonadal function 
within 3 weeks in all patients. 
3. The reported responses in some postmenopausal patients may 
indicate direct antitumour effects in vivo at the level of 
the tumour cells as was observed in vitro. 
4. Sustained release preparations of LHRH agonist may be of 
great advantage if indeed medical castration can be reached 
in all patients. 
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Direct Inhibitory Effects of Somatostatin (Analogues) on the Growth of Human 
Breast Cancer Cells1 
Buddy Setyono·Han. 0\larcel S. Henkelman, John A. Foe kens, and Jan G. M. Klijn2 
lh·rartmt•nt of Endoaine OncoioKY (Rinchemistry and EndocrinO/ofO'). The Dr. Daniel den Hoed Cancer Center and Rotterdam Radio-Therapeutic Institute, 
Rnttl!rdum, Tht> Setht!rlands 
\BSTRACr 
Various hormones and ~rowth factors are involved in the growth 
re~ulation of breast (tumor) cells. In this report we show for the first 
time that an analogue of the neumpeptide somatostatin (Sandostatin) can 
also influence the proliferation of human breast cancer cells (MCF-7). 
namely. in an inhibitory fashion. \Vith respect to dose-response relation-
ship a bell-shaped cune was obsened with the maximal inhibition of 
tumor cell ~rowth at a sharply defined amount of Sandostatin (10 nM). 
The same effects were found with the natural hormone somatostatin-14 
and another analogue {CGP 15-425). These results, together with the 
obsenation that high affinity binding sites for an iodinated derivative of 
Sandostatin are present in MCF-7 cells, support the conclusion that 
somatostatin and analogues act directly on breast cancer cells. 
1:-.iTRODLIITION 
Different steroid hormones (estrogens. progestins. andro-
gens. glucocorticoids). peptide hormones (prolactin, growth 
hormone. insulin. calcitonin). growth factors (epidermal, trans-
forming. and insulin-like growth factors), and other trophic 
substances {iodoth)Tonines. vitamin D. retinoids} are involved 
in the gro~th regulation of breast cancer cells ( 1-1 0). Most of 
these factors are derived from endocrine glands such as the 
pituitary. gonads. and adrenals. Treatment of metastatic breast 
cancer is designed to decrease plasma concentrations of these 
hormones and factors or to antagonize the biological effects of 
these trophic substances directly at the level of the tumor cells. 
Endocrine therapy of breast cancer consists of a variety of 
both medical and surgical treatment modalities including oo-
phorectomy and hypophysectomy. Chronic tre~tment with an-
alogues of LHRH,-' a hypothalamic hormone, causes a ... partial 
hypophysectomy .. and medical castration resulting in breast 
tumor regression in about 40% of premenopausal patients (11-
17}. Recently. neuropeptides of another class. analogues of 
somatostatin. have become available. Somatostatin or its ana-
logues appears to cause suppression of the secretion of a number 
of pituitary and gastrointestinal hormones (18-27) such as GH 
and insulin. In addition. it has been reported that treatment 
with somatostatin analogues can decrease plasma concentra-
tions of some growth factors such as somatomedin C (i.e .• IGF-
1) (25) and EGF (28). IGF-1 and EGF may also function as 
autocrine or paracrine growth factors for MCF-7 human breast 
cancer cells (8-10). The possibility of a 'complete medical 
hypophysectomy' by means of chronic treatment with potent 
long-acting somatostatin analogues in combination with other 
drugs [LHRH analogues. (anti)steroids, prolactin inhibitors] 
Received 6/30/86; revised II/ I 0/86; accepted 12/17/86, 
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makes this class of pep tides of potential value in the treatment 
of breast cancer. Furthermore somatostatin or somatostatin-
like material (20-22, 29) and/or somatostatin receptors (30-
32) have been found in tumors from several origins suggesting 
the possibility of direct effects of somatostatin on tumor cells. 
It has been shown that analogues of somatostatin are able to 
inhibit the growth of a number of classical endocrine (25-27, 
33-37) and nonendocrine tumors (37-39). Somatostatin has 
endocrine effects. but it is believed that somatostatin can act 
locally as a paracrine or autocrine regulator of cell proliferation. 
Until now somatostatin has not been recognized as a hormone 
involved in the regulation of breast (tumor) cell growth. We 
have therefore studied whether the growth of human breast 
tumor cells can be influenced directly by an analogue of soma-
tostatin. This is the first repon showing that a somatostatin 
analogue inhibits the growth of human breast cancer cells. 
MATERIALS AND METHODS 
Chemicals and Materials. Estradiol was obtained from Merck, 
Darmstadt. West Germany. Nonradioactive Sandostatin (SMS201-
995~ o-Phe-Cys:Phe-o-Trp-Lys-Thr-Cys-Thr-ol) and 12!11-labeled Tyrl-
Sandostatin { 1770 Ci/mmol) were kindly provided by Sandoz. Basel. 
as was CGP 15-425 [cyclo-(Asn-Phe-Phe-o-Trp-Lys-Thr-Phe·Gaba)] 
by Ciba-Geigy AG. Basel. Switzerland. Somatostatin-14 (Ala-Giy-Cys-
Lys-Asn-Phe-Phe-Trp-Lys-Thr-Phe-Thr-Ser-Cys) was purchased from 
Sigma. St. Louis. MO. All media. sera, and antibiotics used were 
purchased from Grand Island Biological Co. (Breda, The Netherlarids). 
Insulin was obtained from Organon. Oss. The Netherlands. 
Cell Culture. MCF-7 human breast cancer cells in their 219th passage 
were originally obtained from E.G. and G. Mason Research Institute, 
Worcester, MA. Cells were passaged weekly and were grown in plastic 
T-75 flasks in RPMI 1640 medium containing 5 ,ug/ml phenol red and 
supplemented with penicillin (100 units/ml). streptomycin (100 ,ug/ 
ml). insulin (I 0 ,ug/ml), and I 0% fetal calf serum that had been 
inactivated for 30 min at 56·c (complete growth medium). For exper-
iments. cells growing exponentially were removed by treatment with 
0.1% trypsin and 3 mM EDTA in l ml Oulbecco's phosphate·buffered 
saline free of Ca2+ and Mgl+ for 5 min at 37·c and were plated in T-
25 flasks in 5 ml complete growth medium at a density as indicated in 
the legends to the figures. The following day the monolayers were 
washed twice with 5 ml 0.9% NaCI and 5 ml experimental medium 
were added. Experimental medium consisted of RPM! 1640 medium 
containing phenol red with or without somatostatin (analogues), estra-
diol. and/or insulin. and was supplemented with 5% fetal calf serum 
that had been inactivated and depleted of steroids by two 45-min 
incubations at 50"C with dextran-coated charcoal ( l% charcoal-0.1% 
dextran). Estradiol was added from a concentrated stock solution in 
absolute ethanol. In media without estradiol the same amount of 
ethanol was added (<0.01 %). Other vehicle controls consisted of0.9% 
NaCI solution. Medium containing the respective supplements, includ-
ing somatostatin {analogues). was refreshed as indicated in the legends 
to the figures. When indicated in the text RPMI 1640 medium without 
phenol red was used in the experimental medium. 
Harvesting of Cells. Monolayer cells were harvested following two 
washes with 0.9% NaCI either by a 30 min incubation at 60"C in I ml 
NaOH or by incubation with 0.1% trypsin and 3 mM EDTA in Dul-
becco's phosphate-buffered saline free of Ca1 ... and Mg2 ... for 10 min at 
ambient temperature. DNA and protein contents of the cell lysates 
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1H·re estimated by a fluorimetric method as described before {40) and 
•1-:cording to Bradford (41), respectively. Cells harvested by trypsiniza-
1 ion were counted in a hemocytometer after preparing a single cell 
~u~pension by repeatedly forcing the cells through a 0.6-mm needle. 
Determination of Sandostatin Binding Sites by Scatchard Analysis. 
\ICF-7 cells were cultured in experimental medium in the absence of 
l'~tr:!diol and in the presence of insulin. On day six. after medium 
rl'freshmcnt every second da), monolayer cells were washed twice with 
KPM11640 medium containing 0.5% bovine serum albumin. After two 
~ubsequent incubations for I h at 37"C in medium with the same 
l'Omposition the cells were harvested with a rubber policeman and 
rt'suspended in ice-cold medium. Following centrifugation for 5 min at 
100 x K· the cells were resuspended in receptor buffer consisting of 50 
m\1 4-(2-hyrlroxyethyl)-1-piperazineethanesulfonic acid (pH 7.5) with 
5 m~1 MgCI2. I 0 mgjml bovine serum albumin, 0.02 J.t&/ml phenyl-
methylsulfonyl fluoride, 0.02 J,tg/ml Bacitracin, and 200 Kallikrein 
mhibiting units/ml Trasylol. Cells (3 x JO~>) were aliquoted in 1.5 ml 
conical polypropylene tubes and incubated with 1251-labeled Tyr3-San-
dostatin (specific activity, 1770 Ci/mmol) ranging from 25 to 500 pM, 
m the absence and presence of a 200-fold excess nonlabeled Sandostatin 
to correct for nonspecific binding. After incubation for 2 h at 2ZOC. 
which appeared optimal in initial experiments with cells in suspension, 
the cells were pelleted by centrifugation for 5 min at 13.000 X g. 
Following one wash with 1 ml receptor buffer, radioactivity in the pellet 
fractions was estimated by gamma counting (efficiency, 88%). 
Statistical Analysis. Statistical analysis was performed by the non-
parametric method of Wilcoxon. 
RESULTS 
In initial experiments MCF-7 mammary tumor cells were 
cultured in medium supplemented with 5% steroid-depleted 
feral calf serum and with increasing concentrations of the 
somatostatin analogue Sandostatin both in the absence and the 
presence of estradiol and/or insulin. Tested under these four 
conditions, Sandostatin at a concentration of 1 0 OM resulted in 
a significant inhibition (P < 0.05) of the growth of the cell 
cultures (Fig. 1 ). This inhibition was most profound when the 
cultures were grown in medium with insulin and without estra-
diol. Under this condition there was an 88% inhibition of cell 
growth based on DNA content of the cultures (Fig. I C). Inter-
estingly, maximal suppression of the growth of the cultures was 
obtained at a sharply defined amount of Sandostatin {I 0 nM): 
at lower and higher dosages the inhibition of cell growth was 
less striking. The known stimulating effects of estradiol and 
insulin on MCF-7 cell growth were confirmed from the differ-
ences in the amounts of DNA in the cultures grown in the 
absence of Sandostatin (Fig. 1, left columns). To evaluate 
whether the growth-inhibiting effect of Sandostatin also occurs 
under .. complete estrogen-deprived"' conditions, experiments 
were performed in medium lacking phenol red which was shown 
to have weak estrogenic effects (42). In such medium without 
phenol red and estrogens. I 0 nM Sandostatin resulted in 25 ± 
3% (SE: n = 6) inhibition ofMCF-7 cell growth in the presence 
of insulin (P < 0.02). 
In subsequent experiments with medium containing phenol 
red without estradiol and with insulin, the inhibiting effect of 
Sandostatin on MCF-7 cell proliferation appeared reproduci-
ble. It was found that in addition to its effect on the DNA 
content, Sandostatin at a concentration of 10 nM also caused a 
maximal decrease in the cell number and in the protein content 
of the cultures (Fig. 2). Based on DNA content of the cultures 
from three consecutive experiments. the mean inhibition of cell 
growth caused by the two most effective concentrations of 
Sandostatin were 44 ± l% at 5 nM and 73 ± 18% (n = 3) at 10 
nM Sandostatin. 
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Fig. I. Effect of Sandostatin on the growth of MCF-7 breast cancer cells. 
Cells were plated at a density of 4 x I o~ cells(T-25 flask and were grown in the 
absence {A) or presence of added 30 pM estradiol ( £2) (B), I 0 pg/ml insulin (C). 
and 30 PM estradiol plus 10 JJ.&/ml insulin (D). The medium was refreshed cvet)' 
second day. and after 6 days the cells were solubilized by incubation in I N NaOH 
as described in "Materials and Methods." Values are means± SD (bar.r) (n = 6) 
of JJ.& DNA per flask. •. Statistically significant diiTcrence (P < 0.05) from its 
respective control column. 
ln experiments in which medium was refreshed every day, it 
was found that a concentration of 5 nM Sandostatin caused a 
significantly higher inhibition of cell growth than did a concen-
tration of 10 nM over a 6-day period (Fig. 3). This was in 
contrast to the observations in previous experiments when 
medium was refreshed every second day. This may be explained 
by instability or metabolism of Sandostatin during 2-day cul-
tures or alternatively by the presence of other concentrations of 
autocrine growth factors. With the highest concentrations of 
Sandostatin used, a possible escape of cell growth inhibition is 
observed at day 5 (Fig. 3). suggesting desensitization of the 
cells. 
To evaluate whether the observed inhibiting effects were not 
only restricted to the somatostatin analogue Sandostatin, ad-
ditional experiments were performed with the natural hormone 
somatostatin-14 and with another analogue, CGP 15-425. 
Comparable effects were observed at 10 nM concentrations~ 6-
fold incubations with CGP 15-425 and somatostatin-14 showed 
75 ± 2 and 76 ± 2% inhibition of cell proliferation measured 
by cell number (for both. P < 0.02). Again higher and lower 
concentrations~ 1 11M and 0.1 nM, resulted in significantly less 
inhibition (P < 0.02). 
In in vivo studies using dimethylbenzanthracene-induced 
mammary tumors in rats, we have also observed a bell-shaped 
curve of dose-response relationship~ showing a critical concen-
tration ofSandostatin which causes optimal inhibition of tumor 
growth. Rats were treated twice daily with five different dosages 
(0, 0.05, 0.2, I, 5, and 20 !'g) of Sandostatin for 3 weeks. A 
dose of2 X 0.211g/day appeared to result in maximal inhibition 
(83%) of tumor growth. Dosages of Sandostatin above and 
1567 
368 
SOMATOSTATIN AND BREAST CANCER 
"' 4 I 
~ 
3 
. 
.., 2 E 
" c: 
~ 
0 
20 
.. 15 : 
oC 
10 z 
c 
5 
0 
100 
.. 75 : 
c: 
.. 50 
0 
ii: 25 
0 
SANDOSTATIN (M) 
Fig. 2. Effects of increasing concentrations of Sandostatin on the proliferation 
ofMCF-7 breast cancer cells. Cells were plated at a density of 4 x to• cclis/T-25 
flask and were cultured for 6 days with medium refreshment every second day in 
the absence of estradiol and in the presence of added insulin ( 10 ,ug/mi). Values 
are means ± SD (bars) of 6-fold incubations. Ali doses of Sandostatin used 
caused significant (P < 0.05) inhibition of growth of cell cultures when expressed 
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Fig, 4, Scatchard plot of ~~~!-labeled Tyr-1-Sandostatin binding to M{'F-7 
breast cancer cells. Cells cuhured as described in -Materials and Methods~ to 
near confluency were incubated in ~uspension with increasing concentrations of 
12~1-labeled Tyr-1-Sandostatin (25-500 pM) in the absence and pre~encl! of a 200-
fold excess nonlabeled Sandostatin. Specifit".l.lly bound ~~~!-labeled Tyr-1-Sandos-
tatin is plotted, 
below 2 X 0.2 ;..tg/day were less or not effective in this respect 
(43,44). 
The observation that Sandostatin has a direct inhibitory effect 
on the proliferation of MCF-7 cells in culture may imply the 
presence of specific receptors for somatostatin on MCF-7 cell 
membranes. We have therefore performed binding studies with 
an iodinated derivative of Sandostatin, L!51-labeh!d Tyr3-San-
dostatin. Scatchard analysis of the binding data (Fig. 4) shows 
a single class of high affinity binding sites representing approx-
imately 250 molecules/cell with a K, of 73 pM. 
DISCUSSION 
In this report we show for the first time that somatostatin 
and two Of its analogues can inhibit the growth of breast cancer 
cells. Because of the observ~d specific high-affinity binding of 
the Sandostatin derivative and the observation that a narrow 
concentration range of Saridostatin exists in which maximal 
inhibition of cell proliferation is achieved. it is tempting to 
speculate that within I week desensitization may occur by 
chronic administration of Sandostatin dosages above I 0 nM as 
a result of downregulation of the somatostatin receptors. Re-
cently it has been observed that desensitization of normal GH-
secreting cells to. Sandostatin can occur within 6-10 days in a 
dose-dependent manner (27). A similar phenomenon was ob-
served with other somatostatin analogues (33, 39) and with 
respect to insulin secretion (25, 45). Preliminary experiments 
in our laboratory show indeed disappearance of the specific 
binding sites for 1251-labeled Tyr3-Sandostatin after culturing of 
MCF-7 cells for 6 days in the presence ofSandostatin (data not 
shown). 
With regard to mechanism of action, somatostatin can act 
on mammary tumor cells by different ways. Somatostatin may 
exert its action by directly interacting with its specific receptor 
or by modulation of other receptors. Indirectly. it may act by 
decreasing the secretion of pituitary hormones and growth 
factors such as somatomedin C/IGF-1 and EGF. With respect 
to indirect actions of somatostatin via GH. interesting obser-
vations were made by Murphy eta/. (46). Their results indicated 
that human GH may be a potent ligand for the lactogenic 
receptor in human breast cancer cells in ritro. Furthermore 
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Shiu and lwasiow (47) showed induction of specific proteins by 
CJH and prolactin in human breast cancer cells. The observation 
of increased plasma GH levels in breast cancer patients (48) 
mav be of importance. Somatostatin may also act as a paracrine 
or ;utocrine regulator of tumor cell proliferation or by influ-
L'Ocing secretion of autocrine or paracrine growth factors. The 
interaction of mammogenic peptide hormones (GH. prolactin, 
and insulin). steroids, and EGF with modulation of their re-
'pective receptors (27. 49-54) in addition to the possible inhib-
iting effects of somatostatin on the secretion of EGF and 
•mmatomedin C. suggests a very complex mechanism through 
v.hich somatostatin acts in vivo and in vitro. Antagonizing 
l'ffects of estradiol and somatostatin (analogues) at the level of 
autocrine growth factor secretion. for instance. somatomedin 
C. might explain our observation that the growth inhibiting 
t:ffect ofSandostatin is less pronounced when estradiol is added 
to the medium. 
In conclusion, proliferation of MCF-7 human breast cancer 
cells in vitro is inhibited by somatostatin (analogues) through 
direct action on the tumor cells. It is interesting to note that 
analogues of LHRH (14, 55-58) and somatostatin (this report) 
have direct inhibitory effects on tumor cell growth antagonizing 
in ~·itro especially the biological effects of those steroid (as 
estradiol by LHRH analogues) and peptide hormones (GH and 
insulin by somatostatin analogues) in which secretion in vivo is 
suppressed by pharmacological doses of the same neuropeptide 
analogues. · 
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TRH 
LHRH 
CRF 
GRF 
TSH 
LH 
FSH 
ACTH 
PRL 
GH 
T4 
T3 
E2 
Prog 
(O)GTT 
ITT 
LVP 
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LIST OF ABBREVIATIONS 
thyrotrophin-releasing hormone 
luteinising hormone-releasing hormone 
corticotrophin-releasing factor 
growth hormone-releasing factor 
thyroid stimulating hormone 
luteinising hormone 
follicle-stimulating hormone 
adrenocorticotrophic hormone 
prolactin 
growth hormone 
thyroxine 
triiodothyronine 
oestradiol 
progesterone 
(oral) glucose tolerance test 
insulin tolerance test 
lysin-vasopressin test 
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zijn gekomen. Aansluitend wil ik tevens bedanken mevrouw E.L.A. 
Vonk-Neele en mevrouw M. Westerhout-Kersten van de bibliotheek voor 
het opzoeken van een aantal referenties, hetgeen mij veel tijd 
bespaard heeft, en de mensen van de afdeling Medische Fotografie 
(Johan Marselje, Sten Sliwa en Hans Vuik) voor de snelle service bij 
het maken van een groot aantal afdrukken van figuren en voor het 
verzorgen van de omslag (Johan Marselje) van het proefschrift. 
Tenslotte wil ik hier mijn dank betuigen aan het Koningin Wilhelmina 
Fonds voor de financiele steun aan ons preklinisch onderzoek, en ook 
bedanken een groot aantal medewerkers van diverse pharmaceutische 
bedrijven, niet alleen voor hun financiele steun aan ons klinisch 
onderzoek, maar met name voor de plezierige en nuttige samenwerking op 
wetenschappelijk gebied. 
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CURRICULUM VITAE 
De schrijver van dit proefschrift werd geboren op 20 januari 1945 in 
Amsterdam. In 1964 behaalde hij het diploma gymnasium-S aan het 
Ignatius College te Amsterdam en began zijn medische studie aan de 
Gemeentelijke Universiteit van deze stad. De co-assistentschappen 
werden doorlopen in het Wilhelmina Gasthuis, het Binnen Gasthuis en 
het Onze Lieve Vrouwe Gasthuis. 
In mei 1972 werd de opleiding tot arts voltooid. Na het behalen van 
het artsexamen werd op 1 juli 1972 aangevangen met de opteiding tot 
internist in het ziekenhuis de Mariastichting te Haarlem (opleider J. 
Verwiel). Deze opleiding werd vanaf 1 april 1974 voortgezet op de 
afdeling Hematologie (hoofd Prof. Dr. J. Abels) en vanaf 1 mei 1975 op 
de afdeling Interne Geneeskunde III en Endocrinologie (hoofd Prof. Dr. 
J .c. Birkenhager) van het Academisch Ziekenhuis "Dijkzigt" te 
Rotterdam. Op 1 juli 1977 volgde inschrijving als internist in het 
Specialisten Register. Daarna bleef hij tot 1 maart 1981 werkzaam als 
chef de clinique op de afdeling Interne Geneeskunde III en 
Endocrinologie. Sinds 1 maart 1981 is hij verbonden aan de Dr. Daniel 
den Hoed Kliniek te Rotterdam als hoofd van de afdeling Endocriene 
Oncologie (Endocrinologie en Biochemie) en bleef part-time (0.1) 
werkzaam op de afdeling Interne Geneeskunde III en Endocrinologie van 
het Academisch Ziekenhuis Rotterdam. Tussentijds functioneerde hij van 
oktober 1983 tot 1 januari 1986 tevens als tijdelijk hoofd van de 
Afdeling Interne Geneeskunde van de Dr. Daniel den Hoed Kliniek. 
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